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Abstract
Two galactose-binding receptors, the hepatic asialoglycoprotein receptor
(ASGPR) and the macrophage galactose lectin (MGL) have been investigated. The
ASGPR is believed to function in glycoprotein clearance from serum while MGL is
involved in recognition of pathogens and tumours and in signalling and
immunomodulation. This work describes the analysis of the specificity, structure and
organisation of both receptors in humans and the two MGLs in mice.
The ligand-binding properties of the two subunits of the ASGPR as well as
MGL have been separately tested in glycan array analysis. The results show that
primary binding to ligands in the human ASGPR occurs via the ASGPR-1 subunit. 
MGLs have different specificities even though they are highly similar in sequence and
the two mouse MGLs differ markedly from the single MGL in humans and in rats. One
of the mouse MGLs has a similar specificity to ASGPR-1 that evolved independently.
Hydrodynamic studies of ASGPR-1 revealed that it can form homo-oligomers
and circular dichroism analysis of the neck fragment showed that it has a coiled-coil 
structure. Hetero-oligomer formation was monitored using a mutant version of ASGPR­
1 that allows purification of the complex using double-affinity chromatography on
galactose and mannose. Hetero-oligomers containing both types of subunits are more
stable than homo-oligomers. The results suggest a model that can account for the
variable subunit stoichiometries observed by various investigators. Hydrodynamic
studies and circular dichroism of MGL suggest that the extracellular domain of the
human protein is an oligomer not as stable as previously thought, and that its neck is a 
coiled-coil structure. For both receptors, transmembrane and cytoplasmic domains as
well as glycosylation may have a role in their stability.
The ability of MGL to recognise pathogen glycans was demonstrated using 
Trichinella spiralis secretions. It was found that similar glycoproteins are bound by the
human and mouse receptors.
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Chapter 1. Introduction
Chapter 1.
Introduction
The receptors studied in this work, the hepatic asialoglycoprotein receptor (ASGPR)
and the macrophage galactose lectin (MGL), are closely related members of a group of
proteins known as C-type lectins (Iobst and Drickamer 1996). They have the ability to
recognise glycans, a function that has been employed by nature to accomplish different
tasks in organisms. In addition to introducing the ASGPR and MGL, this chapter
describes the importance of lectins in general, emphasising the group to which these
receptors belong. It also gives an overview of the biology of genus Trichinella, because
we explored the interactions between one of the receptors and the glycans secreted by
this nematode parasite.
1.1. Diversity of glycan-binding proteins
There is a huge variety of glycans expressed by organisms. Just taking into account
N-linked glycosylated proteins, it has been estimated that approximately three quarters
of the proteins deposited in the SWISS-PROT database are modified in such a way
(Apweiler et al. 1999). Taking advantage of this variety, organisms make use of
glycans for their own benefit in a series of physiological processes, many of them
1
 
  
 
 
    
 
 
     
   
     
  
 
  
  
 
 
      
   
 
     
 
    
    
 
 
Chapter 1. Introduction
highly specific. In order to do so, they have an arsenal of glycan-binding proteins that
mediate the recognition of glycans.
We define those glycan-binding proteins as those that recognise and bind
oligosaccharides, without any enzymatic activity (Varki et al. 1999). Apart from
antibodies that can be generated with glycan specificity, most glycan-binding proteins
are referred to as lectins, which can be grouped into a series of families that are 
phylogenetically and structurally distinct (Kocourek and Hořejší 1981; Varki et al.
1999). Lectins bind N- and O-glycans, glycosphingolipids and some sulphated
glycosaminoglycans, often with  high specificity but low affinity, which can be
enhanced by means of multivalency (Varki and Angata 2006).
First discovered in plants more than a hundred years ago, guided by their ability to 
agglutinate red blood cells, lectins are found in every taxonomical group, including
archaeal and bacterial domains and are also represented in viruses (Weis 1997; 
Saunders et al. 2006; Gilboa-Garber et al. 2008). Indeed, in viruses, lectins or
haemagglutinins are essential for the virus-cell fusion and therefore are important from
the medical point of view, which led to the fact that the third solved crystallographic
structure of a lectin was the one of influenza virus haemagglutinin (Wilson et al. 1981).
In plants, the best known lectins are those of leguminosae, after the first purified 
lectin was ricin from Ricinus communis by Stillmark in the nineteenth century
(Stillmark 1888; Olsnes 2004). In the last century a deeper study of ricin was followed
by many others, such as concanvalin A, which have been useful in the purification of
glycoconjugates (Cummings 2008), studying immune regulation, cell differentiation 
2
 
  
 
 
   
     
 
  
 
 
 
  
    
  
    
 
    
      
   
   
 
   
   
 
   
Chapter 1. Introduction
(Falk 1994), cell interactions (Sawchenko and Gerfen 1985) and as diagnostic and
therapeutic tools for illnesses such as cancer (Mody et al. 1995). During the first
decades of lectin study, research was focused into their possible usage in different
applications. Although there is still a huge interest in the application of lectins as tools,
the major attention has turned towards the participation of lectins as determinants in
multiple biological processes.
Lectins in plants have been suggested to participate in many processes, including 
protection against parasites or predators, recognition of pollen and in the symbiotic
relation with rhizobacteria, but many of their functions have not been completely
proved yet (Van Damme et al. 2008). Similar functions in protection and molecular
recognition by lectins are used in many other organisms, including fungi (Guillot and
Konska 1997), algae (Kim et al. 2006) and animals. In invertebrates, the lack of an
adaptive immune system makes lectins essential in the recognition of invading 
pathogens (Loker et al. 2004). Invertebrates also make use of lectins in the recognition
of gametes (Moy et al. 2008), in the regulation of the formation of shells (Matsubara et
al. 2008) and in symbiotic interactions, such as the relation between coral polyps and
dinoflagellates (Wood-Charlson et al. 2006). Even if vertebrates have developed a more 
sophisticated defence system, lectins are still an essential part of innate immune
defence. Specifically, ficolins, a family of lectins characteristed by their fibrinogen-like
and collagen-like domains, and collectins, such as mannose-binding proteins (MBP),
trigger the activation of the complement system, a pathway that arose somewhere
before the divergence of deuterostomes (Nonaka 2001; Fujita 2002).
3
 
  
 
 
 
   
  
  
  
 
 
   
 
   
 
  
    
    
  
    
   
  
  
  
  
   
Chapter 1. Introduction
The discovery of lectins in animals was delayed respective to plant lectins. They
were first proposed to be present in animals for being responsible for the reaggregation 
of sponge cells (Spiegel 1954), although their activity as agglutinins had been
previously observed in snake venoms since the end of the nineteenth century, and there
is some debate about animal animal lectins being discovered previously to plant lectins
(Flexner and Noguchi 1902; Kilpatrick 2002). Since those early discoveries, the
number of lectins discovered in animals increased and eventually their presence in 
mammals was also proved. In 1988, Drickamer recognised that most of the receptors
known until then could be divided into two structural families, C-type and S-type, the 
latter now known as galectins (Drickamer 1988). C-type lectins, which include
collectins, selectins, endocytic receptors and proteoglycans, have roles in cell adhesion,
in the clearance of glycoconjugates, in the recognition of pathogens and as signalling 
receptors in immune functions (Weis et al. 1998; Drickamer 1999). Galectins seem to
be the most ancient and widely distributed family of lectins among animals and are part
of cell-cell and cell-matrix interactions, as well as cell surface signalling and
modulation of cellular functions (Barondes et al. 1994; Kasai and Hirabayashi 1996). 
Like C-type lectins, they participate in immune regulation and inflammation (Vasta et
al. 1999).
After the division between C-type lectins and galectins, more families have been
recognised. The I-type lectins, a grouping proposed by Varki (Powell and Varki 1995)
which include Siglecs, are proteins that belong to the immunoglobulin superfamily. In a
similar fashion to C-type lectins and galectins regarding their role in extracellular
4
 
  
 
 
 
 
  
 
 
      
  
   
  
  
 
    
    
  
    
 
  
    
 
  
  
Chapter 1. Introduction
functions, they are involved in cell adhesion and pathogen recognition. Several other
families have roles in extracellular functions, such as Japanese and European eel
fucolectins which also recognise pathogens (Russell and Lumsden 2005) and pentraxins, 
a family of pentameric proteins that are involved also in pathogen recognition and their
elimination or neutralisation, in the resolution of autoimmune diseases and in
mammalian female fertility (Agrawal et al. 2009). Ficolins, a group of lectins that
contain a collagen-like and a fibrinogen-like domain also play a role in innate immunity,
acting as opsonins and activating the complement pathway (Matsushita and Fujita
2001). Hyaluronan-binding proteins or hyaladherins, a family with still unclear
relations, interact with matrix hyaluronan, regulating amongst other functions, cell
migration, cell-cell adhesion and cell differentiation (Knudson and Knudson 1993). 
Tachylectins, a group of lectins originally discovered in the horseshoe crab Tachypleus
tridentatus, but also present in other animals, including chordates and bony fish, and in
slime molds, are involved in protection against infections by binding to components of
bacterial cell walls (Ju et al. 2009). Another group of lectins that seem to be involved in
innate immunity are X-type lectins, also known as intelectins or eglectins, originally
described in African frog Xenopus laevis, but also present in other vertebrates,
including humans, and in chordates (Tsuji et al. 2007).
Animal lectins can also be involved in intracellular phenomena such as trafficking 
of molecules. P-type lectins, that include cation-dependent mannose 6-phosphate
receptors and insulin-like growth factor II/mannose 6-phosphate receptors, unique
amongst lectins because of their ability to bind phosphorylated mannosyl residues,
5
 
  
 
 
  
 
  
 
     
   
    
 
    
   
     
 
    
  
  
    
  
    
  
 
 
Chapter 1. Introduction
guide newly synthesised lysosomal enzymes with such residues to lysosomes (Dahms
and Hancock 2002). The degradation of misfolded proteins in the endoplasmic
reticulum has several stages that make use of lectins (Nakatsukasa and Brodsky 2008). 
One process involves endoplasmic reticulum lectins that act as chaperones by binding 
to N-linked oligosaccharides. For example, calnexin and calcireticulin facilitate folding
and prevent aggregation (Hebert et al. 1996). When a protein is correctly folded,
glucosidase II removes a final glucose residue from the glycans, preventing the
interaction between the lectins and the proteins (Taylor et al. 2004). Misfolded proteins
are reglucosylated and therefore rebind to the lectins. Terminally misfolded proteins are
identified by another group of proteins, members of the M-type lectins, known also as
endoplasmic reticulum degradation enhancing α-mannosidase-like proteins, after which 
the proteins are retranslocated to the cytoplasm (Hosokawa et al. 2001). In the
cytoplasm, F-box proteins, which include lectin F-box only protein 2, identified as a
mannose-binding protein in mouse (Yoshida et al. 2002), and other ubiquitin ligases
direct misfolded proteins to proteasomes for their further degradation.
Not all lectin families have well known functions. The functions of chitinase-like
lectins or chi-lectins, all related to family 18 of glycosyl hydrolases, are still obscure,
although they have been associated with arthritis, tissue remodelling, fibrosis, cancer,
allergic airway inflammation, fertilisation and early embryonic development (Bussink
et al. 2007).
6
 
  
 
 
 
 
   
 
  
 
  
        
          
     
          
  
  
      
 
 
 
    
     
  
  
Chapter 1. Introduction
1.2. The C-type lectin domain fold
The C-type lectins are characterised by the presence of a globular carbohydrate-
recognition domain (CRD) with a characteristic fold which is designated a C-type CRD
(Drickamer 1993a). In addition to the C-type lectins, other proteins contain similarly
folded domains known as C-type lectin-like domains (CTLDs) (Drickamer 1999). Only
the subset of CRDs that bind sugars are referred to as C-type CRDs. As shown in Fig. 
1.1, the CTLD fold can be described as a long structured loop, in which terminal β­
strands β1 and β5 close the structure in an antiparallel β-sheet. There are two α-helices,
α1 and α2, one at each side of the domain and a β-sheet structure formed at the top by
strands β2, β3 and β4. Inside the domain, the structure includes a loose loop, called the
long loop region, which bulges out from a site flanked by strands β2 and β3. The most
conserved residues in the domain are four cysteines (numbered Cys1-Cys4 in Fig. 1.1)
that form disulphide bridges which stabilise the loops. Cys1 and Cys4 link β5 and helix 
α1, stabilising the whole domain while Cys2 and Cys3 link β2 and β3, which
presumably stabilise the long loop region. It is in the long loop region that Ca2+ and 
carbohydrate binding take place. In some cases, this loop also participates in domain-
swapping dimerisation. Numbering of the secondary structure elements in the figure
follows an extension of the original numbering of the model lectin mannose-binding 
protein A (MBP-A) (Weis et al. 1991) to make other structures comparable. Apart from
the conserved cysteines, it has been noted that there is a conserved sequence “WIGL”
(aromatic-aliphatic-glycine-aliphatic residues) localised in β2 (Drickamer 1993a).
7
 
  
 
 
  
 
  
      
 
  
    
    
  
         
 
 
  
Chapter 1. Introduction
There are different variations in the fold. One of the most significant variants
among the receptors is the presence of the long loop region, which is absent in link or
protein tandem repeat proteins and bacterial CTLDs. Another variance is the presence
of an additional β-structure that forms a β-hairpin with β1, stabilised by an additional
disulphide bridge, which is the case of the CTLD depicted in Fig 1.1. CTLDs that
possess this additional extension are called long form CTLDs (Drickamer 1999).
There are four possible Ca2+ binding sites in a CTLD but zero, one, two, three or the
four of them may actually be present in a given CTLD. The first three sites are located
in the upper part of the fold, while site 4 appears to have a stabilising function in the
formation of a salt bridge between α2 and the sheet formed by β1 and β5 (Drickamer
1993a; Drickamer 1999). 
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Cys4 
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Cys0 
CPVNWVEHERSCYWFSRSGKAWADADNYCRLEDAHLVVVTSWE 
EQKFVQHHIGPVNTWMGLHDQNGPWKWVDGTDYETGFKNWRPE 
QPDDWYGHGLGGGEDCAHFTDDGRWNDDVCQRPYRWVCETEL 
Figure 1.1. C-type lectin fold illustrated by the CRD of subunit 1 of the human
 
asialoglycoprotein receptor (ASGPR-1).
 
The yellow lines in the sequence correspond to disulphide bridges depicted in the model.
 
Model created using UCSF Chimera. PDB ID 1DV8.
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Chapter 1. Introduction
1.3 The hepatic asialoglycoprotein receptor (ASGPR)
The hepatic asialoglycoprotein receptor, which is primarily expressed on the
sinusoidal face of hepatocyte plasma membranes, mediates the uptake of glycoproteins
that contain terminal N-linked galactose from the circulating serum (Hudgin et al.
1974). It was the first C-type lectin discovered in mammals, during studies on the
metabolism of serum glycoproteins. Glycoproteins from which terminal sialic acid
residues on N-linked oligosaccharides had been removed were found to be rapidly
cleared from circulation and degraded in liver cells. 
1.3.1 Endocytosis of glycoprotein ligands
The hepatic asialoglycoprotein receptor has been proposed to be involved in 
binding and internalisation of desialylated serum glycoproteins, in the elimination of
cellular fibronectin, in hepatic lipoprotein metabolism, in IgA uptake from serum, in
phagocytosis and more recently in the homeostasis of von Willebrand factor and
platelets (Windler et al. 1991; Stockert 1995; Rotundo et al. 1999; Grewal et al. 2008). 
Recent studies showed that this receptor may serve to regulate the relative
concentration of plasma glycoproteins that terminate with sialic acid α2,6 linked to
GalNAc or galactose, some of which may be over-expressed in acute situations (Park et
al. 2003; Steirer et al. 2009). These situations can be caused by the presence of bacteria
or by the action of cytokines which have proved to elicit the activity of
sialyltransferases (Hanasaki et al. 1994). The strategic expression of ASGPR on
hepatocytes would facilitate recycling of amino acids and carbohydrates by liver
metabolism. The asialoglycoprotein receptor has also been linked with pathological
10
 
  
 
 
     
      
  
 
  
 
 
    
   
     
   
    
  
   
 
        
    
    
    
Chapter 1. Introduction
conditions, such as infection by hepatitis A, B and C, and Marburg viruses, which 
attach to this receptor via their highly glycosylated envelope glycoproteins (Treichel et
al. 1994; Becker et al. 1995; Saunier et al. 2003).
The isolated human asialoglycoprotein receptor binds glycoconjugates that present
non-reducing terminal galactose or GalNAc residues, binding more tightly to GalNAc­
containing structures (Ruiz and Drickamer 1996). Lee and colleagues showed that the
asialoglycoprotein receptor has a particular affinity towards highly branched glycans,
indicated by an exponential correlation between the number of branches and the degree
of binding to ASGPR (Rice and Lee 1993). However, this specificity was not observed
in a more recent study that showed a linear correlation between the number of exposed 
galactose residues in glycoproteins and their degree of clearance into liver (Takamatsu
et al. 2003). Based on studies in silico, it has been suggested that in the case of a
triantennary glycan, each branch would bind to a different CRD in an ASGPR oligomer
(Ramadugu et al. 2010), however it is more plausible that the branches make secondary
contacts with other regions of the CRD, enhancing the interaction. Several high affinity
ligands for the asialoglycoprotein receptor have been generated, including the highly
glycosylated polypeptides asialo-orosomucoid and asialo-fetuin (Baenziger and
Maynard 1980) and neoglycosylated BSA terminating in sialic acid α2-6 linked to
GalNAc and galactose (Park et al. 2003). The CRD of ASGPR ligates the 3 and 4-OH
groups of galactose or GalNAc, so it can bind glycans where galactose or GalNAc are
capped with α2-6 linked sialic acid but not those where sialic acid is linked α2-3.
11
 
  
 
 
 
 
 
   
   
  
   
   
  
 
   
  
   
   
   
  
  
   
   
 
 
Chapter 1. Introduction
Regardless of the ligand bound by the ASGPR, it has been shown that the way the
receptor mediates internalisation of the ligands is through a pathway involving clathrin­
coated pits (Fig. 1.2). The ASGPR is regarded as a model of endocytic transport
receptors and some of the first observations of this pathway were first made for the
ASGPR (Spiess 1990; Roth 2006). The protein β-adaptin, which links receptor to 
clathrin, binds the cytoplasmic tail of ASGPR-1 (Beltzer and Spiess 1991). The relation 
between the receptor and coated pits has also been demonstrated in living cells and it is
clear that in vivo, it is ASGPR-1 that primarily mediates the formation of the pits
(Rensen et al. 2001). The end of the pathway is the delivery of internalised ligands to
lysosomes, where they are degraded.
1.3.2 ASGPR subunits
The human ASGPR is a type 2 transmembrane protein made up of two types of
subunits, each of which consists of a short N-terminal cytoplasmic tail, an internal,
uncleaved signal sequence and an extracellular region consisting of a neck region and a
single C-terminal CRD (Fig. 1.3). Chemical crosslinking experiments have suggested
that in vivo, the functional asialoglycoprotein receptor is a hetero-oligomer (Bischoff et
al. 1988) formed by the two subunits identified as ASGPR-1 and ASGPR-2, which 
appeared to interact through their neck regions in the form of a coiled-coil of α-helices
(Bider et al. 1996). However the exact organisation has never been fully defined. Some
possible arrangements are depicted in Fig. 1.3. The molar ratio indicates that ASGPR-1 
is more abundant than ASGPR-2 (Bischoff and Lodish 1987), suggesting that the
minimum hetero-oligomer should be a heterotrimer formed by two ASGPR-1 and one
12
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ASGPR-2 subunits. However, it has been found that the ratio of major to minor
subunits is 2:2 when they oligomerise in vitro (Bider et al. 1996). One model suggests
the formation of a trimeric core of ASGPR-1 to which up to three ASGPR-2 subunits
are attached (Weigel and Yik 2002). The possibility that the ASGPR-2 subunits are
annexed to an ASGPR-1 core arose from proteolytic studies of the rat receptor showing 
that ASGPR-2 was easily removed from the complexes, while ASGPR-1 remained at
least trimeric (Ruiz and Drickamer 1996). 
It has been shown for the mouse homologue that both subunits are required for the
formation of high affinity receptors on hepatocytes (Tozawa et al. 2001). Knock-out
mice for MHL-1 were not able to transport the receptor to the cell surface, while MHL-
2-deficient mice were able to express receptors, but at reduced levels. Mice lacking the
expression of functional asialoglycoprotein receptor on the surface of their hepatocytes
have been shown not to be able to internalise exogenous asialoglycoproteins, but no
other abnormality has been detected in their phenotype. However, using competitive in 
vitro degradation, it was found that there are endogenous ligands, other than galactose-
terminating glycoproteins that accumulate in the serum of knock-out mice (Braun et al.
1996). Recently it was discovered that knock-out mice lacking the expression of MHL­
2 accumulate glycoproteins in serum that bear sialic acid α2,6- linked to galactose,
including haptoglobin, a protein highly expressed in serum (Steirer et al. 2009). 
However these ligands might not be the primary ones, as ASGPR shows a higher
affinity for glycans terminating in sialic acid α2,6- linked to GalNAc, all determined by
quantitative western blotting (Park et al. 2003; Park et al. 2005; Steirer et al. 2009). 
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Figure 1.2. Localisation and function of the human hepatic asialoglycoprotein 
receptor. 
A. Shows the expression of the receptor on the basolateral membrane of hepatocytes. B. 
Diagram of the endocytic pathway. 
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General structure 
CRD 
Neck 
Cytoplasmic 
TMD 
tail 
ASGPR-1 trimeric core 
ASGPR-1 
ASGPR-2 
Iso-stoichiometric tetramer 
Figure 1.3. General type 2 receptor structure and different proposed 
stoichiometries forASGPR. 
The first three oligomer models show a trimeric core ofASGPR-1 plusASGPR-2 subunits. 
The other arrangement shows a 2:2 proportion between the subunits. 
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Chapter 1. Introduction
Regarding the human receptor, two isoforms have been reported for ASPGR-1. The
difference between the isoforms is the lack of the transmembrane domain in the most
recently found isoform (ASGPR-1b) (Liu et al. 2010). When localising both isoforms
in hepatoma cells, it is clear that this difference results in a difference in the localisation
of the two proteins. While the canonical isoform (ASGPR-1a) is expressed in the 
plasma membrane, ASGPR-1b is found in intracellular compartments. A soluble
version of ASGPR-1b in complex with soluble ASGPR-2 has been recently suggested
to guide ligands to ASGPR complexes located on the surface of hepatic cells (Liu et al.
2010).
The existence of three different isoforms for ASGPR-2 in humans (ASGPR-2a, 
ASGPR-2b and ASGPR-2c) has been known for some time (Spiess and Lodish 1985; 
Paietta et al. 1992). Of these, only ASGPR-2a does not seem to be functional. ASGPR­
2a is not found on membranes due to the presence of a five amino-acid insertion at the
end of the transmembrane domain, which serves as cleavage signal and results in
ASGPR-2a being found as a soluble version, probably forming complexes with soluble
ASGPR-1b. ASGPR-2b is the canonical sequence and the isoform that is mostly found
forming complexes with ASGPR-1 on membranes, as it lacks the five amino-acid insert.
ASGRP-2c also lacks that five amino-acid insert, as well as 19 amino acids in the
cytoplasmic tail, and its participation in the formation of oligomers and its function as a
lectin have not been clarified. Fig. 1.4 shows an aligment of homologue ASGPR
subunits from human, rat and mouse.
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Cytoplasmic tail
 
ASGPR-1 Human MTKEYQDLQHLDNEESDHH------------QLRK------GPPPPQPLLQ 
ASGPR-1 Rat MTKDYQDFQHLDN-ENDHH------------QLQR------GPPPAPRLLQ 
ASGPR-1 Mouse MTKDYQDFQHLDN-DNDHH------------QLRR------GPPPTPRLLQ 
ASGPR-2 Human MAKDFQDIQQLSSEENDHPFHQGEGPGTRRLNPRRGNPFLKGPPPAQPLAQ 
ASGPR-2 Mouse MEKDCQDIQQLDSEENDHQLSGDDEHGSHVQDPRIENPHWKGQPLSRPFPQ 
ASGPR-2 Rat MEKDFQDIQQLDSEENDHQLIGDEEQGSHVQNLRTENPRWGGQPPSRPFPQ 
TMD
 
ASGPR-1 Human RLCSGPRLLLLSLGLSLLLLVVVCVIGSQN-----SQLQEELRGLRETFSN 
ASGPR-1 Rat RLCSGFRLFLLSLGLSILLLVVVCVITSQN-----SQLREDLRVLRQNFSN 
ASGPR-1 Mouse RLCSGSRLLLLSSSLSILLLVVVCVITSQN—----SQLREDLLALRQNFSN 
ASGPR-2 Human RLCSMVCFSLLALSFNILLLVVICVTGSQSEGHGGAQLQAELRSLKEAFSN 
ASGPR-2 Mouse RLCSTFRLSLLALAFNILLLVVICVVSSQS—----IQLQEEFRTLKETFSN 
ASGPR-2 Rat RLCSKFRLSLLALAFNILLLVVICVVSSQS-----MQLQKEFWTLKETLSN 
Neck
 
ASGPR-1 Human FTASTEAQVKGLSTQGGNVGRKMKSLESQLEKQQKDLSEDHSSLLLHVKQF 
ASGPR-1 Rat FTVSTEDQVKALTTQGERVGRKMKLVESQLEKHQEDLREDHSRLLLHVKQL 
ASGPR-1 Mouse LTVSTEDQVKALSTQGSSVGRKMKLVESKLEKQQKDLTEDHSSLLLHVKQL 
ASGPR-2 Human FSSSTLTEVQAISTHGGSVGDKITSLGAKLEKQQQDLKADHDALLFHLKHF 
ASGPR-2 Mouse FSSSTLMEFGALDTLGGSTNAILTSWLAQLEEKQQQLKADHSTLLFHLKHF 
ASGPR-2 Rat FSTTTLMEFKALDSHGGSRNDNLTSWETILEKKQKDIKADHSTLLFHLKHF 
ASGPR-1 Human VSDLRSLSCQMAALQGNGSERTCCPVNWVEHERSCYWFSRSGKAWADADNY 
ASGPR-1 Rat VSDVRSLSCQMAALRGNGSERICCPINWVEYEGSCYWFSSSVKPWTEADKY 
ASGPR-1 Mouse VSDVRSLSCQMAAFRGNGSERICCPINWVEYEGSCYWFSSSVRPWTEADKY 
ASGPR-2 Human PVDLRFVACQMELLHSNGSQRTCCPVNWVEHQGSCYWFSHSGKAWAEAEKY 
ASGPR-2 Mouse PMDLRTLTCQLAYFQSNGTE--CCPVNWVEFGGSCYWFSRDGLTWAEADQY 
ASGPR-2 Rat PLDLRTLTCQLAFFLSNGTE--CCPVNWVEFGGSCYWFSRDGLTWAEADQY 
Carbohydrate-recognition domain
 
ASGPR-1 Human CRLEDAHLVVVTSWEEQKFVQHHIGPVNTWMGLHDQNGPWKWVDGTDYETG 
ASGPR-1 Rat CQLENAHLVVVTSWEEQRFVQQHMGPLNTWIGLTDQNGPWKWVDGTDYETG 
ASGPR-1 Mouse CQLENAHLVVVTSRDEQNFLQRHMGPLNTWIGLTDQNGPWKWVDGTDYETG 
ASGPR-2 Human CQLENAHLVVINSWEEQKFIVQHTNPFNTWIGLTDSDGSWKWVDGTDYRHN 
ASGPR-2 Mouse CQLENAHLLVINSREEQDFVVKHRSQFHIWIGLTDRDGSWKWVDGTDYRSN 
ASGPR-2 Rat CQMENAHLLVINSREEQEFVVKHRGAFHIWIGLTDKDGSWKWVDGTEYRSN 
ASGPR-1 Human FKNWRPEQPDDWYGHGLGGGEDCAHFTDDGRWNDDVCQRPYRWVCETELDK 
ASGPR-1 Rat FKNWRPGQPDDWYGHGLGGGEDCAHFTTDGHWNDDVCRRPYRWVCETELGK 
ASGPR-1 Mouse FQNWRPEQPDNWYGHGLGGGEDCAHFTTDGRWNDDVCRRPYRWVCETKLDK 
ASGPR-2 Human YKNWAVTQPDNWHGHELGGSEDCVEVQPDGRWNDDFCLQVYRWVCEKRRNA 
ASGPR-2 Mouse YRNWAFTQPDNWQGHEQGGGEDCAEILSDGHWNDNFCQQVNRWVCEKRRNI 
ASGPR-2 Rat FKNWAFTQPDNWQGHEEGGSEDCAEILSDGLWNDNFCQQVNRWACERKRDI 
ASGPR-1 Human ASQEPPLL 
ASGPR-1 Rat AN-----­
ASGPR-1 Mouse AN-----­
ASGPR-2 Human TGEVA--­
ASGPR-2 Mouse TH-----­
ASGPR-2 Rat TY-----­
Figure 1.4. Primary structure of hepatic asialoglycoprotein receptor subunits in 
mammals. 
Alignment indicating the different domains. The amino acids are coloured according to 
their similarity. Yellow indicates similarity > 0.8. Blue or green indicates similarity ≥0.5. 
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1.3.3 Endogenous ligands
To deal with the difficulty of defining endogenous ligands for the
asialoglycoprotein receptor, Weigel (Weigel 1994) proposed that it functions in 
removal of abnormally generated desialylated plasma glycoproteins that occur in non-
homeostatic situations. Grewal et al. (Grewal et al. 2008) proposed that the endogenous
ligands are components of the blood coagulation system, particularly von Willebrand
factor and platelets. These ligands were found after eliminating the function of a
sialyltransferase (ST3Gal-IV), exposing terminal galactose residues that would 
otherwise be unavailable for binding. It was suggested that desialylation of mediators of
thrombosis and coagulation by bacterial sialidases (Corfield 1992) leads to clearance by
the asialoglycoprotein receptor. These desialylated factors would otherwise increase the
probability of coagulation abnormalities that usually occur in severe bacterial infections
(Goldenfarb et al. 1970). Thus, mice that lack the expression of asialoglycoprotein
receptor had shorter survival times when lethally infected by Stretptococcus
pneumoniae (Grewal et al. 2008). 
The interaction evaluated in the studies of Grewal et al. made use of ST3Gal-IV
knock-out mice that glycosylate their proteins in a non-natural way. However, the
genetic manipulation of sialyltransferases has been suggested to emulate other
situations that are present in vivo in which the half-life of ligands in serum would be too
short to be detected (Wahrenbrock and Varki 2006). The idea  that the ASGPR
modulates coagulation in response to bacterial infection represents an elaboration of
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Chapter 1. Introduction
previous suggestions that von Willebrand factor could be a major ligand for the ASGPR
(Sodetz et al. 1978; Ellies et al. 2002).
Interaction of the ASGPR with von Willebrand factor is particularly interesting
since coagulation problems that may arise from it have clinical importance. von
Willebrand factor is a highly glycosylated multimeric protein that is modified with 12
N-linked high-mannose-containing oligosaccharides and 10 O-linked oligosaccharides
per monomer, that jointly account for 19 percent of  the molecular weight of von
Willebrand factor (Jenkins and O’Donnell 2006). von Willebrand factor plays two
essential roles in hemostasis: it participates in the binding of platelets to areas of
damage of the blood vessel wall and it acts as a carrier molecule for procoagulant FVIII.
von Willebrand factor is synthesized as a polypeptide precursor from which the signal
peptide and a 741 amino-acid propeptide that contains domains D1 and D2 are
proteolytically removed. Other posttranslational modifications include dimerization,
glycosylation, sulfation, and mulimerization. von Willebrand factor forms two types of
multimers: small ones secreted by endothelial cells in culture and high-molecular­
weight ones that vary between 10,000 and 20,000 kDa (Furlan 1996).
The diversity of ligands bound by the ASGPR suggests a broader function of the
receptor that would justify the presence of this receptor throughout mammalian
phylogeny. The interaction with von Willebrand factor may not be limited to acute
phase situations. For example, the ASGPR may contribute to the difference in von
Willebrand factor levels in serum of individuals with different ABO blood groups, even
if the glycan array study presented in this thesis would suggest a different scenario to 
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the one that actually happens, with O-type individuals presenting lower concentrations
(Souto et al. 2000). The study of this interaction is important, since it may have
clinically significant effects. The interaction would as well account for the difference of
proportion of individuals having the three different blood group antigens, which has
been suggested to be related to different propensity for pathological conditions and 
differences in susceptibility to infectious agents that have caused high mortality
(Jenkins and O’Donnell 2006). There are some possible ligands with available 
galactose or GalNAc that can be recognised in the recently characterised glycome of
von Willebrand factor (Canis et al. 2010).
Analysis of mice lacking ASGPR-1 showed accumulation of haptoglobin and 
suggested that other ligands may include serine protease inhibitor clade A member 1A,
carboxylesterase, α1-B glycoprotein, inter-α trypsin inhibitor heavy chain 4, IgM and
SAP (Steirer et al. 2009). It was suggested that the ASGPR may buffer the
concentration of these proteins in plasma. It was proposed that the receptor would
almost always be saturated but binding to higher affinity ligands, with terminal
Siaα2,6GalNAc, galactose or GalNAc would still be possible when these less common 
ligands were available.
It was believed previously that the chicken and alligator hepatic lectins were
related to the mammalian ASGPR, but it seems now that they are more related to other
members of the family, probably DC-SIGN, and are not the orthologues in these 
species (Zelensky and Gready 2005). Among mammals, it is clear that the receptor is
quite variable. Studies regarding the specificity in mouse and rat revealed that even
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between these two more closely related species, there are differences in their specificity
(Tsuiji et al. 2002; Coombs et al. 2006). These differences may reflect the need of the
different organisms, the differences arising from the necessity of clearing up different
ligands from serum or the presence of specific parasites.
1.4 The macrophage galactose lectin and its participation in the
recognition of parasitic helminths
The macrophage galactose lectin (MGL) is a macrophage protein that is closely
related to the ASGPR subunits. All the genes of these proteins are localised in the same
cluster on chromosome 17 in humans and 11 in mouse (Fig. 1.5). MGL was discovered
independently in rat peritoneal macrophages by three groups, first by affinity
purification on asialoorosomucoid (Kawasaki et al. 1986), then by affinity purification
from murine peritoneal exudate macrophages, induced by an antitumour streptococcal
125I­preparation (Oda et al. 1988) and finally by autoradiography with 
asialoorosomucoid (Kelm and Schauer 1988). 
1.4.1 MGL in various species
Orthologue proteins have also been identified at the protein level in human and
mouse, and sequences expressing the protein indicate that it is found in other mammals
(Fig. 4.9). Our analysis in different databases, supported by biochemical evidence
reported in this thesis suggest however, that the protein considered to be the orthologue
of MGL in rodents and probably insectivores and chiropters, may have originated in a
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different duplication event to the one that originated the human and most mammalian
proteins. Fig. 1.6 shows the alignment of orthologues in human, rat and mouse.
In mice there are two distinct proteins; mouse MGL1 (mMGL-1) and mouse
MGL2 (mMGL-2), coded by their respective genes. The first one discovered was
mMGL-1, in activated macrophages by affinity purification to β-D-galactose-Bio-Gel
(Oda et al. 1988). mMGL-2 was identified first by BLAST, after which it was cloned
and its biochemistry further studied (Tsuiji et al. 2002). The most obvious difference
between the mouse sequences is a 14 amino acid insertion in the cytoplasmic domain of
mMGL-2. Glycan array studies have established that the rat protein is highly specific
for bi-antennary glycans with terminal galactose or GalNAc residues, including Lewisa 
and Lewisx structures (Coombs et al. 2006). Prefered linkages included galactose bound
to GlcNAc both in β1-4 and in α1-3 configurations, and α1-3 bound to GalNAc.
Terminal GalNAc was recognised preferentially when forming β1-4 linkages to 
GlcNAc.
Human MGL was cloned independently by two groups. It was first cloned from
macrophages by Suzuki et al.(Suzuki et al. 1996). The second group identified a
different isoform of the protein in immature dendritic cells referred to as DC-ASGPR, 
which has an insertion of 27 amino acids and a deletion of 3 amino acids, both in the
neck domain (Valladeau et al. 2001). There are several isoforms (Fig. 1.6), originating
from alternative splicing, as there is only one gene in the human genome related to
MGL. Higashi (Higashi et al. 2002) identified seven different isoforms, resulting from
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deletions in the neck and in the CRD. There are no studies regarding the difference that
arises from these modifications, including possible difference in functions
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Human 
Chromosome 17 
ASGPR-1 ASGPR-2 mMGL-2 mMGL-1 
(Asgr1) (Asgr2) (Mgl2) (Clec10A) 
Figure 1.5. Mapping of asialoglycoprotein receptor genes in human and mouse 
chromosomes. 
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Cytoplasmic tail 
MGL Human 3 MTRTYENFQYLENKVKVQGFKNGP------------LPLQSLLQRLCSGPCH 
MGL Human 2 MTRTYENFQYLENKVKVQGFKNGP------------LPLQSLLQRLCSGPCH 
MGL Human MTRTYENFQYLENKVKVQGFKNGP------------LPLQSLLQRLCSGPCH 
MGL Rat MTMAYENFQNLGSEEKNQEAGKA--------------PPQSFLCNILSWTHL 
mMGL-1 MI--YENLQNSRIEEKTQEPGKA--------------PSQSFLWRILSWTHL 
mMGL-2 MTMRYENFQNLEREEKNQEMRNGDKKGGMESPKFALIPSQSFLWRILSWTHL 
TMD
 
MGL Human 3 LLLSLGLGLLLLVIICVVGFQNSKFQRDLVTLRTDFSNFTSNTVAEIQALTS 
MGL Human 2 LLLSLGLGLLLLVIICVVGFQNSKFQRDLVTLRTDFSNFTSNTVAEIQALTS 
MGL Human LLLSLGLGLLLLVIICVVGFQNSKFQRDLVTLRTDFSNFTSNTVAEIQALTS 
MGL Rat LLFSLGLSLLLLVVISVIGSQNSQLRRDLETLRTTLDNTTSNTKAELQALAS 
mMGL-1 LLFSLGLSLLLLVVVSVIGSQNSQLRRDLGTLRATLDNTTSKIKAEFQSLDS 
mMGL-2 LLFSLGLSLLLLVVISVIGSQNSQLRRDLGTLRAILDNTTSKIKAEFQSLDS 
Neck
 
MGL Human 3 QGSSLEETIASLKAEVEGFKQERQA--------------------------­
MGL Human 2 QGSSLEETIASLKAEVEGFKQERQA--------------------------­
MGL Human QGSSLEETIASLKAEVEGFKQERQAGVSELQEHTTQKAHLGHCPHCPSVCVP 
MGL Rat RGDSLQTGINSLKVEVDDHGQELQAGRGLSQKVASLESTVEKKEQTLRT--­
mMGL-1 RADSFEKGISSLKVDVEDHRQELQAGRDLSQKVTSLESTVEKREQALKT--­
mMGL-2 RADNFEKGISSLKVDVEDHRQELQAGRDLSQKVTSLESTLEKREQALKT--­
MGL Human 3 VHSEMLLRVQQLVQDLKKLTCQVATLNNN---ASTEGTCCPVNWVEHQDSCY 
MGL Human 2 VHSEMLLRVQQLVQDLKKLTCQVATLNNNGEEASTEGTCCPVNWVEHQDSCY 
MGL Human VHSEMLLRVQQLVQDLKKLTCQVATLNNN---ASTEGTCCPVNWVEHQDSCY 
MGL Rat DLSEITDRVQQLGKDLKTLTCQLASLKNN----GSAVACCPLHWMEHEGSCY 
mMGL-1 DLSDLTDHVQQLRKDLKALTCQLANLKNN----GSEVACCPLHWTEHEGSCY 
mMGL-2 DLSDLTDHVQQLETDLKALTCQLANLKNN----GSEVACCPLHWTEHEGSCY 
Carbohydrate-recognition domain
 
MGL Human 3 WFSHSGMSWAEAEKYCQLKNAHLVVINSREEQ*------------------­
MGL Human 2 WFSHSGMSWAEAEKYCQLKNAHLVVINSREEQNFVQKYLGSAYTWMGLSDPE 
MGL Human WFSHSGMSWAEAEKYCQLKNAHLVVINSREEQNFVQKYLGSAYTWMGLSDPE 
MGL Rat WFSQSGKPWPEADKYCQLENSNLVVVNSLAEQNFLQTHMGSVVTWIGLTDQN 
mMGL-1 WFSESEKSWPEADKYCRLENSHLVVVNSLEEQNFLQNRLANVVSWIGLTDQN 
mMGL-2 WFSESEKSWPEADKYCRLENSHLVVVNSLEEQNFLQNRLANVLSWMGLTDQN 
MGL Human 3 ---------------------------------------------------­
MGL Human 2 GAWKWVDGTDYATGFQNWKPGQPDDWQGHGLGGGEDCAHFHPDGRWNDDVCQ 
MGL Human GAWKWVDGTDYATGFQNWKPGQPDDWQGHGLGGGEDCAHFHPDGRWNDDVCQ 
MGL Rat GPWRWVDGTDYEKGFTHWAPKQPDNWYGHGLGGGEDCAHFTSDGRWNDDVCQ 
mMGL-1 GPWRWVDGTDFEKGFKNWAPLQPDNWFGHGLGGGEDCAHITTGGPWNDDVCQ 
mMGL-2 GPWRWVDGTDFDKGFKNWRPLQPDNWHGHMLGGGEDCAHFSYDGRWNDDVCQ 
MGL Human 3 --------------------------­
MGL Human 2 RPYHWVCEAGLGQTSQESH-------­
MGL Human RPYHWVCEAGLGQTSQESH-------­
MGL Rat RPYRWVCEMKLAKDS-----------­
mMGL-1 RTFRWICEMKLAKES-----------­
mMGL-2 RHYHWICETELGKASSAHSPQLIASVP 
Figure 1.6. Primary structure of macrophage asialoglycoprotein receptor subunits 
in mammals. 
The amino acids are coloured according to their similarity. Yellow indicates similarity > 
0.8. Light blue or green indicates similarity ≥0.5. 
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Chapter 1. Introduction
1.4.2 Sugar-binding activity of MGL
Although both mouse proteins bind to galactose- or GalNAc- containing 
structures, mMGL-1 has specificity for Lewisx structure that is not shared by mMGL-2, 
probably establishing secondary contacts with fucose. mMGL-2, on the contrary,
showed a higher affinity for GalNAc compared to galactose, while mMGL-1 does not
show this preference (Tsuiji et al. 2002). The difference in specificity between these
proteins has been explored extensively through point mutations and molecular
modelling (Oo-puthinan et al. 2008). The results suggest that Val228, Ala256, Thr278
and Phe292 are involved in the specificity of mMGL-1. Indeed mutant versions of
mMGL-2 in which the native Arg272 was replaced with Ala bound Lewisx and,
conversely, when the native Ala256 from mMGL-1 was replaced with Arg, mMGL-1
showed higher binding for GalNAc. The strong GalNAc binding of mMGL-2 seems
also to involve Leu244 and His292 (Oo-puthinan et al. 2008).
Human MGL was found to bind galactose or GalNAc in studies with COS-1 
transfectants but showed specificity for GalNAc when using bacterial expression
systems (Suzuki et al., 1996; Iida et al., 1999). Further analysis with glycan arrays
using an MGL-Fc chimera showed that human MGL is specific for terminal α and β­
linked GalNAc residues, having two major ligands: α-GalNAc-Ser/Thr (Tn antigen)
and GalNAcβ1-4GlcNAc (LacdiNAc), followed by GalNAcβ1,4(Fucα1,3)GlcNAc
(fucosylated LacdiNAc or LDNF), LacNAc, Lewisx and the gangliosides GM2 and
GD2, appearing to be more restricted in specificity when compared to the ASGPR (van
Vliet et al. 2005). Tn is expressed in a high proportion of carcinomas and in IgA
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Chapter 1. Introduction
nephropathy and Tn-syndrome (Moreau et al. 1957; Springer et al. 1974; Suzuki et al.
2008). LacdiNAc is more common among human glycans, including pituitary
hormones and glycodelin-A, from amniotic fluid (Green and Baenziger 1988; Dell et al.
1995). LacdiNAc is also abundant in parasitic helminths, including Trichinella spiralis
(Morelle et al. 2000a).
1.4.3 Oligomeric structure
Human and rat MGL are commonly thought to be stable oligomers formed from
only one kind of subunit. As has been proposed for the ASGPR, the neck region would
consist of a coiled coil of α-helices that link to the CRD. However, this structure has
never been proved. In the case of the mouse receptor, because both proteins can be
expressed in the same cell, it is possible that there could be hetero-oligomeric
complexes involving both mMGL-1 and mMGL-2 subunits, as well as homo­
oligomeric complexes (Fig. 1.7).
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Human MGL homo-oligomer 
Mouse mMGL-1 homo-oligomer Mouse mMGL-2 homo-oligomer 
Mouse mMGL-1/2 hetero-oligomer 
Figure 1.7. Proposed assemblies of human and mouse macrophage 
asialoglycoprotein receptors. mMGL hetero-oligomer stoichiometry is just an example 
of possible species, and not the suggestion of its existence. 
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Chapter 1. Introduction
1.4.4 MGL functions
Several functions have been proposed for MGL. It is possible that some
functions are specific to each species, and in the case of mouse, to each homologue. In
the case of humans, it has been shown that MGL binds the mucin-like domain of
filovirus, particularly Zaire virus (Takada et al. 2004). It may be that MGL is used by
filoviruses as a way to enter two of their major targets, macrophages and dendritic cells,
in the same way that the ASGPR is used by Marburg virus to enter hepatocytes.
MGL has also been proposed to be involved in the cellular interactions that
determine localisation and activation of immune cells. Several studies have been made
with mMGL-1 and 2, although many of these made use of antibodies that do not
distinguish which of the two proteins was being detected (van Vliet et al. 2008). Cells
that express mMGL-1/2 have been shown to migrate to lymph nodes in hypersensitivity
tests (Chun et al. 2000). These cells are found in the nodes in an amount proportional to
the efficacy of the sensitisation. Cells expressing mMGL-2 have been shown to 
endocytose antigen and display a dendritic cell morphology within the T cell cortex,
thus seeming to take part in antigen presentation. The migration of macrophages from
skin is inhibited by antibodies to mMGL-1/2, indicating a function of mMGL in
migration of antigen-presenting cells from dermis to lymph nodes where they
accumulate in the subcapsular sinus, interfollicular regions and around high endothelial
venules (Kumamoto et al. 2004). It has been suggested that sialoadhesin, identified as a
counter-receptor for mMGL-1, regulates the localisation of cells expressing it within
lymph nodes (Tsuiji et al. 2004). In humans, the only counter-receptor identified is
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Chapter 1. Introduction
CD45 (van Vliet et al. 2006). MGL preferentially binds to CD45B, an isoform present
in antigen-experienced effector T cells and it seems that the specific glycosylation of
CD45 could influence several immunological pathways through an interaction with
MGL. Studies with knockout mice reveal that mMGL-1 is not required for normal
lymphocyte development but it may be involved in clearance of apoptotic cells and in
granulation tissue formation, probably by secreting interleukin-1α, regulating the
cellular influx and the activation of fibroblasts in preparation for tissue remodelling
(Sato et al. 2005).
MGL is also involved in tumour recognition. Cells expressing mMGL-1 migrate
towards metastatic tumour nodules, probably recognising specific tumour glycans such
as Tn (Imai et al. 1995). Antigen-presenting cells expressing mMGL are part of the 
host defence against tumours. In humans, MGL recognises MUC1 in metastatic tumour
cells when it has altered glycans (Saeland et al. 2007). It has been suggested, however, 
that dendritic cells expressing MGL promote tumour progression (van Vliet 2007). 
1.5. Diversity among C-type lectin-like proteins
In addition to the family of type 2 transmembrane C-type lectins to which the 
ASGPR and MGL belong, there are many other groups of proteins that can be classified
in the C-type lectin-like superfamily. Fig. 1.8 summarises the organisation the C-type
lectin-like proteins present in vertebrates, other than distantly related proteins of snake
venom and those associated with eggshell formation. Short descriptions of these groups
are presented in the following section.
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Selectins 
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Mannose receptor 
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Figure 1.8. Diversity of C-type lectins. Figure drawn by Kurt Drickamer. 
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Chapter 1. Introduction
1.5.1 Type II receptors: asialoglycoprotein and dendritic cell receptors
The asialoglycoprotein receptors studied in this thesis belong to a very well
defined family comprised of type II transmembrane proteins. Each of them contains a
short N-terminal cytoplasmic tail and a single pass transmembrane domain. The
extracellular domain (ECD) is formed by a neck region of variable length and a C-
terminal CTLD. Although the family seems to be well defined in evolutionary terms,
with clear connections between its members, the family is the largest among C-type
lectins and their function and specificity vary enormously (Drickamer 1999). Two main
groups can be considered, based on sequence comparisons presented in this thesis. One
includes the ASGPRs and MGL, as well as langerin, the kupffer cell receptor and the
scavenger receptor C-type lectin, while the other contains DC-SIGN (dendritic cell-
specific intercellular adhesion molecule-3-grabbing non-integrin), together with the
macrophage C-type lectin and related macrophage receptors.
Our review of the available protein sequences and also of genes that appear to
encode asialoglycoprotein receptors (ASGPR and MGL) suggests that this group of
proteins are present at least all along the therians, as there are homologues in 
marsupials. It is clear that the genes that code for the subunits that form these proteins
originated by duplication events. All of these receptors function as lectins, having a
central role in the recognition of both endogenous and pathogen glycans, although the
specific biology of some of them is still poorly understood. 
Langerin is a receptor specific for mannose, GlcNAc and fucose (Stambach and
Taylor 2003) located on the surface of Langerhans cells. It cycles between plasma
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Chapter 1. Introduction
membrane and early endosomes and it is involved in the formation of Birbeck granules
(Valladeau et al. 2000). It seems that langerin participates in antigen uptake by
Langerhans cells and it has been shown to act as a barrier to HIV-1 transmission (de
Witte et al. 2007). Langerin is related to the Kupffer cell receptor, a lectin discovered in
rat liver that may have some overlapping functions with ASGPRs in some mammals.
The Kupffer cell receptor binds GalNAc and galactose without the selectivity found in 
rat ASGPR (Fadden et al. 2003) and has been proposed to be involved in the clearance
of galactose- and fucose-terminated glycoproteins from circulation (Haltiwanger et al.
1986). However, while the Kupffer cell receptors are found in both rat and mouse, the
human gene appears to be a pseudogene. The gene is incomplete and no mRNA
expression has been detected (Fadden et al. 2003).
A recently discovered member of type II C-type lectins is the scavenger
receptor C-type lectin (SRCL). It is a receptor widely expressed in endothelia and has
been demonstrated to bind oxidised low density lipoprotein particles and Gram-
negative bacteria, through a collagen-like region (Ohtani et al 2001; Nakamura et al.
2001). It binds the LewisX epitope primarily via the galactose residue and mediates the 
endocytosis and degradation of specific glycoprotein ligands bearing this epitope
(Coombs et al. 2005; Graham et al. 2011).
DC-SIGN is a receptor expressed by dendritic cells that binds high-mannose
oligosaccharides found on viruses, as well as Lewisx and related structures. It is
involved in endocytosis and has two roles, as a recycling receptor and as a mediator of
T cell adhesion (Steinman 2000). DC-SIGN acts as a receptor for human
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Chapter 1. Introduction
immunodeficiency virus, although on dendritic cells it does not mediate infection but
serves to carry the virus from the periphery to lymph nodes, where it is presented to its
target T cells (Geijtenbeek et al. 2000).
The DC-SIGN-related protein, DC-SIGNR, is also referred to as L-SIGN,
denoting the fact that it is expressed on sinusoid endothelial cells of liver and lymph
nodes. It shows with DC-SIGN, the ability to bind high mannose oligosaccharides, but
it does not bind Lewisx and it does not appear to be an endocytic receptor. Its function
is not well understood (Guo et al. 2004).
LSECtin is a a type II integral membrane protein of 40 kDa and is expressed in
liver and lymph nodes, particularly in sinusoidal endothelial cells, that also express DC­
SIGNR (Liu et al. 2004). Its binding to low molecular weight ligands is one of the
strongest among all C-type lectins, with the best ligand being the disaccharide
GlcNAcβ1-2Man (Powlesland et al. 2008), a motif that can be seen in its main glycan
ligands when studied with glycan arrays.
There are other members of this subfamily with less well defined glycan­
binding activity, such as macrophage-inducible C-type lectin (Mincle), a receptor
expressed in activated phagocytes which senses damaged cells and binds to pathogens
(Yamasaki et al. 2008). The related dendritic cell immunoreceptor (DCIR) group
consists of proteins related to DCIR, a protein expressed by neutrophils (Kanazawa et
al. 2004). The CRD of DCIR contains sequences characteristic of galactose-binding 
lectins, but no glycan ligands have been identified. It acts as an inhibitory receptor via
an intracellular immunoreceptor tyrosine-based inhibitory motif, pairing with another
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member of the family, DC immunoactivating receptor (DCAR). Blood dendritic cell
antigen-2 (BDCA-2) is a protein related to DCAR which is involved in transducing 
signals to regulate cellular functions. Mincle and the DCIR group are related, together
with mouse macrophage C-type lectin (MCL), a protein detected only in macrophages
in mouse (Balch et al. 2002). All these proteins have been proposed to participate in
recognition events on macrophages and dendritic cells.
1.5.2 Collectins
Collectins are involved in the innate immune system, directly binding pathogen
glycans, initiating the complement pathway, and facilitating phagocytosis (Håkansson 
and Reid 2000).  Mannose-binding protein, which provides the prototype for the
description of CTLD, is a member of the collectin family, which also includes
pulmonary surfactant proteins. The name for the family makes reference to the fact that
they present an N-terminal collagen-like region and a C-terminal CRD. Linking the
collagen-like domain are heptad repeats that form coiled-coil structures and are
essential for the formation of oligomers as discussed in Section 1.6 (Håkansson and
Reid 2000). 
1.5.3 Selectins
The selectin family, found exclusively in vertebrates, includes P-, L- and E­
selectin (Springer 2009). Although located in different cell types, such as platelets,
leukocytes and endothelial cells, they all share similar and overlapping functions,
mediating the initial attachment and rolling of leukocytes during inflammation, weakly
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Chapter 1. Introduction
binding to their target glycans. The selectins are all type I transmembrane proteins in
which the extracellular portion consists of an N-terminal CRD connected to the
transmembrane domain through a set of EGF-like and Sushi domains (Springer 2009). 
1.5.4 Mannose receptor family
The macrophage mannose receptor is the prototype for a family of receptors that
present multiple CTLDs. The mannose receptor functions in endocytosis of soluble
glycoproteins released at sites of inflammation and also acts as a pathogen recognition
receptor that binds bacteria and fungi (Apostolopoulos and McKenzie 2001). It is
anchored to the membrane in a type I transmembrane orientation and is characterised
by the presence of a ricin-like cysteine-rich domain in the C-terminus, followed by a
fibronectin domain and eight CTLDs, all in the extracellular portion of the protein. Just
one of the CRDs in the mannose receptor has carbohydrate-binding function on its own,
although the others seem to be essential for binding to ligands with high affinity
(Taylor and Drickamer 1993). The ricin-like domain (R-type CRD) also binds glycan
ligands, specifically those with terminal galactose-sulphate groups (Liu et al. 2000). 
Although the other members of the family are organised in the same way as the
mannose receptor and share the ability to rapidly internalise into the cell, they have
different ligand specificity and only Endo180 has sugar-binding activity (East and
Isacke 2002).
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1.5.5 Proteoglycans
The lectican family of proteoglycans is another well-defined group that contains
C-type CRDs with sugar-binding activity (Yamaguchi 2000). Each member is
characterised by the presence of an immunoglobulin-like domain near the N-terminus
and two link protein-like tandem repeats, followed by a highly diverse central domain
where there are multiple glycosaminoglycan attachments sites. The C-terminal region is
where the CRD is located between one or two epidermal growth factor domains and a 
complement regulatory protein-like domain. The lecticans are expressed in connective
and neural tissues in a very specific way and, apart from aggrecan being an essential
structural part of cartilage, they seem to play essential roles in embryo development and
in the formation of neurites (Yamaguchi 2000). 
1.5.6 Layilin-family
Chondrolectin and layilin are type I transmembrane proteins in which a C-
terminal CTLD is separated from the transmembrane domain via a short neck sequence
(Bono et al. 2001; Weng et al. 2003). Layilin, which is reported to bind hyaluronan, is
expressed in several cell types and may have a role in cell-matrix adhesion, as
endocytic receptor or in the transmission of signals between the extracellular matrix
and the cytoskeleton (Bono et al. 2001). Chondrolectin function is unknown and it has
not been shown to bind hyaluronan (Weng et al. 2003).
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1.5.7 Reg group
Lithostathine or Reg1 (Regenerating protein-1) is a member of a family
identified as the Reg group. Except Reg4, all of its members are located in one gene
cluster, both in humans and mouse (Miyashita et al. 1995; Abe et al. 2000). None of its
members has a classic motif for binding of Ca2+ and have not been shown to bind 
carbohydrates. They are composed of single, independent CTLDs and they act as
growth factors. They also seem to be involved in inflammatory pathological processes
and in the control of bacterial flora in the intestine (Zhang et al. 2003). Lithostathine
CTLD forms amyloid fibrils that may have a function at pancreatic level but seem to be
linked to early stages of Alzheimer’s disease (Duplan et al. 2001). 
1.5.8 Tetranectin family
Tetranectin members are soluble proteins with long N-terminal α-helical
domains and C-terminal CTLDs that are involved in tissue regeneration and
mitogenesis (Mio et al. 1998; Westergaard et al. 2003). The family comprises three
members: tetranectin, stem cell growth factor and CLECSF1. They are structurally
related to collectins because the two families share a similar arrangement of C-terminal 
domains.
1.5.9 Natural killer cell receptors
A large group of proteins in the C-type lectin superfamily constitute the natural
killer receptors. These are proteins expressed on the surface of natural killer cells,
which are lymphoid cells with cytolytic activities against tumor or virally infected cells
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that can be discriminated from normal cells by natural killer receptors (Lanier 1998; 
Yokoyama 1998). Some of these receptors have also been found on other
haematopoietic, endothelial and hepatic cells and they are apparently exclusive to 
vertebrates, although there are similar sequences predicted from a urochordate
(Khalturin et al. 2003). The folding of CTLDs in these receptors is quite divergent from
the canonical fold. For example, CD 94 lacks helix α2 even though some of the amino
acids needed to form the helix are conserved and the loop that is in its place participates
in the formation of dimers (PDB ID 1B6E) (Boyington et al. 1999). 
1.5.10 Polycystin
Polycystin is a large multidomain protein involved in cell-cell and cell-matrix
interactions, regulating the cell cycle and the transcription of differentiation-related
genes. It is found in cell adhesion and junctional complexes (Weston et al. 2003). 
1.5.11 Attractin
The group of attractin contains two highly similar proteins in vertebrates,
attractin and attractin-like-1. Both are type I transmembrane domains, with large
extracellular domains. Orthologues for these proteins have been found in invertebrates,
although in the case of Caenorhabditis elegans the orthologues do not contain a CTLD. 
In mammals, attractin and attractin-like-1 seem to have overlapping functions. Both are
expressed by hematopoietic cells and attractin functions as a co-receptor for Agouti, a
regulator of hair pigmentation (He et al. 2001). They also affect appetite and metabolic 
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rate and they seem to be involved in the protection against neurodegenerative processes,
because they play a role in the myelination process (Kuramoto et al. 2001). 
1.5.12 CTLDs with acidic necks
Two distinct groups of proteins have been identified in what is classified as
CTLDs with acidic necks. The eosinophil major basic protein (EMBP) group has two
members, in both mouse and humans (Plager et al. 1999; Macias et al. 2000). These
proteins are soluble and contain highly basic CTLDs and glycosylated acidic pro­
peptides, which are cleaved in the active forms. Amongst their functions is to be part of
the crystalline core of eosinophil primary granules, where EMBP is deposited in the
form of insoluble polymers (Swaminathan et al. 2001). It is a cytotoxic agent that
protects against parasites and it is involved in hypersensitivity reactions. Bimlec
constitutes the unique member of the other group. It is a type I transmembrane protein,
with an unknown function. Bimlec was discovered in Hodgkin’s lymphoma cells,
where it is expressed in fusion with DEC-205, a member of the macrophage receptor
group (Kato et al. 2003).
1.5.13 Other vertebrate C-type lectins
Three other recently suggested groups via sequence comparison are DGCR2, 
SEEC and CBCP/Frem1/QBRICK groups (Zelensky and Gready 2005). The only
member of the first family, DGCR2 is an integral membrane protein which contains a
von Willebrand domain and a low density lipoprotein-receptor domain in addition to
the CTLD, which does not contain characteristic Ca2+-binding motifs (Kajiwara et al.
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1996; Taylor et al. 1997; Spiegel et al. 2006). Although its function is still unknown, 
DCCR2 is probably involved in cell-cell or cell-matrix interactions (Spiegel et al. 2006). 
The SEEC group contains CLEC18C and Nowa from Hydra (Szyperski et al. 1998; 
Engel et al. 2002). CLEC18C comprises a sperm-coating glycoprotein domain, two 
EGF-like domains and the CTLD domain (Szyperski et al. 1998). The SEEC family is
conserved in vertebrate phylogeny (Zelensky and Gready 2005). The last group,
CBCP/Frem1/QBRICK was created to accommodate QBRICK protein and its
homologues, in which the CTLD fold was only recently identified. Its members contain 
a CTLD that lacks the residues that are needed to bind Ca2+ and has a short major loop.
CBCP group members are essential in embryo development where they mediate 
basement membrane adhesion and to function as an adhesive ligand for skin and hair
follicles cells (Short et al. 2007; Petrou et al. 2008).
1.5.14 Other functions of C-type lectins and their presence in other taxa
Although they are almost exclusively metazoan proteins, foldings similar to C-
type lectins have been found in adhesion and toxic proteins from Escherichia coli, such 
as intimin and invasin from Yersinia pseudotuberculosis, as well as some viral proteins
(Hamburger et al. 1999; Higgins et al. 1999). Although the folding is similar between
bacterial and animal lectins, it is likely that the high difference at sequence level means
that their origin is distinct and therefore the folds originated by convergent evolution. 
Viral proteins however, contain C-type lectin domains that show significant similarity
to mammalian C-type lectins. However, it is known that viruses, as molecular parasites,
integrate host genetic material into their own and so, these would be cases of horizontal
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Chapter 1. Introduction
transmission, as may be the case of algal and plant proteins that contain CTLDs
(Zelensky and Gready 2005). 
Amongst invertebrates, CTLDs take part in diverse functions, such as the
previously mentioned role in their defence system as demonstrated by the discovery of
immulectin from Manduca sexta, that plays a similar role to that of mannose-binding
protein amongst vertebrates (Yu et al. 1999). CTLDs are also part of regulatory
proteins in poriferans, platyhelminthes and cnidarians. In the freshwater cnidarian
genus Hydra, the protein Nowa contains a CTLD and it is involved in the formation of
nematocysts, its specialised urticant cells (Engel et al. 2002)
A function of CTLDs that is related to their ability to bind Ca2+ has been
exploited in biomineralising proteins. It has been shown that lustrin and perlucin from
nacre of abalones contain CTLDs that bind glycans (Weiss et al. 2000). CTLDs have
also been detected in the organic matrix of echinoderm spicules, but without glycan
binding properties. In birds, C-type lectins, such as ovocleidin may participate in the
formation of the eggshell, although these proteins are not lectins either, i. e. do not bind
glycans (Nys et al. 2004). This function is also present in mammals as lithostatine
possibly regulates the nucleation and crystal growth of calcium carbonate in human 
pancreas. Lithostatine, however does not show relation to the bird proteins and the
function is a product of convergent evolution. 
The properties of CTLDs have been exploited in unusual ways by vertebrates.
In snakes they have been found as components of venoms. Several groups of CTLD
containing proteins have been recruited amongst snakes (Fry and Wüster 2004), and 
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Chapter 1. Introduction
only some of them bind glycans. Apparently the origin of these groups is
phylogenetically heterogeneous, and their activities may include binding to platelet
surface glycans and acting as anticoagulants or procoagulants (Ogawa et al. 2005). In
some fish from cold waters, the site that would correspond to the glycan-binding site in
lectins is used to bind ice and they fuction as antifreezing elements (Ewart and Fletcher
1993). 
1.6 Carbohydrate binding principles 
Even if the CTLDs have functions other than binding carbohydrates, it seems
that this function is the basal one as it is present in CTLDs throughout animal
phylogeny. Many interactions involved in the binding to carbohydrates take place via
Ca2+ ions, particularly, the one in site 2 (Fig. 1.9). Five amino acids are involved in the
coordination of this ion and they can be grouped in two highly conserved motifs
(Drickamer 1993a). The first is the QPD/EPN motif, which is located in the long loop.
In both versions of this motif, QPD in the case of galactose-binding receptors or EPN in
the case of mannose-binding receptors, the two carbonyl side chains of glutamine and 
aspartic acid or glutamic acid and asparagine are separated by a cis–proline, residue
that positions the backbone structure so that the carbonyl groups can coordinate the
Ca2+ (Drickamer 1993b). The second motif is the WND motif, located in strand β4. 
This motif is also highly conserved, with the asparagine and aspartic acid residues
coordinating the Ca2+. The final amino acid involved in Ca2+ coordination is a
glutamate residue, corresponding to Glu252 in ASGPR-1 (Fig. 1.9). To date, no other
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Ca2+-binding sites seem to be involved in glycan-binding and the presence of motifs
associated to it are good, although not infallible, predictors of lectin activity (Drickamer
and Taylor 2003).
The mechanism of carbohydrate binding has been studied extensively using 
different techniques, including X-ray crystallography and NMR, with the help of
mutant models. The first description that included structural data was the X-ray 
structure of rat MBP-A in complex with an oligomannose glycan linked to an
asparagine residue (Weis et al. 1992). Since that description, every study has concluded
that carbohydrates are bound through coordination bonds with the Ca2+ in site 2. The
carbohydrate also forms additional hydrogen bonds with acidic and amide groups of the
amino acids coordinating the Ca2+. The most important contacts almost invariably
involve the 3- and 4-OH of pyranose residues (Weis and Drickamer 1996).
There are two major classes of sugar binding sites. CRDs that show specificity
for mannose or GlcNAc, which have equatorial 3- and 4-OH groups, contain the EPN
motif. CRDs that bind galactose or GalNAc, which have equatorial 3-OH and axial 4­
OH groups are characterised by the motif QPD (Drickamer 1992). The second group is
also characterised by the presence of an aromatic residue (Trp243 in Fig. 1.9) that
packs against the hydrophobic B face of the carbohydrate. In ASGPR-1, this residue is
held in place by a region rich in glycines located in the long loop. In both mannose- and
galactose-binding CRDs, the carbohydrate can be bound in two orientations with a
difference of 180° rotation, in a symmetry axis that relates the 3- and 4-OH, swapping 
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Chapter 1. Introduction
them, without any change in the general binding scheme (Poget et al. 1999; Ng et al.
2002; Walker et al. 2004). 
There are additional contacts established between the ligands and the CRDs,
making the proteins more selective for those glycans that can establish that these
secondary contacts. In the case of ASGPR-1, the long loop forms a hydrophobic pocket
that makes secondary contacts for GalNAc and results in the observed preference of
this receptor for GalNAc over galactose (Kolatkar et al. 1998). 
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GalNAc 
Trp243 
1 5 
6 
8 
7 
2 4
3 
Asp241 
Gln239 
Ca
2+ 
Glu252 
Asn264 
Asp265 
ASGPR-1 ----------CPVN----WVEHERSCYWFS---RSGK----------AWADADNYCRLED 
Mutant MBP AIEVKLANMEAEINTLKSKLELTNKLHAFSMGKKSGKKFFVTNHERMPFSKVKALCSELR 
ASGPR-1 AHLVVVTSWEEQKFVQHHIGPVNTWMGLHDQ--NGPWKWVDGTDYETGFKNWRPEQPDDW 
Mutant MBP GTVAIPRNAEENKAIQ-EVAKTSAFLGITDEVTEGQFMYVTGGRLT--YSNWKKDQPDDW 
ASGPR-1 YGHGLGGGEDCAHFTDDGRWNDDVCQRPYRWVCETEL 
Mutant MBP YGHGLGGGEDCVHIVDNGLWNDDSCQRPYTAVCEFPA 
Figure 1.9. Structural alignment of ASGPR-1 CRD (PDB entry 1DV8, cyan) and 
mutant human MBP bound to GalNAc (PDB entry 1FIH, magenta). 
Amino acids involved in the coordination of Ca 
2+ 
and binding of ligand are tagged in the 
figure and highlighted in the corresponding sequences. Numbers in the figure 
correspond to PDB entry 1DV8. 
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1.7 Engineering glycan-binding sites as a tool for understanding the 
mechanism of glycan-binding
Much of what is known about the principles of glycan binding has been
explored using site-directed mutagenesis. In the first experiments of this kind, the
specificity of MBP-A was re-engineered by changing the EPN binding-site motif to
QPD, resulting in binding of galactose (Drickamer 1992; Iobst and Drickamer 1994; 
Iobst et al. 1994). This specificity was increased by adding the tryptophan that packs
against the carbohydrate ring (Iobst and Drickamer 1994; Iobst et al. 1994). Additional
experiments explained at least partially the reason behind the preference for GalNAc
over galactose seen in ASGPR-1, since emulating the hydrophobic pocket for binding
the acetamido groups by adding a histidine residue to the galactose-binding variant of
MBP results in increased affinity for GalNAc (Kolatkar et al. 1998). The subsequent
elucidation of the structure of human ASGPR-1 CRD by X-ray crystallography (Meier
et al. 2000), showed that the amino acids involved in these interactions are localised in 
almost the same place as in the native ASGPR-1, as can be seen in the structural
alignment in Fig. 1.9.
Even though much is known about the basis of carbohydrate binding, there are
still questions to be solved. For example, it seems that the main difference between
EPN and QPD is the symmetry between proton donors and acceptors across the binding 
site, which is asymmetrical for EPN and symmetric for QPD. However, there is no
clear evidence of why that difference may cause the specificity (Kolatkar and Weis
1996). It has also been observed that E- and P-selectins, which possess the EPN
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Chapter 1. Introduction
distribution, can interact with a combination of axial 3-OH and equatorial 4-OH in
fucose (Cooke et al. 1994; Sprengard et al. 1995), which indicates that we still are
ignorant about the stereochemical basis of the specificity of CTLDs. One of the ways to 
complement the information available would be the study of mutants that could reverse
what has been made in previous mutations. One of the strategies employed in the work
presented in this thesis made use of such a mutant, engineering the binding site of
ASGPR-1 to resemble a mannose-binding CRD.
1.8 Differences in the oligomerisation pattern of C-type lectins
Many C-type lectins are oligomers and one of the aims of this thesis is to obtain
insight into how the quaternary structures of two receptors may allow them to achieve
their specificity and affinity. Figs. 1.10 and 1.11 summarise some key modes of
oligomer formation. Some interactions occur via the domains that contain the CTLD.
This possibility first described for a truncated version of MBP, where the hydrophobic
surfaces of the CRDs interact, as the helical neck domain was removed. In this
interaction, the most important contact takes place between the N-terminal β-strands,
with secondary contacts between the C-terminus of helix α2 and the C-terminal β­
strand (Ng et al. 1996). A galactose-binding lectin from the tunicate Polyandrocarpa
misakiensis forms dimers, in a similar fashion, with more extensive contact involving 
α2 (Poget et al. 1999). 
More recently described structures have shown further possibilities for the ways
that CTLDs interact. Snake venom lectins, coagulation factors IX and X-binding 
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protein, and coagulation factor IX-binding protein, from Trimeresaurus flavoviridis 
form dimers interacting in a fashion that has been termed head-to-head, as the
interaction involves a domain swap of the long loop between interacting monomers
(Mizuno et al. 1997; Mizuno et al. 1999). Additional interactions are possible, as in the
case of Crotalus atrox venom lectin, which binds galactose, which is a decamer
consisting of two 5-fold symmetric pentamers. Each monomer is covalently linked
through disulphide bridges to a monomer in the neighbouring pentamer. The complex
maximises the surface distribution of the ten receptor sites in a way that suggests its
participation in multivalent interactions that would lead to platelet aggregation (Walker
et al. 2004). 
As noted previously, there are several C-type lectins in which CRDs are
adjacent to α-helical structures that can be described as neck regions. It has been
suggested that in many of these proteins the main interactions for the formation of
oligomers take place in the neck region, mainly through the formation of coiled-coil
structures, aided by CRD-CRD contacts. The resolution of the trimeric structure of
MBP revealed contacts between the hydrophobic top of the neck and the CRD of the
adjacent monomer and these neck interactions are enough to stabilise the oligomer even
in the absence of the collagen domain of the protein (Weis and Drickamer 1994). 
Similar contacts are established in trimeric pulmonary surfactant-associated protein D
(SP-D) and in tetranectin (Nielsen et al. 1997; Håkansson et al. 1999). 
In contrast, in langerin trimers the CRDs interact directly with the helical neck
region in the same subunit, so although the arrangement looks superficially similar, the
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Chapter 1. Introduction
details of the neck-CRD interactions are actually quite different (Stambach and Taylor
2003; Feinberg et al. 2010). This alternative arrangement is also seen in SP-A (Head et
al. 2003). 
Still greater differences have been observed with DC-SIGN and DC-SIGNR
(Feinberg et al. 2005; Feinberg et al. 2009). Instead of forming trimers, these two
proteins form tetramers through interactions of their neck regions. Their necks are long 
structures formed of tandem repetitions of sequences that form coiled-coil α-helices of
a heptad pattern of hydrophobic residues that pack against each other. The helical
regions are interrupted by small non-helical regions that contain proline residues. In 
these proteins, there are very limited interactions of the CRDs with each other and they
appear in different orientations in different crystal structures, suggesting that they are
flexibly positioned. Differences in the C-terminal repeat of the necks cause DC-SIGN 
and DC-SIGNR tetramers to be different. The final repeat in DC-SIGN is more similar
to the other repeats and forms a closer packed tetramer, while the final repeat in DC­
SIGNR is more opened up. These differences give the two proteins different
orientations of the CRDs which probably cause differences in specificity. Recently it
was discovered that differences in the sequence of the neck repeats can cause a
difference in the compressibility of DC-SIGNR which is responsible for variability in
its ability to bind glycans (Leckband et al. 2011). The length of the neck is also 
important, because when it is shortened in certain genetic variants of DC-SIGNR it 
might be too close to the cellular membrane to be able to bind pathogens (Liu et al.
2006).
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Figure 1.10. Variability in the geometric arrangement of domains in C-type lectins. 
Examples of dimeric and trimeric forms. CRDs are represented as ellipses and Ca 
2+ 
binding sites are represented as dots. Arrows point to carbohydrate-binding sites and 
thick bars represent zones of interaction with proteins. Elements of secondary structure 
are marked as � for � helices, � for � strands and L for loops. Symmetry axes are indicated 
by dotted lines. NK, natural killer; MBP, mannose-binding protein. Figure drawn by Kurt 
Drickamer. 
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Type 2 receptors 
DC-SIGNR (1XAR) 
Lateral view Top view 
Figure 1.11. Different quaternary arrangements of C-type lectins. 
Higher molecular oligomers of collectins and type 2 receptors are shown in the first 
column. Crystallographic structures of primary oligomers are shown from side view in the 
second column and the third column corresponds to top view. The distances are 
calculated between the main binding site for Ca 
2+ 
(green spheres or purple spheres in the 
case of DC-SIGNR). 
53
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1.9. Effects of clustering and branching in glycan binding  
There are many ways in which a receptor can enhance its avidity/specificity and
the strength with which it binds a glycan. Many of these possibilities were recently
analysed, using engineered glycoproteins and fragments of C-type lectins (Coombs et
al. 2010). The different possibilities analysed (Fig. 1.12) revealed that the affinity of the
receptor can be increased up to 3,000 times compared to simple binding of a
monosaccharide to the CRD.
There are two general ways in which the affinity for a ligand can be enhanced.
Secondary contacts in extended binding sites seem to be responsible for binding with
higher affinity to branched glycans, as was observed in solid phase binding assays. This
includes small terminal elaborations, such as the fucose depicted in Fig. 1.12. The
interaction also depends on the surrounding environment of the glycan as secondary
contacts are probably established with the aglycone to which it is attached, including 
proteins.
Binding is also enhanced when there are several glycan modifications in one 
glycoprotein ligand. The source of this enhancement may lie in the ability of multiple
subunits of receptors to interact with additional glycans. This can be related as well to
interactions bridging several glycans when they are closely distributed in a membrane.
It could also happen, as has been suggested for ASGPR (Rice et al. 1990), that different
subunits would interact with different branches in a single glycan. However it seems
that the enhancement given by interactions between multivalent glycans and oligomeric
receptors is quite modest.
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There have been several studies highlighting the importance of the formation of
lattices in lectin-glycan interactions, particularly amongst galectins (Brewer 2002). This
results in an increase of activity only in the cases where the lectin is soluble. Although
the formation of three-dimensional lattices is not possible with receptors anchored to
membranes, studies with immobilised receptors have shown that there is still a 1.5-fold 
increase in the activity that could be partially responsible for the improved activity
shown by ASGPR when glycans with multiple branches interact with the receptor on
hepatocytes (Lee and Lee 2000).
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Figure 1.12. Sources of enhancement of affinity in glycoprotein-receptor 
interactions. 
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1.10 Biology of Trichinella 
One topic of this thesis is an exploration of the biological function of the
ASGPR and MGL. As noted previously, MGL seems to be involved in recognising 
glycans from pathogens. In particular, interaction with the trematode Schistosoma 
mansoni has been described (van Vliet et al. 2005). It is known that Trichinella spp.,
which causes trichinellosis, interacts with macrophages in several ways, including
inhibition of their migration by the parasite (Tan et al. 2001). The monocyte mannose
receptor is involved in some of these interactions but a role for MGL is investigated
here (Gruden-Movsesijan and Milosavljevic 2006).
Trichinellosis is an extended parasitosis, caused by the members of genus
Trichinella, parasitic nematodes in the order Trichocephalidae (Mitreva and Jasmer
2005). These organisms have unusual ways of living among Nematoda, as they are
intracellular parasites during some stages of their lives. Trichinella spp. have the widest
range of potential hosts, infecting mammals, including human beings, birds of prey and
crocodiles in every region of the planet save deserts (Pozio 2001).
Except T. zimbabwensis, all species are able to infect human beings (Dupouy-
Camet 2000). Early hominids may have acquired the parasite when they became
carnivorous and domestication of pigs created a permanent reservoir from which most
modern infections originate. Fire has limited the infections, as cooking of meat destroys
the parasite. Freezing is another method of prevention, except for T. nativa. 
Trichinellosis is most common in rural South America and Asia, although it is
uncommon in urban areas. Nevertheless, there is a high number of patients reported to 
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have the sickness in the European Union, mostly in France, Germany, Spain and Italy.
Infection by the parasite appears to be re-emerging due to several factors, such as
international trade of meat and increased consumption of wild game. T. britovi is the
form mostly found in European and Asian wild mammals. Although it is clear that there
is a high number of infected patients all around the world, it is difficult to extract 
numerical data regarding infected patients due to the bias in the reports of cases in
different countries (Dupouy-Camet 2000).
The life cycle of Trichinella is depicted in Fig. 1.13. The infection of domestic
or wild animals (sylvatic cycle) or humans starts with ingestion of raw or undercooked
meat which contains encysted larvae, except in the cases of T. pseudospiralis and T. 
papuae which do not form the encapsulation (Karmi and Faubert 1981; Pozio et al.
2001). Digestive enzymes in the stomach release the larvae from the muscular tissue
and they accumulate in the upper two thirds of the small intestine. There, the epicuticle
is partially digested, which enables the parasite to receive information from its
environment and to locate a suitable infection site in the small intestine. The worms 
enter columnar epithelium cells at the base of villi and they live intracellularly, within a
row of these cells in a syncytium, because at 1 mm in length they are too long to live
within one (Bruce 1970). The parasites move through the epithelium, leaving trails of
dead cells behind. In the intestinal syncytia, the worms are believed to quickly moult
four times in a period of around thirty hours and become adults that mate, although it
has been difficult to study this stage. After five days, females start producing offspring,
during the period before host immunity develops. The host immune response interferes
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with embryogenesis and force adults to migrate further down the tract, which occurs
after several weeks (Despommier et al. 1995; Despommier 2010).
Newborn larvae, a stage known as L1, start to migrate, opening entry holes
using a stylet, entering the lamina propria and travelling to the bloodstream or
mesenteric lymphatic system in some species (Despommier 2010). Larvae become
distributed throughout the body, after which they leave capillaries and enter different
cells, apparently with no preference (Despommier 2010). Once inside the cells, they
either remain or leave, migrating to other cells. The factors that cause this relocation are
unknown. Excepting skeletal muscles, most cell types die as a result of invasion, and
larvae die with them, although the damage from migration causes pathologies,
particularly if it takes place in myocardium or brain (Despommier 2010).
The parasite life is divided into two major phases, the intestinal phase and the
muscle one (Berntzen 1965). The latter serves as the reservoir for transmission, as it is
from muscle that the next host gets infected through ingestion. The muscle phase is
chronic, lasting up to several years, and it is an interesting phase due to the changes that
take place in both parasite and host. These take place primarily during the first 15 days
postinfection, known as the initiation phase (Despommier et al. 1995). During the first
5 days, the parasite enters into a lag phase, after which exponential growth takes place
(Despommier et al. 1995). During the exponential phase, among other changes, the
parasite develops a set of secretory cells in the oesophagus, called stichocytes, which
are important for the relation with the host (Jasmer 2001) . The parasite genetically
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reprogrammes the cells in which it is located, repressing their normal phenotype
(Jasmer 2001).
The main way in which the parasite communicates with its host is probably
regulated by various secreted products and metabolic wastes, but there is currently
more information regarding proteins secreted by stichocytes. Experiments with T. 
spiralis provide evidence that glycans on the proteins secreted by stichosomes may be
important in these events (Ellis et al. 1997). Antibodies against excreted/secreted
glycoproteins seem to protect rat pups from infection or force the release of the larvae
(Appleton and McGregor 1984). The major glycan structures in the immunologically
important secreted glycoproteins are tri- and tetra-antennary N-linked structures
containing GalNAcβ1-4GlcNAc antennae, which were characterised by fast atom
bombardment-mass spectrometry (Reason et al. 1994). In the case of larvae, these
structures are capped with D-tyvelose (3,6-dideoxy-D-arabinohexose) in β
configuration, and are heavily fucosylated (Fig. 1.14). The dideoxy sugar tyvelose is
most commonly found in pathogenic bacteria lipolysaccharides, where it is also a
highly antigenic determinant (Liu and Thorson 1994). Many of larval glycans are also
modified with phosphorylcholine (Morelle et al. 2000b). It is not known if the proteins
bearing these glycans and other products of δ and γ stychocytes are involved in muscle
cell modifications or if these products are being presynthesised for functions in the
intestinal stage (Jasmer 2001).
It is clear that the parasite surface antigens change according to the stage in the 
life cycle of the parasite.  Even if adults of T. spiralis present similar glycans to those of
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muscle invading larvae, with the common element GalNAcβ1-4GlcNAc, they do not
present tyvelose residues or the fucose residues that modify the GlcNAc in the larval
glycans, even though tyvelose seems to be important for invasion and migration. 
However, tyvelose may only be important for the larvae but not for adults (Morelle et
al. 2000a). Adult glycans also lack phosphorylcholine modifications.
The precise way in which these glycans interact with the host and help the
parasite to evade immune response are largely unkown, but it is known that the
glycoproteins secreted from helminth parasites are recognised by macrophages and
dendritic cells, both antigen-presenting cells (Wing et al. 1979; Maizels and
Yazdanbakhsh 2003; Kane et al. 2004). Some of the interactions probably involve the
phosphorylcholine modifications present in larval glycoproteins (Harnett et al. 1999). 
The interaction with one of the macrophage receptors, the mannose receptor, has
previously being explored and seems to be involved in production of nitric oxide by the
macrophages (Gruden-Movsesijan and Milosavljevic 2006).  As was mentioned before
and as can be observed in Fig. 1.14, MGL may also be involved in the interaction,
because adult glycans possess terminal GalNAc in some of their structures with free 3­
and 4-OH.
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Figure 1.13. Life cycle of Trichinella spiralis. 
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1.11 Plan of thesis
The primary focus of this thesis is the characterisation of human ASGPR and
MGL, particularly their specificity and the way they form oligomers. Chapters 2 and 3
present studies made with the goal of understanding first the organisation of the
polypeptides that form these receptors and how they are assembled into oligomers. The 
thesis is organised so that Chapter 2 presents MGL, which is a simpler model than 
ASGPR, formed from one kind of subunit. Chapter 2 presents studies related to the 
assembly of the receptor. Chapter 3 introduces the more complex ASGPR, formed by
two kinds of subunits and which has since its discovery posed several questions
regarding the nature of its oligomers. Chapter 3 also makes use of glycan array analysis
to determine the specificity of the subunits that form the asialoglycoprotein receptors. It
also shows studies of the formation of hetero-oligomers.
As it is important to correlate biochemical studies with the actual function of the
receptors in organisms, Chapter 4 of this thesis presents studies made with the aim of
understanding the role that MGL has when interacting with parasite glycoproteins. Our
collaborators made use of mouse macrophages which proved to interact with larval
Trichinella spiralis glycoproteins, so the mouse homologues of MGL were 
characterised biochemically and compared with the human protein.
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Chapter 2. Human macrophage asialoglycoprotein receptor
Chapter 2.
Assembly and selectivity of the human macrophage 
asialoglycoprotein receptor
2.1 Introduction
The macrophage asialoglycoprotein receptor (MGL) has been considered a
stable homo-trimeric protein, as evidenced by chemical crosslinking (Iida et al. 1999), 
with the trimer stabilised by the neck region. The fact that this receptor is formed by
just one type of polypeptide suggested that understanding its structure was a good
starting point to interpret the more complicated hetero-oligomeric nature of the hepatic 
asialoglycoprotein receptor, explored in Chapter 3.
In order to understand the receptor in an easier way, several versions of the
protein were created (Fig. 2.1) that included the extracellular domain and the CRD on
its own. The different versions of the protein were analysed by hydrodynamic methods
to determine their apparent molecular weight and therefore calculate their
oligomerisation state. The independence of domains in the extracellular domain was
also analysed by partial proteolysis and by differential scanning calorimetry.
65
 
Chapter 2. Human macrophage asialoglycoprotein receptor 
A.
 
Full-length 
C­
N– 
C­
N– Extracellular domain (ECD) 
Carbohydrate-recognition 
domain (CRD) 
25 50B. 
MTRTYENFQYLENKVKVQGFKNGPLPLQSLLQRLCSGPCHLLLSLGLGLL 
LLVIICVVGFQNSKFQRDLVTLRTDFSNFTSNTVAEIQALTSQGSSLEET 
ECD 
10075 
S S 150125 
IASLKAEVEGFKQERQAGVSELQEHTTQKAHLGHCPHCPSVCVPVHSEML
 
S SS S 
CRD 
200175 
LRVQQLVQDLKKLTCQVATLNNNASTEGTCCPVNWVEHQDSCYWFSHSGM 
225 250S 
SWAEAEKYCQLKNAHLVVINSREEQNFVQKYLGSAYTWMGLSDPEGAWKW 
275 300S S 
VDGTDYATGFQNWKPGQPDDWQGHGLGGGEDCAHFHPDGRWNDDVCQRPY 
S 
HWVCEAGLGQTSQESH 
Neck S S  Probable disulphide bond 
“Loop” Origin of observed CRD fragments 
CRD 
Figure 2.1. A. Expressed versions of macrophage galactose lectin. B. Sequence of 
MGL. 
To serve our purposes variants with different lengths of MGL were expressed. The 
sequence corresponds to MGL reference sequence and the starts of constructions are 
indicated with arrows. Possible sites for digestion based on fragment size and accesibility 
with reference to the crystal structure of the ASGPR-1 CRD (PDB ID 1DV8) are indicated. 
Blue marks correspond to digestion with subtilisin and red to trypsin. 
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Chapter 2. Human macrophage asialoglycoprotein receptor
2.2 Methods
2.2.1 Materials
Agarose and SYBR DNA stain were purchased from Invitrogen Ltd (Paisley,
UK). Ammonium persulfate, D-galactose, Sepharose 6 B, Triton X-100, TEMED and
bovine serum albumin were from Sigma-Aldrich Company Ltd (Poole, UK). 
Restriction enzymes, T4 DNA ligase, calf intestinal phosphatase and protein molecular
weight markers were purchased from New England Biolabs Ltd (Hitchen, UK). SDS
was purchased from BioRad Laboratories Ltd (Hemel Hempstead, UK).
Polyacrylamide gels were made using Acrylagel and bis-Acrylagel from National 
Diagnostics (Atlanta, USA). Isopropyl-β-D-thiogalactoside (IPTG) was purchased from
Fisher Scientific Ltd (Loughborough, UK). MAXIPREP plasmid purification kit is
from QIAGEN Ltd (Crawley, UK). Subtilisin was from Boehringer Mannheim
(Rotkreuz, Switzerland) and trypsin was from Worthington Biochemical Co.
(Lakewood, NJ, USA).
2.2.2 Expression and purification of the extracellular region and carbohydrate-
recognition domain of the human macrophage asialoglycoprotein receptor
The extracellular region of MGL was expressed in Escherichia coli strain
BL21/DE3. The construct, which starts at Phe111 of the full sequence (UniProt
Q8IUN9-1), had been previously cloned into expression vector pT5T from a human
liver cDNA library by Eliot Ward and Kurt Drickamer. For the expression of the 
carbohydrate-recognition domain, the PpuMI-EcoRI CRD fragment from a pGEM
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Chapter 2. Human macrophage asialoglycoprotein receptor
vector that contained the MGL extracellular domain (ECD) sequence was moved into a
pT5T vector that contained the sequence for a biotinylated version of MGL CRD.
Restriction digestions and ligations were conducted using standard molecular biology
techniques (Sambrook and Russell 2001) with all enzyme digestions conducted in an 
appropriate concentration of the manufacturers recommended buffer. All the plasmids
reported in this thesis were sequenced using an ABI PRISM 310 Genetic Analyser
(Applied Biosystems, Carlsbad, CA, USA). Plasmids were purified using the
MAXIPREP kit. The MGL CRD construct starts at Leu153 (Fig. 2.1). The Bacterial
stocks were prepared in 15% glycerol and stored at -80 °C.
The expression of the proteins was done in Luria-Bertani medium containing 50
µg mL-1 ampicillin. An overnight culture (200 mL) was started by inoculation from the
frozen bacterial stocks and grown with shaking at 37 °C. The culture for each protein
was diluted into 6 L of Luria-Bertani medium, and incubated at 37 °C with shaking 
until the optical density at 550 nm reached 0.7. The expression of proteins was induced
by addition of IPTG (100 mg L-1) after which the cultures were incubated for 150 min
at 37 °C with shaking. The bacteria were harvested by centrifugation at 4000 x g for 15
min at 4 °C. Cells were washed in 10 mM Tris-HCl, pH 7.8 (wash buffer), centrifuged
at 10,000 x g for 10 min at 4 °C, resuspended in 200 mL of wash buffer and lysed by
sonication (6 bursts of 30 s duration). The inclusion bodies were separated by
centrifugation at 10,000 x g for 15 min at 4 °C and pellets were solubilised in 100 mL
of 6 M guanidine hydrochloride containing 100 mM Tris-HCl, pH 7.0 by brief
sonication. β-mercaptoethanol was added to 0.01%, followed by gentle stirring for 20
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Chapter 2. Human macrophage asialoglycoprotein receptor
min at 4 °C. The solution was centrifugated at 142,000 x g for 30 min at 4 °C and 
Triton X-100 was added to a concentration of 1 %. The protein was diluted in 400 mL
of 1.25 M NaCl, 25 mM Tris-HCl, pH 7.8 and 25 mM CaCl2 (loading buffer)  and 
renatured by dialysis against 6 volumes of loading buffer with 3 buffer changes.
Insoluble precipitates were removed by centrifugation at 142,000 x g for 1 h at 4 °C in
a Beckman 45Ti rotor. 
Correctly folded proteins were purified by affinity chromatography on 5-mL 
galactose-Sepharose columns (Fornstedt and Porath 1975) pre-equilibrated with loading 
buffer (5 column volumes) and eluted with 6 column volumes of eluting buffer (1.25 M
NaCl containing 25 mM Tris-HCl, pH 7.8 and 2.5 mM EDTA), collecting 2 mL
fractions. All fractions were analysed on 17.5 % SDS-polyacrylamide gels.
2.2.3 Analysis by SDS-polyacrylamide gel electrophoresis
SDS-polyacrylamide gel electrophoresis (SDS-PAGE) was performed using the
method of Laemmli  (Laemmli 1970). Samples were mixed with an equal volume of 2X
sample buffer (80 mM Tris-HCl, pH 6.8, 15% glycerol, 2% SDS, 0.006% bromophenol
blue and 2% β-mercaptoethanol) and heated to 100 °C for 5 min before loading.
Samples were loaded onto SDS-polyacrylamide gels mounted in either a Gibco BRL 
V15-17 vertical gel electrophoresis apparatus or a Bio-Rad mini-PROTEAN Tetra Cell
filled with running buffer (0.19 M glycine, 25 mM Tris and 0.1% SDS). Protein
molecular weight markers were used in all gels and for protein visualisation, gels were
stained with 1.6 mM Coomassie blue stain dissolved in 4.5:4.5:1 (v/v)
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Chapter 2. Human macrophage asialoglycoprotein receptor
methanol:H2O:acetic acid at room temperature and destained with 12:25:3 (v/v)
methanol:H2O:acetic acid.
2.2.4 Proteolytic susceptibility assays
Proteolysis with subtilisin or trypsin was performed in 0.5 M NaCl, 25 mM
Tris-HCl, pH 7.8, 25 mM CaCl2. Aliquots (20 µL) of MGL ECD were combined with 
freshly prepared trypsin or subtilisin solutions to achieve final concentrations of 2, 5,
10, 20 and 50 µg mL-1. One aliquot was left without protease to serve as control. After
incubation for 1 h at 37 °C, proteolysis was stopped by the addition of 20 µL 2X SDS­
PAGE sample buffer, followed by immediate boiling for 5 min and analysis on 17.5 %
polyacrylamide gels. Gels were stained with Coomassie Blue. An aliquot of the
corresponding protease and the MGL CRD were loaded to the gels to serve as
reference.
2.2.5 Gel Filtration chromatography
The ECD and CRD of MGL were analysed by gel filtration using an Amersham
Pharmacia Biotech Superdex 200 FPLC column. The column was eluted with 10 mM
Tris-Cl, pH 7.8, 100 mM NaCl and 2.5 mM EDTA at a flow rate of 0.5 mL min-1. Data
were collected and processed using the UNICORN software.
2.2.6 Circular dichroism
The ECD and CRD of MGL were prepared for circular dichroism analysis by
dilution to a concentration of ~0.2 mg mL-1 and dialysis against 5 mM Tris-Cl, pH 7.8 
and 25 mM NaCl. A volume of 200 µL was used for each sample.
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Chapter 2. Human macrophage asialoglycoprotein receptor
Circular dichroism spectra were obtained using a 1-mm quartz cell in an
Applied Photophysics Chirascan spectropolarimeter, at 22 °C thermostated by a Peltier
temperature controller. The settings used were: band width, 1 nm; step size, 0.5 nm;
time per point, 1s. The spectra presented represent an average of ten scans from which
the signal for the base-line was substracted. The base-line measurements were
performed using identical conditions but without the protein. Data were analysed using
different software methods, CDNN software (Böhm et al. 1992) and the empirical
method of Chen et al. (1974) which calculates the percentage of helical content as
 
% helical content =
100
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, where n is the number of peptide222 
2.57

×
1−
 
n 
bonds. CDNN results are preferred over the empirical method as it is now understood 
that a measurement at a single wavelength does not represent well the contribution
given by each structure to the spectrum and methods that compare it as a whole are
seen as more reliable (Greenfield 2007).
2.2.7 Differential scanning calorimetry
Samples of the ECD and CRD of MGL were dialysed extensively against 25
mM Na-HEPES, pH 7.8, 150 mM NaCl, 1 mM CaCl2 after which 700 µL of the sample
and buffer were degassed for 15 min prior to loading them into the sample and
reference cells of a Calorimetry Sciences Nano III calorimeter. The scans were
preceded by 10 min of equilibration at the starting temperature. Initial scans from 20 to 
35 °C were repeated until a stable base line was obtained. Denaturation experiments
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Chapter 2. Human macrophage asialoglycoprotein receptor
were run from 20 to 80 or 90 °C. Base lines were calculated using a fourth order
polynomial equation to fit the data using SigmaPlot. Protein concentrations were
determined by the alkaline ninhydrin assay (Hirs 1967).
2.2.8 Protein concentration measurement by the alkaline ninhydrin assay
Protein concentration was measured by the alkaline ninhydrin assay (Hirs
1967). Aliquots (up to 50 µL) of the protein samples were added to 0.2 mL of 2 N
NaOH. The protein was hydrolysed using a standard autoclave cycle of 15 min at 122
°C. Hydrolysates were neutralised with 0.2 mL of a 2.4 N acetic acid solution, and 0.1
mL of ninhydrin solution (80 mg ninhydrin, 12 mg hydrindantin, 3 mL dimethyl
sulphoxide, 1 mL 3 M sodium acetate pH 5.2) was added. The reaction took place at
100 °C for 30 min, after which the samples were cooled on ice and 0.5 mL of 50 % v/v
ethanol was added. Absorbance of the samples was read at 570 nm. Standard curves
were prepared using bovine serum albumin.
2.2.9 Visualisation software
All the tri-dimensional models of crystallographic structures in this thesis were
visualised in Chimera 1.5.3 (Pettersen et al. 2004). Structural alignments were also
performed using Chimera integrated software.
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Chapter 2. Human macrophage asialoglycoprotein receptor
2.3 Results
 
2.3.1 Expression and purification of MGL fragments
The extracellular domain and CRD of MGL were expressed in the expression
vector pT5T, a variation of plasmid pJU1003, that employs the T7 promoter system
(Eisenberg et al. 1990) (Fig. 2.1 and 2.2). This vector contains a short leader peptide,
corresponding to the T7 gene 10 translation start ended by a stop codon which is
followed immediately by an in-frame methionine codon. In all of the sequences
reported in this thesis, a codon for alanine was introduced before the desired sequence.
The strain BL21 (DE3), in which expression of T7 gene 1, encoding T7 RNA
polymerase, is controlled by IPTG induction of the lac promotor/operator, was used as
it has been widely used for other C-type animal lectins (Taylor and Drickamer 2003). 
After being expressed in inclusion bodies, proteins were dissolved in guanidine
hydrochloride and renatured by dialysis against Ca2+-containing buffer. The renatured 
proteins exhibited strong binding to galactose-Sepharose, demonstrating their correct
folding (Fig. 2.2). All the proteins reported in this thesis were expressed in E. coli
which means that none of the proteins possessed glycosylations. It has been clear for
other related proteins and for those reported in this thesis that CRD and neck
glycosylations are not needed for their functionality.
The presence of Triton X-100 was found to improve the yield of ECD
production, preventing the protein from precipitating before it refolded. The detergent
was removed during dialysis and affinity chromatography and the proteins were
purified in the absence of detergent. Adding this detergent to the CRD was not
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Chapter 2. Human macrophage asialoglycoprotein receptor
necessary to obtain a good yield, as has been observed for other CRDs (Burrows et al.
1997; Taylor and Drickamer 2003). A biotin-tagged version of the CRD was also 
produced and was used to probe glycan arrays, discussed in Chapter 3. Both versions of
CRDs were used also to analyse interactions with Trichinella spiralis glycoproteins
detailed in Chapter 4.
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Figure 2.2. Cloning, expression and purification of the untagged CRD of MGL. 
The sequence was subcloned from a previously generated vector that contains MGL 
ECD, constructed by Elliot Ward and Kurt Drickamer. The 5 mL column was previously 
washed with loading buffer and elution fractions are 2 mL. 
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Chapter 2. Human macrophage asialoglycoprotein receptor
2.3.2 Independence of domains
The arrangement of the domains and their interdependence was tested by
limited proteolysis. Subtilisin is usually preferred for limited proteolysis experiments
because of its broad specificity, with only limited preference for large, uncharged
amino acids in the 'P1' position N-terminal to the cleavage site (Wells and Estell 1988). 
It can thus be used to probe for sterically accessible sites in a largely sequence-
independent manner. For MGL, subtilisin treatment resulted in fast degradation, even
at the lowest concentrations of the protease (Fig. 2.3). The small portions of protein
observed at the lowest concentrations of subtilisin may correspond to CRD fragments
stabilised by disulphide bonds. 
The rapid degradation of the CRD of MGL by subtilisin suggests that the
protease has access to one or more sites within the CRD. Comparison of the structure of
the CRD from ASGPR-1, which would be closely similar to MGL, with the CRD from
MBP shows that the long loop region near to the Ca2+-binding sites is extended in MGL
and absent in MBP (Figure 1.1), which would make it a likely target in MGL. In other
cases, like the mannose-binding protein from rat liver (MBP-C), digestion with
subtilisin has proved useful to show the structural independence of the neck region and
the CRD, without further degrading the CRD in low concentrations (Ng et al. 1996).
Because of its more restrictive specificity for lysine and arginine residues, trypsin
often does not reveal all flexible linker regions in proteins. However, for MGL trypsin
produced a fragment that corresponds to the molecular weight of the CRD which
formed a stable protease-resistant structure that was released from the neck region even
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at low protease concentrations (Fig. 2.3). It is probable that trypsin cleaved the protein
either at Lys161 or Lys162, since these residues immediately precede the CRD (Fig.
2.1). 
The ability of trypsin to cleave efficiently in this region provides strong 
evidence for the presence of an exposed segment of polypeptide at the base of the CRD.
Cleavage at the neck-CRD junction has been observed previously in other receptors, 
such as DC-SIGN, in which the CRDs are separated from the neck by a flexible linker
(Feinberg et al. 2005), suggesting a similar arrangement in MGL.
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Figure 2.3. Analysis of limited proteolysis of MGL by SDS-PAGE. 
MGL ECD showed a high susceptibility to subtilisin proteolysis even at low concentrations 
and in the case of trypsin, the CRD showed resistance to degradation. Isolated CRD used 
as marker was produced independently. 
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Chapter 2. Human macrophage asialoglycoprotein receptor
2.3.3 Differential scanning calorimetry of extracellular domains of MGL
A further indication of the arrangement of the domains in MGL was obtained
from comparing differential scanning calorimetry results for the CRD alone and in the
presence of the full ECD. Differential scanning calorimetry analysis of the CRD alone
revealed a primary denaturation transition at 64.3 ºC, with some indication of the
presence of a small fraction of less stable material denaturing at lower temperature (Fig.
2.4). Following an initial scan to 90 ºC and cooling to 5 ºC, a second scan showed that
some of the protein was renatured, although the fraction became less on subsequent
scans and there was evidence of precipitation when the sample was removed from the
calorimeter.
Analysis of the ECD proved to be more difficult. Due to the favourable
solubility properties of the CRD, experiments with this fragment could be conducted at
high concentrations (~10 mg/ml). In contrast, the ECD could only be analysed at ~2
mg/ml and there was a strong downward slope at higher temperatures, reflecting rapid
precipitation, so the results are not as clean. However, the denaturation peak for the
CRD is still quite evident and there is some indication that there may be an additional
denaturation event at lower temperature, around 45 ºC. These results suggested that the
neck region might denature at a relatively low temperature, but an alternative strategy
using circular dichroism was required to support this idea.
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Figure 2.4. Differential scanning calorimetry of human MGL. 
Samples were analysed in buffer containing 125 mM NaCl, 25 mM HEPES, pH 7.8 and 5
 
mM CaCl . A. CRD. Protein concentration was 10 mg/ml. B. ECD. Protein concentration
 2
 
was 1.9 mg/mL. 
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Chapter 2. Human macrophage asialoglycoprotein receptor
2.3.4 Circular dichroism analysis of extracellular domains of MGL
The secondary structure content of both the CRD and the ECD fragments of
MGL were examined using circular dichroism. The spectrum of the CRD alone did not
reveal any dominant secondary structure (Fig 2.5 A), as expected from previous results
with other CRDs and the limited amount of α and β structure in the CRD compared to 
the turns and loops (Weis and Drickamer 1994; Meier et al. 2000). Scans taken at
multiple temperatures from 20 to 90 ºC revealed changes in the spectrum at around 60 
ºC, particularly in the positive feature at approximately 230 nm. Peaks in this region are
believed to be due to the presence of signal from aromatic residues (Sang and Gray
1989; Woody 1995) and the dependence of this feature on concentration of Ca2+ is 
investigated further in the next chapter.
A plot of the signal at 230 nm as a function of temperature revealed a mid-point
for the transition corresponding to 67 ºC (Fig. 2.6), which matches well with the
denaturation temperature for the CRD as determined by DSC. Rerunning the spectrum
after returning the sample to 30 ºC showed that the transition is largely reversible (Fig 
2.5 B), which is again consistent with the reversibility noted in the DSC experiments.
The lower concentration of protein used in these experiments (~0.35 mg/ml) resulted in
less precipitation, so essentially all of the protein can be seen to return to its original 
conformation.
The circular dichroism spectrum of the complete extracellular domain showed
much more evidence of helical content (Fig. 2.7). The contribution of the neck domain 
was obtained by taking the difference between the spectra of the ECD and the CRD.
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Chapter 2. Human macrophage asialoglycoprotein receptor
This spectrum showed the characteristics expected of a coiled-coiled domain, including 
the more negative ellipticity at 222 nm compared with the value at 206-208 nm in 
contrast to pure α-helix not in a coiled-coil in which the ellipticity at 222 nm is usually
less negative than that at 206-208 nm (Lau et al. 1984; Wang et al. 1999; Whitmore
and Wallace 2008). The helical content of the difference between the ECD and CRD
circular dichroism spectra was 46 %, taking in account the data between 200 and 260
nm, based on CDNN calculations, and 42 % using the minimum at 222 nm, according 
to the empirical equation of Chen et al. (Chen et al. 1974).
Information about the denaturation of the neck domain was obtained by running 
a series of spectra at increasing temperature and comparing the molar ellipticity at 222
nm (Fig. 2.8). The results indicate that the ellipticity associated with the neck domain
disappears with an apparent midpoint for the transition of 34 ºC. This low value
suggests that the domain is minimally stable at room temperature, which is consistent
with the results of gel filtration discussed in the next section, suggesting a
concentration-dependent equilibrium. The differential scanning calorimetry experiment 
described in the previous section was performed at roughly a 5-fold higher
concentration of 1.9 mg/ml compared to 0.45 mg/ml in the circular dichroism
experiment, which may be why the secondary transition observed in the calorimetry
experiment appears at a temperature higher than 34 ºC. The presence of a partially
stable oligomer would also result in a reduced apparent helical content, as the neck
would be in a helical conformation only part of the time.
82
 
Chapter 2. Human macrophage asialoglycoprotein receptor 
1.0 
A. 
0.5 
0.0 
-0.5 
20 °C 30 °C 40 °C 50 °C 60 °C 70 °C 80 °C 90 °C 
-1.0 
B. 
0.8 
0.4 
Before heating 
0.0 
After heating 
-0.4 
-0.8 
200 210 220 230 240 250 260 
Wavelength (nm) 
Figure 2.5 Circular dichroism spectra of the CRD from MGL. 
Spectra were recorded in 25 mM NaCl, 5 mM Tris-Cl, pH 7.8, 2.5 mM CaCl 2 at a protein 
concentration of 350 �g/ml. A. Spectra obtaining during heating of sample at intervals of 5 
°C. For clarity, only every other spectrum recorded is shown. B. Spectra obtained at 30 °C 
before and after heating to 90 °C. 
83
 
Chapter 2. Human macrophage asialoglycoprotein receptor 
-0.3 
-0.2 
-0.1 
0.0 
0.1 
0.2 
0.3 
20 30 40 50 60 70 80 90 
Temperature (°C) 
Figure 2.6. Denaturation of the CRD from MGL monitored by circular dichroism. 
Values of the molar ellipticity at 228-230 nm were averaged for spectra obtained at 
intervals of 5 °C as described in Figure 2.8. The data were fitted to a sigmoidal decay 
curve using a nonlinear least-squares fitting programme. The apparent T m for the 
transition is 67 °C. 
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Figure 2.7. Secondary structure content of the CRD, ECD and theoretical 
calculation of the neck structure by circular dichroism. 
Buffer used for CRD and ECD was 5 mM Tris-Cl pH 7.8 and 25 mM NaCl. The values of 
molar ellipticity were subtracted to determine the structure content of the neck region. 
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Figure 2.8. Denaturation of the ECD of MGL monitored by circular dichroism. 
A. Spectra were recorded in 25 mM NaCl, 5 mM Tris-Cl, pH 7.8, 2.5 mM CaCl at a protein 2 
concentration of 450 �g/ml. Spectra were obtained at intervals of 5 °C, with every other 
spectrum shown in the figure. B. Values of the molar ellipticity at 221-223 nm were 
averaged and fitted to an exponential decay curve uisng a nonlinear least-suqares fitting 
programme. The apparent T m for the transition is 34 °C . 
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2.3.5 Hydrodynamics of the receptor
The arrangement of subunits in MGL was examined by gel filtration
chromatography. As expected the CRD did not form large oligomers, although the
apparent molecular weight based on standards is 30 kDa, which is higher than the
calculated molecular weight for a monomer of 17 kDa. Chemical crosslinking had 
shown before that MGL CRD behaved purely as a monomer (Iida et al. 1999) but this
does not seem to be clear in gel filtration chromatography. It is possible that the CRD at
least partially dimerises in a similar way to MBP when the neck is removed (Weis et al.
1991), exposing hydrophobic residues (Fig. 1.10).
The apparent molecular weight for the ECD of MGL measured by gel filtration
chromatography (Fig. 2.9) varied between 120 and 140 kDa increasing directly in 
relation with the concentration of the sample, a phenomenon that was further studied in
the case of ASGPR-1 as described in Chapter 3. This molecular weight corresponds to
an oligomer that appears to be bigger than the trimeric structure expected according to
Iida et al. (Iida et al. 1999) and corresponds to a multimer that ranges from a tetramer
up to a hexamer. However the size of the oligomers may be masked by the presence of
an elongated neck region, increasing the apparent hydrodynamic radius. 
The elongated nature of the receptor masks the actual behaviour of the protein.
Because the protein is more similar to a cylinder than a theoretical sphere, the Stokes
𝛽𝐷𝐶radius of the particles can vary enormously, from ║𝑅𝑆 = (where RS is the3(𝑙𝑛2𝛽)−1 
2 
Stokes radius, DC is the cylinder diameter and β is the aspect ratio length/diameter),
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Chapter 2. Human macrophage asialoglycoprotein receptor
2𝛽𝐷𝐶when the major axis is parallel to the motion of the flow, to ┴𝑅𝑆 = when its3ቀ𝑙𝑛2𝛽+1
2
ቁ 
orientation is perpendicular to the flow motion (Henn 1996). However the studies give
a good idea of the behaviour of the population. The shifting of the peak when varying
protein concentration and the asymmetry of it indicate that the oligomer is not stable
and that the population is not homogeneous.
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Figure 2.9. Elution profiles of the ECD and CRD of MGL on size exclusion 
chromatography. 
The Superdex 200 column was equilibrated with 10 mM Tris-HCl (pH 7.8), 100 mM NaCl 
and 2.5 mM EDTA. The markers correspond to bovine thyroglobulin, E. coli �­
galactosidase, sweet-potato �-amylase, BSA, carbonic anhydrase and cytochrome C. 
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Chapter 2. Human macrophage asialoglycoprotein receptor
2.4 Discussion
The results presented in this chapter are consistent with a picture of MGL as a
homo-oligomer that consists of an α-helical coiled-coil stalk linked flexibly to CRDs. 
Although the results suggest that the oligomer is not completely stable, the proteins
analysed here were depleted of their intracellular and transmembrane domains, and it is
possible that these regions stabilise the oligomers. The fact that the neck on its own 
does not fully stabilise the oligomers may reflect the nature of the region in the centre
of the neck, with sequence KAHLGHCPHCPSVCVPVH. This sequence does not show
a high propensity to form a helical structure (Psipred server; (Jones 1999). In addition, 
it is probable that the glycosylation that takes place in Asn173, not present in the
protein produced in bacteria, drives the hydrophobic interactions in the coiled-coil, 
stabilising the oligomers.
The proteolysis assays showed that there is a loose structure connecting the
neck and the CRD, an interpretation confirmed by the finding that these two domains
behave independently when analysed by calorimetry and circular dichroism. Attempts
to express and purify the neck of the protein as an independent domain were
unsuccessful. In retrospect, the difficulty may have resulted in part from the low
stability of the coiled-coil formed by this sequence. Successful expression of a neck
polypeptide from one of the ASGPR subunits is described in the next chapter. The
behaviour of MGL and the results obtained are a fundamental point of comparison with 
the ASGPR studies analysed in Chapter 3.
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Chapter 2. Human macrophage asialoglycoprotein receptor
It is important to indicate that even if there is a high probability of the
proteolytic digestion taking place in the suggested sites, due to the accessibility of the
sites, only further study can clear the actual nature of the peptide fragments. Such study
could be a mass spectrometry analysis or secquencing of the bands. A similar study was
made in the following chapter and a similar study can be used to confirm that the
observed fragment corresponds to the CRD.
Other further studies may include the analysis of fractions that appear later than
the main elution peak. Although this would limit the amount of protein that is available,
it is probable that later fractions may contain a purer protein, without the presence of
aggregates or other proteins that could have stuck in a non-specific way to the column. 
Other ways of avoiding slight contamination, that may be of concern for studies such as
crystallographic ones, an elution in steps using increasing concentrations of EDTA can
be used, or the use of other chromatography to polish the major fractions. 
In the case of gel filtration possible specific binding to the galactosyl residues in
Sepharose was avoided by using EDTA. The possibility of non-specific binding to the
resine can be discarded by using other complementary methods, such as dynamic light
scattering or analytical centrifugation. It should be stated, however that the constantly
changing behaviour of the receptor makes it unsuitable for simple hydrodynamic
studies using such techniques as in current conditions it would be hard to distinguish
populations of different oligomers.
The instability of the neck at temperatures lower than the physiological, which 
was previously noted in crosslinking experiments (Bider et al. 1996) may suggest that
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Chapter 2. Human macrophage asialoglycoprotein receptor
the coiled-coils in the neck are of an unstable kind and would make us wonder why
would evolution favour such structures. However, as previously stated, the
transmembrane and cytoplasmatic domains may be necessary for its stability or the
glycosylations that did not take place in our models due to their production in E. coli. 
Expression in mammal cells may help to elucidate this. Even if the presence of these
components is not necessary the simple attachment to the membrane could also
diminish the mobility, as it would change to a bidimensional plane and so the formation 
of oligomers may be better. Studies using the full protein are planned but studies
involving the purification and analysis of proteins in micelles are always challenging.
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Chapter 3. Human hepatic asialoglycoprotein receptor
Chapter 3. 
Assembly and selectivity of the human hepatic 
asialoglycoprotein receptor
3.1 Introduction
The human hepatic asialoglycoprotein receptor (ASGPR) is known to be formed 
from two orthologous subunits, designated ASGPR-1 and ASGPR-2. It has been
suggested that the receptor is formed by a core of ASGPR-1 subunits to which ASGPR­
2 subunits bind, but the arrangement has never been fully established. As noted in
Chapter 1, the function of the receptor and its natural ligands are also not well defined.
Insights into the receptor stoichiometry as well as its specificity obtained using novel
approaches to in vitro assembly of receptor oligomers are reported in this chapter.
3.2 Methods
3.2.1 Expression and purification of the extracellular region of asialoglycoprotein
receptors
The extracellular regions of ASGPR-1 and ASGPR-2 were expressed in
Escherichia coli strain BL21/DE3. These constructs had been previously cloned into 
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Chapter 3. Human hepatic asialoglycoprotein receptor
vector pT5T by Eliot Ward and Kurt Drickamer. The homologous rat proteins
(Drickamer et al. 1984) were expressed in the same way in order to be used in
comparisons. Bacterial stocks were prepared in 15% glycerol and stored at -80 °C.
Expression of the proteins was performed in Luria-Bertani medium containing 
50 µg mL-1 ampicillin. An overnight culture (200 mL) was started by inoculation from
the frozen bacterial stocks and grown with shaking at 37 °C. The culture for each
protein was diluted into 6 L of Luria-Bertani medium, and incubated at 37 °C with
shaking until the optical density at 550 nm reached 0.7. Expression was induced by
addition of isopropyl-β-D-thiogalactoside (IPTG) (100 mg L-1), after which the cultures
were incubated for a further 150 min at 37 °C with shaking. The bacteria were
harvested by centrifugation at 4,000 x g for 15 min at 4 °C. Cells were washed in 10
mM Tris-HCl, pH 7.8 (wash buffer), centrifuged at 10,000 x g for 10 min at 4 °C, 
resuspended in 200 mL of wash buffer and lysed by sonication (6 bursts of 30 s
duration). The inclusion bodies were isolated by centrifugation at 10,000 x g for 15 min 
at 4 °C and pellets were solubilised in 100 mL of 6 M guanidine hydrochloride
containing 100 mM Tris-HCl, pH 7.0 by brief sonication followed by addition of β­
mercaptoethanol to 0.01 % and gentle stirring for 20 min at 4 °C. After dilution in 400 
mL of loading buffer, the proteins were renatured by dialysis against 6 volumes of
loading buffer with 3 buffer changes. Insoluble precipitates were removed by
centrifugation at 142,000 x g for 1 h at 4 °C in a Beckman 45Ti rotor. 
Correctly folded proteins were purified by affinity chromatography on 5-mL 
galactose-Sepharose columns (Fornstedt and Porath 1975) pre-equilibrated with loading 
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Chapter 3. Human hepatic asialoglycoprotein receptor
buffer (5 column volumes) and eluted with 6 column volumes of eluting buffer (1.25 M
NaCl containing 25 mM Tris-HCl, pH 7.8 and 2.5 mM EDTA), in 2 mL fractions. All 
fractions were analysed on SDS-polyacrylamide gels.
3.2.2 Expression and purification of the His tagged neck region of ASGPR-1
A BamH1/BspM1 fragment encoding the neck region of ASGPR-1, together
with synthetic double-stranded oligonucleotides encoding either 2- or 6-histidine tails
and a stop codon at the 3’ end were inserted in a BamH1/EcoR1 digested pGEM vector.
The construct was transferred to the expression vector pT5T, and transferred to E. coli
strain BL21/DE3. Bacterial stocks were prepared in 15% glycerol and stored at -80 °C.
For protein expression Luria-Bertani medium containing 50 µg mL-1 ampicillin
was used. Medium (3 L) was inoculated with 3 x 30 mL of an overnight culture that
had been inoculated with the frozen bacteria and grown at 25 °C with shaking. The
culture was grown with shaking at 37 °C to an optical density of 0.8 at 550 nm at which
point IPTG (100 mg L-1) was added. After growth for a further 150 min at 37 °C with
shaking, cells were harvested by centrifugation at 400 x g for 15 min at 4°C. Bacterial
pellets were resuspended in 30 mL of cold wash buffer, followed by centrifugation at
8,000 x g for 15 min at 4 °C. The supernatants were discarded and the pelleted bacteria
were frozen. Cells were thawed and resuspended in 60 mL of cold lysis buffer (25 mM
Tris-HCl, pH 7.8, 0.5 M NaCl, 8 M urea) containing 20 mM imidazole, and lysed by
sonication. The lysate was centrifuged at 167,000 x g in a Beckman 55.2 Ti rotor for 30
min at 6°C. The supernatant was passed over a 2-mL NTA agarose column (QIAGEN)
(Schmitt et al. 1993) that was preloaded with 10 mL of 50 mM NiSO4 and equilibrated
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Chapter 3. Human hepatic asialoglycoprotein receptor
in lysis buffer containing 20 mM imidazole. The column was washed with 10 mL of
lysis buffer containing 20 mM imidazole and eluted with a stepped gradient consisting 
of 3 column volumns each of lysis buffer containing 50 mM, 100 mM and 200 mM
imidazole, followed by 6 column volumes of lysis buffer containg 10 mM EDTA. 
Elution fractions were analysed on SDS-polyacrylamide gels.
3.2.3 Gel Filtration chromatography and chemical crosslinking
Gel filtration characterisation of extracellular domains and neck regions were
performed using an Amersham Pharmacia Biotech Superdex 200 FPLC column. The
column was equilibrated in 10 mM Tris-Cl, pH 7.8, 100 mM NaCl and 2.5 mM EDTA
at a flow rate of 0.5 mL min-1. Data were collected and processed using the UNICORN 
software.
Crosslinking was performed using the homobifunctional reagents
bis(sulphosuccinimidyl)suberate (BS3) and 1,5-difluoro-2,4-dinitrobenzene (DFDNB)
(Pierce Chemical Co., Rockford, USA). Before crosslinking, the protein was purified
by gel filtration, using the column equilibrated in 25 mM HEPES, pH 7.5 and 100 mM
NaCl at a flow rate of 0.5 mL min-1. The protein (~10 μg/mL ) was allowed to interact
with different concentrations of the crosslinking reagents in a volume of 25 μL for one
hour at room temperature and the reactions were stopped by adding 2 x sample buffer
containing β-mercaptoethanol. All the samples were immediately analysed on SDS­
polyacrylamide gels (Laemmli 1970).
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Chapter 3. Human hepatic asialoglycoprotein receptor
3.2.4 Analytical methods
SDS-polyacrylamide gel electrophoresis, protein concentration measurements, gel
filtration, circular dichroism and differential scanning calorimetry were conducted
under the same conditions as human MGL (Section 2.2). In the case of ASGPR-1, 
circular dichroism was used to monitor the effects of the presence of Ca2+ on structure
content and determine binding kinetics. To perform this, spectra were acquired from the
same sample, first in the absence of Ca2+, removed by dialysis and then adjusting the
concentration of CaCl2 to 1, 2, 5, 10, 20, 50 and 100 μM, using the same protein sample
to avoid other variables. Circular dichroism data was also analysed using three software
programmes based on different analytical methods: K2D3 based on neural networks
(Louis-Jeune et al. 2011), SELCON2, a multiple selection method (Sreerama and
Woody 1993) and CONTIN, based on ridge regressions (Provencher 1982).
3.2.5 Affinity tag of ASGPR-1 by mutation of binding site and formation of hetero­
oligomers
A double-stranded synthetic oligonucleotide encoding the mannose-binding 
sequence of human LSECtin was used to change the sequence in the CRD of ASGPR-1 
to encode EPNDAWGR in place of native QPDDWYGHGLGGG by overlap extension
PCR, using as template a previously created pGEM construct containing the
extracellular region of ASGPR-1. The construction was transferred into a pT5T vector
and expressed in E. coli strain BL21/DE3. 
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Chapter 3. Human hepatic asialoglycoprotein receptor
Purification of the protein was performed analogously to purification of native
extracellular region of ASGPR-1, except that after renaturation by dialysis, affinity
chromatography was performed on a mannose-Sepharose affinity column.
Hetero-oligomers containing both mannose-binding ASGPR-1 and native 
ASGPR-2 were isolated by double affinity chromatography. The subunits were mixed
in different ratios and analysed by SDS-PAGE to determine the amount to be used in 
order to get an approximate ratio of 1:1 for the two subunits. After mixing the proteins,
CaCl2 was added to a concentration of 25 mM and the sample was first loaded on a 5­
mL galactose-Sepharose column equilibrated with loading buffer. Chromatography was
done as when purifying the extracellular domain (ECD), and the fractions were
analysed by SDS-gel electrophoresis. The fractions that bound to the column were
repurified on a 5-mL mannose-Sepharose column. An alternative way of purifying the
hetero-oligomer, which gave a slightly higher yield, consisted of extracting the protein
resulting from 6 L of culture of bacteria producing ASGPR-2 and 3 L of culture of
bacteria producing ASGPR-1. The inclusion bodies were collected, extracted,
denatured and refolded as reported for the ECDs of the individual proteins and  hetero­
oligomers were purified first on a 5-mL galactose-Sepharose and then on a 5-mL 
mannose-Sepharose as in the first approach.
3.2.6 Competition assays
The engineered ECD of ASGPR-1 was immobilised in Immulon-4 polystyrene
wells in a 96-well plate from Dynex Technologies (Chantilly, VA, USA) by overnight
incubating with 50 μL of 10 μg/mL protein in loading buffer (25 mM Tris-HCl, pH 7.8,
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Chapter 3. Human hepatic asialoglycoprotein receptor
0.15 M NaCl, 25 mM CaCl2) at 4 °C. The plate was washed with loading buffer and
blocked with loading buffer containing 5 % BSA for 2 h at 4 °C. After a second
washing with loading buffer, aliquots (100 μL) of mannose or GlcNAcβ1-2Man
solutions were added to individual wells and double dilutions were made in loading 
buffer, leaving all wells with a volume of 50 μL, after which 50 μL of 2X buffer 
containing 0.3 M NaCL, 50 mM Tris-Cl, pH 7.8, 50 mM CaCl2, 0.2% BSA and 10
μg/mL 125I-mannose-BSA were added. The plate was incubated for 2 hours at 4 °C.
After three washes with loading buffer, the wells were individually analysed on a
Wallac 1470 Wizard gamma counter. The samples were run in duplicate for the assays
and data were fitted using a nonlinear least squares fitting algorithm (Sigmaplot) to
determine concentrations of competing ligand required for 50% inhibition of reporter
ligand binding.
3.2.7 Expression of tetrameric asialoglycoprotein receptors CRDs and glycan array
analysis
The CRDs of these proteins were subcloned from pGEM vectors encoding the
full length extracellular domains. Synthetic oligonucleotides were used to append a 15­
amino acid biotinylation sequence at the C termini of the CRDs. The constructs were
made by PCR and the sequences were subcloned into the expression vector pT5T. The
biotinylated proteins were expressed in E. coli strain BL21/DE3 containing plasmid
pACYC-184 encoding the birA gene (Avidity, Denver). Bacterial stocks were kept
frozen.
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Chapter 3. Human hepatic asialoglycoprotein receptor
Luria-Bertani medium (2 L) containing 50 µg mL-1 ampicillin and 20 µg mL-1 
chloramphenicol, was inoculated with 2 x 30 mL of an overnight culture. The culture
was grown with shaking at 37 °C until the optical density at 550 nm reached 0.7, at
which point IPTG (100 mg L-1) and biotin (150 mg L-1, dissolved in 50 mM sodium
phosphate buffer, pH 7.5) were added. After growing for further 150 min, the cells
were harvested and the proteins were extracted analogously to the extracellular regions.
Correctly folded proteins were purified by affinity chromatography on
galactose-Sepharose columns (2 mL) pre-equilibrated with loading buffer (5 column 
volumes) and eluted with 6 column volumes of eluting buffer (1.25 M NaCl containing 
25 mM Tris-HCl, pH 7.8 and 2.5 mM EDTA), in 1 mL fractions. All fractions were
analysed on SDS-polyacrylamide gels. The integrity of the proteins was checked by
Western-blot analysis using streptavidin coupled to horseradish peroxidise and by
sequencing ten amino acids at the N-terminus of each.
The purified proteins were allowed to interact with Alexa Fluor 488-labelled
streptavidin after addition of CaCl2 to 25 mM. The reaction was performed with 0.4-0.6
mg of the proteins and 0.1 mg of the fluorescently marked streptavidin, diluted in 1 mL
of eluting buffer as previously described (Powlesland et al. 2008). After overnight
incubation at 4 °C, the proteins were purified on galactose-Sepharose columns. The
active fraction for ASGPR-1 and MGL were further purified by gel filtration 
chromatography using an Amersham Pharmacia Biotech Superdex 200 FPLC column 
after addition of EDTA (2.5 mM). The correctly formed tetramers were sent to Core H
of the Consortium for Functional Glycomics (http://www.functionalglycomics.org), for 
100
 
  
 
 
 
    
  
  
  
  
   
  
  
  
  
    
  
  
   
 
 
    
  
    
   
 
Chapter 3. Human hepatic asialoglycoprotein receptor
screening version 3.1 glycan arrays for all the CRDs. ASGPR CRD was additionally
screened on version 4, following the standard Core H protocols.
3.2.8 Mass spectrometry analysis
The neck of ASGPR-1 was analysed by electrospray ionisation mass
spectrometry, kindly performed by Maria Panico (Imperial College London). The
protein was dissolved in 30 and 60 % acetonitrile containing 0.1 % TFA and analysed
using a hybrid quadrupole orthogonal acceleration time of flight mass spectrometer
(Micromass, UK). Data were acquired in the positive mode, using collision energies
between 50-90 eV. Data were processed using Masslynx (Micromass, UK).
3.2.9 Software analysis
The model of the neck was generated by automated remote homology
modelling, using the sequence of the experimentally expressed neck without the added
histidines, on CPHmodels 3.0 (Nielsen et al. 2010), using as template the sequence and 
structure of Ndel1 (PDB 2V71). An alternative mode of modelling the neck was created
by cutting the neck region of langerin (PDB 3KQG), repeating it until a sequence equal
in amino acid number to the neck of ASGPR-1 was achieved. The construction was
made in Coot 0.6.1 (Emsley et al. 2010). Both models were adjusted to avoid clashes,
regions of high energy and violations of the Ramachandran plot and hydrodynamic
calculations were made using HydroPro bead models (García de la Torre et al. 2000; 
Ortega et al. 2011). 
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Chapter 3. Human hepatic asialoglycoprotein receptor
3.3  Results
3.3.1 Expression and purification of ASGPR subunits
In a similar way to what was done with human MGL, the ECDs and CRDs of 
both ASGPR subunits were expressed in expression vector pT5T (Figs. 3.1 and 3.2). In
addition, extended forms of CRDs (E-CRD) were created, including a region 
immediately adjacent to CRD that is predicted to possess a low probability of helical
structure and that seemed to connect the theoretically alpha-helical neck domains to the
CRDs. In the case of ASGPR-1, this corresponds to the segment starting at Glu118 and 
in the case of ASGPR-2, it starts at Ala141 (Fig. 3.1). All the versions correspond to
isoform 1 of each subunit, which is the canonical sequence in each case.
All the proteins were directed to inclusion bodies that were initially separated
by centrifugation, then denatured with guanidine hydrochloride and finally refolded by
dialysis. While the sequences of the two subunits are highly similar, their stability and
folding behaviours are dissimilar. ASGPR-1 ECD requires the addition of Triton X-100
to avoid unfolded hydrophobic regions interacting in undesired ways that lead to
precipitation and renaturation was most efficient when it was diluted prior to dialysis, 
the same treatments resulted in diminishment of ASGPR-2 ECD yield. As with the
CRD of MGL, none of the CRDs or E-CRDs of the ASGPR subunits required the
presence of detergent or dilution prior to dialysis (Fig. 3.2).
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150125 
CRDS 175SS S 200 
KHFPVDLRFVACQMELLHSNGSQRTCCPVNWVEHQGSCYWFSHSGKAWAE 
S 225 250 
AEKYCQLENAHLVVINSWEEQKFIVQHTNPFNTWIGLTDSDGSWKWVDGT 
S 
275 S S 300 
DYRHNYKNWAVTQPDNWHGHELGGSEDCVEVQPDGRWNDDFCLQVYRWVC 
EKRRNATGEVA 
Neck 
“Loop” 
CRD 
S SProbable disulphide bond 
Origin of observed CRD fragments 
Figure 3.1. Expressed versions of ASGPR subunits. 
Sequences correspond to reference sequence in UniProt. The starts of constructions are 
indicated with arrows. Possible sites for digestion based on fragment size and accesibility 
with reference to the crystal structure of the ASGPR-1 CRD (Fig. 1.1). Blue marks 
correspond to digestion with subtilisin and red marks correspond to digestion with trypsin. 
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ASGPR-2 Extended CRD 
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Figure 3.2. Expression and purification of the CRDs and Extended CRDs of ASGPR­
1 and ASGPR-2. 
For both subunits, their sequences were subcloned from pGEM3 vectors carrying the 
ECD sequence. The elution fractions were analysed by 17.5 % SDS-PAGE, loading 20 
�L. Gels were stained with Coomassie Blue. 
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Chapter 3. Human hepatic asialoglycoprotein receptor
3.3.2 Difference in specificities for receptor subunits
Information about the ligand-binding specificity of each ASGPR subunit was
obtained by glycan array analysis. MGL was also analysed in order to have
comparative data from a protein at least a partially stable homo-oligomer in vivo. 
Glycan arrays test the ability of lectins to bind a wide variety of complex glycans and
can mimic the interactions that happen in vivo (Drickamer and Taylor 2002; Maierhofer
et al. 2007). This kind of analysis is useful to establish information about natural
ligands, which have not yet been well defined for the asialoglycoprotein receptor. Due
to the generally low affinity of glycan-binding receptors towards glycans and in order
to get comparable results between ASGPR-1, ASGPR-2 and MGL subunits, tetramers
were formed by tagging CRDs with biotin to allow interaction with the four binding 
sites of fluorescently tagged streptavidin (Fig. 3.3). This strategy has already been used 
to compare properties of mouse DC-SIGN-related proteins (Powlesland et al. 2006).
Complete data for glycan arrays presented in this dissertation can be found in the
appendix.
The data obtained from the arrays suggest that the specificities of ASGPR-1 and
MGL CRDs are similar (Fig. 3.4). The ligands towards which ASGPR-1 showed 
highest specificity were O-linked glycans with exposed GalNAc or galactose residues
at the non-reducing end, with a preference for GalNAc as was previously found for the
rat receptor (Drickamer, 1992; Coombs et al., 2006). The ligand that showed the
highest signal was a structure similar to ABO blood groups, but modified with an α1-4 
linked GalNAc residue (GalNAcα1-4(Fucα1-2)Galβ1-4GlcNAc). A similar structure,
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Chapter 3. Human hepatic asialoglycoprotein receptor
with β1-3 linked GalNAc (GalNAcβ1-3(Fucα1-2)Gal), was also well recognised. These
structures are shared ligands with MGL. Two of the most preferred ligands, GlcNAcβ1­
6GalNAc and Galβ1-4GlcNAcβ1-6GalNAc, confirmed that substitution on the 6­
position of GalNAc is not only well tolerated, as it does not interfere with the
interaction of 3- and 4- hydroxyl groups with Ca2+ ions, but that a substitution with
GlcNAc enhances the interaction as has been reported (Park et al. 2003), probably as a
result of secondary contacts. However the results did not show a particularly high
affinity toward Siaα2-6GalNAc or Siaα2-6Gal. One of the ligands that is bound with 
medium affinity bears a Siaα2-6Gal modification (NeuAcα2-6Galβ1-4GlcNAcβ1­
2Manα1-3(Galβ1-4GlcNAcβ1-2Manα1-6)Manβ1-4GlcNAcβ1-4GlcNAc). However
this glycan has a galactosyl substituent in its other branch that could serve to improve
the binding of ASGPR-1. Previous studies  have suggested binding of the
asialoglycoprotein receptor to glycoproteins that present 2,6-linked sialic acid, acting as
a buffer for these glycoproteins (Park et al. 2003; Steirer et al. 2009). Examples of such
glycoproteins are serine protease inhibitor clade A member 1A, carboxylesterase, α1-B 
glycoprotein, inter-α trypsin inhibitor heavy chain 4, IgM, haptoblobin and soluble
amyloid precursor protein. This specificity of the receptor has not been corroborated by
our studies.
One of the most prominent ligands for MGL CRD was a monoantennary
carbohydrate that is substituted with GlcNAc on the 3- position of galactose. This result 
is surprising, as this substitution would interfere in the coordination of Ca2+ ions and 
needs to be checked in future studies. All the other detected ligands bear exposed
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Chapter 3. Human hepatic asialoglycoprotein receptor
galactose or GalNAc residues. Comparing the results with the previously analysed rat
macrophage galactose/GalNAc lectin (rMGL) (Coombs et al. 2006) it can be seen that
the two proteins bind similar sets of sugars. Although the human protein binds glycans
with terminal Gal or GalNAc residues, in two branches, as does rMGL, the best ligands
are linear and preferentially have one terminal GalNAc, including 6-LacNAc-Tn. 
LacNAc has been previously reported to be bound, but with low affinity by MGL (van 
Vliet et al. 2005), and the Tn antigen has been suggested as a natural ligand (Suzuki et 
al. 1996). Like rMGL, human MGL also binds glycans with adjacent fucose or NeuAc
residues, which are shared ligands with ASGPR-1. Compared to ASGPR-1, MGL does
not show strong preference for GalNAc over galactose. This difference probably results
from differences in region 1 of the CRD that modify the position of His256 as has been
reported for RHL-1 and rMGL (Iobst and Drickamer 1996).
The overlapping activity of ASGPR and MGL has been shown in a previous
study in which they both were shown to clear asialofetuin and GalNAc-α-O-methyl 
glycoside which mimics the Tn antigen (Wahrenbrock and Varki 2006). That study
provided evidence that both receptors, in mice, have a role in the elimination of mucins
in bloodstream arising from either tumors or inflammation states but did not show they
were the main receptors involved in the process, which involves other hepatic
receptors.
The results from ASGPR-2 were not conclusive. The recombinant protein ran 
anomalously on SDS-PAGE, appearing to be ~10 kDa smaller in size than its
calculated molecular weight, while the CRDs of ASGPR-1 and MGL ran as expected.
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Chapter 3. Human hepatic asialoglycoprotein receptor
Such behaviour is highly anomalous as its sequence does not show to possess an 
unusual number of charged amino acids. However, expressed ASGPR-2 was functional, 
since it bound tightly to galactose-Sepharose. The presence of the biotin tag was
confirmed by western blot analysis, using streptavidin-alkaline phosphatase conjugate,
which confirmed the integrity of the COOH-terminus. N-terminal amino acid sequence
also confirmed that ASGPR-2 was not suffering degradation. The ASGPR-2 CRD­
streptavidin complex was analysed twice and the results indicate that it did not bind any
ligand with high affinity in the glycan array. This result can be interpreted as a
difference in function of the ASGPR-1 and ASGPR-2 subunits. While the primary
binding to ligands would occur via ASGPR-1, ASGPR-2 might have a more
supplementary role. When being purified by affinity chromatography, ASGPR-2 does
not bind as tightly as ASGPR-1, which supports this interpretation. The difference in
specificity has been previously suggested by analysis of ASGPR-2 homo-oligomers
that circulate intracellularly and do not bind asialo-orosomucoid (Saxena et al. 2002). 
The presence of ASGPR-2 in hetero-oligomers, which is necessary for binding of
asialo-orosomucoid in normal levels of expression, might help to create a special spatial
organisation of CRDs, analogous to the one proposed by Ramadugu (Ramadugu et al.
2010).
As noted in Chapter 1, it has been suggested that a major function of ASGPR is
removal of clotting factors from blood that may increase the formation of clots after
desialylation occurred during acute infections (Grewal et al. 2008). However, the
receptor has been proved to be flexible and involved in other processes of
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internalisation for further degradation (Park et al. 2003). The identification of these 
ligands can be helped by analysing the glycoconjugates that present the structures
recognised by ASGPR-1 in this study.
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3.3.3 Independence of domains
Partial proteolytic digestions of ASGPR ECDs showed a similar result to that 
observed in the case of MGL (see Chapter 2). Both subtilisin and trypsin degraded the
protein, even in the lowest concentrations (Fig. 3.5). Trypsin left intact the CRD of both
subunits, probably cutting at Arg151 for ASGPR-1 and at Arg158 for ASGPR-2.
Subtilisin, on the other side, degraded the CRDs of both subunits, cutting probably in
the long loop in which the binding site is located.
The calorimetric data from ASGPR-1 ECD shows that it behaves as a unit, in a
similar way to MGL ECD, with a Tm of 58.7 °C (Fig. 3.6). Similar to MGL, the event is
dominated by CRD denaturation probably masking the neck region denaturation, which 
probably occurs at a lower temperature.
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3.3.4 Partial instability of homo-oligomers of asialoglycoprotein receptor
extracellular domains
The ability of asialoglycoprotein receptor subunits to form homo-oligomers has
been previously reported as well as their presence in human serum (Yago et al. 1995; 
Saxena et al. 2002; Liu et al. 2010). However, there has been no study to quantify the
stability of such homo-oligomers which could be used to test the idea that the
asialoglycoprotein receptor is formed with a core of homo-oligomeric ASGPR-1 to 
which ASGPR-2 is attached. 
In an attempt to characterise homo-oligomeric fragments of the ECD of
ASGPR-1 and ASGPR-2, both were analysed by gel filtration. In the case of ASGPR-1, 
the elution position of the isolated CRD on gel filtration is approximately 25 kDa,
compared to calculated molecular weight of 18 kDa. A similar elution position has been
observed for the CRD of DC-SIGN, which is a well characterised monomer (Mitchell
et al 2001; Snyder et al 2004).
Both the extended CRD and the full ECD elute at apparent molecular weights of
45 kDa (Fig. 3.7). For the extended CRD, this might correspond to the formation of a
dimer of 20 kDa fragments, but it is somewhat smaller than the expected size of a dimer
of ECD fragments of 25 kDa. Experiments with the ECD at different concentrations
revealed that the elution position varies with concentration (Fig. 3.8), reaching a plateau
of 50 kDa. This behaviour is due to the fact that, in a polydisperse particle population in 
equilibrium, the system reacts to the increase in availability of building blocks by
increasing the formation of the higher molecular weight species. These results suggest
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Chapter 3. Human hepatic asialoglycoprotein receptor
that the ECD may form a dissociating oligomer, perhaps a dimer. It is difficult to know
if the oligomers formed by the extended CRDs are natural or are artefacts provoked by
the removal of the neck as explained in Chapter 4.
The oligomerisation state of the isolated subunits was also studied in protein-
protein crosslinking experiments using a bifunctional N-hydroxysulphosuccinimidyl
ester (BS3) and difluorodinitrobenzene. The results show that the extracellular domain 
of ASGPR-1 in vitro can be crosslinked to give some dimer and even less trimer (Fig.
3.9). The crosslinking was inefficient, consistent with the suggestion that the oligomers
are not very stable in the absence of ASGPR-2. 
The behaviour of ASGPR-2 was more complex, with the extended CRD eluting
as a monomer at 20 kDa and the ECD eluting at 35 kDa, which suggests that there is
little self-association of these fragments. The CRD eluted as two peaks that might
correspond to monomeric and dimeric forms. Dimerisation of CRDs when they are
separated from adjacent domains has been observed in the case of mannose-binding 
protein (Ng et al. 1996), as discussed in Section 1.8.
Taken together, these results suggest that the separate subunits do not form
stable, well defined oligomers.
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Figure 3.7. Elution profiles of the ECDs, CRDs and extended CRDs of ASGPR 
subunits on size exclusion chromatography. 
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and 2.5 mM EDTA. The markers correspond to bovine thyroglobulin, E. coli β­
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117 
Protein concentration (mg mL )
-1
0 0.02 0.04 0.06 0.08 0.10 0.12
A
p
p
a
re
n
t 
M
W
 (
k
D
a
)
25
30
35
40
45
50
55
Figure 3.8. Relation between the hydrodynamic radius of ASGPR-1 ECD homo-
oligomers and its concentration analysedby gel filtration chromatography.
The Superdex column was equilibrated with 10 mM Tris-HCl (pH 7.8), 100 mM NaCl and
2.5 mM EDTAand chromatography was monitored at 280 nm.Apparent molecular weight
was calculated by linear regression, using the molecular weight markers depicted in Fig.
3.7.
118
Chapter 3. Human hepatic asialoglycoprotein receptor
Figure 3.9. Chemical crosslinkingof theASGPR-1 extracellular domain.
A. Results obtained using the homobifunctional reagent . B. Results obtained using
DFDNB. ASGPR-1 purified by affinity chromatography was allowed to interact with
different concentrations of the reagents diluted in 25 mM HEPES (pH 7.5) and 100 mM
NaCl. After 1 h at RT, reactions were stopped by adding sample buffer containing 2-
mercaptoethanol and samples were directly analysed on 17.5 % SDS-polyacrylamide
gels stained with Coomassie blue.
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3.3.5 Structure content
The secondary structure content of the various versions of the two ASGPR
subunits was compared by circular dichroism spectroscopy. All the spectra were 
normalised to the amount of protein present, but the results from the CRDs, which were
present only in limited amounts, are quite noisy, so the primary comparison made was
from the extended CRDs and the ECDs, which differ only by the presence of the neck
region, that is composed of heptad repeats.
The spectra of the CRDs are complex, showing a mixture of α-helical and β­
structures and turns, as reflected in the 3-dimensional structure of the CRD (See Fig.
1.1). The calculated content deduced from the structure of the ASGPR CRD alone is
compared with the content deduced from the extended CRD fragments using two
different deconvolution programmes (Table 3.1). In order to determine if the neck
region contributes to the α-helical content of the molecule, we calculated the difference
in signal between the extended CRDs and the ECDs for both subunits (Fig. 3.10 and
Fig. 3.11). The difference spectrum for ASGPR-1 shows the minima at 206 and 222 nm
typical of helical structures, which represent the π-π║* transition and that is one of the
bands that correspond to helical structure (Chen et al. 1974). This difference spectrum
is typical of that expected for a coiled-coil, in which the ratio of Θ222/Θ206 is 1.08 (Fig.
3.11). Values greater than 1 are associated with the super-helical patch of coiled-coils
(Lau et al. 1984; Wang et al. 1999; Whitmore and Wallace 2008). Based on a length of
77 residues for the neck region, the mean residue ellipticity at 222 nm is calculated as
Θ222 = 5 X 106 Deg∙cm2/dmole/77 residues = 64935 Deg∙cm2/dmole. This corresponds
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Chapter 3. Human hepatic asialoglycoprotein receptor
to a largely α-helical content (Chen et al. 1974). However, when the value for the E­
CRD is substracted from the ECD values, the spectrum generated is very different. It
suggests that the E-CRD has an aberrant structure, which again indicates that the
oligomers observed in gel filtration may not be natural structures.
The calculation made for ASGPR-2 was only done using the ECD and the E­
CRD. ASGPR-2 presented a difference spectrum with a different shape, as the
minimum at 206 nm is deeper than that of 222 nm., and the spectrum is not typical of
an α-helical structure. 
When analysing the different versions of the molecules by circular dichroism a
difference in the spectra was noted when Ca2+ was added to the buffer. The addition 
caused an increase of signal at ~232 nm and a dip at 234 nm in the CD spectra of the 
ECD of ASGPR-1 and ASGPR-2, in the E-CRD and CRD of ASGPR-2. Although it is
normally assumed that the contribution of aromatic residues to CD spectra is low in the
UV region, conformation-dependent signals for tryptophan in the 230-235 nm region 
have been noted (Grishina and Woody 1994; Woody 1994). The Ca2+-dependence of
the signal was quantified by measuring the difference between the ellipticities at 231.5 
and 234 nm (Fig. 3.12). The change can be modelled by simple first-order dependence
of Ca2+ concentration, with a KCa = 8 µM.
One possible source of an aromatic signal is the tryptophan residue that lies
directly under the cis-proline residue in the QPD sequence in Ca2+ binding site 2 (Fig.
3.13 A). The Ca2+-dependence of sugar ligand binding is second order, with a KCa ≈ 0.5 
mM (Wragg and Drickamer 1999). This constant incorporates the linked binding of two
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Chapter 3. Human hepatic asialoglycoprotein receptor
Ca2+, at sites 1 and 2, but the contributions of individual sites are not known, so this
signal may provide a way of obtaining insight into the separate interactions of the
individual sites. In this case, the presence of a negative peak at 235 nm from the
extended CRD of ASGPR-1 might reflect a low level of contamination with residual
Ca2+ in the sample.
Alternatively, the signal might reflect binding of Ca2+ at a third site observed in 
the crystal structure of ASGPR-1 CRD at the N-terminal end of helix 2 (Site 4 in Fig.
1.1 and Fig. 3.13 B). Nothing is currently known about the affinity of this site for Ca2+ . 
This interpretation would be consistent with the absence of a peak near 235 nm in the
CD spectrum of the CRD from mannose-binding protein, which does not contain this
site (Weis and Drickamer 1994). In this case the difference in the behaviour of the ECD
and E-CRD of ASGPR-1 would reflect a change in the structure of this portion of the
CRD when the neck region is removed, which could affect one or more of the several
aromatic residues that are associated with helix 2. This would then be the first time a
measurement is done of a Ca2+-binding site not involved directly in carbohydrate
binding. As this Ca2+ binds at a much lower concentration than the ones needed for
carbohydrate binding, it would be undetectable when monitored by glycan binding 
ability. Measurements of individual binding sites are difficult as many times different
states with different binding sites occupied do not follow a straightforward path (Ng 
and Weis 1998). Experimentally measured constants may also correspond to the
geometric mean of simultaneously occurring phenomena (Keller et al. 1982; 
Kavanaugh et al. 1992; Ng and Weis 1998).
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Structure α-helix β-strand
Method K2D3 SELCON2 CONTIN K2D3 SELCON2 CONTIN
ECD 0.06 0.29 0.01 0.34 0.18 0.51
CRD 0.04 0.33 0.11 0.37 0.22 0.31
ECD ­ CRD 0.14 0.65 0.08 0.34 0.25 0.34
ECD - ECRD 0.01 0.17 0.01 0.15 0.05 0.27
Isolated neck 0.02 0.14 0.05 0.23 0.18 0.60
Table 3.1. Deconvolution of circular dichroism data. 

The results from three different programmes are shown. K2D3 is based on neural
 
networks, CONTIN on ridge regression and SELCON2 is a variable selection 

method.
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Figure 3.10. CD analysis of the ECDs, extended CRDs and CRDs of ASGPR
subunits in presenceandabsenceof 10mMCaCl .2
Blue lines correspond to spectra recorded in absence of Ca . CaCl was added up to a
concentration of 10 mM and the red spectra were recorded afterwards. The graphs
represent the average of 10 spectra each. All were obtained in 25 mM NaCl, 5 mM Tris-
HCl, pH 7.8.ExceptASGPR-2 CRD which was analysed at 0.05 mg/mL, the proteins were
analysed at a concentration of 0.2 mg/mL.
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Figure 3.11. Neck segment circular dichroism signal calculated from substraction
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Figure 3.12. Analysis of the effect of Ca on the secondary structure content of
ASGPR-1ECD.
2+
A. Difference between [ ] and . The line corresponds to a curve for first order
binding fitted to the experimental data. Ten spectra were recorded for each concentration
and data was averaged. All were obtained in 25 mM NaCl, 5 mM Tris-HCl, pH 7.8 and the
protein had a concentration of 0.2 mg/mL. B.Averaged original data.
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A. Shows Ca -binding sites 1 and 2. The tryptophan residues marked in magenta are
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3.3.6 Stability of homo-oligomers of neck portions of ASGPR-1
It has been previously suggested that asialoglycoprotein receptor subunits
interact primarily through their neck regions, forming α-helical coiled coils and that the
ASGPR-1 neck is able to form homodimers and homotrimers in cross-linking st udies
(Bider et al. 1996). In order to test the ability of ASGPR-1 neck region to form such
homo-oligomers, it was expressed in isolation, free of the CRD.
Two strategies were designed to purify the neck region, illustrated in Fig. 3.14. 
The first approach was based on the assumption that the neck regions form oligomers.
The polypeptides were tagged with 2-histidine tags following a strategy used for the
neck region of DC-SIGN (Feinberg et al. 2009). These tags are shorter than the
commonly used 6-histidine tag. However they were sufficient to selectively purify
asialoglycoprotein receptor neck oligomers, because after formation of homo­
oligomers, histidines from single chains form a group that can bind Ni2+. The shorter
tags would be less likely to affect the behaviour of the oligomers, eliminating the need
to remove them by proteolysis. Neck polypeptide was purified in this way, although it
eluted from the NTA-agarose column at low imidazole concentration and the yield was
low (Fig. 3.15 A).
The second strategy consisted in the purification of the neck region under
denaturing conditions. As they were going to be purified as monomers, they were
tagged with 6-histidine tags. It proved possible to purify ASGPR-1 neck in a good yield
using this method (Fig. 3.15 B). Identification of the neck was performed by 
electrospray ionisation mass spectrometry (ESI-MS) which showed a maximum peak 
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for the expected mass of the polypeptide (Fig. 3.16). Other peaks, that differ by 43 Da,
probably corresponded to successive carbamylations that can occur onto lysine side
chains. Other unknown modifications took place, showing differences in 20 Da. The
purification with urea accounts for this modification, as urea is in equilibrium with
ammonium isocyanate in solution, and isocyanate attacks the side chains of arginine
and lysine residues (Stark 1965).
The purified neck from ASGPR-1 was analysed in a similar way to that of
extracellular domains by gel filtration chromatography. The chromatography was
monitored at 214 nm due to the absence of aromatic residues in the neck region of the
protein. As can be seen from the chromatograms (Fig. 3.17), the ASGPR-1 neck seems
to form stable trimers, apparently corroborating the results obtained by Bider et al.
(Bider et al. 1996) who studied this region by chemical crosslinking analysis. However,
using a very rough model of the neck based on a purely alpha helical structure,
constructed by threading to a coiled-coil region of Ndel1 (PDB 2v71 (chainA)) after
which the model was further adjusted using Coot software to eliminate clashes, regions
of high energy and violations in the Ramachandran plot, calculations using a HydroPro
bead model (García de la Torre et al. 2000) gave a theoretical RS of 24 Å, which shows
that the peak observed in gel filtration may correspond to a monomeric species. The
problem arises from the cylindrical shape of the molecule. The necks of DC-SIGN and 
DC-SIGNR have also proved to present different sedimentation and diffusion 
coefficients than those expected due to their elongated nature (Feinberg et al. 2005). A
calculation of the difference in Stokes radius from the alpha helical model of ASGPR-1 
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Chapter 3. Human hepatic asialoglycoprotein receptor
neck as previously mentioned, ∆𝑅𝑆 = ║𝑅𝑆 − ┴𝑅𝑆, indicated that the difference in it due
to the molecule position can be as big as 40 Å.
The neck region contains a repetition of heptad motifs that contribute to its high
stability as an oligomer that theoretically forms coiled coils. Bider et al. (Bider et al.
1996) suggested that this stability is, nevertheless, not enough for the stability of the
whole protein as it was stated that its melting point appears to be lower than
physiological temperature in a result not shown. The presence of the CRD in homo­
oligomers formed by ASGPR-1 may destabilise the structure at the proximal region as
it possibly needs the presence of the ASGPR-2 subunit to form a more stable complex.
Circular dichroism spectroscopy of the isolated neck (Fig. 3.18) showed 
different structure content to that calculated from the difference of structure content
between the ECD and CRD as it was more similar to the one calculated for ASGPR-2 
in shape. The content of alpha helix was also lower and just accounted for 16 % as
analysed by CDNN, with a high content (47 %) of random coil. The difference may
arise from the fact that the CRD is necessary for stability of the oligomer, a fact
previously shown by size exclusion chromatography. The isolated neck may not be
forming oligomers and therefore parts of its structure that should be forming coiled-
coils are not behaving as such. The minimum at 202 nm shown by this spectrum
however has been observed in synthetic poly-L-glutamine coils (Chen et al. 1974)
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Figure 3.15. Purification of His tagged ASGPR-1 by affinity chromatography on
Ni -NTA-Agarose.
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A. In native conformation and B. under denaturing conditions (urea). Both panels show
17.5% SDS-polyacrylamide gels stained with Coomassie blue.
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Figure 3.16. Transformed data from electrospray mass spectrometry of ASGPR-1
neckdomain.
The blue lines correspond to differences in 43 Da, attributable to carbamylations. The
orange lines correspond to differences in 20 Da, of unknown origin and which could be
combination of different modifications . Mass spectrometry run by Maria Panico.
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Figure 3.17. Elution profile of the neck domain of ASGPR-1 on size exclusion
chromatography.
The Superdex 200 column was equilibrated with 10 mM Tris-HCl (pH 7.8) and 100 mM
NaCl. The markers correspond to carbonic anhydrase, horse myoglobin and bovine lung
aprotinin. Chromatography was monitored at 216 nm due to the absence of aromatic
groups inASGPR-1 neck. Protein concentration was 0.5 mg/mL.
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Figure 3.18. Secondary structure content of the neck domain ofASGPR-1 analysed
bycircular dichroism.
The graph represents the average of ten spectra recorded in 5 mM Tris-Cl, pH 7.8, 2.5 mM
CaCl and 25 mM NaCl. Protein concentration was 0.3 mg/mL.2
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Chapter 3. Human hepatic asialoglycoprotein receptor
3.3.7 Tagging of AGPR-1 by engineering its affinity and formation of in vitro hetero­
oligomers
A strategy of affinity tagging by changing specificity was developed in order to
facilitate characterisation and purification of hetero-oligomers. A similar procedure has
been successfully used to study the extracellular segment of DC-SIGNR (Guo et al.
2006). If two different subunits have different specificities, the presence of hetero­
oligomers can be demonstrated by double affinity chromatography using the different
preferred ligands of the subunits. Reversing the approach used with DC-SIGNR,
ASGPR-1 was engineered to change the QPD motif associated with affinity for
galactose to EPN, which is associated with affinity for mannose. The initial choice of a
sequence to give altered binding specificity was based on a search for a homologue
with the highest similarity but with a specificity other than galactose (Fig. 3.19).
In the first instance, a sequence from rat serum mannose-binding protein A
(MBP-A) was used, because the amino acid preceding the EPN motif is an aspartic acid 
in the rat protein, corresponding to a glutamic acid in ASGPR-1. The region transferred
into the ASGPR-1 subunit was a short sequence containing the “EPN” motif
characteristic of mannose-binding CRDs but lacking the adjacent region including a
tryptophan residue that forms part of the galactose-binding sites, but is not found in
mannose-binding sites. Although the engineered protein was produced in good yield, it
did not bind to mannose-Sepharose (Fig. 3.20).
A second attempt to change to mannose-binding specificity was based on
emulating the binding site of liver and lymph node sinusoidal endothelial cell C-type
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Chapter 3. Human hepatic asialoglycoprotein receptor
lectin (LSECtin), a lectin related to DC-SIGNR, that binds to mannose, GlcNAc and
fucose (Liu et al. 2004). The decision was taken due to the fact that LSECtin has a
higher affinity for mannose than MBP-A. Incorporating a similar segment of LSECtin
did result in successful binding to mannose-Sepharose affinity column (Fig. 3.21), 
although the affinity for mannose (KI = 17.1 mM) appeared to be lower than that of
LSECtin in solid phase binding competition assay (Fig. 3.22). The competition assay
(conducted with Dr. Zoi Pipirou) also showed that engineered ASGPR-1 binds
GlcNAcβ1-2Man, but does not show the much higher affinity for  this disaccharide in
relation to mannose that is shown by LSECtin (Powlesland et al. 2008). This difference
provides insight into the nature of the interaction of LSECtin with GlcNAcβ1-Man, 
since the enhanced affinity must not result from interactions in the main binding site of
the protein incorporated into ASGPR-1, but by secondary contacts with other regions of
LSECtin. The original specificity of the ASGPR-1 subunit for galactose was
eliminated, demonstrated in parallel experiments in which two aliquots of the
engineered protein were loaded onto galactose-Sepharose and mannose-Sepharose for
affinity chromatography (Fig. 3.21). The modified protein passed through the
galactose-Sepharose column but was retained by mannose-Sepharose. Some protein
was washed away in the purification by affinity for mannose, but this effect may be due
to the relatively weak binding of mannose and the intrinsic instability of ASGPR-1 
homo-oligomers. The inability of ASGPR-2 to bind mannose was demonstrated in a
similar test in which an aliquot of the protein was passed over a mannose-Sepharose
affinity column and the wash and elution fractions were analysed (data not shown). 
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VDGTDYETGFKNWRPEQPDDWYGHGLGGGEDCAHFTDDGRWNDDVCQR
VTGGRL--TYSNWKKDEPNDH-GSG----EDCVTIVDNGLWNDISCQA
VDGVSL--SFSHWNQGEPNDAWGR-----ENCVMMLHTGLWNDAPCDS
ASGPR-1
Rat MBP
LSECtin
Gal binding
Man binding
Gal-binding site Man-binding site
Figure 3.19. Engineeringmannose-bindingactivity into theCRDofASGPR-1.
Diagrams of galactose- and mannose-binding sites and alignment of sequences of native
ASGPR-1, which has a galactose-binding site, and mannose-binding proteins.
Sequences from rat mannose-binding protein and LSECtin that were inserted into
ASGPR-1 to change binding-specificity are indicated.
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Figure 3.20. Inability of mutated ASGPR-1 containing portions of the rat MBP-A
sequence tobindmannose-Sepharose.
The extract was passed over a 5-mL column. Wash fractions are 5 mL and elution
fractions 2 mL. 20 L of fractions were run on a 17.5 % SDS-polyacrylamide gel and
stained with Coomassie blue.
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Figure 3.21. Change from galactose-binding to mannose-binding affinity after
mutatingASGPR-1basedonLSECtin sequence.
Extracts were passed over a 5-mLcolumn. Wash fractions are 5 mLand elution fractions 2
mL. Aliquots (20 L) of fractions were run on 17.5 % SDS-polyacrylamide gels stained
with Coomassie blue.
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Figure 3.22. Solid-phase competition assays of binding of LSECtin and mutant
ASGPR-1.
Plates were coated with the ECD of mutantASGPR-1 ECD, based on LSECtin sequence.
Increasing concentrations of competing ligands were tested in the presence of I-
mannose-BSA, which served as a reporter ligand. Data were fitted to a non-linear least-
squares fitting algorithm using Sigmaplot. Experiment conducted with Zoi Pipirou.
LSECtin data are from Powlesland (Powlesland 2008).
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Chapter 3. Human hepatic asialoglycoprotein receptor
To create hetero-oligomers the affinity-modified ASGPR-1 was mixed with
native ECD of ASGPR-2, denatured and renatured by dialysis, before purification by
double-affinity chromatography, first on mannose-Sepharose and then on galactose-
Sepharose (Fig. 3.23). Following initial purification on mannose-Sepharose, the bound
and eluted material would represent monomeric and homo-oligomeric ASGPR-1 as
well as ASGPR-1/ASGPR-2 hetero-oligomers. The presence of hetero-oligomers is
indicated by the retention of ASGPR-2 subunits on the column, since these subunits do 
not bind to the column on their own and must therefore be associated with ASGPR-1 
subunits. Repurification on galactose-Sepharose then resulted in purification of these
hetero-oligomers, since monomeric and homo-oligomeric ASGPR-1 subunits elute in 
the wash fractions.
After two weeks the hetero-oligomers were reloaded to a mannose-Sepharose
column to test the stability of the hetero-oligomers (Fig. 3.24). The finding of
functional hetero-oligomers after this time shows that the interactions formed by these
complexes stabilise the complexes beyond the instability of the homo-oligomers, noted
in the earlier size exclusion chromatography. These results indicate not only that the
natural hetero-oligomeric nature of the receptor can be emulated in vitro, but also
provides a way to trace the correctly formed hetero-oligomers and to examine their
stability and structural properties.
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Figure 3.23. Hetero-oligomer formation by extracellular domain fragments of
ASGPR.
Equal amounts of mannose-binding ECD of ASGPR-1 and unmodified ECD of ASGPR-2
were combined in urea and renatured by dialysis, after which they were loaded onto a
mannose-Sepharose affinity column (top). The peak elution fraction was repurified on
galactose-Sepharose (bottom). Hetero-oligomers containing both subunits were able to
bind to both columns. Aliquots (20 L) of each fraction were analysed on 17.5 % SDS-
polyacrylamide gels that were stained with Coomassie Blue.
μ
175
83
62
47.5
32.5
25
16.5
6.5
S FT Washes (Ca )
2+
Elution (EDTA)
Mannose-Sepharose
ASGPR-1
ASGPR-2
175
83
62
47.5
32.5
25
16.5
6.5
FT Washes (Ca )
2+
Elution (EDTA)
Galactose-Sepharose
ASGPR-1
ASGPR-2
Hetero-oligomers containing both
ASGPR-1 and ASGPR-2 subunits
ASGPR-1
(mannose)
ASGPR-2
(galactose)
+
Denaturation in
8 M urea
Dialysis
Affinity chromatography
mannose-Sepharose
Affinity chromatography
galactose-Sepharose
143
Chapter 3. Human hepatic asialoglycoprotein receptor
175
83
62
47.5
32.5
25
16.5
6.5
Elutions (EDTA)
Mannose-Sepharose
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
ASGPR-1
ASGPR-2
Figure 3.24. Stability of previously purified hetero-oligomers tested by affinity
chromatographyonmannose-Sepharose.
The fractions with activity were kept at 4 °C for two weeks and passed over a 10-mL
mannose-Sepharose column. Wash was 50 mL and elutions 2 mL. Aliquots (20 L) of
each fraction were loaded to a 17.5 % SDS-polyacrylamide gel stained with Coomassie
blue.
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Chapter 3. Human hepatic asialoglycoprotein receptor
3.4 Discussion
The results obtained suggest a scenario in which ASGPR-1 and ASGPR-2 by 
themselves do not form stable oligomers, a fact that has complicated previous studies. 
The structural data also show that, while the neck of ASGPR-1 is a coiled-coil in the
unstable homo-oligomers that include the presence of the CRD, it does not seem to be
helical when isolated. The data suggest that both the CRD and neck are needed to make
oligomers. Combining the two subunits increases the stability of the oligomers.
ASGPR-2 was found to be in excess in the eluate from galactose-Sepharose
even though ASGPR-2 subunits that had not associated with ASGPR-1 were washed
away in the previous purification on mannose-Sepharose. This result is different to
what is observed in the protein isolated from rat liver, in which it seems that AGSPR-1 
is the dominant component (Ruiz and Drickamer 1996), although the ratio of subunits
in the human receptor is less clear. What is observed is possibly a mixture of (ASGPR­
1)2 (ASGPR-2)1 and (ASGPR-1)1(ASGPR-2)2. The ratio of the two different oligomeric
states may be determined by the availability of the two subunits in the solution. This
behaviour, in which the subunits are capable of forming hetero-oligomers of distinct 
natures, would account for the disagreement of different results obtained to date. The
finding that ASGPR-2 is essential for formation of stable oligomers suggests that rather
than serving as an additional subunit binding to a core of ASGPR-1 as previously
thought, ASGPR-2 is taking part in central interactions with all the other subunits that
form the hetero-oligomer. The structural rather than functional role of ASGPR-2 in the
formation of the hetero-oligomer can be further studied in some ways such as
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Chapter 3. Human hepatic asialoglycoprotein receptor
mutagenesis of ASGPR-1 to emulate key differences with regards to ASGPR-2 and 
observe if it can also form highly stable oligomers. The study of the hetero-oligomers
by analytical centrifugation would prove difficult due to the constant variation in the
population of oligomers.
Based on these results showing that hetero-oligomers can be prepared in vitro, it 
would be useful to produce hetero-oligomers with native specificity so that their
binding capabilities can be tested in glycan array analysis and competition assays
adding information that would help towards the determination of the natural ligands of
this receptor.
The usage of Sepharose to immobilise the ligands in order to perform the
purification of C-type lectins has been used in several cases (Taylor and Drickamer
2003). The fact of Sepharose intrinsically containing galactose does not seem to affect
the binding and mutant ASGPR-1 did not bind to the mannose-Sepharose column.
Further confirmation of this would involve testing native ASGPR-1 with unmodified
Sepharose to determine if it sticks to the column.
One of the most outstanding results reported in this chapter is the KCa observed
for ASGPR-1 in circular dichroism. As previously commented, the result obtained is an 
order of magnitude lower than the reported constants for other receptors. However
reported constants refer to the functionality of the receptor, rather than structural
changes. Previously reported constants may refer to the combination of several
constants because it is probable that more than one site must be occupied in order to 
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Chapter 3. Human hepatic asialoglycoprotein receptor
bind the carbohydrate. The low constant reported here may correspond to a single
binding site and may be related to binding site 4. 
Several of the results could indicate that ASGPR-2 fails to correctly fold, 
including its low yield, the lack of structure in circular dicroism and multiple species in
gel filtration. However it should be stated that all the versions of this subunit were
active, binding galactose and the extracellular domain could form functional and stable
oligomers with ASGPR-1. The anomalous behaviour in SDS-PAGE for ASGPR-2 
CRD is difficult to explain but we are clear that its N- and C-termini are both intact. As
is the case for all the constructions reported in this thesis, final construct for ASGPR-2 
was sequenced and no mutations or deletions could be observed. Mass spectrometry
analysis of the CRD could determine the correct mass of the protein. The lack of
activity of ASGPR-2 CRD when tested in glycan arrays can be explained by difference
in the way galactose is presented in the arrays compared to the column, and the higher
concentration of galactosyl residues in the column. Other explanations could include
damage during lyophilisation and transport of the protein or partial unfolding as
previously explained. 
ESI-MS of ASGPR-1 neck detected carbamylations of the protein due to it
being extracted in urea. A way of avoiding this, which could be affecting the results in
its characterisation, could be the usage of guanidine-HCl during its extraction and
purification. 
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Chapter 4. 
Interactions of human and mouse macrophage galactose lectins
with Trichinella spiralis glycoproteins
4.1 Introduction
As discussed in Chapter 1, it has been previously noted that T. spiralis and its
host have highly complex interaction pathways. Parts of these interactions involve the
participation of activated macrophages secreting nitric oxide, protecting the host against 
the intestinal phase of T. spiralis. Infection by helminthic parasites elicits the
production of alternatively activated macrophages via the dominance of type II
cytokine secretion. Alternatively activated macrophages have an enhanced expression
of macrophage mannose receptor and are distinguished from classically activated
macrophages because they possess a different pathway to process L-arginine (Gordon
2003). They balance pro and anti-inflammatory reactions and are involved in
angiogenesis and wound healing. Human and murine MGLs are overexpressed in 
alternatively activated macrophages during helminthic infection. In mouse, mMGL-1 is 
more induced at the beginning of the infection while mMGL-2 increases gradually
during the infection (Raes et al. 2005). Together with other receptors in the
macrophages, MGLs seem to be involved in recognition of immunomodulatory
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Chapter 4. Interactions of MGL with T. spiralis glycoproteins
glycosylated compounds, particularly those found in helminths (van Vliet et al. 2005; 
van Vliet et al. 2008). Other macrophage receptors have been tested and also seem to
interact with the parasite (Gruden-Movsesijan and Milosavljevic 2006). 
After being isolated from its host, larval T. spiralis secrete a high number of
products that would normally help it to communicate with its host. Glycoproteins
secreted by this parasite have been shown to stimulate the secretion of cytokines and
initiate an oxidative bust in macrophages (Modha et al. 2000; Dzik et al. 2010). This
stimulation has been shown to be blocked by GalNAc, suggesting that MGL may be
involved in the mechanism by which the glycoproteins provoke a response in the
macrophages (Emily Eleftheriou and Kleoniki Gounaris, personal communication). In
order to demonstrate that the glycoproteins of T. spiralis do indeed bind to MGL, we
explored the interaction in vitro using the human receptor. 
As many of the studies of the immunomodulatory effects of T. spiralis
glycoproteins have been undertaken with mouse macrophages, it was important to
compare the properties of human and mouse MGLs. In addition, understanding the
biochemistry of homologues of human asialoglycoprotein receptors in other mammals
may help us in understanding the human versions as well as revealing features that
reflect the different properties of the species that express them.
The proteins considered to be the homologues of human MGL in mouse,
mMGL-1 and mMGL-2 are 60% identical to the human protein. Mouse is different to
humans and apparently to all mammals, as it possesses two versions of the gene
resulting from a duplication that may have taken place after the mouse derived from its
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Chapter 4. Interactions of MGL with T. spiralis glycoproteins
rodent common ancestors with the rat, around 41 million years ago (Kumar and Hedges
1998). They are both abundant in connective tissues, being expressed in macrophages
and bone marrow derived dendritic cells and probably forming hetero-oligomers or
interacting in other ways (Tsuiji et al. 2002). It has been suggested, however that the
function of both proteins may be distinct, as their specificity is clearly different.
4.2 Methods
4.2.1 Expression and purification of the extracellular domains of mMGL-1 and 
mMGL-2
The sequences corresponding to the extracellular domains of mMGL-1 and
mMGL-2 were identified by aligning them with better known type II C-type lectins. 
Corresponding cDNAs were amplified from a mouse lung cDNA library using PCR. 
Forward primer 5’-AAGGATCCGATCTTGGAGGATGATTAAATGGCCTTAAGGA
GGGACCTAGGCACCCT-3’ was used for both sequences.  This primer introduces
restriction sites, including BamH1, a termination codon, an initiation methionine codon
and a codon for alanine before the beginning of the corresponding cDNA. All these
modifications are useful for subcloning and for the correct expression in pT5T vector.
Reverse primers were 5’-GCTCCTAGCTCTCCTTGCCAG-3’ for mMGL-1 and 5’­
GGCTTATGGACTGAGGCTATAAG-3’ for mMGL-2. Both sequences start at the
codon corresponding to Leu77 (UniProt P49300 for mMGL-1 and Q8JZN1 for mMGL­
2). The amplified material was cloned in vector pCRII-TOPO (Invitrogen, Carlsbad,
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Chapter 4. Interactions of MGL with T. spiralis glycoproteins
CA, USA). Sequences contained in BamH1-EcoR1 fragments were subcloned into
expression vector pT5T. pT5T constructions were inserted in E. coli strain BL21/DE3 
in which the proteins were expressed as described for human MGL (Section 2.2.2).
4.2.2 Analytical methods
SDS-polyacrylamide gel electrophoresis, protein concentration measurements, gel
filtration and circular dichroism of extracellular domains were conducted as for human
MGL (Section 2.2).
4.2.3 Expression of biotinylated CRDs and strategies for glycan array analysis
The CRDs of mMGL-1 and mMGL-2 were subcloned from the plasmids
containing the extracellular domain (ECD) sequences. Synthetic oligonucleotides were
used to append a 15-amino acid biotinylation sequence at the C termini. Biotinylated
proteins were expressed and purified in the same way as their human homologues 
(Section 2.2.5).
The purified proteins were reacted with Alexa Fluor 488-labelled streptavidin.
The reaction was performed with 0.4 mg of the proteins and 0.1 mg of the fluorescently 
tagged streptavidin, diluted in 1 mL of eluting buffer, after addition of CaCl2 to 25 mM
(Powlesland et al. 2008). The tetramers were purified by chromatography on galactose-
Sepharose columns. Correctly formed tetramers were sent to Core H of the Consortium
for Functional Glycomics for screening version 5 of the glycan array.
The purified proteins were also sent to Core H in monomeric form after
fluorescent labelling. Protein (~250 µg) was dialysed against water, lyophilised and 
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Chapter 4. Interactions of MGL with T. spiralis glycoproteins
dissolved in 0.5 mL of 0.5 M NaCL, 20 mM Na-bicine, 5 mM CaCl2, before reacting
with 75 µg of fluorescein isothyocyanate (FITC), dissolved at 1 mg/mL in dimethyl
sulphoxide, added in five aliquots of 15 µL, which was allowed to react overnight at
4 °C. After addition of EDTA to a concentration of 10 mM, the proteins were repurified
by gel filtration on a Superdex 200 column, eluted with 0.1 NaCl, 10 mM Tris-HCl, pH 
7.8, 2.5 mM EDTA. These proteins were analysed in the same way as the tetramers.
The protein was allowed to interact with the glycan array printed slide and the slide was
washed and scanned. After addition of Cy5-streptavidin and washing, the slide was
read again.
4.2.4 Preparation of human MGL affinity column and fractionation of larval
Trichinella spiralis secretions
The extracellular domain of human MGL (10 mg) diluted in 3 mL of elution 
buffer was dialysed against 100 mM HEPES pH 7.8, 150 mM NaCl and 50 mM CaCl2. 
The protein was added to 1 mL of Affi-Gel 10 resin (Bio-Rad) and allowed to interact
for 4 h, after which the resin was washed extensively with low salt loading buffer.
The secretions of isolated larval T. spiralis were kindly provided by Emily
Eleftheriou and Kleoniki Gounaris (Imperial College London), as this was a
collaborative experiment. The larvae were isolated from Sprague-Dawley rats five 
weeks after oral infection, maintained in culture and the secretions were filtered and
concentrated as previously reported (Gounaris et al. 2001). The secretions diluted in 25 
mM HEPES, pH 7.5, were filtered through a 0.2 µm filter and 2 mL of the secretions
were applied to the MGL-affinity column previously equilibrated in loading buffer.
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Unbound material was removed with 5 X 1 mL loading buffer washes after which 5 X
500 µL fractions were collected using elution buffer. The fractions were analysed on 12%
SDS-polyacrylamide gel electrophoresis stained with Coomassie blue.
4.2.5 Western blots
The ECD of human and mouse MGLs were repurified on a 1-mL galactose-
Sepharose column, which was washed with four column volumes of 150 mM NaCl, 
100 mM bicine pH 8.5, 25 mM CaCl2 and eluted with 5 X 0.5 mL 150 mM NaCl, 100
mM bicine pH 8.5, 2.5 mM EDTA. Fractions containing the protein were pooled 
together.
Approximately 500 µg of each protein, diluted in 0.5 mL, was reacted with 0.5
mCi of 125I-Bolton-Hunter reagent freshly labelled and dried from benzene (Bolton and
Hunter 1973) and reacted for 30 minutes at room temperature. The labelled protein was
repurified on a 1-mL galactose-Sepharose column which was washed with 5 mL of
loading buffer and was eluted with 5 X 0.5 mL low-salt eluting buffer. The fractions
were analysed on 17.5% SDS-polyacrylamide gels and the radioactivity incorporated 
was counted on a Wallac 1470 Wizard gamma counter.
Aliquots of the fractions (15 µL) from the fractionation of T. spiralis
glycoproteins were run on 12% SDS-polyacrylamide gels and the gels were blotted
onto nitrocellulose. The membranes were blocked with 2% haemoglobin in loading 
buffer overnight at 4 °C in the presence of 0.02% NaN3. The membrane was incubated
with approximately 100 µg of the radio-iodinated ECDs for 90 min at room
temperature, followed by 4 X 5 min washes with cold loading buffer. Radioactivity was
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Chapter 4. Interactions of MGL with T. spiralis glycoproteins
detected using a phosphorimager from Molecular Dynamics (Chesham,
Buckinghamshire, UK).
For western blots using biotinylated CRDs, the glycoproteins of T. spiralis were
blotted in the same way as for the radio-iodinated version but were blocked in 5% BSA
in loading buffer for 60 min at room temperature and incubated with biotin tagged 
CRDs of the proteins for 90 min at room temperature. The membranes were washed 3
X 5 min either with loading or eluting buffer, and incubated with avidin coupled to 
alkaline phosphatase (~0.01 μg/mL) (Sigma Aldrich, Saint Louis, MO, USA) for 30 
min. After washing 3 X 5 min with loading or eluting buffer, the blots were developed
using BCIP/NBT alkaline phosphatase substrate.
4.2.6 Solid-phase binding competition assays
The ECD of human MGL was immobilised in Immulon-4 polystyrene wells in a
96-well plate from Dynex Technologies (Chantilly, VA, USA) by overnight incubation
with 50 µL of 10 µg/mL protein in loading buffer at 4 °C. The plate was washed with
loading buffer and blocked with loading buffer containing 5% BSA for 2 h at 4 °C.
After a second washing with loading buffer, serial 2-fold dilutions  of either galactose
or T. spiralis glycoprotein secretions were made in water in a mixing plate (50 μL per
well) after which 2X buffer containing 0.3 M NaCl, 50 mM Tris-Cl, pH 7.8, 50 mM
CaCl2, 0.2% BSA and 10 μg/mL 125I-galactose30-BSA was added to the well. Diluted 
samples were transferred to the assay plate, which was incubated for 2 hours at 4 °C. 
After three washes with loading buffer, the wells were analysed on a Wallac 1470 
Wizard gamma counter. The samples were run in duplicate for the assays and data were
154
 
     
 
 
 
     
  
 
 
 
 
     
 
 
  
 
 
   
 
     
 
 
 
Chapter 4. Interactions of MGL with T. spiralis glycoproteins
fitted using a nonlinear least squares fitting algorithm (Sigmaplot) to determine
concentrations of competing ligand required for 50% inhibition of reporter ligand
binding. 
4.2.7 Phylogeny analysis
The revised protein sequences of mammalian proteins with a C-type lectin 
domain were retrieved from Uniprot database and aligned to calculate the score of
similarity using different methods: Geneious alignment Version 5.1.6 (Drummond et al
2008), MUSCLE (Edgar 2004) and ClustalX2.1 (Larkin et al. 2007), allowing the N-
terminus to be aligned freely. Maximum parsimony consensus phylogenetic trees were
reconstructed by maximum likelihood using Geneious integrated software, allowing 20
iterations. Trees were visualised using Treview.
4.3 Results
4.3.1 Expression of mMGLs
Based on the previous localisation of both mouse MGLs principally in
connective tissue, in skin, testis and lung (Mizuochi et al. 1997; Tsuji et al. 2007), both 
MGL sequences were obtained from cDNA libraries made from testis and lung, using 
oligonucleotides designed to copy the extracellular domains (ECDs) of the proteins.
The same DNA extensions were used to allow expression as described previously for
the ECDs of human ASGPR and MGL. For both cases, the highest amount of DNA
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Chapter 4. Interactions of MGL with T. spiralis glycoproteins
was obtained from lung tissue. Previously it has been found that due to its specific
localisation in lung connective tissue, mMGL-1 can be used as a macrophage marker in 
lung tissue (Imai et al. 1995). As can be seen in Fig. 4.1, both ECD were active and
bound to the galactose columns in the presence of Ca2+ and were eluted specifically
with EDTA.
4.3.2 Structure content of mMGLs
Initial hydrodynamic characterisation of the receptors by means of size-
exclusion chromatography made clear that, although both proteins seem to form homo­
oligomers, their nature is different (Fig. 4.2). In each case there is not a single
monodisperse population. mMGL-1 seems to be the more stable oligomer. The main 
population of mMGL-1 corresponds to the molecular weight expected for a trimer,
while there is a second population that would correspond possibly to a larger oligomer.
mMGL-2 is divided in more subpopulations. There is a major population that can be
interpreted as a dimer, but the peak is visibly asymmetric, including a minor
subpopulation corresponding to a trimer. mMGL-2 also contains a population that
would correspond to a higher molecular weight oligomer.
The homo-oligomers formed by each protein appear to be unstable, because 
after a week of storage at 4 °C the distribution of the populations changed. The major
peak for mMGL-1 shifted slightly towards a higher molecular weight, suggesting that
equilibrium between oligomer populations is tilted towards bigger oligomers or
possible formation of small aggregates. In the case of mMGL-2, the subpopulation
corresponding to a trimer in the asymmetric peak became the major component while 
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Chapter 4. Interactions of MGL with T. spiralis glycoproteins
the lower molecular weight subpopulation diminished drastically. The behaviour of
both mouse proteins is different from the mostly stable human MGL, with mMGL-2 
being particularly unstable. The behaviour of mMGL-2 resembles the highly unstable
behaviour of ASGPR-2. 
The ECDs of mMGL-1 and 2 were also examined by circular dichroism (Fig.
4.3). The secondary structure content of the two proteins is quite dissimilar. mMGL-1 
seems to be more typical of stable members of this family and resembles the structure
of human MGL As described in Chapter 2, this spectrum represents a superposition of a 
largely α-helical neck with the mixed α-helical/β-strand structure of the CRD, as
previously reported for mannose-binding protein MBP and human MGL (Fig. 2.5) 
(Weis and Drickamer 1994). In contrast, the CD spectrum of mMGL-2 is anomalous. 
Although it presents a minimum at 222 nm corresponding to its high content of α-helix,
there is a minimum at 233 nm that is not commonly observed in proteins. However, it
has been described before that minima at this wavelength correspond to the Cotton
effect of α-helix (Gratzer 1967) and shows further differences between the two
receptors and between the mouse receptors and other members of the family.  
The different behaviour when compared to human MGL, which is more stable,
may be explained by differences in the neck of these proteins (Fig. 4.4 B). There are
multiple differences in the sequences of human and mouse MGLs and there is a
difference in neck length, as the human protein is shorter by 34 amino acids. The
differences between the two mMGLs is more surprising as they are highly similar in
sequence. The results suggest that mMGL-1 may form oligomers, perhaps trimers, with
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Chapter 4. Interactions of MGL with T. spiralis glycoproteins
extended α-helical neck regions, but that the neck of mMGL-2 does not achieve an α­
helical conformation, so that the protein forms lower molecular weight aggregates. As
discussed in Chapter 1, in the absence of a coiled-coil neck region, the CRDs of MBP
dimerise through the region that would normally interact with the neck region. It is
possible that a similar type of aggregation occurs for mMGL-2 (Fig. 4.4 A). This may
also be the disposition of CRDs in isolated oligomers formed by the ECD of ASGPR-1. 
Although it would be expected for mMGL-1 and mMGL-2 to have a higher similarity
in structure content, it should be noted that although highly similar the sequences are
not identical. Comparison of the neck sequences (Fig. 4.4 B) shows that although there
are only four amino acids that differ, there are significant differences in the sequences
of the C-terminal portions of the CRDs (Fig. 4.4 C). Many of these differences are
found contiguous to the binding site, but residues near the C-terminus, including the
extension of 12 amino acids present in mMGL-2, would lie near the interface and could
affect oligomer formation. Oligomer formation by mMGL-1 may be further stabilising
the structure in its neck, through the formation of coiled-coils. That would account as
well for the higher homogeneity of oligomer populations after one week storage
observed for mMGL-1.
The possible changes in structure derived from the presence of Ca2+ were 
explored in both mouse receptors (Fig. 4.3). None of the proteins showed the changes
of ASGPR-1 ECD regarding the difference between the molar ellipticity at 231 and 234
nm analysed in Chapter 3. mMGL-1 did not show major changes in the general shape
of the spectrum, although there is a slight depression at 233 nm which is an indicator of
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α-helical structure content (Chen et al. 1974). The spectrum of mMGL-2 showed slight
changes in the region between 212 and 225 nm, also observed in the ECD of ASGPR-1,
which is an indicator of their possible similarity.
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Figure 4.2. Elution profiles of the ECDs of mouse mMGL-1 and mMGL-2 on size
exclusionchromatography.
The blue chromatogram was performed immediately after purification and the red after
one week at 4 °C.The Superdex 200 column was equilibrated with 10 mM Tris-HCl (pH
7.8), 100 mM NaCl and 2.5 mM EDTA. The markers correspond to bovine thyroglobulin,
-galactosidase, sweet-potato -amylase, BSA, carbonic anhydrase and cytochrome
C. mMGL-1 was analysed at 0.15 mg/mLand mMGL-2 at 0.1 mg/mL.
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Figure 4.3. CDanalysis of theECDsofmMGL-1 andmMGL-2.
Blue lines correspond to spectra recorded in absence of Ca . CaCl was added to a
concentration of 10 mM and the red spectra were recorded afterwards. The graphs
represent the average of 10 spectra each. All were obtained in 25 mM NaCl, 5 mM Tris-
HCl, pH 7.8. Both proteins were evaluated at a concentration of 0.15 mg/mL.
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mMGL1  QNSQLRRDLGTLRATLDNTTSKIKAEFQSLDSRADSFEKGISSLKVDVE
mMGL2  QNSQLRRDLGTLRAILDNTTSKIKAEFQSLDSRADNFEKGISSLKVDVE
hMGL   QNSKFQRDLVTLRTDFSNFTSNTVAEIQALTSQGSSLEETIASLKAEVE
mMGL1  DHRQELQAGRDLSQKVTSLESTVEKREQALKTDLSDLTDHVQQLRKDLKAL
mMGL2  DHRQELQAGRDLSQKVTSLESTLEKREQALKTDLSDLTDHVQQLETDLKAL
hMGL                                     GFKQERQAVHSEMLLR
mMGL1  TCQLANLKNNGSEVACCPLHWTEHEGSCYWFSESEKSWPEADKYCRLENSH
mMGL2  TCQLANLKNNGSEVACCPLHWTEHEGSCYWFSESEKSWPEADKYCRLENSH
mMGL1  LVVVNSLEEQNFLQNRLANVVSWIGLTDQNGPWRWVDGTDFEKGFKNWAPL
mMGL2  LVVVNSLEEQNFLQNRLANVLSWMGLTDQNGPWRWVDGTDFDKGFKNWRPL
mMGL1  QPDNWFGHGLGGGEDCAHITTGGPWNDDVCQRTFRWICEMKLAKES
mMGL2  QPDNWHGHMLGGGEDCAHFSYDGRWNDDVCQRHYHWICETELGKASSAHSP
mMGL2  QLIASVP
B.  Comparison of neck sequences
A. Differences in oligomeric structures of mouse MGLs
C.  Comparison of CRD sequences
mMGL-1 mMGL-2
C
C
N
NN
Figure 4.4. ComparisonofmMGL-1 andmMGL-2.
A. Apparent differences in the oligomeric structure are indicated. The extended region
near the C-terminus of mMGL-2 is highlighted in red. B. Comparison of the sequences of
neck regions of mMGL-1, mMGL-2 and human MGL (hMGL) are shown, with heptad
repeats highlighted in green and differences between mMGL-1 and mMGL-2 highlighted
in red. C. Comparison of the sequences of the CRDs in mMGL-1 and mMGL-2, with
conserved cysteine residues highlighted in yellow, conserved Ca site 2 ligand
highlighted in blue and differences between the sequences highlighted in red.
2+
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Chapter 4. Interactions of MGL with T. spiralis glycoproteins
4.3.3 Ligand binding by mMGLs
The specificity of mMGL-1 and 2 was explored by glycan array analysis, using 
three different approaches, all of them based on CRDs to which biotin tags were
appended at the C-terminus. For the first approach, the biotin-tagged CRDs were
complexed with Alexa488-streptavidin, as used for the other asialoglycoprotein 
receptors reported in this thesis (Fig. 4.5 A). The complex is made with an excess of
CRDs to ensure that each streptavidin tetramer is bound to four CRDs. Separation of
the tetramer from the remaining monomers is made under the assumption that tetramers
bind with higher affinity than the monomers during repurification on short galactose-
Sepharose columns. However, the strategy was not completely effective for the mouse
receptors because there was tight binding of monomeric CRDs to the galactose columns, 
unlike the weaker binding of mannose-binding CRDs where it has worked well
(Powlesland et al. 2006; Graham et al. 2009). Interestingly, in contrast with the
succesful studies presented for human ASGPR-1 and MGL, these samples did not yield
any results on the glycan array, suggesting that excess unlabelled monomers were
competing with labelled tetramers.
In a second approach, the CRDs were directly labelled with fluorescein
isothyocyanate (FITC) (Fig. 4.5 B). In this case, there was a good labelling yield and
CRDs remained active as tested by repurification on galactose-Sepharose. Probing of
the glycan arrays using this strategy gave good results with mMGL-2 (Fig. 4.6) but not
with mMGL-1 (Fig.4.7).
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Chapter 4. Interactions of MGL with T. spiralis glycoproteins
Finally, the slides with bound FITC-labelled, biotin-tagged CRD were re-probed
with Cy5-labelled streptavidin (Fig. 4.5 C). This approach depends on tight-binding of
the CRDs because they need to remain bound during more extensive washing. Due to
the weaker binding of other CRDs, this strategy had not been used previously. However,
based on tight binding of monomeric mouse MGLs to the galactose-Sepharose columns, 
it was explored for this case. The results for mMGL-2 did not show a change in the
specificity shown with the directly tagged CRDs but there was a large increase in the
signal and some increase in the signal-to-noise ratio (Fig. 4.6). The strategy proved 
useful for mMGL-1 which finally showed signal (Fig. 4.7).
The results obtained from mMGL-2 indicate that it has a high affinity for
terminal GalNAc residues. In this sense, it is similar to human ASGPR-1 that shows
this preference, but mMGL-2 is clearly more specific, as all the ligands bound with 
high affinity have terminal GalNAc and ligands with terminal galactose appear at less
less than 10% of the maximal signal. Among the shared ligands with ASGPR-1, 
GalNAcβ1,3(Fucα1,2)Galβ is also shared by human MGL, although it is not one of the
main ligands for the latter protein. 6-LacNAc-Tn and Core 6 glycans are also shared by
all asialoglycoprotein receptors. mMGL-2 binds 6-LacNAc-Tn with a higher affinity, in
a similar fashion to ASGPR-1. Glycans A and B present terminal galactose and there is
some possitibility that this galactose may be the residue bound by the protein, but in
those glycans the GalNAc residue is fully available and, as the surrounding ligands do 
not possess available galactose residues, it seems more likely that GalNAc is the
residue bound at the primary binding site. It may be that ligands such as 6-LacNAc-Tn
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Chapter 4. Interactions of MGL with T. spiralis glycoproteins
are bound via the GalNAc residue in all asialoglycoprotein receptors. In general, the
specificity of mMGL-2 is also similar to the one observed for rat MGL (Coombs et al.
2006) and human ASGPR-1 and MGL reported here and previous reports for human
MGL-Fc chimeras (van Vliet et al. 2005).
As observed in Fig. 4.8, mMGL-2 shows a very rapid fall from the high
specificity for GalNAc-terminated glycans (in red) to 10 % or less of maximal binding 
after fewer than 20 glycans. This shows a higher specificity than human 
asialoglycoprotein receptors, similar to the one reported for LSECtin (Powlesland et al.
2008). After that, other positives in the top 100 ligands are glycans with terminal
galactose (green), often more than one. mMGL-2 shows unexpected binding to glycans
shown in purple, which contain extended poly-N-acetyllactosamine chains that should
be capped with GlcNAc. It is possible that there may be some molecules in which the
last modification did not take place, due to probable inefficiency of the reaction, so
there are exposed terminal galactose residues that serve as ligands for the receptor.
The results of mMGL-1 obtained with the two-steps approach showed a very
different pattern, with much more gradual decline in signal so that more than 100
glycans give signal greater than 10% of the maximal signal (Fig. 4.8). Of these, almost
all are galactose terminated, with one bearing terminal GalNAc. The poly-N­
acetyllactosamine structures also show signal, as for mMGL-2. The results are in
general similar to the pattern previously reported for mouse MGLs fused with Fc
(Singh et al. 2009).
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Chapter 4. Interactions of MGL with T. spiralis glycoproteins
The difference in binding of mMGL-1 and mMGL-2 is remarkable given their
structural similarity. As explained in Chapter 1, current information suggests that the
specificity of mMGL-2 is determined primarily by Arg89 and also involves Leu61 and
His109. mMGL-1 has an alanine in place of Arg89, which also seems to be essential for
its specificity towards LewisX structures (Oo-puthinan et al. 2008). However the rat
homologue has a preference for GalNAc, even though the amino acids thought to be
decisive for the specificity of mMGL-1, except a phenylalanine corresponding to the 
position of Phe125 in mMGL-1, are present (Coombs et al. 2006).
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Figure 4.6. Probing of glycan arrays with monomeric mMGL-2 CRDs, directly
labelled andusinga two-stepmethod.
The ligands with maximimum signal are depicted and marked red in the graph. Glycan
arrays in this figure and Figs. 4.7 and 4.8 were perfomed by Core H of the Consortium for
Functional Glycomics.
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Figure 4.7. Probing of glycan arrays with monomeric mMGL-1 CRDs, directly
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Chapter 4. Interactions of MGL with T. spiralis glycoproteins
4.3.4 Evolution of asialoglycoprotein receptors
Since mouse MGLs were discovered recently, they have been thought to be the
orthologues of human MGL. When doing a simple alignment, using the human
sequences for MGL and ASGPR subunits, this seems to be a correct assumption. 
However when comparing the available protein sequences in mammals it is clear that
rodent proteins seem to be more distantly related.  All of the sequences have a high 
similarity, particularly in the CRD, as all of them originated from one sequence which
has undergone multiple duplications during evolution (Fig. 4.9 A and B).
However, if more organism sequences are taken in account, it is clear that, in
general, rodent MGLs are dissimilar to their orthologues in other organisms. The high
similarity amongst all asialoglycoprotein receptors makes it difficult to interpret these
findings. When weighing the information with taxonomical data, it seems that the first 
duplication originated ASGPR-2, with ASGPR-1 and MGL deriving later. This result is
also supported by data available at Ensembl (Fig. 4.9 B). However, the data described
in this thesis, added to previously known facts, suggests that ASGPR-2 is majorly
unable to function as a lectin in absence of its counterpart ASGPR-1. 
Gene trees constructed with Ensembl data show the relationship between
asialoglycoprotein receptors, closely related LSECtin and other type 2 receptors.
According to the database there are reptilian and fish proteins more closely related to
the asialoglycoprotein receptors than even other type 2 receptors. However, none of
these non-mammalian proteins have been well characterised and the results should be
taken carefully.
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Figure 4.9. Evolutionof asialoglycoprotein receptors.
A
The alignment depicted corresponds to amino acid alignment, which is
automatically done in Muscle. The relations with fish proteins and are not
well understood yet and proteins have not been characterised. B
depicts an insight into the relations between eutherian asialoglycoprotein receptors.
The alignment of UniProt sequences was done in Muscle and tree is visualised using
Treeview.
shows the gene tree
available at Ensembl.
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4.3.5 Binding of Trichinella spiralis glycoproteins
In the first approach to analysing the role of MGL in T. spiralis infection,
secretions of larval T. spiralis were fractionated by affinity chromatography on
immobilised human MGL, to determine the possibility that the glycoproteins involved 
in stimulatory activity could be specifically retained on the column. This strategy would
show a correlation between the ability of glycoproteins to bind human MGL and to
stimulate or inhibit macrophages. Following binding of the glycoproteins to the column 
in the presence of Ca2+, the column was washed with Ca2+-containing buffer and bound
proteins were eluted with EDTA. Analysis of the flow-through, wash, and elution 
fractions by SDS-polyacrylamide gel electrophoresis revealed that most of the 
glycoproteins, stained with Coomassie blue, appeared in the wash fractions (Fig. 4.10
A).
In order to identify glycoproteins that can be bound by MGL, the ECD of
human MGL was tagged with radioactive iodine using the Bolton-Hunter reaction, 
which attaches the iodine to lysine residues and has proved to be an efficient way to
mark CRDs of glycan-binding proteins without disturbing their activity (Taylor and
Drickamer 2003). This was true for the human MGL, as the labelled protein was
efficiently separated from excess radioactive reagent by affinity to galactose-Sepharose.
When the radio-iodinated ECD was used to probe blots of gels of the fractions from the
affinity column, multiple glycoproteins were recognised (Fig. 4.10 B). The specificity
of the protein is evident, as the flow-through, which contains a higher number of
proteins in high concentration as seen in the Coomassie stained gel, did not possess
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Chapter 4. Interactions of MGL with T. spiralis glycoproteins
MGL ligands in such a high concentration as the washing fractions. The ability of
human MGL to bind galactose as well as the glycoproteins secreted by larval T. spiralis
was also tested in solid-phase binding competition assays and gave positive results (Fig.
125I­4.11). The nematode glycoproteins inhibited binding of the reporter ligand 
galactose-BSA to human MGL with a KI of 5.9 ± 0.3 μg/mL. If we considered an
extreme case in which the glycan content is equivalent to the protein content, taking 
into account an average molecular weight for the glycans of 200 µg/mole, the KI would
be 30 µM, which is lower than the KI for galactose monosaccharide, which inhibited 
binding with a KI of 3.2 ± 0.7 mM, meaning that there must be good ligands for MGL
in the extract.
The delay in the elution of some of these glycoproteins suggested a weak
binding. The difference in binding between the protein in the column and the ECD in
the blot show that interactions depend on the way in which glycans are presented and in 
which receptors are localised. The receptors attached in the column do not have the
opportunity to form multiple interactions and the glycoproteins in the gel form clusters
that are not present during the chromatography. The presentation of the ligands is also
different, probably being in high density in the blot. As a result, this approach did not
result in effective separation of MGL ligands from glycoproteins that do not bind MGL.
Further blotting experiments were undertaken to probe the interaction of MGL
with T. spiralis glycoproteins. Although Bolton-Hunter labelled human MGL showed
specific binding (Fig. 4.10 B), it was not an entirely satisfactory, due to the rapid decay
of the activity. The mouse MGLs did not label efficiently, possibly due to a lysine
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Chapter 4. Interactions of MGL with T. spiralis glycoproteins
being modified that caused instability in their CRD, and did not show any binding. The
interaction with mMGL-1 and 2 was therefore analysed using biotinylated versions of
the CRDs as employed previously for glycan array analysis. In order to make a 
comparable analysis using the human MGL, it was also tested in a similar fashion. The
results obtained with this method showed that both mMGLs bound in a similar pattern 
in spite of differences in their specificity. Fig. 4.12 shows that there are only slight
differences between the pattern of glycoproteins bound by mMGLs and human MGL.
Human MGL is evidently the most dissimilar of the three, as it binds more ligands in
the higher molecular weight area of the gel, which are bound only slightly by the mouse
MGLs. The specificity of the interaction was shown by the finding that no binding was
detected when the interaction took place in elution buffer containing EDTA or when the
blots were probed in the presence of Ca2+ and then washed in elution buffer (data not
shown).
The interpretation of these results is still unclear, because larval glycans appear
to bear terminal tyvelose capping the GalNAc residues that would be the natural ligands
of these proteins. It would be expected that some adult glycans would bind to
asialoglycoprotein receptors, because many of them present terminal GalNAc residues. 
However, glycans in larval and adult T. spiralis seem to be very different and it is
unlikely that adult glycans discussed in Chapter 1 may be the ligands observed in this
analysis. It is possible that there is a small fraction of uncapped glycans to which the
receptors may bind. Even though larval T. spiralis glycoproteins have terminal tyvelose, 
there is an abundance of GalNAc-GlcNAc, a preferred ligand for all MGLs as shown
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Chapter 4. Interactions of MGL with T. spiralis glycoproteins
by the glycan arrays (Figs. 3.4, 4.6 and 4.7). These small amounts of uncapped
structures would be consistent with the weak binding to the affinity column as they
could probably represent less than 1% of the total. In the mass spectrometry studies
used to characterise the glycans, the species with high abundance may be masking the
presence of this small fraction of uncapped glycans. Probing blots with Wisteria
floribunda lectin provides further evidence for the presence of GalNAc-GlcNAc
structures available for binding (Sabine Jégouzo, personal communication). The
alternative possibility that the MGL bind tyvelose seems unlikely because the
hydroxyls normally used to interact with galactose and GalNAc are not available in this
carbohydrate (Fig. 4.13).
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A. Coomassie blue
B. Western Blot
Figure 4.10. glycoproteins fractioned by affinity for humanMGL
analysedbySDS-polyacrylamidegel electrophoresis.
Trichinella spiralis
A. Analysis of total protein by Coomassie blue staining. B. Ligands for MGL detected by
blotting with radiolabelled ECD of human MGL. glycoproteins used in this figure
and in Figs. 4.11 and 4.12 were provided by Emily Eleftheriou.
T. spiralis
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Figure 4.11.Bindingcompetition assay for humanMGL.
Plates were coated with the ECD of human MGL. Increasing concentrations of competing
ligands were tested in the presence of I-galactose-BSA, which served as a reporter
ligand. K values were determined by fitting to a non-linear least-squares fitting
programme.
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Western blots using glycoproteins fractioned by affinity for MGL (Fig. 4.10). Ligands were
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Chapter 4. Interactions of MGL with T. spiralis glycoproteins
4.4 Discussion
The difference in results from mouse and human MGLs suggest that there may
be functions specific to each species. The differences in specificity seem to arise from
very slight changes which possibly can appear very quickly in evolution.
While the approach of using the immobilised human MGL to fractionate
glycoproteins from T. spiralis was not completely satisfactory, it is probable that the
use a of a longer column would make up for the low affinity of the binding as there
would be increased retardation, with a higher abundance of receptors able to interact for
a longer time with the ligands. Although proteins, such as selectins actually function
better when faster flows happen, this is because of specific dynamics in which those
lectins release and bind ligands in a fast way and is needed for their biological role in
binding cells. Such behaviour is not known for type 2 C-type lectins. The higher
specificity for GalNAc shown by mMGL-2 suggests that fractionation of T. spiralis
glycoproteins might be more efficient on a column with immobilised mMGL-2.
Purification of the ligands by this approach would allow analysis of the glycans from
the bound fraction to see if they are enriched for GalNAc termini, possibly confirming 
the suggestion that some glycans do not bear tyvelose caps. Material bound could also
be tested for macrophage stimulation to demonstrate a correlation between MGL
binding and stimulatory activity.
Positive and good recognition of T. spiralis glycoproteins took place in western
blots. Although the protein in the column may be in high concentration and being able
to form complexes, it is the distrtibution and position of the glycans that may be
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Chapter 4. Interactions of MGL with T. spiralis glycoproteins
decisive for a good interaction. The similitude of the pattern of proteins bound by the
three receptors analysed in this chapter may be related to the fact that even if they have
different specificities, they can still bind galactose or GalNAc in different degrees.
Another explanation may be related to the fact that proteins with different
glycosylations may have similar masses. The idea that the proteins bound by human 
MGL and observed in the gel are glycoproteins can be easily tested by staining the gel 
with fuchsin.
Regarding the glycan array studies presented in this and in other chapters it is
important to have in account that such studies serve only as guidance to possible natural
ligands. Although the way in which the glycans are presented is close to they being on
the surface of a cell there are factors that cannot take place in the arrays, such as
interaction with multiple glycosylations, glycans in high concentration or interactions
with the aglycone.
Circular dichroism of mMGL-1 revealed an uncommon structure content for
type II C-type lectins and even for proteins. However, as commented before it can still
be attributable to its α-helical content or probable interfaces between helices and other
more relaxed structures.
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Chapter 5.

General Discussion
 
Comparing the results discussed in the preceding three chapters, it is useful to 
summarise some of the key results and outstanding questions as well as drawing some
comparisons between asialoglycoprotein receptors in different species and tissues.
5.1 MGL organisation
Previously it was assumed that these homo-oligomeric receptors are stable trimers
because of the clear pattern in the amino acid sequence suggesting a coiled-coil neck
region. The data reported here suggest that the predicted organisation is correct but that
the extracellular domain is not fully stable as a trimer in the absence of the
transmembrane domain and appropriate glycosylation of the neck region. Similar
results were obtained with the mouse receptors. MGL appears to resemble other type 2
transmembrane receptors with C-type CRDs in some but not all respects. The data
suggest a relatively flexible linkage of the CRDs to the coiled-coil neck, as seen in DC­
SIGN (Feinberg et al. 2005), but unlike in the case of DC-SIGN the interactions
between the neck polypeptides is probably not stable enough to make it an autonomous
oligomerisation domain (Yu et al. 2009) (Figure 5.1 A).
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Chapter 5. General discussion
Based on the finding that the unglycosylated extracellular domain oligomer of MGL
is potentially only partially stable at room temperature, it would be of interest to
compare an equivalent oligomer produced in yeast or Chinese hamster ovary cells that
would be glycosylated, in order to provide a direct test of the importance of
glycosylation in driving the hydrophobic interactions in the coiled-coil domain. 
Defining a stable oligomer would significantly simplify hydrodynamic analysis to
establish the stoichiometry of the receptor using sedimentation analysis.
5.2 ASGPR organisation
A key outcome of the work described here is the finding that the hepatic
asialoglycoprotein receptor does assemble into stable hetero-oligomers that appear to
be more stable than oligomers made with the ASGPR-1 subunit. This finding suggests
an intimate association of the polypeptides, rather than appendaging of the ASGPR-2 
subunit onto a preformed ASGPR-1 core. In the proposed scenario, the variable
stoichiometry observed in previous studies would reflect the ability to assemble into
different type of hetero-oligomers depending on the ratio of subunits available (Fig. 5.1
B).
The affinity tagging approach developed here opens up the possibility of producing 
hetero-oligomers for more extensive physical characterisation. Mixing of subunits in
different ratios would potentially allow preparation of oligomers of different
stoichiometries and their organisation and apparent stability could be further
investigated using the types of partial proteolysis, circular dichroism and 
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Chapter 5. General discussion
hydrodynamics experiments described for the homo-oligomeric proteins. Additional 
observations documenting the presence of a high affinity Ca2+-binding site also warrant
further study, perhaps using mutagenesis to test the idea that the site measured is site
four, located away from the Ca2+-binding sites that are involved in sugar binding
(Meier et al. 2000).
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A. Human MGL
B. ASGPR
Attached to membrane
Attached to membrane
Isolated ECDs in solution
Oligomer Monomer
Isolated ECDs in solution
(ASGPR-1) (ASGPR-2)2 1
(ASGPR-1) (ASGPR-2)1 2
Figure 5.1.Oligomermodels.
A. Instability caused by the removal of transmembrane and intracellular domains in MGL.
In solution, MGL oligomers are in equilibrium with monomeric forms in which the neck
loses its -helical confomation. B. In solutionASGPR forms oligomers but their population
is in equilibrium between two different stoichiometries. The diagram shows that when
attached to the membrane possibly both species exist.ASGPR-1 subunits are coloured in
blue andASGPR-2 in yellow.
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Chapter 5. General discussion
5.3 Comparison of the family of related receptors
Combining the current studies of the ligand-binding properties of human forms of
MGL and ASGPR subunits and the two mouse MGLs with previous work on rat MGL
and ASGPR allows some interesting comparisons. The receptors generally fall into two
categories (Table 5.1). Receptors in the first group show high selectivity for GalNAc
over galactose both at the monosaccharide level and in glycan array screening. These
proteins generally bind a broad spectrum of GalNAc-containing ligands. Receptors in
the second group bind with similar affinities to the two monosaccharides and generally
bind best to galactose-terminated structures on the glycan array, but with a range of
affinities. The comparison serves to highlight the unusual properties of the two mouse
MGLs compared to MGLs from other species.
From the structure of a GalNAc binding mutant of mannose-binding protein, 
residues that might mediate selectivity for GalNAc over galactose have been identified
(Kolatkar et al. 1998), although the presence of these specific residues is not well
correlated with the observed specificity (Chapter 4). This finding, along with the
observed evolutionary divergence of the receptors in rodents, suggest that the
specificity for GalNAc may have evolved independently on more than one occasion in 
ASGPR-1 and separately in rat ASGPR-2, using slightly different mechanisms,
although the involvement of an arginine, that corresponds to Arg237 in ASGPR-1, as
observed previously in mMGL-1 (Oo-puthinan et al. 2008), seems to be characteristic
of GalNAc binding, as well as the conservation of the amino acids corresponding to
Phe258 and Tyr273, in different degrees.
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Chapter 5. General discussion
Receptor Species
Preference
Gal > GalNAc GalNAc ≈ Gal GalNAc > Gal GalNAc >> Gal
MGL
Human
Rat
Mouse (MGL-1)
Mouse (MGL-2)
ASGPR-1
Human
Rat
Mouse
ASGPR-2
Human
Rat
Mouse
Table 5.1. Different preferences for GalNAc over galactose in rodent and human
asialoglycoprotein receptors.
Except the homologue of ASGPR-2 in rat, known as RHL-2/3, the diversity of ligands
has been observed in glycan array analysis. Results from analysis of human ASGPR-2 
were inconclusive and mouse ASGPR subunits have not yet been analysed. Rat MGL
and ASGPR-1 were analysed by Coombs et al. (2006) and rat ASGPR-2 by Ruiz and 
Drickamer (1996). Mouse MGLs were previously analysed by Sing et al. (2009), 
using a different approach.
5.4 MGL and nematode proteins
Good evidence was obtained to indicate that the receptors are able to bind secreted
glycoproteins from Trichinella spiralis, supporting the idea that this receptor is
involved in macrophage stimulation by the secreted glycoproteins of the parasite and
that this interaction probably involves a small fraction of exposed terminal GalNAc
residues. As well as binding to the human receptor, binding to both of the mouse MGLs
was demonstrated, validating the use of mouse macrophages as a model for potential
interactions with human macrophages, even if the specificities of the three proteins
differed when analysed on glycan arrays.
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Chapter 5. General discussion
The result would be further strengthened by isolation of a sub-fraction of
glycoproteins that display such residues. In retrospect, it seems likely that the binding is
weak so that the binding fraction was only slightly retarded on the 1-mL affinity
column used. The best way forward would likely be affinity chromatography using
longer columns, possibly best on mMGL-2, since it has the highest affinity for GalNAc.
The expression system developed would allow production of tens of miligrams of
protein from modest volumes of bacterial culture, so the construction of larger columns
should be feasible. Analysis of a glycoprotein fraction enriched for MGL binding 
would potentially allow detection of a sub-fraction bearing terminal GalNAc using
mass spectrometric analytical approaches and it could be employed to demonstrate a
correlation between the ability to bind MGL and the ability to stimulate macrophages.
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Appendix
Appendix
Glycan array results
Human MGL
Chart Glycan structure RFU2 STDEV3 SEM4 %CV5 Number1 
17 b-D-Glc–Sp8 31883 2220 1110 7
149 Galb1-4GlcNAcb1-6GalNAca-Sp8 30371 7401 3701 24
173 GlcNAcb1-6GalNAca-Sp8 21566 782 391 4
9 a-GalNAc–Sp8 19457 775 388 4
329 GalNAcb1-3Gala1-4Galb1-4GlcNAcb1-3Galb1-4Glcb-Sp0 16719 804 402 5
300 GalNAcb1-3Galb-Sp8 15529 969 485 6
85 GalNAca1-4(Fuca1-2)Galb1-4GlcNAcb-Sp8 14287 287 143 2
87 GalNAcb1-3(Fuca1-2)Galb-Sp8 14264 8643 4322 61
164 GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb-Sp0 12617 3821 1911 30
88
NeuAca2-8NeuAca2-8NeuAca2-8NeuAca2-3(GalNAcb1-
GalNAcb1-3Gala1-4Galb1-4GlcNAcb-Sp0 11236 245 122 2
201 11156 1629 815 154)Galb1-4Glcb-Sp0
273 Galb1-3-(Galb1-4GlcNacb1-6)GalNAc-Sp14 10364 5431 2715 52
292 Galb1-3Galb1-4GlcNAcb-Sp8 8665 2033 1017 23
19
Neu5Aca2-8Neu5Aca2-8Neu5Aca2-3(GalNAcb1-4)Galb1-
b-GalNAc–Sp8 8242 426 213 5
202 7313 2563 1282 354Glcb-Sp0
137 Galb1-4[6OSO3]Glcb–Sp0 7284 232 116 3
150 Galb1-4GlcNAcb–Sp0 6868 1596 798 23
139 Galb1-4GalNAca1-3(Fuca1-2)Galb1-4GlcNAcb-Sp8 6723 2200 1100 33
200 Neu5Aca2-3Galb1-3GalNAca-Sp8 6567 4267 2133 65
125 Galb1-3GalNAcb1-3Gala1-4Galb1-4Glcb-Sp0 6498 692 346 11
112 Galb1-2Galb–Sp8 6382 331 165 5
118 Galb1-3(Galb1-4GlcNAcb1-6)GalNAca-Sp8 6277 553 276 9
179 Glcb1-6Glcb-Sp8 5814 840 420 14
163 GlcNAcb1-3Galb1-4GlcNAcb-Sp8 5655 838 419 15
28 [3OSO3]Galb1-4(6OSO3)Glcb–Sp0 5630 1194 597 21
84 GalNAca1-3Galb–Sp8 5613 250 125 4
70 Fuca1-2Galb1-4GlcNAcb–Sp0 5445 12198 6099 224
127
138
Galb1-3GalNAcb1-4Galb1-4Glcb–Sp8
Galb1-4[6OSO3]Glcb–Sp8
5180
4897
990
2889
495
1444
19
59
239 Galb1-4GlcNAcb1-2Mana1-3(Fuca1-3(Galb1-4)GlcNAcb1­2Mana1-6)Manb1-4GlcNAcb1-4GlcNAcb-Sp20 4314 2688 1344 62
114 Galb1-3(Fuca1-4)GlcNAcb1-3Galb1-4GlcNAcb-Sp0 4199 381 190 9
15 b-Neu5Ac-Sp8 4165 1237 619 30
126 Galb1-3GalNAcb1-4(Neu5Aca2-3)Galb1-4Glcb-Sp0 4036 4133 2067 102
180 G-ol-Sp8 3920 1076 538 27
11 a-L-Fuc–Sp9 3669 4637 2319 126
160 GlcNAcb1-3Galb-Sp8 3290 2107 1054 64
79 GalNAca1-3(Fuca1-2)Galb1-4GlcNAcb-Sp0 3132 502 251 16
287 6-H2PO3Glcb-Sp10 2982 1575 788 53
1 Chart numbers are identifiers of glycans assigned by the Consortium for Functional Glycomics.
 
2 Relative Fluorescence Units.
 
3 Standard Deviation.
 
4 Standard Error of the Mean.
 
5 Coefficient of Variation.
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Appendix
263 [3OSO3]Galb1-4(Fuca1-3)(6OSO3)Glc-Sp0 2800 942 471
261 Neu5Gca2-6Galb1-4GlcNAcb–Sp0	 2534 1260 630 50
151 Galb1-4GlcNAcb–Sp8 2414 2317 1159
80 GalNAca1-3(Fuca1-2)Galb1-4GlcNAcb–Sp8	 2368 1221 610 52
212 Neu5Aca2-3GalNAca-Sp8	 2262 1817 908
Galb1-3(Fuca1-4)GlcNAcb1-3Galb1-4(Fuca1-3)GlcNAcb­ 2205 1252 626 57Sp0
GlcNAca1-4Galb1-4GlcNAcb1-3Galb1-4GlcNAcb-Sp0 1968 1842 921 94
210
36
NeuAca2-3(NeuAca2-3Galb1-3GalNAcb1-4)Galb1-4Glcb­
Sp0
[3OSO3]Galb1-4GlcNAcb-Sp8
1940
1936
1240
179
620
90
64
9
268 Fuca1-2Galb1-4[6OSO3]GlcNAc-Sp8 1922 1339 669 70
102 Gala1-3Galb1-3GlcNAcb-Sp0 1825 87 44 5
331
189
GalNAca1-3(Fuca1-2)Galb1-4GlcNAcb1-3Galb1­
4GlcNAcb1-3Galb1-4GlcNAcb-Sp0
Mana1-2Mana1-3Mana-Sp9
1825
1803
1037
1035
519
518
57
57
178 Glcb1-4Glcb-Sp8 1785 1481 740 83
94 Gala1-3(Fuca1-2)Galb1-4(Fuca1-3)GlcNAcb-Sp0 1782 345 172 19
Neu5Aca2-6Galb1-4GlcNAcb1-2Mana1-3(Galb1­317	 1773 547 274 314GlcNAcb1-2Mana1-6)Manb1-4GlcNAcb1-4GlcNAcb-Sp12
35 [3OSO3]Galb1-4GlcNAcb–Sp0 1772 1265 633 71
362 Neu5Aca2-6GlcNAcb1-4GlcNAc-Sp21	 1716 641 320 37
294 Galb1-4GlcNAcb1-3(Galb1-4GlcNAcb1-6)Galb1-4GlcNAc­Sp0 1706 1242 621 73
161	 GlcNAcb1-3Galb1-3GalNAca-Sp8 1614 1066 533 66
NeuAca2-6Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1­
4GlcNAcb-Sp0327 1601 720 360 45
Mana1-2Mana1-2Mana1-3(Mana1-2Mana1-3(Mana1­192	 1518 453 227 302Mana1-6)Mana1-6)Manb1-4GlcNAcb1-4GlcNAcb-Sp12
162 GlcNAcb1-3Galb1-4GlcNAcb–Sp0 1495 1255 628 84
363 Neu5Aca2-6GlcNAcb1-4GlcNAcb1-4GlcNAc-Sp21 1483 839 420 57
211 Neu5Aca2-3(Neu5Aca2-6)GalNAca-Sp8 1479 517 258 35
91 GalNAcb1-4GlcNAcb–Sp8	 1469 692 346 47
177 Glca1-6Glca1-6Glcb-Sp8 1394 621 311 45
(Neu5Aca2-3-Galb1-3)(((Neu5Aca2-3-Galb1-4(Fuca1­332	 1385 2339 1170 1693))GlcNAcb1-6)GalNAc–Sp14
92 Gala1-2Galb–Sp8 1344 1227 613 91
38 [4OSO3][6OSO3]Galb1-4GlcNAcb-Sp0	 1230 521 260 42
27 [3OSO3]Galb1-4Glcb-Sp8 1201 746 373 62
Mana1-2Mana1-6(Mana1-3)Mana1-6(Mana2Mana2Mana1­191	 1189 640 320 543)Manb1-4GlcNAcb1-4GlcNAcb-Sp12
339 GlcNAca1-4Galb1-3GalNAc-Sp14 1179 364 182
Fuca1-2Galb1-3(Fuca1-4)GlcNAcb1-2Mana1-3[Fuca1­
371	 2Galb1-3(Fuca1-4)GlcNAcb1-2Mana1-6]Manb1-4GlcNAcb1- 1173 545 273 47
4GlcNAcb-Sp19
182 GlcAb-Sp8 1158 459 229 40
GlcNAcb1-2Mana1-3(Neu5Aca2-6Galb1-4GlcNAcb1­302	 1149 953 476 832Mana1-6)Manb1-4GlcNAcb1-4GlcNAcb-Sp12
315 Neu5Aca2-3Galb1-3GalNAc–Sp14 1146 517 259
Galb1-3(Fuca1-4)GlcNAcb1-2Mana1-3[Galb1-3(Fuca1­350	 1120 990 495 884)GlcNAcb1-2Mana1-6]Manb1-4GlcNAcb1-4GlcNAcb-Sp19
49 Mana1-3(Mana1-6)Manb1-4GlcNAcb1-4GlcNAcb-Sp13 1106 2137 1068 193
101 Gala1-3Galb1-4(Fuca1-3)GlcNAcb–Sp8	 1104 927 464 84
275 Galb1-3-(Neu5Aa2-3Galb1-4GlcNacb1-6)GalNAc-Sp14 1035 633 316 61
90 GalNAcb1-4GlcNAcb–Sp0 950 1690 845 178
325 NeuAca2-6Galb1-4GlcNAcb1-3Galb1-3GlcNAcb-Sp0 945 322 161 34
Fuca1-2Galb1-4(Fuca1-3)GlcNAcb1-2Mana1-3[Fuca1­
358	 2Galb1-4(Fuca1-3)GlcNAcb1-2Mana1-6]Manb1-4GlcNAcb1- 931 2009 1005 216
4GlcNAb-Sp20
128 Galb1-3Galb–Sp8	 926 694 347
269 Fuca1-2[6OSO3]Galb1-4[6OSO3]Glc-Sp0	 887 358 179 40
340 4GlcNAcb1-4GlcNAc-Sp12 841 662 331 79
100 Gala1-3GalNAcb–Sp8 819 65 32 8
Mana1-3(Neu5Aca2-6Galb1-4GlcNAcb1-2Mana1-6)Manb1-
249 Neu5Aca2-6Galb–Sp8	 802 1218 609
351 (6SO3)GlcNAcb1-3Gal b1-4GlcNAc-b-Sp0	 783 1022 511 131
209
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Appendix
NeuAca2-3Galb1-3(Fuca1-4)GlcNAcb1-3Galb1-3(Fuca1­326 4)GlcNAcb-Sp0 776 316 158 41
Neu5Aca2-6Galb1-4GlcNAcb1-2Mana1-3(GlcNAcb1­ 760 2310 1155 3042Mana1-6)Manb1-4GlcNAcb1-4GlcNAcb-Sp12
26 [3OSO3][6OSO3]Galb1-4GlcNAcb-Sp0 752 694 347 92
136 Galb1-4(Fuca1-3)GlcNAcb1-4Galb1-4(Fuca1-3)GlcNAcb1­4Galb1-4(Fuca1-3)GlcNAcb–Sp0 743 2080 1040 280
16 b-D-Gal–Sp8 688 1276 638 186
206 Neu5Aca2-3(6-O-Su)Galb1-4(Fuca1-3)GlcNAcb–Sp8 683 557 278 82
14 a-Neu5Ac–Sp11 680 253 126 37
106 Gala1-4(Fuca1-2)Galb1-4GlcNAcb-Sp8 670 2350 1175 351
334 GlcNAca1-4Galb1-4GlcNAcb-Sp0 588 297 149 51
377 Galb1-3GalNAca1-3(Fuca1-2)Galb1-4GlcNAc-Sp14 587 370 185 63
131 Galb1-3GlcNAcb–Sp0 577 2550 1275 442
123 Galb1-3GalNAca-Sp8 560 2785 1392 497
193 Mana1-3(Mana1-6)Mana-Sp9 555 1400 700 252
115 Galb1-3(Fuca1-4)GlcNAc–Sp0 554 501 250 90
234 Neu5Aca2-3Galb1-4GlcNAcb–Sp0 546 363 182 66
328 Gala1-4Galb1-4GlcNAcb1-3Galb1-4Glcb-Sp0 520 92 46 18
64 Fuca1-2Galb1-4(Fuca1-3)GlcNAcb1-3Galb1-4(Fuca1­3)GlcNAcb-Sp0 498 844 422 169
37 [3OSO3]Galb–Sp8 465 704 352 152
262 Neu5Gca-Sp8 455 303 152 67
375 GalNAcb1-4GlcNAcb1-2Mana1-6(GalNAcb1-4GlcNAcb1­2Mana1-6)Manb1-4GlcNAcb1-4GlcNAc-Sp12 449 472 236 105
260 Neu5Gca2-6GalNAca-Sp0 446 307 154 69
285 [3OSO3][4OSO3]Galb1-4GlcNacb-SpSp0 432 215 108 50
308 Mana1-3(Mana1-6)Manb1-4GlcNAcb1-4GlcNAcb-Sp12 426 393 196 92
288 Gala1-3(Fuca1-2)Galb–Sp18 423 165 82 39
361
Galb1-3(Fuca1-4)GlcNAcb1-2Mana1-3[Galb1-3(Fuca1­
4)GlcNAcb1-2Man a1-6]Manb1-4GlcNAcb1-4(Fuca1­
6)GlcNAcb-Sp22
404 216 108 53
244 Neu5Aca2-6Galb1-4GlcNAcb–Sp8 383 307 154 80
301 GlcAb1-3GlcNAcb-Sp8 371 411 206 111
312 Mana1-2Mana1-2Mana1-3(Mana1-2Mana1-6(Mana1­2Mana1-3)Mana1-6)Mana-Sp9 361 96 48 27
222 NeuAca2-3Galb1-3GlcNAcb1-3Galb1-4GlcNAcb-Sp0 346 76 38 22
246 Neu5Aca2-6Galb1-4GlcNAcb1-3Galb1-4GlcNAcb-Sp0 343 103 52 30
190 334 96 48 29
303 GlcNAcb1-2Mana1-3(GlcNAcb1-2Mana1-6)Manb1­4GlcNAcb1-4GlcNAcb-Sp12 334 41 21 12
276 Galb1-3GalNAc-Sp14 313 134 67 43
258 Neu5Gca2-3Galb1-4GlcNAcb–Sp0 310 197 98 64
183 GlcAb1-3Galb-Sp8 305 484 242 159
Neu5Aca2-3Galb1-4GlcNAcb1-2Mana1-3(Neu5Aca2­
316 6Galb1-4GlcNAcb1-2Mana1-6)Manb1-4GlcNAcb1­ 299 68 34 23
4GlcNAcb-Sp12
266 [3OSO3]Galb1-4[Fuca1-3]GlcNAc-Sp0 294 150 75 51
159 GlcNAcb1-3GalNAca-Sp8 289 260 130 90
214 Neu5Aca2-3Galb1-3(6OSO3)GlcNAc-Sp8 285 716 358 252
224 Neu5Aca2-3Galb1-3GlcNAcb–Sp8 281 260 130 92
298 GalNAca-Sp15 255 494 247 193
357 Fuca1-2Galb1-4GlcNAcb1-2Mana1-3(Fuca1-2Galb1­4GlcNAcb1-2Mana1-6)Manb1-4GlcNAcb1-4GlcNAcb-Sp20 247 252 126 102
81 GalNAca1-3(Fuca1-2)Galb1-4Glcb-Sp0 240 132 66 55
349 Galb1-3GlcNAcb1-2Mana1-3(Galb1-3GlcNAcb1-2Mana1­6)Manb1-4GlcNAcb1-4(Fuca1-6)GlcNacb-Sp22 228 343 172 150
304 GlcNAcb1-3Man-Sp10 219 154 77 70
346 Galb1-4GlcNAcb1-2Mana1-3(Mana1-6)Manb1-4GlcNAcb1­4GlcNAcb-Sp12 198 159 79 80
Mana1-6(Mana1-2Mana1-3)Mana1-6(Mana2Mana1-
3)Manb1-4GlcNAcb1-4GlcNAcb-Sp12
314 Neu5Aca2-3Galb1-3(Neu5Aca2-6)GalNAc-Sp14 197 222 111 113
89 GalNAcb1-4(Fuca1-3)GlcNAcb-Sp0 189 335 168 177
231 Neu5Aca2-3Galb1-4(Fuca1-3)GlcNAcb1-3Galb1-4GlcNAcb­Sp8 179 275 138 154
53 Neu5Aca2-6Galb1-4GlcNAcb1-2Mana1-3(Neu5Aca2- 171 103 51 60
210
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Appendix
6Galb1-4GlcNAcb1-2Mana1-6)Manb1-4GlcNAcb1­
4GlcNAcb-Sp8
47 9NAcNeu5Aca-Sp8 145 950 475 653
20 b-GlcNAc–Sp0 133 132 66 99
103 Gala1-3Galb1-4GlcNAcb–Sp8 116 210 105
271 Fuca1-2-Galb1-4[6OSO3]Glc-Sp0 105 203 101 192
197
Neu5Aca2-6Galb1-4GlcNAcb1-2Mana1-3(Neu5Aca2­
3Galb1-4GlcNAcb1-2Mana1-6)Manb1-4GlcNAcb1­
4GlcNAcb-Sp12
101 194 97 191
Galb1-3(Neu5Aca2-3Galb1-4(Fuca1-3)GlcNAcb1­ 101 88 44 876)GalNAc–Sp14
174 GlcNAcb1-6Galb1-4GlcNAcb-Sp8 101 1568 784 1558
240 Neu5Aca2-6GalNAca-Sp8 97 641 320 662
198 Manb1-4GlcNAcb-Sp0 82 176 88 216
352
133
KDNa2-3Galb1-4(Fuca1-3)GlcNAc-Sp0
Galb1-4(Fuca1-3)GlcNAcb–Sp0
72
67
720
220
360
110
1002
327
204 Neu5Aca2-8Neu5Aca2-3(GalNAcb1-4)Galb1-4Glcb–Sp0 64 962 481 1506
299 GalNAca1-3(Fuca1-2)Galb–Sp18 61 239 120 392
171 GlcNAcb1-4GlcNAcb1-4GlcNAcb–Sp8 60 397 198 656
341 Neu5Aca2-6Galb1-4GlcNAcb1-2Mana1-3(Mana1-6)Manb1­4GlcNAcb1-4GlcNAc-Sp12 59 955 478 1628
62 Fuca1-2Galb1-3GlcNAcb–Sp0 56 111 55 199
41 [6OSO3]Galb1-4Glcb–Sp0 52 213 107 407
Galb1-4GlcNAcb1-2Mana1-3(Neu5Aca2-6Galb1­254 45 297 148 6554GlcNAcb1-2Mana1-6)Manb1-4GlcNAcb1-4GlcNAcb-Sp21
52
Neu5Aca2-6Galb1-4GlcNAcb1-2Mana1-3(Neu5Aca2­
6Galb1-4GlcNAcb1-2Mana1-6)Manb1-4GlcNAcb1­
4GlcNAcb-Sp13
39 69 34 177
GlcNAca1-4Galb1-4GlcNAcb1-3Galb1-4(Fuca1­337 36 285 143 7903)GlcNAcb1-3Galb1-4(Fuca1-3)GlcNAcb-Sp0
256 Neu5Gca2-3Galb1-3GlcNAcb-Sp0 27 109 55 402
267 Fuca1-2[6OSO3]Galb1-4GlcNAc-Sp0 24 320 160 1308
Fuca1-2Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1­69 23 118 59 5194GlcNAcb-Sp0
185 KDNa2-3Galb1-3GlcNAcb–Sp0 15 131 65 866
129 Galb1-3GlcNAcb1-3Galb1-4GlcNAcb-Sp0 12 1125 562 9413
145 Galb1-4GlcNAcb1-3Galb1-4GlcNAcb–Sp0 12 229 114 1930
8 a-D-Man–Sp8 3 77 38 2749
122 Galb1-3(Neu5Aca2-6)GlcNAcb1-4Galb1-4Glcb-Sp10 0 121 60 61051
10 a-L-Fuc–Sp8 -9 138 69 -1499
23 (Galb1-4GlcNAcb)2-3,6-GalNAca-Sp8 -25 922 461 -3678
74 Fuca1-3GlcNAcb-Sp8 -41 308 154 -742
277 Galb1-3GlcNAcb1-3Galb1-3GlcNAcb-Sp0 -44 206 103 -469
253 Neu5Acb2-6Galb1-4GlcNAcb-Sp8 -80 267 133 -333
99 Gala1-3GalNAca-Sp8 -93 94 47 -101
320 Fuca1-2Galb1-3GalNAca-Sp14 -94 93 46 -99
140 Galb1-4GalNAcb1-3(Fuca1-2)Galb1-4GlcNAcb-Sp8 -104 305 153 -293
321 Galb1-3(Neu5Aca2-6)GalNAca-Sp14 -108 266 133 -247
354 KDNa2-3Galb1-4Glc-Sp0 -110 185 93 -169
110 -112 246 123 -220
366
GalNAca1-3(Fuca1-2)Galb1-4GlcNAcb1-2Mana1­
3[GalNAca1-3(Fuca1-2)Galb1-4GlcNAcb1-2Mana1­ -117 608 304 -521
6]Manb1-4GlcNAcb1-4GlcNAcb-Sp20
Gala1-4GlcNAcb–Sp8
57 Fuca1-2Galb1-3GalNAca-Sp8 -120 345 172 -288
Mana1-3(Galb1-4GlcNAcb1-2Mana1-6)Manb1-4GlcNAcb1­360 -122 330 165 -2704GlcNAcb-Sp12
GlcNAcb1-2Galb1-3GalNAca-Sp8 -124 120 60 -97
Galb1-3GlcNAcb1-2Mana1-3(Galb1-3GlcNAcb1-2Mana1­4 -124 401 201 -3236)Manb1-4GlcNAcb1-4GlcNAcb-Sp19
43 [6OSO3]Galb1-4GlcNAcb–Sp8 -126 260 130 -207
13 a-Neu5Ac–Sp8 -127 307 153 -242
250 Neu5Aca2-8Neu5Aca-Sp8 -138 231 116
355 KDNa2-3Galb1-3GalNAca-Sp14 -156 1089 544 -698
220 Neu5Aca2-3Galb-Sp8 -159 230 115
Neu5Aca2-6Galb1-4GlcNAcb1-2Mana1-3Manb1­ -167 274 137 -1644GlcNAcb1-4GlcNAc-Sp12
211
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Appendix
7 a-D-Glc–Sp8 -169 42 21 -25
67 Fuca1-2Galb1-4(Fuca1-3)GlcNAcb–Sp8	 -170 157 79 -93
264 [3OSO3]Galb1-4(Fuca1-3)Glc-Sp0 -171 233 116
22 b-GlcN(Gc)-Sp8	 -193 12 6 -6
143 Galb1-4GlcNAcb1-3Galb1-4(Fuca1-3)GlcNAcb1-3Galb1­4(Fuca1-3)GlcNAcb-Sp0 -197 447 224 -227
176 Glca1-4Glca-Sp8	 -197 289 145 -147
31 [3OSO3]Galb1-3GalNAca-Sp8 -198 76 38 -39
GlcNAcb1-2Mana1-3(GlcNAcb1-2Mana1-6)Manb1­347	 -208 1021 511 -4924GlcNAcb1-4(Fuca1-6)GlcNAcb-Sp22
148 Galb1-4GlcNAcb1-6(Galb1-3)GalNAca-Sp8 -208 171 86 -82
105 Gala1-3Galb–Sp8	 -210 78 39 -37
76 Fucb1-3GlcNAcb-Sp8 -216 175 87 -81
58 Fuca1-2Galb1-3GalNAcb1-4(Neu5Aca2-3)Galb1-4Glcb-Sp0 -219 244 122 -111
309 Mana1-6Manb-Sp10	 -232 142 71 -61
230 Neu5Aca2-3Galb1-4(Fuca1-3)GlcNAcb1-3Galb-Sp8 -234 681 341 -291
368
Gala1-3Galb1-4(Fuca1-3)GlcNAcb1-2Mana1-3[Gala1­
3Galb1-4(Fuca1-3)GlcNAcb1-2Mana1-6]Manb1-4GlcNAcb1­
4GlcNAcb-Sp20
-248 277 138 -111
282 Neu5Aca2-3Galb1-3GlcNAcb1-3Galb1-3GlcNAcb-Sp0 -251 257 128 -102
96 Gala1-3(Fuca1-2)Galb1-4Glcb-Sp0 -260 125 63 -48
175 Glca1-4Glcb–Sp8	 -261 198 99 -76
296 Galb1-4GlcNAca1-6Galb1-4GlcNAcb-Sp0 -262 590 295 -225
55 Fuca1-2Galb1-3GalNAcb1-3Gala1-4Galb1-4Glcb-Sp9 -262 262 131 -100
165 GlcNAcb1-3Galb1-4Glcb–Sp0 -263 372 186 -142
93 Gala1-3(Fuca1-2)Galb1-3GlcNAcb-Sp0	 -264 255 127 -97
66 Fuca1-2Galb1-4(Fuca1-3)GlcNAcb–Sp0 -267 221 111 -83
372 NeuAca2-3Galb1-4GlcNAcb1-3GalNAc-Sp14	 -272 446 223 -164
25 [3OSO3][6OSO3]Galb1-4[6OSO3]GlcNAcb-Sp0 -276 221 110 -80
Galb1-4GlcNAcb1-2Mana1-3(Galb1-4GlcNAcb1-2Mana1­51	 -277 330 165 -1196)Manb1-4GlcNAcb1-4GlcNAcb-Sp13
147 Galb1-4GlcNAcb1-3Galb1-4Glcb–Sp8 -278 290 145
Galb1-4(Fuca1-3)GlcNAcb1-3Galb1-3(Fuca1-4)GlcNAcb­280	 -285 524 262 -184Sp0
374 NeuAca2-3[Fuca1-3]Galb1-4GlcNAcb1-3GalNAc-Sp14 -290 422 211 -145
279 Galb1-4[Fuca1-3][6OSO3]Glc-Sp0	 -290 87 44 -30
323 NeuAc(9Ac)a2-3Galb1-4GlcNAcb-Sp0 -292 570 285 -195
Galb1-4GlcNAcb1-2Mana1-3(Neu5Aca2-6Galb1­293	 -297 291 145 -984GlcNAcb1-2Mana1-6)Manb1-4GlcNAcb1-4GlcNAcb-Sp12
188 Mana1-2Mana1-3(Mana1-2Mana1-6)Mana-Sp9 -302 194 97 -64
306 GlcNAcb1-4GlcNAcb-Sp12	 -318 317 158 -100
281 Galb1-4GlcNAcb1-3Galb1-3GlcNAcb-Sp0 -320 385 193 -120
54 Fuca1-2Galb1-3GalNAcb1-3Gala-Sp9	 -325 111 55 -34
72 Fuca1-2Galb1-4Glcb–Sp0 -326 229 114 -70
GlcNAcb1-2Mana1-3(GlcNAcb1-2Mana1-6)Manb1­50	 -328 146 73 -454GlcNAcb1-4GlcNAcb-Sp13
181 GlcAa-Sp8 -334 131 66
Neu5Aca2-6Galb1-4GlcNAcb1-2Mana1-3(Neu5Aca2­
319	 6Galb1-4GlcNAcb1-2Mana1-6)Manb1-4GlcNAcb1- -334 232 116 -69
4GlcNAcb-N(LT)AVL
56 Fuca1-2Galb1-3(Fuca1-4)GlcNAcb–Sp8 -335 89 44 -27
153 Galb1-4Glcb–Sp8	 -335 87 43 -26
187 Mana1-2Mana1-2Mana1-3Mana-Sp9 -344 294 147 -86
Mana1-2Mana1-2Mana1-3(Mana1-2Mana1-6(Mana1­311	 -351 228 114 -653)Mana1-6)Mana-Sp9
104 Gala1-3Galb1-4Glcb–Sp0 -363 219 109 -60
59 Fuca1-2Galb1-3GalNAcb1-4(Neu5Aca2-3)Galb1-4Glcb-Sp9 -373 189 94 -51
195 Mana1-6(Mana1-3)Mana1-6(Mana2Mana1-3)Manb1­4GlcNAcb1-4GlcNAcb-Sp12 -380 350 175 -92
73 Fuca1-2Galb–Sp8 -384 92 46 -24
373 NeuAca2-6Galb1-4GlcNAcb1-3GalNAc-Sp14 -386 480 240 -124
284 [3OSO3]Galb1-4[6OSO3]GlcNAcb-Sp0	 -386 250 125 -65
215 Neu5Aca2-3Galb1-3(Fuca1-4)GlcNAcb–Sp8 -387 378 189
242 Neu5Aca2-6Galb1-4[6OSO3]GlcNAcb-Sp8	 -387 818 409 -211
18 b-D-Man–Sp8	 -388 62 31 -16
283 Neu5Aca2-3Galb1-4GlcNAcb1-3Galb1-3GlcNAcb-Sp0 -390 432 216 -111
212
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Appendix
274 Galb1-3(GlcNacb1-6)GalNAc-Sp14 -390 212 106
40 6-H2PO3Mana-Sp8	 -391 172 86 -44
238 Neu5Aca2-3Galb1-4Glcb–Sp8 -391 280 140
12 a-L-Rha-Sp8	 -397 105 53 -27
135 Galb1-4(Fuca1-3)GlcNAcb1-4Galb1-4(Fuca1-3)GlcNAcb­Sp0 -405 258 129 -64
124 Galb1-3GalNAcb–Sp8	 -412 205 103 -50
60 Fuca1-2Galb1-3GlcNAcb1-3Galb1-4Glcb–Sp10 -427 196 98 -46
45 NeuAca2-3[6OSO3]Galb1-4GlcNAcb–Sp8 -429 508 254 -119
34 [3OSO3]Galb1-4[6OSO3]GlcNAcb-Sp8 -433 136 68 -31
226 Neu5Aca2-3Galb1-4(Fuca1-3)(6OSO3)GlcNAcb–Sp8 -433 67 34 -16
97 Gala1-3(Fuca1-2)Galb–Sp8 -435 226 113 -52
130 Galb1-3GlcNAcb1-3Galb1-4Glcb–Sp10	 -436 114 57 -26
108 Gala1-4Galb1-4GlcNAcb–Sp8 -440 312 156 -71
Fuca1-2Galb1-4(Fuca1-3)GlcNAcb1-3Galb1-4(Fuca1­65	 -442 382 191 -863)GlcNAcb1-3Galb1-4(Fuca1-3)GlcNAcb-Sp0
61 Fuca1-2Galb1-3GlcNAcb1-3Galb1-4Glcb–Sp8 -449 333 166 -74
170 (GlcNAcb1-4)5b-Sp8	 -450 168 84 -37
48 9NAcNeu5Aca2-6Galb1-4GlcNAcb-Sp8 -452 108 54 -24
29
1
[3OSO3]Galb1-4(6OSO3)Glcb–Sp8
Neu5Aca2-8Neu5Acb-Sp17
-467
-467
428
333
214
167
-92
-71
24 GlcNAcb1-3(GlcNAcb1-4)(GlcNAcb1-6)GlcNAc-Sp8 -473 382 191 -81
117 Galb1-3(Fuca1-4)GlcNAcb–Sp8 -474 124 62 -26
6
251
a-D-Gal–Sp8
Neu5Aca2-8Neu5Aca2-3Galb1-4Glcb–Sp0
-474
-479
129
198
64
99
-27
-41
168 GlcNAcb1-4Galb1-4GlcNAcb-Sp8 -488 185 93 -38
376 Galb1-3GalNAca1-3(Fuca1-2)Galb1-4Glc-Sp14 -489 209 104 -43
3 Neu5Gcb2-6Galb1-4GlcNAc-Sp8	 -490 72 36 -15
255 Neu5Gca2-3Galb1-3(Fuca1-4)GlcNAcb-Sp0 -496 89 44 -18
71 Fuca1-2Galb1-4GlcNAcb–Sp8	 -498 281 140 -56
107 Gala1-4Galb1-4GlcNAcb–Sp0 -498 46 23 -9
322 Galb1-4GlcNAcb1-3GalNAc-Sp14	 -502 159 80 -32
134 Galb1-4(Fuca1-3)GlcNAcb–Sp8 -509 346 173 -68
248 Neu5Aca2-6Galb1-4Glcb–Sp8	 -509 224 112 -44
364 Fuca1-2Galb1-3GlcNAcb1-3[Galb1-4(Fuca1-3)GlcNAcb1­6]Galb1-4Glc-Sp21 -511 307 153 -60
166 GlcNAcb1-4MDPLys	 -513 133 66 -26
217 Neu5Aca2-3Galb1-3(Neu5Aca2-3Galb1-4)GlcNAcb-Sp8 -514 112 56 -22
78 GalNAca1-3(Fuca1-2)Galb1-4(Fuca1-3)GlcNAcb-Sp0 -516 104 52 -20
158 GlcNAcb1-3(GlcNAcb1-6)Galb1-4GlcNAcb–Sp8 -520 485 242 -93
152 Galb1-4Glcb–Sp0	 -521 306 153 -59
32 [3OSO3]Galb1-3GlcNAcb–Sp8 -530 69 35 -13
209 Neu5Aca2-3(GalNAcb1-4)Galb1-4Glcb–Sp0	 -546 361 180 -66
289 Gala1-3GalNAca-Sp16 -550 20 10 -4
194 Mana1-3(Mana1-2Mana1-2Mana1-6)Mana-Sp9 -558 289 145 -52
259 Neu5Gca2-3Galb1-4Glcb–Sp0 -559 278 139 -50
155 GlcNAca1-6Galb1-4GlcNAcb-Sp8	 -566 82 41 -14
109 Gala1-4Galb1-4Glcb–Sp0 -566 116 58 -21
207 Neu5Aca2-3(GalNAcb1-4)Galb1-4GlcNAcb-Sp0 -572 169 84 -29
208 Neu5Aca2-3(GalNAcb1-4)Galb1-4GlcNAcb-Sp8 -577 70 35 -12
297 Galb1-4GlcNAcb1-6Galb1-4GlcNAcb-Sp0	 -584 514 257 -88
290 Galb1-3GalNAca-Sp16 -587 558 279 -95
270 Fuca1-2-(6OSO3)-Galb1-4Glc-Sp0	 -593 231 115 -39
39 [4OSO3]Galb1-4GlcNAcb-Sp8 -603 190 95 -32
119	 Galb1-3(GlcNAcb1-6)GalNAca-Sp8 -604 178 89 -29
Galb1-4GlcNAcb1-2Mana1-6Manb1-4GlcNAcb1-4GlcNAc­345 -608 229 114 -38Sp12
132 Galb1-3GlcNAcb–Sp8	 -608 71 35 -12
336 GlcNAca1-4Galb1-4GlcNAcb1-3Galb1-4Glcb-Sp0 -610 677 339
Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb– -624 258 129 -41Sp0
370
Gala1-3(Fuca1-2)Galb1-3GlcNAcb1-2Mana1-3[Gala1­
3(Fuca1-2)Galb1-3GlcNAcb1-2Mana1-6]Manb1-4GlcNAcb1­
4GlcNAcb-Sp20
-629 411 205 -65
77 GalNAca1-3(Fuca1-2)Galb1-3GlcNAcb-Sp0 -636 311 156 -49
241 Neu5Aca2-6GalNAcb1-4GlcNAcb-Sp0 -636 83 41 -13
213
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Appendix
243 Neu5Aca2-6Galb1-4GlcNAcb–Sp0 -656 258 129 -39
356 Fuca1-2Galb1-3GlcNAcb1-2Mana1-3(Fuca1-2Galb1­3GlcNAcb1-2Mana1-6)Manb1-4GlcNAcb1-4GlcNAcb-Sp20 -659 60 30 -9
247 Neu5Aca2-6Galb1-4Glcb–Sp0 -665 432 216 -65
265 [3OSO3]Galb1-4[Fuca1-3][6OSO3]GlcNAc-Sp8 -675 138 69 -20
Galb1-4GlcNAcb1-2(Galb1-4GlcNAcb1-4)Mana1-3[Galb1­ -680 1338 669 -1974GlcNAcb1-2Mana1-6]Manb1-4GlcNAcb1-4GlcNAc-Sp21
46 [6OSO3]GlcNAcb–Sp8 -682 66 33 -10
228
98
Neu5Aca2-3Galb1-4(Fuca1-3)GlcNAcb–Sp0
Gala1-3(Gala1-4)Galb1-4GlcNAcb-Sp8
-683
-689
174
281
87
140
-25
-41
146 Galb1-4GlcNAcb1-3Galb1-4Glcb–Sp0 -706 637 319 -90
295 Galb1-4GlcNAcb1-3(GlcNAcb1-6)Galb1-4GlcNAc-Sp0 -708 207 104 -29
169 (GlcNAcb1-4)6b-Sp8 -710 157 79 -22
333 GlcNAca1-4Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1­4GlcNAcb-Sp0 -711 318 159 -45
221 NeuAca2-3Galb1-3GalNAcb1-3Gala1-4Galb1-4Glcb-Sp0 -719 246 123 -34
141
Neu5Aca2-3Galb1-4GlcNAcb1-2Mana1-3(Neu5Aca2­
3Galb1-4GlcNAcb1-2Mana1-6)Manb1-4GlcNAcb1­
4GlcNAcb-Sp12
-721 115 57 -16
186 KDNa2-3Galb1-4GlcNAcb–Sp0 -721 212 106 -29
225 Neu5Aca2-3Galb1-4[6OSO3]GlcNAcb-Sp8 -734 358 179 -49
229 Neu5Aca2-3Galb1-4(Fuca1-3)GlcNAcb–Sp8 -756 145 73 -19
286 [6OSO3]Galb1-4[6OSO3]GlcNacb-Sp0 -765 381 191 -50
116 Galb1-3(Fuca1-4)GlcNAc–Sp8 -767 437 219 -57
369
GalNAca1-3(Fuca1-2)Galb1-3GlcNAcb1-2Mana1­
3[GalNAca1-3(Fuca1-2)Galb1-3GlcNAcb1-2Mana1­
6]Manb1-4GlcNAcb1-4GlcNAcb-Sp20
-775 270 135 -35
252 Neu5Acb2-6GalNAca-Sp8 -776 170 85 -22
82 GalNAca1-3(Fuca1-2)Galb–Sp8 -788 324 162 -41
33 [3OSO3]Galb1-4(Fuca1-3)GlcNAcb–Sp8 -790 296 148 -37
359 4GlcNAcb1-2Mana1-6)Manb1-4GlcNAcb1-4GlcNAcb-Sp20 -803 352 176 -44
157 GlcNAcb1-3(GlcNAcb1-6)GalNAca-Sp8 -806 455 228 -56
Gala1-3Galb1-4GlcNAcb1-2Mana1-3(Gala1-3Galb1-
95 Gala1-3(Fuca1-2)Galb1-4GlcNAc-Sp0 -807 336 168 -42
184
30
GlcAb1-6Galb-Sp8
[3OSO3]Galb1-3(Fuca1-4)GlcNAcb–Sp8
-808
-815
144
231
72
115
-18
-28
216 NeuAca2-3Galb1-3(Fuca1-4)GlcNAcb1-3Galb1-4(Fuca1­3)GlcNAcb Sp0 -829 250 125 -30
305 GlcNAcb1-4GlcNAcb-Sp10 -832 237 118 -28
310
Neu5Aca2-3Galb1-4GlcNAcb1-3Galb1-4(Fuca1-3)GlcNAc-
Mana1-6(Mana1-3)Mana1-6(Mana1-3)Manb-Sp10 -836 334 167 -40
232 -841 175 88 -21Sp0
203 Neu5Aca2-8Neu5Aca2-8Neu5Aca2-3Galb1-4Glcb–Sp0 -845 169 84 -20
21 b-GlcNAc–Sp8 -854 238 119 -28
121 Galb1-3(Neu5Acb2-6)GalNAca-Sp8 -859 678 339 -79
213 Neu5Aca2-3GalNAcb1-4GlcNAcb-Sp0 -863 308 154 -36
5
Neu5Aca2-6Galb1-4GlcNAcb1-2Mana1-3(Neu5Aca2­
6Galb1-4GlcNAcb1-2Mana1-6)Manb1-4GlcNAcb1­
4GlcNAcb-Sp12
-874 161 81 -18
348 6)Manb1-4GlcNAcb1-4(Fuca1-6)GlcNAcb-Sp22 -878 528 264 -60
86 GalNAcb1-3GalNAca-Sp8 -878 139 69 -16
Galb1-4GlcNAcb1-2Mana1-3(Galb1-4GlcNAcb1-2Mana1-
223 Neu5Aca2-3Galb1-3GlcNAcb–Sp0 -882 504 252 -57
257 Neu5Gca2-3Galb1-4(Fuca1-3)GlcNAcb-Sp0 -885 396 198 -45
353 KDNa2-6Galb1-4GlcNAc-Sp0 -889 501 250 -56
GalNAca1-3(Fuca1-2)Galb1-4GlcNAcb1-3Galb1-4GlcNAcb­330 -900 334 167 -37Sp0
42 [6OSO3]Galb1-4Glcb–Sp8 -909 266 133 -29
278 Galb1-4[Fuca1-3][6OSO3]GlcNAc-Sp0 -915 276 138 -30
63 Fuca1-2Galb1-3GlcNAcb–Sp8 -943 102 51 -11
120 Galb1-3(Neu5Aca2-6)GalNAca-Sp8 -950 208 104 -22
344 Galb1-4GlcNAcb1-2Mana1-3Manb1-4GlcNAcb1-4GlcNAc­Sp12 -954 550 275 -58
83 GalNAca1-3GalNAcb–Sp8 -965 406 203 -42
307 HOOC(CH3)CH-3-O-GlcNAcb1-4GlcNAcb-Sp10 -971 540 270
68 Fuca1-2Galb1-4GlcNAcb1-3Galb1-4GlcNAc–Sp0 -975 410 205 -42
214
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Appendix
Neu5Aca2-3Galb1-3[6OSO3]GalNAca-Sp8 -978 428 214 -44
Neu5Aca2-6Galb1-4GlcNAcb1-2Mana1-6Manb1­ -978 310 155 -324GlcNAcb1-4GlcNAc-Sp12
335 GlcNAca1-4Galb1-3GlcNAcb-Sp0 -979 284 142
44 [6OSO3]Galb1-4[6OSO3]Glcb-Sp8 -981 243 121 -25
2 Neu5Aca2-8Neu5Aca2-8Neu5Acb-Sp8 -995 347 173 -35
235 Neu5Aca2-3Galb1-4GlcNAcb–Sp8	 -1001 210 105 -21
142 Galb1-4GlcNAcb1-3GalNAca-Sp8 -1030 191 95
219
167
Neu5Aca2-3Galb1-3(Neu5Aca2-6)GalNAca-Sp8
GlcNAcb1-4(GlcNAcb1-6)GalNAca-Sp8
-1034
-1035
178
723
89
362
-17
-70
245 Neu5Aca2-6Galb1-4GlcNAcb1-3Galb1-4(Fuca1­3)GlcNAcb1-3Galb1-4(Fuca1-3)GlcNAcb-Sp0 -1040 206 103 -20
237 Neu5Aca2-3Galb1-4Glcb–Sp0 -1044 294 147 -28
111 Gala1-6Glcb-Sp8	 -1060 103 51 -10
75 Fuca1-4GlcNAcb–Sp8	 -1091 115 57 -11
236 Neu5Aca2-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb-Sp0 -1108 644 322 -58
272 Galb1-3(Fuca1-4)GlcNAcb1-3Galb1-3(Fuca1-4)GlcNAcb­Sp0 -1123 414 207 -37
Mana1-6(Mana1-3)Mana1-6(Mana1-3)Manb1-4GlcNAcb1-4 196	 -1184 38 19 -3GlcNAcb-Sp12
 
Neu5Aca2-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1­233 -1189 424 212 -364GlcNAcb–Sp0
172 GlcNAcb1-6(Galb1-3)GalNAca-Sp8	 -1204 182 91 -15
227
154 GlcNAca1-3Galb1-4GlcNAcb-Sp8
-1228
-1259
557
289
278
144
-45
-23
Neu5Aca2-3Galb1-4(Fuca1-3)GlcNAcb1-3Galb1-4(Fuca1-
3)GlcNAcb1-3Galb1-4(Fuca1-3)GlcNAcb–Sp0
324 NeuAc(9Ac)a2-3Galb1-3GlcNAcb-Sp0 -1285 469 235 -36
199
205
Fuca1-3(Galb1-4)GlcNAcb1-2Mana1-3(Fuca1-3(Galb1­
4)GlcNAcb1-2Mana1-6)Manb1-4GlcNAcb1-4GlcNAcb-Sp20
Neu5Aca2-8Neu5Aca2-8Neu5Aca-Sp8
-1357
-1404
81
239
40
120
-6
-17
313 Neu5Aca2-3Galb1-3(Neu5Aca2-3Galb1-4GlcNAcb1­6)GalNAc–Sp14 -1750 620 310 -35
367
Gala1-3(Fuca1-2)Galb1-4GlcNAcb1-2Mana1-3[Gala1­
3(Fuca1-2)Galb1-4GlcNAcb1-2Mana1-6]Manb1-4GlcNAcb1­
4GlcNAcb-Sp20
-1823 402 201 -22
ASGPR-1
 
Chart
Number Glycan structure RFU STDEV SEM %CV
85 GalNAca1-4(Fuca1-2)Galb1-4GlcNAcb-Sp8 41764 3000 1500 7
173 GlcNAcb1-6GalNAca-Sp8 41275 2566 1283 6
9 a-GalNAc–Sp8 40484 1007 504 2
88	 GalNAcb1-3Gala1-4Galb1-4GlcNAcb-Sp0 30857 2822 1411 9
GalNAcb1-3Gala1-4Galb1-4GlcNAcb1-3Galb1-4Glcb­329 30807 1789 894 6Sp0
149 Galb1-4GlcNAcb1-6GalNAca-Sp8	 25674 18759 9380 73
300 GalNAcb1-3Galb-Sp8 23561 1169 585 5
87 GalNAcb1-3(Fuca1-2)Galb-Sp8 21006 9518 4759 45
84 GalNAca1-3Galb–Sp8 18421 1199 600 7
NeuAca2-8NeuAca2-8NeuAca2-8NeuAca2­201	 14382 1036 518 73(GalNAcb1-4)Galb1-4Glcb-Sp0
298 GalNAca-Sp15 14261 1892 946 13
349
Galb1-3GlcNAcb1-2Mana1-3(Galb1-3GlcNAcb1­
2Mana1-6)Manb1-4GlcNAcb1-4(Fuca1-6)GlcNacb­
Sp22
13147 6187 3094 47
148 Galb1-4GlcNAcb1-6(Galb1-3)GalNAca-Sp8 12598 8231 4116
146 Galb1-4GlcNAcb1-3Galb1-4Glcb–Sp0	 11834 13569 6784 115
90 11635 4088 2044 35
317
Neu5Aca2-6Galb1-4GlcNAcb1-2Mana1-3(Galb1­
4GlcNAcb1-2Mana1-6)Manb1-4GlcNAcb1-4GlcNAcb­
Sp12
11409 3801 1900 33
GalNAcb1-4GlcNAcb–Sp0
215
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Appendix
270 Fuca1-2-(6OSO3)-Galb1-4Glc-Sp0 10791 12903 6452 120
337 GlcNAca1-4Galb1-4GlcNAcb1-3Galb1-4(Fuca1­3)GlcNAcb1-3Galb1-4(Fuca1-3)GlcNAcb-Sp0 10699 3922 1961 37
161 GlcNAcb1-3Galb1-3GalNAca-Sp8 10645 3688 1844 35
126 Galb1-3GalNAcb1-4(Neu5Aca2-3)Galb1-4Glcb-Sp0 10358 2313 1157 22
54 Fuca1-2Galb1-3GalNAcb1-3Gala-Sp9 9282 14842 7421 160
224 Neu5Aca2-3Galb1-3GlcNAcb–Sp8 9171 5678 2839 62
315 Neu5Aca2-3Galb1-3GalNAc–Sp14 8867 3745 1873 42
263 [3OSO3]Galb1-4(Fuca1-3)(6OSO3)Glc-Sp0 8783 1914 957 22
159 GlcNAcb1-3GalNAca-Sp8 8344 6947 3474 83
140 Galb1-4GalNAcb1-3(Fuca1-2)Galb1-4GlcNAcb-Sp8 8160 2049 1025 25
115 Galb1-3(Fuca1-4)GlcNAc–Sp0 8137 2909 1455 36
264 [3OSO3]Galb1-4(Fuca1-3)Glc-Sp0 8109 3908 1954 48
213 Neu5Aca2-3GalNAcb1-4GlcNAcb-Sp0 7793 2658 1329 34
232 Neu5Aca2-3Galb1-4GlcNAcb1-3Galb1-4(Fuca1­3)GlcNAc-Sp0 7699 1996 998 26
NeuAca2-6Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1­
3Galb1-4GlcNAcb-Sp0
44 [6OSO3]Galb1-4[6OSO3]Glcb-Sp8 7279 5528 2764 76
335
164 GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb-Sp0
7097
7059
4051
3493
2025
1746
57
49
341 6)Manb1-4GlcNAcb1-4GlcNAc-Sp12 6930 5269 2635 76
19 b-GalNAc–Sp8 6845 871 435 13
269 Fuca1-2[6OSO3]Galb1-4[6OSO3]Glc-Sp0 6819 1814 907 27
56 Fuca1-2Galb1-3(Fuca1-4)GlcNAcb–Sp8 6816 4236 2118 62
261 Neu5Gca2-6Galb1-4GlcNAcb–Sp0 6774 1775 887 26
360 Mana1-3(Galb1-4GlcNAcb1-2Mana1-6)Manb1­4GlcNAcb1-4GlcNAcb-Sp12 6583 4027 2014 61
98 Gala1-3(Gala1-4)Galb1-4GlcNAcb-Sp8 6216 4590 2295 74
58 Fuca1-2Galb1-3GalNAcb1-4(Neu5Aca2-3)Galb1­4Glcb-Sp0 6134 776 388 13
15 b-Neu5Ac-Sp8 6120 4831 2415 79
364 Fuca1-2Galb1-3GlcNAcb1-3[Galb1-4(Fuca1­3)GlcNAcb1-6]Galb1-4Glc-Sp21 6022 1105 553 18
249 Neu5Aca2-6Galb–Sp8 5928 1510 755 25
323 NeuAc(9Ac)a2-3Galb1-4GlcNAcb-Sp0 5895 2938 1469 50
138 Galb1-4[6OSO3]Glcb–Sp8 5612 1768 884 31
374 NeuAca2-3[Fuca1-3]Galb1-4GlcNAcb1-3GalNAc-Sp14 5503 1544 772 28
327 7670 1623 812 21
GlcNAca1-4Galb1-3GlcNAcb-Sp0
Neu5Aca2-6Galb1-4GlcNAcb1-2Mana1-3(Mana1-
65 Fuca1-2Galb1-4(Fuca1-3)GlcNAcb1-3Galb1-4(Fuca1­3)GlcNAcb1-3Galb1-4(Fuca1-3)GlcNAcb-Sp0 5427 2473 1236 46
123 Galb1-3GalNAca-Sp8 5403 4996 2498 92
25 [3OSO3][6OSO3]Galb1-4[6OSO3]GlcNAcb-Sp0 5389 1173 587 22
347 GlcNAcb1-2Mana1-3(GlcNAcb1-2Mana1-6)Manb1­4GlcNAcb1-4(Fuca1-6)GlcNAcb-Sp22 5290 4433 2216 84
28 [3OSO3]Galb1-4(6OSO3)Glcb–Sp0 5277 875 437 17
124 Galb1-3GalNAcb–Sp8 5272 1882 941 36
190 3)Manb1-4GlcNAcb1-4GlcNAcb-Sp12 5169 3245 1622 63
136 Galb1-4(Fuca1-3)GlcNAcb1-4Galb1-4(Fuca1­3)GlcNAcb1-4Galb1-4(Fuca1-3)GlcNAcb–Sp0 5161 3186 1593 62
188 Mana1-2Mana1-3(Mana1-2Mana1-6)Mana-Sp9 5115 3067 1533 60
352 KDNa2-3Galb1-4(Fuca1-3)GlcNAc-Sp0 5103 2089 1044 41
67 Fuca1-2Galb1-4(Fuca1-3)GlcNAcb–Sp8 5070 2923 1462 58
292 Galb1-3Galb1-4GlcNAcb-Sp8 5001 2388 1194 48
101 Gala1-3Galb1-4(Fuca1-3)GlcNAcb–Sp8 4968 1243 622 25
92 Gala1-2Galb–Sp8 4962 2425 1213 49
Mana1-6(Mana1-2Mana1-3)Mana1-6(Mana2Mana1-
319
Neu5Aca2-6Galb1-4GlcNAcb1-2Mana1-3(Neu5Aca2­
6Galb1-4GlcNAcb1-2Mana1-6)Manb1-4GlcNAcb1­
4GlcNAcb-N(LT)AVL
4960 1865 933 38
103 Gala1-3Galb1-4GlcNAcb–Sp8 4903 1434 717 29
286 [6OSO3]Galb1-4[6OSO3]GlcNacb-Sp0 4813 1099 550 23
362 Neu5Aca2-6GlcNAcb1-4GlcNAc-Sp21 4800 3863 1931 80
275 Galb1-3-(Neu5Aa2-3Galb1-4GlcNacb1-6)GalNAc-Sp14 4746 3589 1794 76
91 GalNAcb1-4GlcNAcb–Sp8 4710 320 160 7
209 Neu5Aca2-3(GalNAcb1-4)Galb1-4Glcb–Sp0 4623 2499 1250 54
216
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373 NeuAca2-6Galb1-4GlcNAcb1-3GalNAc-Sp14 4529 2264 1132 50
33 [3OSO3]Galb1-4(Fuca1-3)GlcNAcb–Sp8 4496 1398 699 31
267 Fuca1-2[6OSO3]Galb1-4GlcNAc-Sp0 4465 2561 1281 57
38 [4OSO3][6OSO3]Galb1-4GlcNAcb-Sp0 4454 1858 929 42
46 [6OSO3]GlcNAcb–Sp8 4393 2193 1097 50
134 Galb1-4(Fuca1-3)GlcNAcb–Sp8 4372 1930 965 44
325 NeuAca2-6Galb1-4GlcNAcb1-3Galb1-3GlcNAcb-Sp0 4339 2449 1225 56
34 [3OSO3]Galb1-4[6OSO3]GlcNAcb-Sp8 4304 1448 724 34
Neu5Aca2-3Galb1-4GlcNAcb1-2Mana1-3(Neu5Aca2­
141 3Galb1-4GlcNAcb1-2Mana1-6)Manb1-4GlcNAcb1­ 4229 1729 865 41
4GlcNAcb-Sp12
120 Galb1-3(Neu5Aca2-6)GalNAca-Sp8 4197 3761 1881 90
245 Neu5Aca2-6Galb1-4GlcNAcb1-3Galb1-4(Fuca1­3)GlcNAcb1-3Galb1-4(Fuca1-3)GlcNAcb-Sp0 4189 535 267 13
23
304 GlcNAcb1-3Man-Sp10
4167
4154
1766
4906
883
2453
42
118
(Galb1-4GlcNAcb)2-3,6-GalNAca-Sp8
302 GlcNAcb1-2Mana1-3(Neu5Aca2-6Galb1-4GlcNAcb1­2Mana1-6)Manb1-4GlcNAcb1-4GlcNAcb-Sp12 4063 4384 2192 108
271 Fuca1-2-Galb1-4[6OSO3]Glc-Sp0 4054 3217 1608 79
375
GalNAcb1-4GlcNAcb1-2Mana1-6(GalNAcb1­
4GlcNAcb1-2Mana1-6)Manb1-4GlcNAcb1-4GlcNAc­
Sp12
4053 1885 942 46
128 Galb1-3Galb–Sp8 4030 1009 504 25
32
142 Galb1-4GlcNAcb1-3GalNAca-Sp8
3995
3992
614
2760
307
1380
15
69
129 Galb1-3GlcNAcb1-3Galb1-4GlcNAcb-Sp0 3826 3696 1848 97
259 Neu5Gca2-3Galb1-4Glcb–Sp0 3739 805 402 22
233
207
Neu5Aca2-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1­
Neu5Aca2-3(GalNAcb1-4)Galb1-4GlcNAcb-Sp0
3729
3726
571
2324
286
1162
15
62
13 a-Neu5Ac–Sp8 3723 1687 843 45
57 Fuca1-2Galb1-3GalNAca-Sp8 3721 4019 2010 108
[3OSO3]Galb1-3GlcNAcb–Sp8
3Galb1-4GlcNAcb–Sp0
358
Fuca1-2Galb1-4(Fuca1-3)GlcNAcb1-2Mana1-3[Fuca1­
2Galb1-4(Fuca1-3)GlcNAcb1-2Mana1-6]Manb1­
4GlcNAcb1-4GlcNAb-Sp20
3695 943 472 26
205 Neu5Aca2-8Neu5Aca2-8Neu5Aca-Sp8 3665 2017 1008 55
311 3)Mana1-6)Mana-Sp9 3660 3288 1644 90
257 Neu5Gca2-3Galb1-4(Fuca1-3)GlcNAcb-Sp0 3647 1084 542 30
Mana1-2Mana1-2Mana1-3(Mana1-2Mana1-6(Mana1-
313 Neu5Aca2-3Galb1-3(Neu5Aca2-3Galb1-4GlcNAcb1­6)GalNAc–Sp14 3618 128 64 4
235 Neu5Aca2-3Galb1-4GlcNAcb–Sp8 3588 458 229 13
221 NeuAca2-3Galb1-3GalNAcb1-3Gala1-4Galb1-4Glcb­Sp0 3547 651 326 18
121 Galb1-3(Neu5Acb2-6)GalNAca-Sp8 3526 590 295 17
211 Neu5Aca2-3(Neu5Aca2-6)GalNAca-Sp8 3512 2867 1433 82
277 Galb1-3GlcNAcb1-3Galb1-3GlcNAcb-Sp0 3494 835 418 24
5
Neu5Aca2-6Galb1-4GlcNAcb1-2Mana1-3(Neu5Aca2­
6Galb1-4GlcNAcb1-2Mana1-6)Manb1-4GlcNAcb1­
4GlcNAcb-Sp12
3474 936 468 27
36 [3OSO3]Galb1-4GlcNAcb-Sp8 3368 4186 2093 124
86 GalNAcb1-3GalNAca-Sp8 3243 3001 1501 93
Fuca1-3(Galb1-4)GlcNAcb1-2Mana1-3(Fuca1-3(Galb1­
199 4)GlcNAcb1-2Mana1-6)Manb1-4GlcNAcb1-4GlcNAcb­ 3167 290 145 9
Sp20
296 Galb1-4GlcNAca1-6Galb1-4GlcNAcb-Sp0 3163 134 67 4
42 [6OSO3]Galb1-4Glcb–Sp8 3136 363 181 12
174 GlcNAcb1-6Galb1-4GlcNAcb-Sp8 3112 1169 585 38
186 KDNa2-3Galb1-4GlcNAcb–Sp0 3097 1180 590 38
157
255 Neu5Gca2-3Galb1-3(Fuca1-4)GlcNAcb-Sp0
3075
3074
1086
2228
543
1114
35
72
113 3)GlcNAcb-Sp0 3074 3346 1673 109
297 Galb1-4GlcNAcb1-6Galb1-4GlcNAcb-Sp0 3022 1987 994 66
151
353 KDNa2-6Galb1-4GlcNAc-Sp0
2991
2961
797
2982
399
1491
27
101
GlcNAcb1-3(GlcNAcb1-6)GalNAca-Sp8
Galb1-3(Fuca1-4)GlcNAcb1-3Galb1-4(Fuca1-
Galb1-4GlcNAcb–Sp8
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Appendix
247 Neu5Aca2-6Galb1-4Glcb–Sp0 2802 1436 718 51
214 Neu5Aca2-3Galb1-3(6OSO3)GlcNAc-Sp8 2785 1386 693 50
Mana1-6(Mana1-3)Mana1-6(Mana1-3)Manb1- 2783 1332 666 484GlcNAcb1-4 GlcNAcb-Sp12
219 Neu5Aca2-3Galb1-3(Neu5Aca2-6)GalNAca-Sp8 2744 1059 530 39
77 GalNAca1-3(Fuca1-2)Galb1-3GlcNAcb-Sp0 2715 2060 1030 76
11 a-L-Fuc–Sp9 2676 478 239 18
294 Galb1-4GlcNAcb1-3(Galb1-4GlcNAcb1-6)Galb1­4GlcNAc-Sp0 2669 2931 1465 110
203 Neu5Aca2-8Neu5Aca2-8Neu5Aca2-3Galb1-4Glcb–Sp0 2648 431 216 16
273 Galb1-3-(Galb1-4GlcNacb1-6)GalNAc-Sp14 2619 2136 1068 82
152 Galb1-4Glcb–Sp0 2562 1471 735 57
111 Gala1-6Glcb-Sp8 2512 696 348 28
192
Mana1-2Mana1-2Mana1-3(Mana1-2Mana1-3(Mana1­
2Mana1-6)Mana1-6)Manb1-4GlcNAcb1-4GlcNAcb­ 2489 1668 834 67
Sp12
330 GalNAca1-3(Fuca1-2)Galb1-4GlcNAcb1-3Galb1­4GlcNAcb-Sp0 2475 2146 1073 87
288 Gala1-3(Fuca1-2)Galb–Sp18 2448 2534 1267 104
184 GlcAb1-6Galb-Sp8 2432 849 424 35
Neu5Aca2-6Galb1-4GlcNAcb1-2Mana1-3(GlcNAcb1­318 2403 2458 1229 1022Mana1-6)Manb1-4GlcNAcb1-4GlcNAcb-Sp12
289 Gala1-3GalNAca-Sp16 2362 639 319 27
243 Neu5Aca2-6Galb1-4GlcNAcb–Sp0 2325 1219 609 52
194 Mana1-3(Mana1-2Mana1-2Mana1-6)Mana-Sp9 2253 724 362 32
80 GalNAca1-3(Fuca1-2)Galb1-4GlcNAcb–Sp8 2250 2599 1299 115
283 Neu5Aca2-3Galb1-4GlcNAcb1-3Galb1-3GlcNAcb-Sp0 2225 501 251 23
116 Galb1-3(Fuca1-4)GlcNAc–Sp8 2209 1563 782 71
30 [3OSO3]Galb1-3(Fuca1-4)GlcNAcb–Sp8 2196 289 145 13
172 GlcNAcb1-6(Galb1-3)GalNAca-Sp8 2191 704 352 32
17 b-D-Glc–Sp8 2178 1103 552 51
230 Neu5Aca2-3Galb1-4(Fuca1-3)GlcNAcb1-3Galb-Sp8 2114 206 103 10
75 Fuca1-4GlcNAcb–Sp8 2089 405 202 19
170 (GlcNAcb1-4)5b-Sp8 2087 579 290 28
154 GlcNAca1-3Galb1-4GlcNAcb-Sp8 2076 4041 2020 195
Neu5Aca2-8Neu5Aca2-3(GalNAcb1-4)Galb1-4Glcb– 204 2030 1577 789 78Sp0
202 Neu5Aca2-8Neu5Aca2-8Neu5Aca2-3(GalNAcb1­4)Galb1-4Glcb-Sp0 2008 1077 539 54
339 GlcNAca1-4Galb1-3GalNAc-Sp14 2007 3101 1551 155
109 Gala1-4Galb1-4Glcb–Sp0 2002 140 70 7
104 Gala1-3Galb1-4Glcb–Sp0 1978 1237 619 63
328 Gala1-4Galb1-4GlcNAcb1-3Galb1-4Glcb-Sp0 1925 1507 753 78
365
Galb1-4GlcNAcb1-2(Galb1-4GlcNAcb1-4)Mana1­
3[Galb1-4GlcNAcb1-2Mana1-6]Manb1-4GlcNAcb1­
4GlcNAc-Sp21
1916 2199 1100 115
47 9NAcNeu5Aca-Sp8 1882 1985 993 105
73 Fuca1-2Galb–Sp8 1870 1390 695 74
7 a-D-Glc–Sp8 1827 1011 506 55
63 Fuca1-2Galb1-3GlcNAcb–Sp8 1793 865 432 48
225 Neu5Aca2-3Galb1-4[6OSO3]GlcNAcb-Sp8 1786 1208 604 68
299 GalNAca1-3(Fuca1-2)Galb–Sp18 1764 295 148 17
176 Glca1-4Glca-Sp8 1754 1048 524 60
180 G-ol-Sp8 1748 1179 590 67
376 Galb1-3GalNAca1-3(Fuca1-2)Galb1-4Glc-Sp14 1740 414 207 24
139 Galb1-4GalNAca1-3(Fuca1-2)Galb1-4GlcNAcb-Sp8 1678 824 412 49
40 6-H2PO3Mana-Sp8 1641 486 243 30
182 GlcAb-Sp8 1639 481 241 29
94 Gala1-3(Fuca1-2)Galb1-4(Fuca1-3)GlcNAcb-Sp0 1613 722 361 45
278 Galb1-4[Fuca1-3][6OSO3]GlcNAc-Sp0 1501 1805 903 120
68 Fuca1-2Galb1-4GlcNAcb1-3Galb1-4GlcNAc–Sp0 1415 647 323 46
Mana1-3(Neu5Aca2-6Galb1-4GlcNAcb1-2Mana1­ 1406 978 489 706)Manb1-4GlcNAcb1-4GlcNAc-Sp12
162 GlcNAcb1-3Galb1-4GlcNAcb–Sp0 1392 1155 577
178 Glcb1-4Glcb-Sp8 1347 962 481 71
331 GalNAca1-3(Fuca1-2)Galb1-4GlcNAcb1-3Galb1­ 1322 820 410 62
218
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Appendix
4GlcNAcb1-3Galb1-4GlcNAcb-Sp0
21 b-GlcNAc–Sp8 1316 1342 671 102
305 GlcNAcb1-4GlcNAcb-Sp10 1315 1440 720 109
165 GlcNAcb1-3Galb1-4Glcb–Sp0 1285 1155 578 90
127 1248 1204 602 96
69 Fuca1-2Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1­4GlcNAcb-Sp0 1224 646 323 53
48 9NAcNeu5Aca2-6Galb1-4GlcNAcb-Sp8 1223 1235 617 101
Galb1-4GlcNAcb1-2Mana1-3(Neu5Aca2-6Galb1­
293 4GlcNAcb1-2Mana1-6)Manb1-4GlcNAcb1-4GlcNAcb­ 1175 823 412 70
Sp12
291 6)GalNAc–Sp14 1174 385 193 33
143 Galb1-4GlcNAcb1-3Galb1-4(Fuca1-3)GlcNAcb1­3Galb1-4(Fuca1-3)GlcNAcb-Sp0 1153 1556 778 135
343 Neu5Aca2-6Galb1-4GlcNAcb1-2Mana1-3Manb1­4GlcNAcb1-4GlcNAc-Sp12 1143 647 324 57
342 Neu5Aca2-6Galb1-4GlcNAcb1-2Mana1-6Manb1­4GlcNAcb1-4GlcNAc-Sp12 1115 939 470 84
Galb1-3GalNAcb1-4Galb1-4Glcb–Sp8
Galb1-3(Neu5Aca2-3Galb1-4(Fuca1-3)GlcNAcb1-
197
Neu5Aca2-6Galb1-4GlcNAcb1-2Mana1-3(Neu5Aca2­
3Galb1-4GlcNAcb1-2Mana1-6)Manb1-4GlcNAcb1­
4GlcNAcb-Sp12
1099 1005 502 91
242 Neu5Aca2-6Galb1-4[6OSO3]GlcNAcb-Sp8 1086 811 405 75
366
GalNAca1-3(Fuca1-2)Galb1-4GlcNAcb1-2Mana1­
3[GalNAca1-3(Fuca1-2)Galb1-4GlcNAcb1-2Mana1­
6]Manb1-4GlcNAcb1-4GlcNAcb-Sp20
1053 917 459 87
70 Fuca1-2Galb1-4GlcNAcb–Sp0 1037 1919 959 185
250 Neu5Aca2-8Neu5Aca-Sp8 1033 1176 588 114
344 Galb1-4GlcNAcb1-2Mana1-3Manb1-4GlcNAcb1­4GlcNAc-Sp12 1026 1814 907 177
279 Galb1-4[Fuca1-3][6OSO3]Glc-Sp0 978 596 298 61
Gala1-3Galb1-4(Fuca1-3)GlcNAcb1-2Mana1-3[Gala1­
368 3Galb1-4(Fuca1-3)GlcNAcb1-2Mana1-6]Manb1­ 969 447 223 46
4GlcNAcb1-4GlcNAcb-Sp20
4 Galb1-3GlcNAcb1-2Mana1-3(Galb1-3GlcNAcb1­2Mana1-6)Manb1-4GlcNAcb1-4GlcNAcb-Sp19 956 848 424 89
60 Fuca1-2Galb1-3GlcNAcb1-3Galb1-4Glcb–Sp10 954 874 437 92
265 [3OSO3]Galb1-4[Fuca1-3][6OSO3]GlcNAc-Sp8 884 304 152 34
29 [3OSO3]Galb1-4(6OSO3)Glcb–Sp8 867 1112 556 128
316
Neu5Aca2-3Galb1-4GlcNAcb1-2Mana1-3(Neu5Aca2­
6Galb1-4GlcNAcb1-2Mana1-6)Manb1-4GlcNAcb1­
4GlcNAcb-Sp12
851 539 269 63
102 Gala1-3Galb1-3GlcNAcb-Sp0 788 882 441 112
253 Neu5Acb2-6Galb1-4GlcNAcb-Sp8 767 723 362 94
27 [3OSO3]Galb1-4Glcb-Sp8 758 318 159 42
82 GalNAca1-3(Fuca1-2)Galb–Sp8 753 507 254 67
179 Glcb1-6Glcb-Sp8 746 569 285 76
237 Neu5Aca2-3Galb1-4Glcb–Sp0 745 489 244 66
351 (6SO3)GlcNAcb1-3Gal b1-4GlcNAc-b-Sp0 709 534 267 75
320
97 Gala1-3(Fuca1-2)Galb–Sp8
704
687
428
424
214
212
61
62
49 Mana1-3(Mana1-6)Manb1-4GlcNAcb1-4GlcNAcb-Sp13 682 468 234 69
307 HOOC(CH3)CH-3-O-GlcNAcb1-4GlcNAcb-Sp10 675 1486 743 220
153 Galb1-4Glcb–Sp8 667 819 409 123
Mana1-2Mana1-6(Mana1-3)Mana1­
191 6(Mana2Mana2Mana1-3)Manb1-4GlcNAcb1­ 663 189 95 29
4GlcNAcb-Sp12
251 Neu5Aca2-8Neu5Aca2-3Galb1-4Glcb–Sp0 659 581 291 88
238 Neu5Aca2-3Galb1-4Glcb–Sp8 657 871 435 133
256
166 GlcNAcb1-4MDPLys
657
652
523
480
261
240
80
74
285 [3OSO3][4OSO3]Galb1-4GlcNacb-SpSp0 642 770 385 120
171 GlcNAcb1-4GlcNAcb1-4GlcNAcb–Sp8 641 635 318 99
39 [4OSO3]Galb1-4GlcNAcb-Sp8 598 404 202 68
117 Galb1-3(Fuca1-4)GlcNAcb–Sp8 596 471 236 79
282 Neu5Aca2-3Galb1-3GlcNAcb1-3Galb1-3GlcNAcb-Sp0 568 856 428 151
Fuca1-2Galb1-3GalNAca-Sp14
Neu5Gca2-3Galb1-3GlcNAcb-Sp0
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Appendix
131 Galb1-3GlcNAcb–Sp0 527 733 366 139
314 Neu5Aca2-3Galb1-3(Neu5Aca2-6)GalNAc-Sp14 526 712 356 135
200 Neu5Aca2-3Galb1-3GalNAca-Sp8 524 174 87 33
31 [3OSO3]Galb1-3GalNAca-Sp8 522 585 293 112
303 GlcNAcb1-2Mana1-3(GlcNAcb1-2Mana1-6)Manb1­4GlcNAcb1-4GlcNAcb-Sp12 519 287 143 55
114 Galb1-3(Fuca1-4)GlcNAcb1-3Galb1-4GlcNAcb-Sp0 511 276 138 54
Neu5Aca2-6Galb1-4GlcNAcb1-2Mana1-3(Neu5Aca2­
53 6Galb1-4GlcNAcb1-2Mana1-6)Manb1-4GlcNAcb1­ 499 363 181 73
4GlcNAcb-Sp8
150 Galb1-4GlcNAcb–Sp0 492 317 159 65
167 GlcNAcb1-4(GlcNAcb1-6)GalNAca-Sp8 475 797 398 168
99 Gala1-3GalNAca-Sp8 474 518 259 109
280 Galb1-4(Fuca1-3)GlcNAcb1-3Galb1-3(Fuca1­4)GlcNAcb-Sp0 474 846 423 179
231 4GlcNAcb-Sp8 470 468 234 100
276 Galb1-3GalNAc-Sp14 468 145 72 31
227 463 155 77 33
Fuca1-2Galb1-3(Fuca1-4)GlcNAcb1-2Mana1-3[Fuca1­
371 2Galb1-3(Fuca1-4)GlcNAcb1-2Mana1-6]Manb1­ 459 228 114 50
4GlcNAcb1-4GlcNAcb-Sp19
Neu5Aca2-3Galb1-4(Fuca1-3)GlcNAcb1-3Galb1-
Neu5Aca2-3Galb1-4(Fuca1-3)GlcNAcb1-3Galb1-
4(Fuca1-3)GlcNAcb1-3Galb1-4(Fuca1-3)GlcNAcb–Sp0
370
Gala1-3(Fuca1-2)Galb1-3GlcNAcb1-2Mana1-3[Gala1­
3(Fuca1-2)Galb1-3GlcNAcb1-2Mana1-6]Manb1­
4GlcNAcb1-4GlcNAcb-Sp20
450 482 241 107
181 GlcAa-Sp8 450 558 279 124
193 Mana1-3(Mana1-6)Mana-Sp9 448 468 234 104
218 Neu5Aca2-3Galb1-3[6OSO3]GalNAca-Sp8 445 110 55 25
18 b-D-Man–Sp8 441 186 93 42
GalNAca1-3(Fuca1-2)Galb1-3GlcNAcb1-2Mana1­
369 3[GalNAca1-3(Fuca1-2)Galb1-3GlcNAcb1-2Mana1­ 415 245 122 59
6]Manb1-4GlcNAcb1-4GlcNAcb-Sp20
106 Gala1-4(Fuca1-2)Galb1-4GlcNAcb-Sp8 410 392 196 95
216 NeuAca2-3Galb1-3(Fuca1-4)GlcNAcb1-3Galb1­4(Fuca1-3)GlcNAcb Sp0 408 237 118 58
355 KDNa2-3Galb1-3GalNAca-Sp14 407 354 177 87
212 Neu5Aca2-3GalNAca-Sp8 400 147 74 37
96 Gala1-3(Fuca1-2)Galb1-4Glcb-Sp0 390 272 136 70
105 Gala1-3Galb–Sp8 390 317 159 81
195 4GlcNAcb1-4GlcNAcb-Sp12 385 369 185 96
308 Mana1-3(Mana1-6)Manb1-4GlcNAcb1-4GlcNAcb-Sp12 385 465 232 121
163 GlcNAcb1-3Galb1-4GlcNAcb-Sp8 365 175 87 48
6 a-D-Gal–Sp8 363 160 80 44
226 Neu5Aca2-3Galb1-4(Fuca1-3)(6OSO3)GlcNAcb–Sp8 362 317 158 88
372 NeuAca2-3Galb1-4GlcNAcb1-3GalNAc-Sp14 359 349 174 97
110 Gala1-4GlcNAcb–Sp8 358 429 214 120
215 Neu5Aca2-3Galb1-3(Fuca1-4)GlcNAcb–Sp8 349 278 139 80
133
363 Neu5Aca2-6GlcNAcb1-4GlcNAcb1-4GlcNAc-Sp21
347
332
290
94
145
47
84
28
GlcNAca1-4Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1­
3Galb1-4GlcNAcb-Sp0
168 GlcNAcb1-4Galb1-4GlcNAcb-Sp8 321 420 210 131
274
130 Galb1-3GlcNAcb1-3Galb1-4Glcb–Sp10
319
317
248
184
124
92
78
58
183 GlcAb1-3Galb-Sp8 309 231 116 75
322 Galb1-4GlcNAcb1-3GalNAc-Sp14 299 182 91 61
266 [3OSO3]Galb1-4[Fuca1-3]GlcNAc-Sp0 296 254 127 86
83 GalNAca1-3GalNAcb–Sp8 296 150 75 51
321 Galb1-3(Neu5Aca2-6)GalNAca-Sp14 293 142 71 49
16 b-D-Gal–Sp8 284 275 138 97
81 GalNAca1-3(Fuca1-2)Galb1-4Glcb-Sp0 279 110 55 39
93 Gala1-3(Fuca1-2)Galb1-3GlcNAcb-Sp0 278 260 130 93
122
254 Galb1-4GlcNAcb1-2Mana1-3(Neu5Aca2-6Galb1­
273
265
307
298
154
149
113
113
Mana1-6(Mana1-3)Mana1-6(Mana2Mana1-3)Manb1-
Galb1-4(Fuca1-3)GlcNAcb–Sp0
333 327 236 118 72
Galb1-3(GlcNacb1-6)GalNAc-Sp14
Galb1-3(Neu5Aca2-6)GlcNAcb1-4Galb1-4Glcb-Sp10
220
 
  
 
 
 
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
 
 
    
      
      
      
      
      
      
 
 
    
      
      
      
      
      
 
 
    
      
      
      
      
      
      
      
      
      
 
 
    
      
      
      
      
 
 
    
      
      
      
     
Appendix
4GlcNAcb1-2Mana1-6)Manb1-4GlcNAcb1-4GlcNAcb­
Sp21
71 Fuca1-2Galb1-4GlcNAcb–Sp8 254 297 148 117
244 Neu5Aca2-6Galb1-4GlcNAcb–Sp8 242 119 60 49
119
8 a-D-Man–Sp8
239
237
154
92
77
46
65
39
229 Neu5Aca2-3Galb1-4(Fuca1-3)GlcNAcb–Sp8 235 162 81 69
125 Galb1-3GalNAcb1-3Gala1-4Galb1-4Glcb-Sp0 233 260 130 111
61
252 Neu5Acb2-6GalNAca-Sp8
232
230
218
137
109
68
94
59
Galb1-3(GlcNAcb1-6)GalNAca-Sp8
Fuca1-2Galb1-3GlcNAcb1-3Galb1-4Glcb–Sp8
50 GlcNAcb1-2Mana1-3(GlcNAcb1-2Mana1-6)Manb1­4GlcNAcb1-4GlcNAcb-Sp13 228 90 45 40
155 GlcNAca1-6Galb1-4GlcNAcb-Sp8 226 276 138 122
241 Neu5Aca2-6GalNAcb1-4GlcNAcb-Sp0 223 220 110 99
72 Fuca1-2Galb1-4Glcb–Sp0 221 252 126 114
377 Galb1-3GalNAca1-3(Fuca1-2)Galb1-4GlcNAc-Sp14 217 276 138 127
107 Gala1-4Galb1-4GlcNAcb–Sp0 214 56 28 26
281 Galb1-4GlcNAcb1-3Galb1-3GlcNAcb-Sp0 210 192 96 92
169 (GlcNAcb1-4)6b-Sp8 207 123 62 60
367
Gala1-3(Fuca1-2)Galb1-4GlcNAcb1-2Mana1-3[Gala1­
3(Fuca1-2)Galb1-4GlcNAcb1-2Mana1-6]Manb1­
4GlcNAcb1-4GlcNAcb-Sp20
204 333 167 163
334 GlcNAca1-4Galb1-4GlcNAcb-Sp0 201 234 117 116
144
220
Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1­
Neu5Aca2-3Galb-Sp8
192
189
104
190
52
95
54
101
20 b-GlcNAc–Sp0 189 163 82 86
295 Galb1-4GlcNAcb1-3(GlcNAcb1-6)Galb1-4GlcNAc-Sp0 183 195 98 106
4GlcNAcb–Sp0
51 Galb1-4GlcNAcb1-2Mana1-3(Galb1-4GlcNAcb1­2Mana1-6)Manb1-4GlcNAcb1-4GlcNAcb-Sp13 182 141 71 78
Fuca1-2Galb1-3GlcNAcb1-2Mana1-3(Fuca1-2Galb1­
356 3GlcNAcb1-2Mana1-6)Manb1-4GlcNAcb1-4GlcNAcb­ 175 247 124 141
Sp20
74 Fuca1-3GlcNAcb-Sp8 173 107 54 62
326 NeuAca2-3Galb1-3(Fuca1-4)GlcNAcb1-3Galb1­3(Fuca1-4)GlcNAcb-Sp0 156 175 87 112
310 Mana1-6(Mana1-3)Mana1-6(Mana1-3)Manb-Sp10 156 96 48 61
78 GalNAca1-3(Fuca1-2)Galb1-4(Fuca1-3)GlcNAcb-Sp0 145 70 35 48
206 Neu5Aca2-3(6-O-Su)Galb1-4(Fuca1-3)GlcNAcb–Sp8 141 139 70 99
Fuca1-2Galb1-4GlcNAcb1-2Mana1-3(Fuca1-2Galb1­
357 4GlcNAcb1-2Mana1-6)Manb1-4GlcNAcb1-4GlcNAcb­ 140 132 66 94
Sp20
258 Neu5Gca2-3Galb1-4GlcNAcb–Sp0 138 141 70 102
147 Galb1-4GlcNAcb1-3Galb1-4Glcb–Sp8 137 115 58 84
62 Fuca1-2Galb1-3GlcNAcb–Sp0 127 34 17 27
43 [6OSO3]Galb1-4GlcNAcb–Sp8 125 82 41 66
354 KDNa2-3Galb1-4Glc-Sp0 124 170 85 137
260 Neu5Gca2-6GalNAca-Sp0 124 90 45 73
3 Neu5Gcb2-6Galb1-4GlcNAc-Sp8 123 46 23 37
312 Mana1-2Mana1-2Mana1-3(Mana1-2Mana1-6(Mana1­2Mana1-3)Mana1-6)Mana-Sp9 120 81 40 67
76 Fucb1-3GlcNAcb-Sp8 120 99 50 83
Neu5Aca2-6Galb1-4GlcNAcb1-2Mana1-3(Neu5Aca2­
52 6Galb1-4GlcNAcb1-2Mana1-6)Manb1-4GlcNAcb1­ 116 55 28 48
4GlcNAcb-Sp13
185 KDNa2-3Galb1-3GlcNAcb–Sp0 115 77 39 67
336 GlcNAca1-4Galb1-4GlcNAcb1-3Galb1-4Glcb-Sp0 114 77 38 67
112 Galb1-2Galb–Sp8 110 26 13 24
198 Manb1-4GlcNAcb-Sp0 110 20 10 18
350
Galb1-3(Fuca1-4)GlcNAcb1-2Mana1-3[Galb1-3(Fuca1­
4)GlcNAcb1-2Mana1-6]Manb1-4GlcNAcb1-4GlcNAcb­
Sp19
109 105 52 96
41 [6OSO3]Galb1-4Glcb–Sp0 108 90 45 83
248 Neu5Aca2-6Galb1-4Glcb–Sp8 104 140 70 135
306 GlcNAcb1-4GlcNAcb-Sp12 103 84 42 82
346 Galb1-4GlcNAcb1-2Mana1-3(Mana1-6)Manb1­ 103 143 72 140
221
 
  
 
 
 
      
      
      
      
      
      
      
      
      
      
      
 
 
    
 
 
    
      
      
      
      
      
      
      
      
      
      
      
      
      
 
 
    
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
135
69
Appendix
4GlcNAcb1-4GlcNAcb-Sp12
228 Neu5Aca2-3Galb1-4(Fuca1-3)GlcNAcb–Sp0 102 149 75 146
22 b-GlcN(Gc)-Sp8 100 245 122 246
222 NeuAca2-3Galb1-3GlcNAcb1-3Galb1-4GlcNAcb-Sp0 99 32 16 32
59 Fuca1-2Galb1-3GalNAcb1-4(Neu5Aca2-3)Galb1­4Glcb-Sp9 99 44 22 44
Galb1-4(Fuca1-3)GlcNAcb1-4Galb1-4(Fuca1­ 95 117 59 1243)GlcNAcb-Sp0
236 Neu5Aca2-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb-Sp0 94 65 32
290 Galb1-3GalNAca-Sp16 93 23 12 25
345 Galb1-4GlcNAcb1-2Mana1-6Manb1-4GlcNAcb1­4GlcNAc-Sp12 87 81 40 92
246 Neu5Aca2-6Galb1-4GlcNAcb1-3Galb1-4GlcNAcb-Sp0 85 48 24 57
132 Galb1-3GlcNAcb–Sp8 84 77 39 92
145 Galb1-4GlcNAcb1-3Galb1-4GlcNAcb–Sp0 82 29 14 35
359
Gala1-3Galb1-4GlcNAcb1-2Mana1-3(Gala1-3Galb1­
4GlcNAcb1-2Mana1-6)Manb1-4GlcNAcb1-4GlcNAcb­
Sp20
81 69 34 85
Galb1-3(Fuca1-4)GlcNAcb1-2Mana1-3[Galb1-3(Fuca1­
361 4)GlcNAcb1-2Man a1-6]Manb1-4GlcNAcb1-4(Fuca1­ 77 58 29 75
6)GlcNAcb-Sp22
10 a-L-Fuc–Sp8 77 150 75 195
301 GlcAb1-3GlcNAcb-Sp8 77 37 18 48
95
284 [3OSO3]Galb1-4[6OSO3]GlcNAcb-Sp0
75
74
230
79
115
40
306
107
Gala1-3(Fuca1-2)Galb1-4GlcNAc-Sp0
217 Neu5Aca2-3Galb1-3(Neu5Aca2-3Galb1-4)GlcNAcb­Sp8 64 173 86 270
156 GlcNAcb1-2Galb1-3GalNAca-Sp8 63 56 28 88
187 Mana1-2Mana1-2Mana1-3Mana-Sp9 63 101 50 159
100 Gala1-3GalNAcb–Sp8 63 74 37 117
66 Fuca1-2Galb1-4(Fuca1-3)GlcNAcb–Sp0 60 55 27 90
64 Fuca1-2Galb1-4(Fuca1-3)GlcNAcb1-3Galb1-4(Fuca1­3)GlcNAcb-Sp0 53 30 15 56
12 a-L-Rha-Sp8 51 45 23 88
208 Neu5Aca2-3(GalNAcb1-4)Galb1-4GlcNAcb-Sp8 51 57 29 113
309 Mana1-6Manb-Sp10 48 63 32 130
Galb1-4GlcNAcb1-2Mana1-3(Galb1-4GlcNAcb1­
348 2Mana1-6)Manb1-4GlcNAcb1-4(Fuca1-6)GlcNAcb­ 48 30 15 62
Sp22
272 Galb1-3(Fuca1-4)GlcNAcb1-3Galb1-3(Fuca1­4)GlcNAcb-Sp0 43 28 14 64
1 Neu5Aca2-8Neu5Acb-Sp17 38 47 23 122
24 GlcNAcb1-3(GlcNAcb1-4)(GlcNAcb1-6)GlcNAc-Sp8 38 45 22 117
234 Neu5Aca2-3Galb1-4GlcNAcb–Sp0 36 61 31 172
189 Mana1-2Mana1-3Mana-Sp9 28 61 31 216
137 Galb1-4[6OSO3]Glcb–Sp0 28 33 17 121
35 [3OSO3]Galb1-4GlcNAcb–Sp0 26 41 20 156
223 Neu5Aca2-3Galb1-3GlcNAcb–Sp0 22 4 2 18
26 [3OSO3][6OSO3]Galb1-4GlcNAcb-Sp0 19 108 54 578
175 Glca1-4Glcb–Sp8 18 35 18 191
45 NeuAca2-3[6OSO3]Galb1-4GlcNAcb–Sp8 16 46 23 295
14 a-Neu5Ac–Sp11 13 69 35 529
37 [3OSO3]Galb–Sp8 12 43 21 352
287 6-H2PO3Glcb-Sp10 12 39 20 337
177
118 Galb1-3(Galb1-4GlcNAcb1-6)GalNAca-Sp8
11
7
26
105
13
53
233
1451
268 Fuca1-2Galb1-4[6OSO3]GlcNAc-Sp8 5 36 18 682
89 GalNAcb1-4(Fuca1-3)GlcNAcb-Sp0 -1 73 37 -7956
324 NeuAc(9Ac)a2-3Galb1-3GlcNAcb-Sp0 -1 40 20 -3751
158 GlcNAcb1-3(GlcNAcb1-6)Galb1-4GlcNAcb–Sp8 -2 15 7 -622
108 Gala1-4Galb1-4GlcNAcb–Sp8 -3 43 21 -1354
160 GlcNAcb1-3Galb-Sp8 -7 10 5 -144
338 GlcNAca1-4Galb1-4GlcNAcb1-3Galb1-4GlcNAcb-Sp0 -8 25 12 -296
79 GalNAca1-3(Fuca1-2)Galb1-4GlcNAcb-Sp0 -16 23 12 -146
210 4Glcb-Sp0 -18 75 37 -420
Glca1-6Glca1-6Glcb-Sp8
NeuAca2-3(NeuAca2-3Galb1-3GalNAcb1-4)Galb1-
222
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Appendix
262 Neu5Gca-Sp8	 -25 38 19 -149
Neu5Aca2-8Neu5Aca2-8Neu5Acb-Sp8 -26 55 28 -208
Galb1-4GlcNAcb1-2Mana1-3(Fuca1-3(Galb1­
239	 4)GlcNAcb1-2Mana1-6)Manb1-4GlcNAcb1-4GlcNAcb- -33 27 13 -82
Sp20
240 Neu5Aca2-6GalNAca-Sp8 -38 25 13 -66
(Neu5Aca2-3-Galb1-3)(((Neu5Aca2-3-Galb1-4(Fuca1­332	 -41 126 63 -3093))GlcNAcb1-6)GalNAc–Sp14
-76 9 5 -12Fuca1-2Galb1-3GalNAcb1-3Gala1-4Galb1-4Glcb-Sp9
ASGPR-2
 
Chart
Number
Glycan structure RFU STDEV SEM %CV
374 Neu5Aca2-3Galb1-4(Fuca1-3)GlcNAcb1-3GalNAca-Sp14 133 18 9 13
307 Mana1-6(Mana1-3)Mana1-6(Mana1-3)Manb-Sp10 122 60 30 49
299
28 [3OSO3]Galb1-3GlcNAcb-Sp8
110
92
19
120
10
60
17
130
350 Galb1-3(Fuca1-4)GlcNAcb1-2Mana1-3(Galb1-3(Fuca1­
4)GlcNAcb1-2Mana1-6)Manb1-4GlcNAcb1-4GlcNAcb-Sp19
68 6 3 9
GlcAb1-3GlcNAcb-Sp8
246 Neu5Aca2-3Galb1-4(Fuca1-3)GlcNAcb1-3Galb1-4GlcNAcb-Sp8 68 34 17 50
54 Neu5Aca2-6Galb1-4GlcNAcb1-2Mana1-3(Neu5Aca2-6Galb1­
4GlcNAcb1-2Mana1-6)Manb1-4GlcNAcb1-4GlcNAcb-Sp13
68 30 15 45
370 Gala1-3(Fuca1-2)Galb1-3GlcNAcb1-2Mana1-3(Gala1-3(Fuca1- 64 62 31 97
2)Galb1-3GlcNAcb1-2Mana1-6)Manb1-4GlcNAcb1-4GlcNAcb­
Sp20
358 Fuca1-2Galb1-4(Fuca1-3)GlcNAcb1-2Mana1-3(Fuca1-2Galb1­
4(Fuca1-3)GlcNAcb1-2Mana1-6)Manb1-4GlcNAcb1-4GlcNAb­
Sp20
63 36 18 57
390 Gala1-3Galb1-3GlcNAcb1-2Mana1-3(Gala1-3Galb1-3GlcNAcb1­
2Mana1-6)Manb1-4GlcNAcb1-4GlcNAc-Sp19
59 47 23 80
344 Galb1-4GlcNAcb1-2Mana1-3Manb1-4GlcNAcb1-4GlcNAc-Sp12 57 58 29 101
337 GlcNAca1-4Galb1-4GlcNAcb1-3Galb1-4(Fuca1-3)GlcNAcb1- 57 27 14 48
3Galb1-4(Fuca1-3)GlcNAcb-Sp0
323 Neu5Ac(9Ac)a2-3Galb1-4GlcNAcb-Sp0 57 30 15 52
420 Gala1-3(Fuca1-2)Galb1-3GlcNAcb1-3GalNAc-Sp14 56 37 18 66
277 Galb1-3(Neu5Aca2-3Galb1-4GlcNAcb1-6)GalNAca-Sp14 55 18 9 33
348 Galb1-4GlcNAcb1-2Mana1-3(Galb1-4GlcNAcb1-2Mana1- 53 22 11 42
6)Manb1-4GlcNAcb1-4(Fuca1-6)GlcNAcb-Sp22
280 Galb1-4(Fuca1-3)[6OSO3]GlcNAc-Sp0 51 29 14 57
247	 Neu5Aca2-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1- 49 34 17 70
4GlcNAcb-Sp0
220 Neu5Aca2-3(6-O-Su)Galb1-4(Fuca1-3)GlcNAcb-Sp8 48 55 27 113
22 [3OSO3]Galb1-4(Fuca1-3)[6OSO3]Glc-Sp0	 48 8 4 17
132 Galb1-3GalNAca-Sp16 47 57 29 120
346	 Galb1-4GlcNAcb1-2Mana1-3(Mana1-6)Manb1-4GlcNAcb1- 47 36 18 77
4GlcNAcb-Sp12
198 Mana1-2Mana1-2Mana1-3Mana-Sp9 47 17 9 36
400 Gala1-4Galb1-4GlcNacb1-2Mana1-3(Gala1-4Galb1-4GlcNacb1- 47 10 5 22
2Mana1-6)Manb1-4GlcNacb1-4GlcNacb-LVaNKT
99 Gala1-3(Fuca1-2)Galb1-4(Fuca1-3)GlcNAcb-Sp0 46 23 11 49
180 (GlcNAcb1-4)5b-Sp8 46 24 12 53
386 Fuca1-2Galb1-3GalNAca1-3(Fuca1-2)Galb1-4GlcNAcb-Sp0 44 36 18 81
161 Galb1-4GlcNAcb-Sp8 43 19 9 43
300 GlcNAcb1-2Mana1-3(Neu5Aca2-6Galb1-4GlcNAcb1-2Mana1­ 43 6 3 14
6)Manb1-4GlcNAcb1-4GlcNAcb-Sp12
127 Galb1-3(Neu5Aca2-6)GalNAca-Sp8 43 23 12 55
207 Mana1-6(Mana1-3)Mana1-6(Mana1-3)Manb1-4GlcNAcb1-4 43 20 10 46
GlcNAcb-Sp12
428 GlcNAcb1-2Mana1-3(GlcNAcb1-4)(GlcNAcb1-2Mana1-6)Manb1- 43 28 14 67
4GlcNacb1-4GlcNAc-Sp21
13 Manb-Sp8 42 36 18 86
36 [4OSO3][6OSO3]Galb1-4GlcNAcb-Sp0	 42 19 9 45
223
 
  
 
 
      
      
 
 
    
      
      
 
 
    
 
 
    
 
 
    
      
 
 
    
 
 
    
 
 
    
      
      
 
 
    
      
      
 
 
    
      
      
      
      
      
      
      
      
 
 
    
 
 
    
      
      
      
      
 
 
    
      
      
      
      
      
      
      
 
 
    
      
      
 
 
    
      
      
 
 
    
      
     
Appendix
239 Neu5Aca2-3Galb1-3GlcNAcb-Sp8 41 28 14 67
244 Neu5Aca2-3Galb1-4(Fuca1-3)GlcNAcb-Sp8 41 40 20 99
51 Neu5Aca2-6Galb1-4GlcNAcb1-2Mana1-3(Neu5Aca2-6Galb1­ 41 13 6 31
4GlcNAcb1-2Mana1-6)Manb1-4GlcNAcb1-4GlcNAcb-N(LT)AVL
281 Galb1-4(Fuca1-3)[6OSO3]Glc-Sp0 41 36 18 88
186 Glca1-4Glcb-Sp8 40 10 5 26
53 Neu5Aca2-6Galb1-4GlcNAcb1-2Mana1-3(Neu5Aca2-6Galb1­
4GlcNAcb1-2Mana1-6)Manb1-4GlcNAcb1-4GlcNAcb-Sp12
40 27 13 67
357 Fuca1-2Galb1-4GlcNAcb1-2Mana1-3(Fuca1-2Galb1-4GlcNAcb1­
2Mana1-6)Manb1-4GlcNAcb1-4GlcNAcb-Sp20
40 28 14 70
364 Fuca1-2Galb1-3GlcNAcb1-3(Galb1-4(Fuca1-3)GlcNAcb1-6)Galb1- 39 21 11 54
4Glc-Sp21
128 Galb1-3(Neu5Aca2-6)GalNAca-Sp14 38 27 13 70
383 Galb1-4GlcNacb1-2(Galb1-4GlcNacb1-4)Mana1-3(Galb1­ 38 25 13 66
4GlcNacb1-2(Galb1-4GlcNacb1-6)Mana1-6)Manb1-4GlcNacb1­
4GlcNacb-Sp21
66 Fuca1-2Galb1-4(Fuca1-3)GlcNAcb1-3Galb1-4(Fuca1-3)GlcNAcb­ 38 25 13 67
Sp0
347	 GlcNAcb1-2Mana1-3(GlcNAcb1-2Mana1-6)Manb1-4GlcNAcb1- 38 15 7 39
4(Fuca1-6)GlcNAcb-Sp22
303 GlcNAcb1-4GlcNAcb-Sp10 37 21 11 57
104 Gala1-3GalNAca-Sp8	 37 35 17 95
321 Neu5Aca2-6Galb1-4GlcNAcb1-2Mana1-3(Neu5Aca2-3Galb1­
4GlcNAcb1-2Mana1-6)Manb1-4GlcNAcb1-4GlcNAcb-Sp12
37 10 5 28
124 Galb1-4GlcNAcb1-6GalNAca-Sp8	 35 17 9 49
421 GalNAca1-3(Fuca1-2)Galb1-3GlcNAcb1-3GalNAc-Sp14 35 23 12 67
308 Mana1-2Mana1-2Mana1-3(Mana1-2Mana1-6(Mana1-3)Mana1­ 34 36 18 104
6)Mana-Sp9
302 GlcNAcb1-3Man-Sp10 34 26 13 75
126 Galb1-3(GlcNAcb1-6)GalNAc-Sp14	 34 30 15 88
80 GalNAca1-3(Fuca1-2)Galb1-4(Fuca1-3)GlcNAcb-Sp0 34 12 6 35
97 Gala1-2Galb-Sp8	 34 25 13 74
177 GlcNAcb1-4(GlcNAcb1-6)GalNAca-Sp8 34 25 13 75
77 Fuca1-4GlcNAcb-Sp8	 33 22 11 68
151
137 Galb1-3Galb-Sp8
33
33
9
3
5
1
28
8
382 Galb1-3GlcNAcb1-3(Galb1-3GlcNAcb1-3Galb1-4(Fuca1­
3)GlcNAcb1-6)Galb1-4Glc-Sp21
33 16 8 50
Galb1-4GlcNAcb1-3GalNAc-Sp14
331	 GalNAca1-3(Fuca1-2)Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1- 33 29 15 90
3Galb1-4GlcNAcb-Sp0
413 Fuca1-2Galb1-4(Fuca1-3)GlcNAcb1-3GalNAca-Sp14 33 6 3 17
317 Neu5Aca2-8Neu5Aca2-8Neu5Acb-Sp8	 32 35 18 109
267 Neu5Acb2-6GalNAca-Sp8 32 28 14 86
291 Galb1-3Galb1-4GlcNAcb-Sp8 32 25 12 77
399 Gala1-4Galb1-3GlcNacb1-2Mana1-3(Gala1-4Galb1-3GlcNacb1­
2Mana1-6)Manb1-4GlcNacb1-4GlcNacb-Sp19
32 28 14 87
68 Fuca1-2Galb1-4(Fuca1-3)GlcNAcb-Sp0 32 20 10 62
257 Neu5Aca2-6Galb1-4GlcNAcb-Sp0 32 28 14 89
199 Mana1-2Mana1-3(Mana1-2Mana1-6)Mana-Sp9	 31 23 12 74
129 Galb1-3(Neu5Acb2-6)GalNAca-Sp8	 31 20 10 64
44 [6OSO3]GlcNAcb-Sp8	 31 18 9 58
396 Fuca1-2Galb1-4GlcNacb1-3GalNaca-Sp14 31 7 4 23
113 Gala1-4Galb1-4GlcNAcb-Sp0	 31 25 13 82
375 (GalNAcb1-4GlcNAcb1-2Mana1-6)GalNAcb1-4GlcNAcb1­
2Mana1-3Manb1-4GlcNAcb1-4GlcNAc-Sp12
30 20 10 67
134 Galb1-3GalNAcb1-3Gala1-4Galb1-4Glcb-Sp0	 30 8 4 27
226 Neu5Aca2-3GalNAca-Sp8 30 8 4 25
67 Fuca1-2Galb1-4(Fuca1-3)GlcNAcb1-3Galb1-4(Fuca1­ 30 13 6 42
3)GlcNAcb1-3Galb1-4(Fuca1-3)GlcNAcb-Sp0
256 Neu5Aca2-6Galb1-4[6OSO3]GlcNAcb-Sp8	 30 34 17
335 GlcNAca1-4Galb1-3GlcNAcb-Sp0	 30 12 6 40
441 Fuca1-2Galb1-4GlcNAcb1-2(Fuca1-2Galb1-4GlcNAcb1-4)Mana1­
3(Fuca1-2Galb1-4 GlcNAcb1-2Mana1-6)Manb1-4GlcNAcb1­
4GlcNAcb-N
29 5 3 17
46 Neu5Ac(9Ac)a2-6Galb1-4GlcNAcb-Sp8 29 6 3 19
327 Neu5Aca2-6Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1­ 29 14 7 50
224
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Appendix
4GlcNAcb-Sp0
304 GlcNAcb1-4GlcNAcb-Sp12	 28 13 7 47
295 Galb1-4GlcNAca1-6Galb1-4GlcNAcb-Sp0 28 10 5 37
312 Neu5Aca2-3Galb1-3GalNAca-Sp14 28 16 8 56
50 Galb1-4GlcNAcb1-2Mana1-3(Galb1-4GlcNAcb1-2Mana1­ 28 16 8 58
6)Manb1-4GlcNAcb1-4GlcNAcb-Sp12
213 Fuca1-2[6OSO3]Galb1-4[6OSO3]Glc-Sp0 28 17 8 60
298 GalNAcb1-3Galb-Sp8 28 7 4
87 GalNAca1-3(Fuca1-2)Galb-Sp18 28 17 9 63
103 Gala1-3(Gala1-4)Galb1-4GlcNAcb-Sp8 27 18 9 65
422 Gala1-3Galb1-3GlcNAcb1-3GalNAc-Sp14	 27 29 15 108
9 Neu5Aca-Sp11 27 18 9 64
316 Neu5Aca2-8Neu5Acb-Sp17	 27 31 16 115
63 Fuca1-2Galb1-3GlcNAcb1-3Galb1-4Glcb-Sp10 27 20 10 73
145 Galb1-4(Fuca1-3)GlcNAcb1-4Galb1-4(Fuca1-3)GlcNAcb1-4Galb1­ 26 6 3 24
4(Fuca1-3)GlcNAcb-Sp0
248 Neu5Aca2-3Galb1-4GlcNAcb-Sp0 26 34 17 129
362 Neu5Aca2-6GlcNAcb1-4GlcNAc-Sp21	 26 16 8 63
385 Fuca1-2Galb1-3GalNAca1-3(Fuca1-2)Galb1-4Glcb-Sp0 26 8 4 32
387 Galb1-3GlcNAcb1-3GalNAca-Sp14 26 24 12 93
167 GlcNAcb1-3(GlcNAcb1-6)GalNAca-Sp8 26 10 5 38
309 Mana1-2Mana1-2Mana1-3(Mana1-2Mana1-6(Mana1-2Mana1- 26 15 7 58
3)Mana1-6)Mana-Sp9
154 Galb1-4GlcNAcb1-3Galb1-4GlcNAcb-Sp0	 26 30 15 116
47 Mana1-3(Mana1-6)Manb1-4GlcNAcb1-4GlcNAcb-Sp12 26 14 7 55
55 Fuca1-2Galb1-3GalNAcb1-3Gala-Sp9 26 31 15 119
146 Galb1-4[6OSO3]Glcb-Sp0	 26 19 10 76
376 Galb1-3GalNAca1-3(Fuca1-2)Galb1-4Glc-Sp0 26 38 19 149
206	 Mana1-6(Mana1-3)Mana1-6[Mana1-2Mana1-3]Manb1- 25 18 9 69
4GlcNAcb1-4GlcNAcb-Sp12
351 [6OSO3]GlcNAcb1-3Gal b1-4GlcNAc-b-Sp0 25 5 2 20
41 [6OSO3]Galb1-4GlcNAcb-Sp8 25 15 8 62
320 Neu5Aca2-3Galb1-4GlcNAcb1-2Mana1-3(Neu5Aca2-3Galb1­ 25 6 3 22
4GlcNAcb1-2Mana1-6)Manb1-4GlcNAcb1-4GlcNAcb-Sp12
286 [3OSO3][4OSO3]Galb1-4GlcNAcb-Sp0 25 16 8 65
21 [3OSO3][6OSO3]Galb1-4GlcNAcb-Sp0 25 18 9 73
409 Neu5Aca2-3Galb1-3GalNAcb1-4(Neu5Aca2-8Neu5Aca2-3)Galb1- 25 22 11 91
4Glcb-Sp0
264 Neu5Aca2-8Neu5Aca-Sp8 24 25 12 102
61
189
Fuca1-2Galb1-3GalNAcb1-4(Neu5Aca2-3)Galb1-4Glcb-Sp9
Glcb1-4Glcb-Sp8
24
24
5
26
2
13
19
109
171 GlcNAcb1-3Galb-Sp8 24 30 15 127
89 GalNAca1-3Galb-Sp8 24 29 14 122
359	 Gala1-3Galb1-4GlcNAcb1-2Mana1-3(Gala1-3Galb1-4GlcNAcb1- 24 18 9 75
2Mana1-6)Manb1-4GlcNAcb1-4GlcNAcb-Sp20
122 Galb1-3(Fuca1-4)GlcNAc-Sp8 23 23 12 99
249 Neu5Aca2-3Galb1-4GlcNAcb-Sp8	 23 19 10 83
279 Galb1-3GlcNAcb1-3Galb1-3GlcNAcb-Sp0 23 31 15 132
394 GlcNAcb1-2Mana1-3(Galb1-4GlcNAcb1-2Mana1-6)Manb1­ 23 11 6 49
201
4GlcNAcb1-4GlcNAc-Sp12
Mana1-6[Mana1-2Mana1-3]Mana1-6[Mana1-2Mana1-3]Manb1­
4GlcNAcb1-4GlcNAcb-Sp12
23 23 12 101
319 Galb1-3GlcNAcb1-2Mana1-3(Galb1-3GlcNAcb1-2Mana1­ 23 18 9 79
6)Manb1-4GlcNAcb1-4GlcNAcb-Sp19
290 Galb1-3(Neu5Aca2-3Galb1-4(Fuca1-3)GlcNAcb1-6)GalNAca­ 23 33 16 144
Sp14
152 Galb1-4GlcNAcb1-3Galb1-4(Fuca1-3)GlcNAcb1-3Galb1-4(Fuca1­
3)GlcNAcb-Sp0
23 32 16 139
125 Galb1-3(GlcNAcb1-6)GalNAca-Sp8 23 34 17
115 Gala1-4Galb1-4Glcb-Sp0 23 36 18 159
150 Galb1-4GlcNAcb1-3GalNAca-Sp8 23 23 11 100
259 Neu5Aca2-6Galb1-4GlcNAcb1-3Galb1-4(Fuca1-3)GlcNAcb1- 23 19 10 85
3Galb1-4(Fuca1-3)GlcNAcb-Sp0
313 Neu5Aca2-3Galb1-4GlcNAcb1-2Mana1-3(Neu5Aca2-6Galb1­
4GlcNAcb1-2Mana1-6)Manb1-4GlcNAcb1-4GlcNAcb-Sp12
22 16 8 70
221 Neu5Aca2-3(GalNAcb1-4)Galb1-4GlcNAcb-Sp0	 22 4 2 16
225
 
150
  
 
 
      
      
      
      
      
 
 
    
      
      
      
      
      
      
      
      
      
      
      
      
      
 
 
    
 
 
    
      
      
 
 
    
 
 
    
 
 
    
 
 
    
      
      
      
      
      
      
      
      
      
 
 
    
      
 
 
    
      
      
      
      
 
 
    
 
 
    
 
 
    
      
 
 
    
     
248
44
52
Appendix
240 Neu5Aca2-3Galb1-4[6OSO3]GlcNAcb-Sp8 22 56 28
188 Glca1-6Glca1-6Glcb-Sp8	 22 12 6 54
439 [6OSO3]Galb1-3GlcNAcb-Sp0 22 10 5
10 Neu5Acb-Sp8	 22 11 6 51
411
379 Galb1-3GlcNAcb1-3(Galb1-4(Fuca1-3)GlcNAcb1-6)Galb1-4Glc­
22
22
8
41
4
20
37
182
Sp21
GalNAca1-3(Fuca1-2)Galb1-4GlcNAcb1-3GalNAca-Sp14
255 Neu5Aca2-6GalNAcb1-4GlcNAcb-Sp0 22 12 6
253 Neu5Aca2-3Galb1-4Glcb-Sp8 22 11 5 49
148 Galb1-4GalNAca1-3(Fuca1-2)Galb1-4GlcNAcb-Sp8 22 9 4 40
192 GlcAa-Sp8	 22 59 29 270
408 Galb1-3GalNAcb1-4(Neu5Aca2-8Neu5Aca2-3)Galb1-4Glcb-Sp0 22 8 4 39
261 Neu5Aca2-6Galb1-4Glcb-Sp0	 22 11 6 53
275 Neu5Gca2-6Galb1-4GlcNAcb-Sp0 22 6 3 29
165 GlcNAca1-6Galb1-4GlcNAcb-Sp8 22 21 10 96
282 Galb1-4(Fuca1-3)GlcNAcb1-3Galb1-3(Fuca1-4)GlcNAcb-Sp0 21 21 11 98
412 GalNAca1-3GalNAcb1-3Gala1-4Galb1-4Glcb-Sp0	 21 19 9 88
405 GlcNAcb1-6(GlcNAcb1-3)GalNAca-Sp14 21 13 7 63
377 Galb1-3GalNAca1-3(Fuca1-2)Galb1-4GlcNAc-Sp0	 21 19 10 91
143
433 Galb1-4GlcNAcb1-4(Galb1-4GlcNAcb1-2)Mana1-3(GlcNAcb1­
21
21
30
7
15
4
145
35
4)(Galb1-4GlcNAcb1-2Mana1-6)Manb1-4GlcNAcb1-4GlcNAc­
Sp21
Galb1-4(Fuca1-3)GlcNAcb-Sp8
407 Neu5Aca2-6Galb1-3GlcNAcb1-3(Galb1-4GlcNAcb1-6)Galb1-4Glc­
Sp21
21 17 8 82
373 Neu5Aca2-6Galb1-4GlcNAcb1-3GalNAc-Sp14	 20 9 5 45
11 Galb-Sp8 20 43 21 209
49	 GlcNAcb1-2Mana1-3(GlcNAcb1-2Mana1-6)Manb1-4GlcNAcb1- 20 23 11 111
4GlcNAcb-Sp13
381 Fuca1-2Galb1-3(Fuca1-4)GlcNAcb1-3(Galb1-4(Fuca1­ 20 24 12 118
3)GlcNAcb1-6)Galb1-4Glc-Sp21
340 Mana1-3(Neu5Aca2-6Galb1-4GlcNAcb1-2Mana1-6)Manb1- 20 30 15 150
4GlcNAcb1-4GlcNAc-Sp12
434 Galb1-4GlcNAcb1-2Mana1-3(GlcNAcb1-4)(Galb1-4GlcNAcb1­
6(Galb1-4GlcNAcb1-2)Mana1-6)Manb1-4GlcNAcb1-4GlcNAc­
Sp21
20 12 6 59
184 GlcNAcb1-6GalNAca-Sp14	 20 11 6 56
414 Gala1-3(Fuca1-2)Galb1-4(Fuca1-3)GlcNAcb1-3GalNAc-Sp14 20 9 5 45
305 HOOC(CH3)CH-3-O-GlcNAcb1-4GlcNAcb-Sp10	 20 16 8 82
397 Galb1-4(Fuca1-3)GlcNacb1-3GalNaca-Sp14	 20 10 5 49
273 Neu5Gca2-3Galb1-4Glcb-Sp0	 20 15 8 79
170 GlcNAcb1-3GalNAca-Sp14 19 35 18 183
265 Neu5Aca2-8Neu5Aca2-3Galb1-4Glcb-Sp0	 19 21 10 106
325 Neu5Aca2-6Galb1-4GlcNAcb1-3Galb1-3GlcNAcb-Sp0 19 17 8 87
5 Fuca-Sp8 19 35 17 181
202 Mana1-2Mana1-6(Mana1-3)Mana1-6[Mana1-2Mana1-2Mana1­ 19 22 11 114
3]Manb1-4GlcNAcb1-4GlcNAcb-Sp12
200 Mana1-2Mana1-3Mana-Sp9 19 27 14 142
341 Neu5Aca2-6Galb1-4GlcNAcb1-2Mana1-3(Mana1-6)Manb1­
4GlcNAcb1-4GlcNAc-Sp12
19 15 8 81
196 KDNa2-3Galb1-3GlcNAcb-Sp0	 19 17 8 88
23 [3OSO3]Galb1-4Glcb-Sp8 19 33 16 174
85 GlcNAcb1-3Galb1-3GalNAca-Sp8	 19 12 6 64
403 Galb1-3GlcNAca1-6Galb1-4GlcNAcb-Sp0 19 24 12 130
391 Gala1-3Galb1-3(Fuca1-4)GlcNAcb1-2Mana1-3(Gala1-3Galb1­ 19 15 8 83
3(Fuca1-4)GlcNAcb1-2Mana1-6)Manb1-4GlcNAcb1-4GlcNAc­
Sp19
366 GalNAca1-3(Fuca1-2)Galb1-4GlcNAcb1-2Mana1-3(GalNAca1­
3(Fuca1-2)Galb1-4GlcNAcb1-2Mana1-6)Manb1-4GlcNAcb1­
4GlcNAcb-Sp20
18 10 5 52
360 Mana1-3(Galb1-4GlcNAcb1-2Mana1-6)Manb1-4GlcNAcb1- 18 12 6 67
4GlcNAcb-Sp12
222 Neu5Aca2-3(GalNAcb1-4)Galb1-4GlcNAcb-Sp8 18 13 6
332	 (Neu5Aca2-3-Galb1-3)(((Neu5Aca2-3-Galb1-4(Fuca1- 18 8 4 45
3))GlcNAcb1-6)GalNAc-Sp14
417 Fuca1-2Galb1-4GlcNAcb1-2Mana1-3(Fuca1-2Galb1-4GlcNAcb1­ 18 21 10 114
226
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Appendix
2Mana1-6)Manb1-4GlcNAcb1-4(Fuca1-6)GlcNAcb-Sp22
60 Fuca1-2Galb1-3GalNAcb1-4(Neu5Aca2-3)Galb1-4Glcb-Sp0 18 24 12 131
176 GlcNAcb1-4-MDPLys 18 16 8
288 6-H2PO3Glcb-Sp10 18 13 6 71
227 Neu5Aca2-3GalNAcb1-4GlcNAcb-Sp0 18 10 5
293 Galb1-4GlcNAcb1-3(Galb1-4GlcNAcb1-6)Galb1-4GlcNAc-Sp0 18 23 11 129
272 Neu5Gca2-3Galb1-4GlcNAcb-Sp0 18 8 4
187 Glca1-4Glca-Sp8 18 36 18 206
69
367 Gala1-3(Fuca1-2)Galb1-4GlcNAcb1-2Mana1-3(Gala1-3(Fuca1­
2)Galb1-4GlcNAcb1-2Mana1-6)Manb1-4GlcNAcb1-4GlcNAcb­
17
17
19
21
10
11
110
122
Sp20
Fuca1-2Galb1-4(Fuca1-3)GlcNAcb-Sp8
245 Neu5Aca2-3Galb1-4(Fuca1-3)GlcNAcb1-3Galb-Sp8 17 11 5 63
225 Neu5Aca2-3(Neu5Aca2-6)GalNAca-Sp8 17 10 5 59
102 Gala1-3(Fuca1-2)Galb-Sp8 17 14 7 82
16 GlcNAcb-Sp8 17 12 6 71
232 Neu5Aca2-3Galb1-3[6OSO3]GalNAca-Sp8 17 14 7 85
139 Galb1-3GlcNAcb1-3Galb1-4Glcb-Sp10 17 13 6 75
355 KDNa2-3Galb1-3GalNAca-Sp14 17 27 14 161
330 GalNAca1-3(Fuca1-2)Galb1-4GlcNAcb1-3Galb1-4GlcNAcb-Sp0 17 16 8 96
136 Galb1-3GalNAcb1-4Galb1-4Glcb-Sp8 17 11 6 67
209 Neu5Aca2-3Galb1-4GlcNAcb1-3Galb1-4(Fuca1-3)GlcNAc-Sp0 17 2 1 15
274 Neu5Gca2-6GalNAca-Sp0 17 18 9 108
30 [3OSO3]Galb1-4(Fuca1-3)GlcNAcb-Sp8 16 18 9 109
37 [4OSO3]Galb1-4GlcNAcb-Sp8 16 18 9 112
278 Galb1-3GalNAca-Sp14 16 9 4 54
211 Fuca1-2[6OSO3]Galb1-4GlcNAc-Sp0 16 14 7 84
86 GalNAca1-3(Fuca1-2)Galb-Sp8 16 13 7 81
179 (GlcNAcb1-4)6b-Sp8 16 18 9 110
108 Gala1-3Galb1-3GlcNAcb-Sp0 16 8 4 51
178 GlcNAcb1-4Galb1-4GlcNAcb-Sp8 16 13 7 81
296 Galb1-4GlcNAcb1-6Galb1-4GlcNAcb-Sp0 16 13 7 83
369 GalNAca1-3(Fuca1-2)Galb1-3GlcNAcb1-2Mana1-3(GalNAca1­
3(Fuca1-2)Galb1-3GlcNAcb1-2Mana1-6)Manb1-4GlcNAcb1­
4GlcNAcb-Sp20
16 12 6 74
365 Galb1-4GlcNAcb1-2(Galb1-4GlcNAcb1-4)Mana1-3(Galb1- 16 10 5 66
4GlcNAcb1-2Mana1-6)Manb1-4GlcNAcb1-4GlcNAc-Sp21
163 Galb1-4Glcb-Sp8 16 4 2 27
95 GalNAcb1-4GlcNAcb-Sp0 15 13 6 82
162 Galb1-4Glcb-Sp0 15 14 7 89
160 Galb1-4GlcNAcb-Sp0 15 20 10 132
236 Neu5Aca2-3Galb1-3GlcNAcb1-3Galb1-4GlcNAcb-Sp0 15 16 8 103
395 Neu5Aca2-3Galb1-3GlcNAcb1-3GalNAca-Sp14 15 11 6 75
436 Galb1-6Galb-Sp10 15 10 5 66
195 GlcAb1-6Galb-Sp8 15 12 6 77
120 Galb1-3(Fuca1-4)GlcNAcb1-3Galb1-4GlcNAcb-Sp0 15 25 12 164
322 Fuca1-3(Galb1-4)GlcNAcb1-2Mana1-3(Fuca1-3(Galb1­ 15 12 6 79
4)GlcNAcb1-2Mana1-6)Manb1-4GlcNAcb1-4GlcNAcb-Sp20
345 Galb1-4GlcNAcb1-2Mana1-6Manb1-4GlcNAcb1-4GlcNAc-Sp12 15 12 6 78
197
175
KDNa2-3Galb1-4GlcNAcb-Sp0
GlcNAcb1-3Galb1-4Glcb-Sp0
15
15
11
17
5
8
72
113
388 Neu5Aca2-3(GalNAcb1-4)Galb1-4GlcNAcb1-3GalNAca-Sp14 15 18 9 118
109 Gala1-3Galb1-4GlcNAcb-Sp8 15 16 8 109
14 GalNAcb-Sp8 15 16 8 108
191 G-ol-Sp8 15 11 5 73
258 Neu5Aca2-6Galb1-4GlcNAcb-Sp8 15 10 5 66
100 Gala1-3(Fuca1-2)Galb1-4GlcNAc-Sp0 14 23 11
105 Gala1-3GalNAca-Sp16 14 7 3 48
118 Galb1-2Galb-Sp8 14 19 10 134
393 Galb1-4GlcNAcb1-2Mana1-3(GlcNAcb1-2Mana1-6)Manb1­
4GlcNAcb1-4GlcNAc-Sp12
14 2 1 15
75 Fuca1-2Galb-Sp8 14 19 9 132
263 Neu5Aca2-6Galb-Sp8 14 18 9 126
429 GlcNAcb1-4(GlcNAcb1-2)Mana1-3(GlcNAcb1-4)(GlcNAcb1­
2Mana1-6)Manb1-4GlcNAcb1-4GlcNAc-Sp21
14 19 9 133
42 [6OSO3]Galb1-4[6OSO3]Glcb-Sp8 14 17 9 124
227
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Appendix
356 Fuca1-2Galb1-3GlcNAcb1-2Mana1-3(Fuca1-2Galb1-3GlcNAcb1­ 14 18 9 130
2Mana1-6)Manb1-4GlcNAcb1-4GlcNAcb-Sp20
70 Fuca1-2Galb1-4GlcNAcb1-3Galb1-4GlcNAcb-Sp0 14 12 6 85
144 Galb1-4(Fuca1-3)GlcNAcb1-4Galb1-4(Fuca1-3)GlcNAcb-Sp0 14 25 12 178
6 Fuca-Sp9 14 11 5 79
352 KDNa2-3Galb1-4(Fuca1-3)GlcNAc-Sp0 13 8 4 60
415 GalNAca1-3(Fuca1-2)Galb1-4(Fuca1-3)GlcNAcb1-3GalNAc-Sp14 13 5 2 36
380 Fuca1-2Galb1-3(Fuca1-4)GlcNAcb1-3(Galb1-4GlcNAcb1-6)Galb1­
4Glc-Sp21
13 6 3 42
32 [3OSO3]Galb1-4[6OSO3]GlcNAcb-Sp8 13 10 5 78
111 Gala1-3Galb-Sp8 13 3 1 19
205 Mana1-3(Mana1-2Mana1-2Mana1-6)Mana-Sp9 13 6 3 48
78 Fucb1-3GlcNAcb-Sp8 13 31 16 239
324 Neu5Ac(9Ac)a2-3Galb1-3GlcNAcb-Sp0 13 7 4 57
193
214 Neu5Aca2-3Galb1-3GalNAca-Sp8
13
13
8
20
4
10
66
159
349 Galb1-3GlcNAcb1-2Mana1-3(Galb1-3GlcNAcb1-2Mana1­ 12 10 5 82
6)Manb1-4GlcNAcb1-4(Fuca1-6)GlcNAcb-Sp22
73 Fuca1-2Galb1-4GlcNAcb-Sp8 12 12 6 96
378 Galb1-3GlcNacb1-3(Galb1-3GlcNacb1-3Galb1-4GlcNacb1­ 12 15 7 119
6)Galb1-4Glcb-Sp0
361 Galb1-3(Fuca1-4)GlcNAcb1-2Mana1-3(Galb1-3(Fuca1­ 12 20 10 162
4)GlcNAcb1-2Mana1-6)Manb1-4GlcNAcb1-4(Fuca1-6)GlcNAcb­
Sp22
419 Fuca1-2Galb1-3GlcNAcb1-3GalNAc-Sp14 12 5 2 41
252 Neu5Aca2-3Galb1-4Glcb-Sp0 12 21 10 169
43 Neu5Aca2-3[6OSO3]Galb1-4GlcNAcb-Sp8 12 7 3 54
204 Mana1-3(Mana1-6)Mana-Sp9 12 21 10 170
101 Gala1-3(Fuca1-2)Galb1-4Glcb-Sp0 12 23 11 188
133 Galb1-3GalNAcb-Sp8 12 13 7 112
88 GalNAca1-3GalNAcb-Sp8 12 22 11 185
173 GlcNAcb1-3Galb1-4GlcNAcb-Sp8 12 12 6 100
223 Neu5Aca2-3(GalNAcb1-4)Galb1-4Glcb-Sp0 12 17 9 147
116 Gala1-4GlcNAcb-Sp8 12 7 4 59
241
234 Neu5Aca2-3Galb-Sp8
12
12
35
12
17
6
293
103
83 GalNAca1-3(Fuca1-2)Galb1-4GlcNAcb-Sp8 12 18 9 151
91 GalNAcb1-3GalNAca-Sp8 12 9 4 77
147 Galb1-4[6OSO3]Glcb-Sp8 12 21 11 183
159 Galb1-3(Galb1-4GlcNAcb1-6)GalNAc-Sp14 11 3 2 29
106 Gala1-3GalNAcb-Sp8 11 12 6 106
203 Mana1-2Mana1-2Mana1-3(Mana1-2Mana1-3(Mana1-2Mana1­ 11 20 10 173
GlcAb-Sp8
Neu5Aca2-3Galb1-4(Fuca1-3)[6OSO3]GlcNAcb-Sp8
6)Mana1-6)Manb1-4GlcNAcb1-4GlcNAcb-Sp12
326 Neu5Aca2-3Galb1-3(Fuca1-4)GlcNAcb1-3Galb1-3(Fuca1­
4)GlcNAcb-Sp0
11 9 5 80
130 Galb1-3(Neu5Aca2-6)GlcNAcb1-4Galb1-4Glcb-Sp10 11 30 15 266
389 GalNAca1-3(Fuca1-2)Galb1-3GalNAca1-3(Fuca1-2)Galb1­ 11 21 10 185
4GlcNAcb-Sp0
329 GalNAcb1-3Gala1-4Galb1-4GlcNAcb1-3Galb1-4Glcb-Sp0 11 34 17 306
242 Neu5Aca2-3Galb1-4(Fuca1-3)GlcNAcb1-3Galb1-4(Fuca1­ 11 50 25 457
3)GlcNAcb1-3Galb1-4(Fuca1-3)GlcNAcb-Sp0
12 Glcb-Sp8 11 7 3 61
251 Fuca1-2Galb1-4[6OSO3]Glc-Sp0 11 22 11 199
285 Neu5Aca2-3Galb1-4GlcNAcb1-3Galb1-3GlcNAcb-Sp0 11 13 6 115
271
426 Fuca1-2Galb1-3GlcNAcb1-3(Galb1-4GlcNAcb1-6)Galb1-4Glc­
11
11
14
25
7
12
128
233
Sp21
237 Fuca1-2[6OSO3]Galb1-4Glc-Sp0 11 11 6 105
169 GlcNAcb1-3GalNAca-Sp8 11 8 4 80
334
243 Neu5Aca2-3Galb1-4(Fuca1-3)GlcNAcb-Sp0
11
10
20
9
10
4
193
85
423 Fuca1-2Galb1-3GlcNAcb1-2Mana1-3(Fuca1-2Galb1-3GlcNAcb1­ 10 19 10 183
2Mana1-6)Manb1-4GlcNAcb1-4(Fuca1-6)GlcNAcb-Sp22
230 Neu5Aca2-3Galb1-3(Fuca1-4)GlcNAcb1-3Galb1-4(Fuca1­ 10 22 11 212
3)GlcNAcb-Sp0
297 GalNAca-Sp15 10 16 8 159
Neu5Gca2-3Galb1-4(Fuca1-3)GlcNAcb-Sp0
GlcNAca1-4Galb1-4GlcNAcb-Sp0
228
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Appendix
93 GalNAcb1-3Gala1-4Galb1-4GlcNAcb-Sp0 10 13 7 130
4 GalNAca-Sp8 10 12 6 114
432 Galb1-4GlcNAcb1-2Mana1-3(GlcNAcb1-4)(Galb1-4GlcNAcb1­ 10 3 1 28
2)Manb1-4GlcNAcb1-4GlcNAc-Sp21
112
301 GlcNAcb1-2Mana1-3(GlcNAcb1-2Mana1-6)Manb1-4GlcNAcb1­
10
10
7
11
3
5
68
108
4GlcNAcb-Sp12
Gala1-4(Fuca1-2)Galb1-4GlcNAcb-Sp8
140 Galb1-3GlcNAcb-Sp0 10 10 5
229 Neu5Aca2-3Galb1-3(Fuca1-4)GlcNAcb-Sp8 10 16 8 156
190 Glcb1-6Glcb-Sp8 10 23 12 235
215 Neu5Aca2-8Neu5Aca2-8Neu5Aca2-8Neu5Aca2-3(GalNAcb1- 10 14 7 144
4)Galb1-4Glcb-Sp0
438 GalNAcb1-6GalNAcb-Sp8 10 3 2 32
217 Neu5Aca2-8Neu5Aca2-8Neu5Aca2-3Galb1-4Glcb-Sp0 10 11 5 112
384 GlcNacb1-2(GlcNacb1-4)Mana1-3(GlcNacb1-2Mana1-6)Manb1­ 10 4 2 40
4GlcNacb1-4GlcNac-Sp21
182 GlcNAcb1-6(Galb1-3)GalNAca-Sp8 10 5 3 54
336 GlcNAca1-4Galb1-4GlcNAcb1-3Galb1-4Glcb-Sp0 10 10 5 101
92 GalNAcb1-3(Fuca1-2)Galb-Sp8 10 13 7 137
284 Neu5Aca2-3Galb1-3GlcNAcb1-3Galb1-3GlcNAcb-Sp0 10 12 6 126
31 [3OSO3]Galb1-4[6OSO3]GlcNAcb-Sp0 10 14 7 145
158 Galb1-3(Galb1-4GlcNAcb1-6)GalNAca-Sp8 9 9 4 93
121 Galb1-3(Fuca1-4)GlcNAcb-Sp0 9 22 11 240
138 Galb1-3GlcNAcb1-3Galb1-4GlcNAcb-Sp0 9 10 5 103
142 Galb1-4(Fuca1-3)GlcNAcb-Sp0 9 18 9 194
185 GlcNAcb1-6Galb1-4GlcNAcb-Sp8 9 10 5 109
233 Neu5Aca2-3Galb1-3(Neu5Aca2-6)GalNAca-Sp8 9 17 9 189
306 Mana1-6Manb-Sp10 9 14 7 155
260 Neu5Aca2-6Galb1-4GlcNAcb1-3Galb1-4GlcNAcb-Sp0 9 5 3 59
333 GlcNAca1-4Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1­ 9 14 7 156
4GlcNAcb-Sp0
231 Neu5Aca2-3Galb1-3(Neu5Aca2-3Galb1-4)GlcNAcb-Sp8 9 6 3 67
210 [3OSO3]Galb1-4(Fuca1-3)[6OSO3]GlcNAc-Sp8 9 29 15 324
157 Galb1-4GlcNAcb1-6(Galb1-3)GalNAca-Sp8 9 19 10 212
98 Gala1-3(Fuca1-2)Galb1-3GlcNAcb-Sp0 9 17 8 190
141 Galb1-3GlcNAcb-Sp8 9 10 5 118
17 GlcN(Gc)b-Sp8 9 8 4 88
155 Galb1-4GlcNAcb1-3Galb1-4Glcb-Sp0 9 11 5 127
442 Fuca1-2Galb1-4(Fuca1-3)GlcNAcb1-2(Fuca1-2Galb1-4(Fuca1­
3)GlcNAcb1-4)Mana1-3(Fuca1-2Galb1-4(Fuca1-3)GlcNAcb1­
2Mana1-6)Manb1-4GlcNAcb1-4GlcNAcb-N
8 20 10 235
57 Fuca1-2Galb1-3(Fuca1-4)GlcNAcb-Sp8 8 8 4 94
153 Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb-Sp0 8 12 6 145
437 Neu5Aca2-3Galb1-4GlcNAcb1-3Galb-Sp8 8 12 6 147
166 GlcNAcb1-2Galb1-3GalNAca-Sp8 8 19 10 234
314 Neu5Aca2-6Galb1-4GlcNAcb1-2Mana1-3(Galb1-4GlcNAcb1­ 8 16 8 199
2Mana1-6)Manb1-4GlcNAcb1-4GlcNAcb-Sp12
250 Neu5Aca2-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb-Sp0 8 6 3 76
172 GlcNAcb1-3Galb1-4GlcNAcb-Sp0 8 9 5 114
339
371 Fuca1-2Galb1-3(Fuca1-4)GlcNAcb1-2Mana1-3(Fuca1-2Galb1­
3(Fuca1-4)GlcNAcb1-2Mana1-6)Manb1-4GlcNAcb1-4GlcNAcb­
8
8
18
7
9
3
222
86
Sp19
GlcNAca1-4Galb1-3GalNAc-Sp14
76 Fuca1-3GlcNAcb-Sp8 8 22 11 279
18 Galb1-4GlcNAcb1-3(Galb1-4GlcNAcb1-6)GalNAca-Sp8 8 11 5 142
135 Galb1-3GalNAcb1-4(Neu5Aca2-3)Galb1-4Glcb-Sp0 8 14 7 185
110 Gala1-3Galb1-4Glcb-Sp0 8 7 4 93
287 [6OSO3]Galb1-4[6OSO3]GlcNAcb-Sp0 8 16 8
74 Fuca1-2Galb1-4Glcb-Sp0 8 14 7 181
183
342 Neu5Aca2-6Galb1-4GlcNAcb1-2Mana1-6Manb1-4GlcNAcb1­
7
7
8
15
4
8
109
205
4GlcNAc-Sp12
GlcNAcb1-6GalNAca-Sp8
168 GlcNAcb1-3(GlcNAcb1-6)Galb1-4GlcNAcb-Sp8 7 10 5
90 GalNAca1-4(Fuca1-2)Galb1-4GlcNAcb-Sp8 7 16 8 217
71 Fuca1-2Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb­ 7 18 9 252
Sp0
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Appendix
24 [3OSO3]Galb1-4[6OSO3]Glcb-Sp0	 7 19 9 263
81 [3OSO3]Galb1-4(Fuca1-3)Glc-Sp0 7 22 11 322
8 Neu5Aca-Sp8	 7 4 2 53
435 Galb1-4Galb-Sp10 7 15 8
114 Gala1-4Galb1-4GlcNAcb-Sp8 7 10 5 161
353 KDNa2-6Galb1-4GlcNAc-Sp0 6 10 5 149
269 Neu5Gca2-3Galb1-3(Fuca1-4)GlcNAcb-Sp0	 6 9 5 141
219 Neu5Aca2-8Neu5Aca2-8Neu5Aca-Sp8 6 14 7
174
254
GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb-Sp0
Neu5Aca2-6GalNAca-Sp8
6
6
4
10
2
5
66
168
363 Neu5Aca2-6GlcNAcb1-4GlcNAcb1-4GlcNAc-Sp21 6 11 6 205
181 GlcNAcb1-4GlcNAcb1-4GlcNAcb-Sp8 6 11 6 203
45 Neu5Ac(9Ac)a-Sp8	 6 5 3 92
289 Gala1-3(Fuca1-2)Galb-Sp18 6 15 7 269
238
131
Neu5Aca2-3Galb1-3GlcNAcb-Sp0
Galb1-3GalNAca-Sp8
5
5
8
10
4
5
152
176
328 Gala1-4Galb1-4GlcNAcb1-3Galb1-4Glcb-Sp0 5 12 6 233
2 Glca-Sp8 5 9 4 173
424 Gala1-3(Fuca1-2)Galb1-4GlcNAcb1-2Mana1-3(Gala1-3(Fuca1­
2)Galb1-4GlcNAcb1-2Mana1-6)Manb1-4GlcNAcb1-4(Fuca1­
5 26 13 532
6)GlcNAcb-Sp22
372 Neu5Aca2-3Galb1-4GlcNAcb1-3GalNAc-Sp14 5 10 5 213
235 Neu5Aca2-3Galb1-3GalNAcb1-3Gala1-4Galb1-4Glcb-Sp0 5 9 4 184
266 Galb1-3(Fuca1-4)GlcNAcb1-3Galb1-3(Fuca1-4)GlcNAcb-Sp0 4 9 4 193
79 GalNAca1-3(Fuca1-2)Galb1-3GlcNAcb-Sp0	 4 7 3 157
276 Neu5Gca-Sp8 4 15 7 339
294 Galb1-4GlcNAcb1-3(GlcNAcb1-6)Galb1-4GlcNAc-Sp0 4 8 4 188
404 GalNAcb1-3Gala1-6Galb1-4Glcb-Sp8 4 6 3 138
25 [3OSO3]Galb1-4[6OSO3]Glcb-Sp8 4 6 3 159
418 GlcNAcb1-2Mana1-3(GlcNAcb1-2(GlcNAcb1-6)Mana1-6)Manb1­ 3 28 14 825
4GlcNAcb1-4GlcNAcb-Sp19
82 GalNAca1-3(Fuca1-2)Galb1-4GlcNAcb-Sp0 3 9 4 301
406 Gala1-3(Fuca1-2)Galb1-4(Fuca1-3)Glcb-Sp21 3 25 13 860
15 GlcNAcb-Sp0	 3 6 3 204
58 Fuca1-2Galb1-3GalNAca-Sp8	 3 17 8 625
7 Rha-Sp8	 3 11 6 440
94 GalNAcb1-4(Fuca1-3)GlcNAcb-Sp0 2 12 6 518
38 6-H2PO3Mana-Sp8	 2 8 4 325
216 Neu5Aca2-8Neu5Aca2-8Neu5Aca2-3(GalNAcb1-4)Galb1-4Glcb­
Sp0
2 20 10 886
228 Neu5Aca2-3Galb1-3[6OSO3]GlcNAc-Sp8	 2 18 9 896
19 GlcNAcb1-3(GlcNAcb1-4)(GlcNAcb1-6)GlcNAc-Sp8 2 9 4 497
338 GlcNAca1-4Galb1-4GlcNAcb1-3Galb1-4GlcNAcb-Sp0 2 17 8 957
425 Galb1-3GlcNAcb1-2Mana1-3(Galb1-3GlcNAcb1-2(Galb1­
3GlcNAcb1-6)Mana1-6)Manb1-4GlcNAcb1-4GlcNAcb-Sp19
2 12 6 700
262 Neu5Aca2-6Galb1-4Glcb-Sp8	 2 9 5 546
224 Neu5Aca2-3(Neu5Aca2-3Galb1-3GalNAcb1-4)Galb1-4Glcb-Sp0 2 13 7 804
343 Neu5Aca2-6Galb1-4GlcNAcb1-2Mana1-3Manb1-4GlcNAcb1- 2 3 2 217
4GlcNAc-Sp12
270 Neu5Gca2-3Galb1-3GlcNAcb-Sp0 2 14 7 872
65 Fuca1-2Galb1-3GlcNAcb-Sp8 1 4 2 300
310 Neu5Aca2-3Galb1-3(Neu5Aca2-3Galb1-4GlcNAcb1-6)GalNAca­ 1 24 12 1837
Sp14
427	 Galb1-4GlcNAcb1-3Galb1-4(Fuca1-3GlcNAcb1-6)Galb1-4Glc- 1 12 6 965
Sp21
39 [6OSO3]Galb1-4Glcb-Sp0 1 6 3 599
119 Galb1-3(Fuca1-4)GlcNAcb1-3Galb1-4(Fuca1-3)GlcNAcb-Sp0 1 8 4 842
84 GalNAca1-3(Fuca1-2)Galb1-4Glcb-Sp0 1 13 6 1554
212 Fuca1-2Galb1-4[6OSO3]GlcNAc-Sp8	 0 12 6 3210
283
416 Galb1-4(Fuca1-3)GlcNAcb1-2Mana1-3(Galb1-4(Fuca1­
0
0
12
19
6
9
4812
9402
3)GlcNAcb1-2Mana1-6)Manb1-4GlcNAcb1-4(Fuca1-6)GlcNAcb­
Sp22
Galb1-4GlcNAcb1-3Galb1-3GlcNAcb-Sp0
3 Mana-Sp8 0 13 7 7425
292 Galb1-4GlcNAcb1-2Mana1-3(Neu5Aca2-6Galb1-4GlcNAcb1­ 0 29 15 23567
2Mana1-6)Manb1-4GlcNAcb1-4GlcNAcb-Sp12
230
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Appendix
123 Galb1-3(Fuca1-4)GlcNAcb-Sp8 0 6 3 6127
354 KDNa2-3Galb1-4Glc-Sp0 0 13 7 -
12145
0 24 12Manb1-4GlcNAcb-Sp0 -
16480
56 Fuca1-2Galb1-3GalNAcb1-3Gala1-4Galb1-4Glcb-Sp9 0 12 6 -4459
72 Fuca1-2Galb1-4GlcNAcb-Sp0 -1 13 7 -1999
430 GlcNAcb1-2Mana1-3(GlcNAcb1-4)(GlcNAcb1-6(GlcNAcb1­ -1 10 5 -1190
431
2)Mana1-6)Manb1-4GlcNAcb1-4GlcNAc-Sp21
GlcNAcb1-4(GlcNAcb1-2)Mana1-3(GlcNAcb1-4)(GlcNAcb1­
6(GlcNAcb1-2)Mana1-6)Manb1-4GlcNAcb1-4GlcNAc-Sp21
-1 20 10 -2265
315 Neu5Aca2-6Galb1-4GlcNAcb1-2Mana1-3(GlcNAcb1-2Mana1­ -1 11 6 -1238
6)Manb1-4GlcNAcb1-4GlcNAcb-Sp12
62 Fuca1-2Galb1-3GlcNAcb1-3Galb1-4Glcb-Sp8 -2 7 4 -363
33 [3OSO3]Galb1-4GlcNAcb-Sp0 -2 9 4 -420
398 GalNaca1-3GalNacb1-3Gala1-4Galb1-4GlcNacb-Sp0 -2 16 8 -670
27 [3OSO3]Galb1-3GalNAca-Sp8	 -3 11 6 -336
96 GalNAcb1-4GlcNAcb-Sp8 -3 11 5 -322
29 [3OSO3]Galb1-4(Fuca1-3)GlcNAc-Sp0	 -4 17 9 -475
268 Neu5Acb2-6Galb1-4GlcNAcb-Sp8	 -4 17 8 -431
35 [3OSO3]Galb-Sp8	 -5 4 2 -94
194 GlcAb1-3Galb-Sp8 -5 15 7 -278
311 Neu5Aca2-3Galb1-3(Neu5Aca2-6)GalNAca-Sp14	 -5 16 8 -309
401 Gala1-3Galb1-4GlcNacb1-3GalNaca-Sp14	 -5 9 4 -162
107 Gala1-3Galb1-4(Fuca1-3)GlcNAcb-Sp8	 -6 7 3 -115
59 Fuca1-2Galb1-3GalNAca-Sp14 -6 21 11 -367
392 Neu5Aca2-3Galb1-3GlcNAcb1-2Mana1-3(Neu5Aca2-3Galb1­ -6 19 9 -325
3GlcNAcb1-2Mana1-6)Manb1-4GlcNAcb1-4GlcNAc-Sp19
164 GlcNAca1-3Galb1-4GlcNAcb-Sp8 -6 16 8 -250
26 [3OSO3]Galb1-3(Fuca1-4)GlcNAcb-Sp8	 -7 22 11 -328
64 Fuca1-2Galb1-3GlcNAcb-Sp0 -7 20 10 -292
318 Neu5Gcb2-6Galb1-4GlcNAc-Sp8	 -7 10 5 -139
156 Galb1-4GlcNAcb1-3Galb1-4Glcb-Sp8 -7 16 8 -225
117 Gala1-6Glcb-Sp8	 -7 3 1 -39
20 [3OSO3][6OSO3]Galb1-4[6OSO3]GlcNAcb-Sp0	 -7 5 2 -66
48 Mana1-3(Mana1-6)Manb1-4GlcNAcb1-4GlcNAcb-Sp13 -8 15 7 -191
34 [3OSO3]Galb1-4GlcNAcb-Sp8 -8 10 5 -119
149 Galb1-4GalNAcb1-3(Fuca1-2)Galb1-4GlcNAcb-Sp8	 -8 10 5 -121
1 Gala-Sp8 -9 9 5 -107
218 Neu5Aca2-8Neu5Aca2-3(GalNAcb1-4)Galb1-4Glcb-Sp0 -9 10 5 -114
410 Gala1-3(Fuca1-2)Galb1-4GlcNAcb1-3GalNAca-Sp14 -9 14 7 -158
368	 Gala1-3Galb1-4(Fuca1-3)GlcNAcb1-2Mana1-3(Gala1-3Galb1- -11 30 15 -270
4(Fuca1-3)GlcNAcb1-2Mana1-6)Manb1-4GlcNAcb1-4GlcNAcb­
Sp20
440 [6OSO3]Galb1-3[6OSO3]GlcNAc-Sp0 -15 8 4 -56
40 [6OSO3]Galb1-4Glcb-Sp8	 -16 19 9 -114
402 Galb1-3GlcNAcb1-6Galb1-4GlcNAcb-Sp0 -19 9 5 -50
52 Neu5Aca2-6Galb1-4GlcNAcb1-2Mana1-3(Neu5Aca2-6Galb1­
4GlcNAcb1-2Mana1-6)Manb1-4GlcNAcb1-4GlcNAcb-Sp8
-20 9 5 -47
231
 
  
 
 
 
 
     
 
 
     
     
     
     
     
     
     
 
 
   
     
     
     
     
     
 
 
   
      
     
     
     
     
 
 
   
 
 
   
     
     
 
 
   
     
     
 
 
   
 
 
   
     
     
     
 
 
   
     
     
     
     
    
Appendix
mMGL-1 FITC
Chart %Glycan structure Average RFU StDevNumber CV
133 Galb1-4GlcNAcb1-6GalNAc-Sp14 26 27 101
155 Galb1-4(Fuca1-3)GlcNAcb1-3Galb1-4(Fuca1-3)GlcNAcb1-3Galb1­4(Fuca1-3)GlcNAcb-Sp0 24 16 66
154 Galb1-4(Fuca1-3)GlcNAcb1-3Galb1-4(Fuca1-3)GlcNAcb-Sp0 24 15 63
46 Neu5Aca2-3(6S)Galb1-4GlcNAcb-Sp8 24 13 54
24 (3S)Galb1-4(Fuca1-3)(6S)Glc-Sp0 24 7 30
5 GalNAca-Sp15 24 5 22
108 Gala1-3(Fuca1-2)Galb-Sp8 23 12 50
Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1­
548 2Mana1-6(Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1­ 22 6 25
4GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-Sp12
408 Galb1-3GlcNAca1-6Galb1-4GlcNAcb-Sp0 22 4 17
431 Fuca1-3GlcNAcb1-6(Galb1-4GlcNAcb1-3)Galb1-4Glc-Sp21 21 10 45
167 Galb1-4GlcNAcb1-6(Galb1-3)GalNAca-Sp8 21 5 22
275 Neu5Aca2-6Galb-Sp8 21 7 33
153 21 4 18
Neu5Aca2-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1­
608 4GlcNAcb1-2Mana1-6(Neu5Aca2-3Galb1-4GlcNAcb1-3Galb1­4GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1­ 21 19 93
4GlcNAcb-Sp12
533
98 GalNAcb1-4(Fuca1-3)GlcNAcb-Sp0
20
20
11
6
56
32
9 Neu5Aca-Sp8 20 7 36
175 GlcNAca1-6Galb1-4GlcNAcb-Sp8 19 10 50
60 19 6 31
Galb1-3GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1­
6(Galb1-3GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAb1­
572 2)Mana1-6(Galb1-3GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1­ 19 1 6
4GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4(Fuca1-6)GlcNAcb­
Sp24
Galb1-4(Fuca1-3)GlcNAcb-Sp8
Galb1-4GlcNAcb1-2 Mana1-6(Galb1-4GlcNAcb1-4)(Galb1-
4GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4(Fuca1-6)GlcNAc-Sp21
Fuca1-2Galb1-3GalNAcb1-3Gala1-4Galb1-4Glcb-Sp9
439
Galb1-4GlcNAcb1-6(Galb1-4GlcNAcb1-2)Mana1-6(GlcNAcb1­
4)(Galb1-4GlcNAcb1-4(Galb1-4GlcNAcb1-2)Mana1-3)Manb1­
4GlcNAcb1-4GlcNAc-Sp21
19 13 69
382 Galb1-3GalNAca1-3(Fuca1-2)Galb1-4GlcNAc-Sp0 18 10 54
132 Galb1-4GlcNAcb1-6GalNAca-Sp8 18 7 39
Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-6(Galb1­
542 4GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1­ 18 8 44
4GlcNAcb-Sp12
42 (6S)Galb1-4Glcb-Sp0 18 12 65
453 Neu5Aca2-8Neu5Aca2-3Galb1-3GalNAcb1-4(Neu5Aca2­8Neu5Aca2-3)Galb1-4Glcb-Sp0 18 14 74
587
Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1­
4GlcNAcb1-6(Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1­
4GlcNAcb1-3Galb1-4GlcNAb1-2)Mana1-6(Galb1-4GlcNAcb1­
3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1­
2Mana1-3)Manb1-4GlcNAcb1-4(Fuca1-6)GlcNAcb­
18 14 76
Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1­
551 4GlcNAcb1-2Mana1-6(Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1­3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-3)Manb1­ 18 2 11
4GlcNAcb1-4GlcNAcb-Sp25
138 Neu5Acb2-6(Galb1-3)GalNAca-Sp8 18 8 47
15 GalNAcb-Sp8 18 12 68
260 Neu5Aca2-3Galb1-4GlcNAcb-Sp0 18 9 49
Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-6(Galb1­
543 4GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1­ 18 8 43
4GlcNAcb-Sp24
21 GlcNAcb1-6(GlcNAcb1-4)(GlcNAcb1-3)GlcNAc-Sp8 17 8 46
97 GalNAcb1-3Gala1-4Galb1-4GlcNAcb-Sp0 17 14 81
33 (3S)Galb1-4(Fuca1-3)GlcNAc-Sp8 17 11 62
152 Galb1-4(Fuca1-3)GlcNAcb-Sp0 17 4 25
395 Gala1-3Galb1-3GlcNAcb1-2Mana1-6(Gala1-3Galb1-3GlcNAcb1­ 17 11 64
232
 
  
 
 
 
 
 
   
     
     
 
 
   
     
     
 
 
   
     
     
     
 
 
   
     
     
     
     
 
 
   
 
 
   
     
     
     
     
 
 
   
     
     
     
     
 
 
   
     
     
     
     
 
 
   
     
     
     
     
Appendix
2Mana1-3)Manb1-4GlcNAcb1-4GlcNAc-Sp19
GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-6(GlcNAcb1­
584 3Galb1-4GlcNAcb1-3Galb1-4GlcNAb1-2)Mana1-6(GlcNAcb1­3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-3)Manb1­ 17 8 50
4GlcNAcb1-4(Fuca1-6)GlcNAcb-Sp24
343 3Galb1-4(Fuca1-3)GlcNAcb-Sp0 17 8 51
110 Gala1-4(Gala1-3)Galb1-4GlcNAcb-Sp8 16 12 75
GlcNAca1-4Galb1-4GlcNAcb1-3Galb1-4(Fuca1-3)GlcNAcb1-
560
Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-6(Galb1-4GlcNAcb1­
3Galb1-4GlcNAcb1-2)Mana1-6(Galb1-4GlcNAcb1-3Galb1­
4GlcNAcb1-2Mana1-3)Mana1-4GlcNAcb1-4GlcNAc-Sp24
16 8 49
511 Galb1-3(6S)GlcNAcb-Sp8 16 5 30
591 Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-6(Galb1-3)GalNAca-Sp14 16 6 40
Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1­
580 4GlcNAcb1-2Mana1-6(Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1­3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-3)Manb1­ 16 8 51
4GlcNAcb1-4(Fuca1-6)GlcNAcb-Sp24
82 Fucb1-3GlcNAcb-Sp8 16 13 81
503 Neu5Aca2-6GalNAcb1-4(6S)GlcNAcb-Sp8 16 15 93
506 Fuca1-2Galb1-3GlcNAcb1-6(Fuca1-2Galb1-3GlcNAcb1­3)GalNAca-Sp14 16 4 25
Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-6(Galb1­
576 4GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1­ 16 13 86
4(Fuca1-6)GlcNAcb-Sp24
87 GalNAca1-3(Fuca1-2)Galb1-4GlcNAcb-Sp8 16 11 74
590 Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3GalNAca-Sp14 16 9 61
102 Gala1-3(Fuca1-2)Galb1-3GlcNAcb-Sp0 15 7 43
513 (6S)GalNAcb1-4GlcNAc-Sp8 15 13 86
607
Neu5Aca2-6Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1­
4GlcNAcb1-2Mana1-6(Neu5Aca2-6Galb1-4GlcNAcb1-3Galb1­
4GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1­
4GlcNAcb-Sp12
15 7 48
Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1­
549 2Mana1-6(Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1­ 15 9 58
4GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-Sp24
221 Fuca1-2(6S)Galb1-4GlcNAcb-Sp0 15 9 60
326 Neu5Aca2-3Galb1-4GlcNAcb1-2Mana1-6(Neu5Aca2-3Galb1­4GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-Sp12 15 12 82
1 Gala-Sp8 15 17 110
198 Glca1-6Glca1-6Glcb-Sp8 15 5 34
566
Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1­
4GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-6(Galb1-4GlcNAcb1­
3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1­
3Galb1-4GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-Sp25
15 5 33
4 GalNAca-Sp8	 15 4 28
267 Neu5Aca2-6GalNAcb1-4GlcNAcb-Sp0 15 7 46
3 Mana-Sp8	 15 9 64
31 (3S)Galb1-3GlcNAcb-Sp8 15 11 74
Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1­
2Mana1-6(Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1­578	 15 11 774GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4(Fuca1-6)GlcNAcb­
Sp24
 
164 Galb1-4GlcNAcb1-3Galb1-4GlcNAcb-Sp0 15 20 136
134 GlcNAcb1-6(Galb1-3)GalNAca-Sp8	 14 14 98
120 Gala1-4(Fuca1-2)Galb1-4GlcNAcb-Sp8	 14 16 114
255	 Neu5Aca2-3Galb1-4(Fuca1-3)GlcNAcb-Sp0 14 9 66
Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1­
585 14
6(Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAb1-
2)Mana1-6(Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-
4GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4(Fuca1-6)GlcNAcb-
6 43
Sp24
225 Neu5Aca2-3Galb1-3GalNAca-Sp14 14 10 72
426 Gala1-3Galb1-3GlcNAcb1-3GalNAc-Sp14 14 12 84
129 Galb1-3(Fuca1-4)GlcNAc-Sp0 14 7 51
56 4GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-Sp13 14 14 100
Neu5Aca2-6Galb1-4GlcNAcb1-2Mana1-6(Neu5Aca2-6Galb1-
233
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Appendix
Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1­
589
4GlcNAcb1-3Galb1-4GlcNAcb1-6(Galb1-4GlcNAcb1-3Galb1­
4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1­ 14 7 46
4GlcNAb1-2)Mana1-6(Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1­
3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4G
257 Neu5Aca2-3Galb1-4(Fuca1-3)GlcNAcb1-3Galb-Sp8 14 13 92
330 Neu5,9Ac2a2-3Galb1-3GlcNAcb-Sp0 14 2 15
61 Fuca1-2Galb1-3(Fuca1-4)GlcNAcb-Sp8 14 9
187
379
GlcNAcb1-4-MDPLys
Neu5Aca2-3Galb1-4(Fuca1-3)GlcNAcb1-3GalNAca-Sp14
14
14
7
8
51
55
349 Neu5Aca2-6Galb1-4GlcNAcb1-2Mana1-3Manb1-4GlcNAcb1­4GlcNAc-Sp12 14 8 54
16 GlcNAcb-Sp0 14 9 63
39 (6S)(4S)Galb1-4GlcNAcb-Sp0 14 4 31
78 Fuca1-2Galb1-4Glcb-Sp0 14 3 19
Fuca1-2Galb1-4(Fuca1-3)GlcNAcb1-2Mana1-6(Fuca1-2Galb1­
447	 4(Fuca1-3)GlcNAcb1-4(Fuca1-2Galb1-4(Fuca1-3)GlcNAcb1- 14 10 74
2)Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-Sp12
140 Galb1-3GalNAca-Sp8 14 8 55
291 Galb1-4(Fuca1-3)(6S)GlcNAcb-Sp0 13 13 99
266 Neu5Aca2-6GalNAca-Sp8 13 8 60
99 GalNAcb1-4GlcNAcb-Sp0	 13 3 23
573
Galb1-3GlcNAcb1-3Galb1-4GlcNAcb1-6(Galb1-3GlcNAcb1­
3Galb1-4GlcNAb1-2)Mana1-6(Galb1-3GlcNAcb1-3Galb1­
4GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4(Fuca1-6)GlcNAcb­
Sp24
13 9 70
GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1­
4GlcNAcb1-6(GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1­
586	 3Galb1-4GlcNAb1-2)Mana1-6(GlcNAcb1-3Galb1-4GlcNAcb1- 13 16 119
3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-3)Manb1­
4GlcNAcb1-4(Fuca1-6)GlcNAcb-Sp24
121 Gala1-4Galb1-4GlcNAcb-Sp0 13 16 123
85 (3S)Galb1-4(Fuca1-3)Glcb-Sp0	 13 5 40
427
13 Glcb-Sp8
13
13
11
7
86
51
Fuca1-2Galb1-3GlcNAcb1-2Mana1-6(Fuca1-2Galb1-3GlcNAcb1-
2Mana1-3)Manb1-4GlcNAcb1-4(Fuca1-6)GlcNAcb-Sp22
239 Neu5Aca2-3Galb1-3(6S)GlcNAc-Sp8 13 5 37
489 Galb1-3GlcNAcb1-6GalNAca-Sp14	 13 5 39
404
207 KDNa2-3Galb1-4GlcNAcb-Sp0
13
13
14
7
106
51
Gala1-4Galb1-3GlcNAcb1-2Mana1-6(Gala1-4Galb1-3GlcNAcb1-
2Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-Sp19
504 GalNAcb1-4(Fuca1-3)(6S)GlcNAcb-Sp8 13 2 14
101 Gala1-2Galb-Sp8	 13 8 65
359 KDNa2-3Galb1-4Glc-Sp0 13 7 57
Gala1-3Galb1-4GlcNAcb1-2Mana1-6(Gala1-3Galb1-4GlcNAcb1­364	 13 112Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-Sp20
96 GalNAcb1-3(Fuca1-2)Galb-Sp8 13 6 47
252 Neu5Aca2-3Galb1-4(6S)GlcNAcb-Sp8	 13 8 60
386 Galb1-4(Fuca1-3)GlcNAcb1-6(Fuca1-4(Fuca1-2Galb1-3)GlcNAcb1­3)Galb1-4Glc-Sp21 13 5 41
76 Fuca1-2Galb1-4GlcNAcb-Sp0	 13 9 68
444 (6S)Galb1-3GlcNAcb-Sp0 13 9 67
341 GlcNAca1-4Galb1-3GlcNAcb-Sp0	 13 8 65
81 Fuca1-4GlcNAcb-Sp8 13 5 36
144 Galb1-3GalNAcb1-3Gala1-4Galb1-4Glcb-Sp0 12 7 54
139 Neu5Aca2-6(Galb1-3)GlcNAcb1-4Galb1-4Glcb-Sp10 12 8 64
Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-6(Galb1-4GlcNAcb1­
3Galb1-4GlcNAb1-2)Mana1-6(Galb1-4GlcNAcb1-3Galb1­583	 12 11 874GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4(Fuca1-6)GlcNAcb­
Sp24
 
312 GlcNAcb1-4GlcNAcb-Sp12 12 6 47
103 Gala1-3(Fuca1-2)Galb1-3GlcNAcb-Sp8	 12 6 47
230 Neu5Aca2-8Neu5Aca2-8Neu5Aca-Sp8 12 10
234 GalNAcb1-4(Neu5Aca2-3)Galb1-4Glcb-Sp0	 12 8 67
610 GlcNAcb1-3Fuca-Sp21	 12 5
220 (3S)Galb1-4(Fuca1-3)(6S)GlcNAcb-Sp8	 12 15 129
234
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Appendix
GlcNAcb1-6GalNAca-Sp14 12 13 108
Fuca1-4(Fuca1-2Galb1-3)GlcNAcb1-2Mana1-3(Fuca1-4(Fuca1­376	 12 7 622Galb1-3)GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-Sp19
223 Fuca1-2(6S)Galb1-4(6S)Glcb-Sp0 12 7
402
6
Galb1-4(Fuca1-3)GlcNAcb1-3GalNAca-Sp14
Fuca-Sp8
12
12
8
9
65
78
211 Mana1-6(Mana1-2Mana1-3)Mana1-6(Mana1-2Mana1-3)Manb1­4GlcNAcb1-4GlcNAcb-Sp12 12 8 68
352
40 (4S)Galb1-4GlcNAcb-Sp8
12
12
9
13
74
113
Mana1-6(Galb1-4GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-
4GlcNAcb-Sp12
165 Galb1-4GlcNAcb1-3Galb1-4Glcb-Sp0 12 10 90
Neu5Aca2-6Galb1-4 GlcNAcb1-6(Neu5Aca2-6Galb1-4GlcNAcb1­482	 12 113)GalNAca-Sp14
135 GlcNAcb1-6(Galb1-3)GalNAca-Sp14	 12 8 71
285 Neu5Gca2-3Galb1-4Glcb-Sp0	 12 7 64
411 Galb1-4GlcNAcb1-6(Neu5Aca2-6Galb1-3GlcNAcb1-3)Galb1-4Glc­Sp21 12 3 29
515 GalNAcb1-4(6S)GlcNAc-Sp8	 11 7 65
69 Fuca1-2Galb1-3GlcNAcb-Sp8	 11 3 24
315 Mana1-6(Mana1-3)Mana1-6(Mana1-3)Manb-Sp10	 11 12 102
476 GlcNAcb1-6(GlcNAcb1-2)Mana1-6(GlcNAcb1-2Mana1-3)Manb1- 11 64GlcNAcb1-4(Fuca1-6)GlcNAcb-Sp24
GlcNAcb1-2Mana1-6(GlcNAcb1-4(GlcNAcb1-2)Mana1-3)Manb1­389	 11 6 534GlcNAcb1-4GlcNAc-Sp21
7 Fuca-Sp9 11 4 37
29 (3S)Galb1-3GalNAca-Sp8	 11 6 58
322 Neu5Aca2-8Neu5Acb-Sp17 11 7 61
222 Fuca1-2Galb1-4(6S)GlcNAcb-Sp8	 11 9 80
228 Neu5Aca2-8Neu5Aca2-8Neu5Aca2-3Galb1-4Glcb-Sp0 11 7 66
Neu5Aca2-6Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-6(Galb1­602	 11 33)GalNAca-Sp14
247 Neu5Aca2-3Galb1-3GalNAcb1-3Gala1-4Galb1-4Glcb-Sp0 11 6 53
465
Neu5Aca2-6Galb1-4GlcNAcb1-4Mana1-6(GlcNAcb1-4)(Neu5Aca2­
6Galb1-4GlcNAcb1-4(Neu5Aca2-6Galb1-4GlcNAcb1-2)Mana1­ 11 8 75
3)Manb1-4GlcNAcb1-4GlcNAcb-Sp21
107 Gala1-3(Fuca1-2)Galb1-4Glcb-Sp0 11 11 98
127 Galb1-3(Fuca1-4)GlcNAcb1-3Galb1-4(Fuca1-3)GlcNAcb-Sp0 11 4 40
455
GalNAca1-3(Fuca1-2)Galb1-4GlcNAcb1-2Mana1-6(GalNAca1­
3(Fuca1-2)Galb1-4GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1­
4(Fuca1-6)GlcNAcb-Sp22
11 8 73
11 Neu5Acb-Sp8	 11 6 50
22 6S(3S)Galb1-4(6S)GlcNAcb-Sp0 11 10 93
50 Mana1-6(Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-Sp12	 11 5 51
106 Gala1-3(Fuca1-2)Galb1-4GlcNAc-Sp0 11 9 80
500 Fuca1-2Galb1-4GlcNAcb1-2Mana-Sp0	 11 3 31
290 Galb1-3GlcNAcb1-3Galb1-3GlcNAcb-Sp0 11 5 46
Galb1-4GlcNAcb1-2Mana1-6(Galb1-4GlcNAcb1-2Mana1-3)Manb1­54	 11 17 1614GlcNAcb1-4GlcNAcb-Sp12
250 Neu5Aca2-3Galb1-3GlcNAcb-Sp0 11 5 45
Gala1-3Galb1-4GlcNAcb1-2Mana1-6(Gala1-3Galb1-4GlcNAcb1­561	 11 22Mana1-3)Manb1-4GlcNAcb1-4GlcNAc-Sp24
501 Fuca1-2Galb1-3(6S)GlcNAcb-Sp0 11 4 37
557 Neu5Gca2-8Neu5Gca2-6Galb1-4GlcNAc-Sp0 11 6 59
397 Neu5Aca2-3Galb1-3GlcNAcb1-2Mana1-6(Neu5Aca2-3Galb1­3GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4GlcNAc-Sp19 11 11 104
Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1­
4GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-6(Galb1-4GlcNAcb1­
582	 3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1- 11 11 105
3Galb1-4GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4(Fuca1­
6)GlcNAcb-Sp19
297 4S(3S)Galb1-4GlcNAcb-Sp0 11 3
357 KDNa2-3Galb1-4(Fuca1-3)GlcNAc-Sp0	 10 6 59
495 Fuca1-2Galb1-4GlcNAcb1-6GalNAca-Sp14 10 4
538 Gala1-3(Fuca1-2)Galb1-3GalNAcb1-3Gala1-4Galb1-4Glc-Sp21 10 9 88
128 Galb1-3GlcNAcb1-3Galb1-4(Fuca1-3)GlcNAcb-Sp0 10 9 89
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Appendix
178 GlcNAcb1-6(GlcNAcb1-3)GalNAca-Sp14	 10 4 42
115 Gala1-3Galb1-3GlcNAcb-Sp0 10 8
419 GalNAca1-3(Fuca1-2)Galb1-4(Fuca1-3)GlcNAcb1-3GalNAc-Sp14 10 7 66
277 Neu5Aca2-8Neu5Aca2-3Galb1-4Glcb-Sp0 10 12
Galb1-4GlcNAcb1-6(Galb1-4GlcNAcb1-2)Mana1-6(Galb1­459	 10 7 714GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-Sp19
253 Neu5Aca2-3Galb1-4(Fuca1-3)(6S)GlcNAcb-Sp8 10 8 82
199 Glcb1-4Glcb-Sp8 10 9 89
143 Galb1-3GalNAcb-Sp8 10 1 13
GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1­
4GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-6(GlcNAcb1-3Galb1­565	 10 10 1034GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1­
4GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-Sp25
 
100 GalNAcb1-4GlcNAcb-Sp8 10 6 62
GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1­
577 6(GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1­
3)Manb1-4GlcNAcb1-4(Fuca1-6)GlcNAcb-Sp24
10 8 79
2 Glca-Sp8 10 4 36
445 (6S)Galb1-3(6S)GlcNAc-Sp0	 10 5 45
268 Neu5Aca2-6Galb1-4(6S)GlcNAcb-Sp8	 10 8 77
93 GalNAca1-3Galb-Sp8	 10 4 42
8 Rhaa-Sp8 10 7 75
38 (3S)Galb-Sp8	 10 10 98
183 GlcNAcb1-3Galb1-4GlcNAcb-Sp0	 10 8 85
516 (3S)GalNAcb1-4GlcNAc-Sp8	 10 5 52
111 Gala1-3GalNAca-Sp8 10 4 38
493 (3S)Galb1-3(Fuca1-4)GlcNAcb-Sp0	 10 3 33
77 Fuca1-2Galb1-4GlcNAcb-Sp8 10 7 68
570 (3S)GlcAb1-3Galb1-4GlcNAcb1-3Galb1-4Glc-Sp0	 10 10 101
158 Galb1-4GalNAca1-3(Fuca1-2)Galb1-4GlcNAcb-Sp8 10 2 18
GalNAcb1-4GlcNAcb1-2Mana1-6(GalNAcb1-4GlcNAcb1-2Mana1­380	 10 11 1103)Manb1-4GlcNAcb1-4GlcNAc-Sp12
281 Neu5Gca2-3Galb1-3(Fuca1-4)GlcNAcb-Sp0 10 6 59
168 Galb1-4GlcNAcb1-6(Galb1-3)GalNAc-Sp14 10 5 55
369 Galb1-4(Fuca1-3)GlcNAcb1-6(Fuca1-2Galb1-4GlcNAcb1-3)Galb1­4Glc-Sp21 10 6 57
Neu5Aca2-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1­
604	 6(Neu5Aca2-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1- 10 3 32
3)Manb1-4GlcNAcb1-4GlcNAcb-Sp12
469 Gala1-3(Fuca1-2)Galb1-3GalNAcb-Sp8 10 3 31
Galb1-4GlcNAcb1-2Mana1-6(Galb1-4GlcNAcb1-2Mana1-3)Manb1­354	 10 11 1134GlcNAcb1-4(Fuca1-6)GlcNAcb-Sp22
147 Galb1-3Galb-Sp8 10 9 97
123 Gala1-4Galb1-4Glcb-Sp0	 9 17 176
79 Fuca1-2Galb-Sp8 9 7 71
470 Glca1-6Glca1-6Glca1-6Glcb-Sp10	 9 2 24
360 KDNa2-3Galb1-3GalNAca-Sp14 9 5 49
Neu5Aca2-8Neu5Aca2-3Galb1-3GalNAcb1-4(Neu5Aca2-3)Galb1­574	 9 54Glc-Sp21
185 GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb-Sp0	 9 9 92
265 Neu5Aca2-3Galb1-4Glcb-Sp8	 9 3 32
546
GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1­
6(GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1­
3)Manb1-4GlcNAcb1-4GlcNAcb-Sp12
9 6 60
381 Galb1-3GalNAca1-3(Fuca1-2)Galb1-4Glc-Sp0	 9 5 58
575
GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-6(GlcNAcb1-3Galb1­
4GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4(Fuca1-6)GlcNAcb­
Sp24
9 5 54
35 (3S)Galb1-4(6S)GlcNAcb-Sp8	 9 9 102
448 Galb1-4(Fuca1-3)GlcNAcb1-6GalNAc-Sp14	 9 7
45 (6S)Galb1-4(6S)Glcb-Sp8	 9 8 85
70 Sp0 9 1 13
262 Neu5Aca2-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb-Sp0 9 6 61
Fuca1-2Galb1-4(Fuca1-3)GlcNAcb1-3Galb1-4(Fuca1-3)GlcNAcb-
280 Neu5Acb2-6Galb1-4GlcNAcb-Sp8	 9 5
214 Mana1-6(Mana1-3)Mana-Sp9	 9 5 55
236
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47
Appendix
203 GlcAb-Sp8 9 6
62 Fuca1-2Galb1-3GalNAca-Sp8	 9 6 69
306 Galb1-4GlcNAcb1-6Galb1-4GlcNAcb-Sp0 9 13
149 Galb1-3GlcNAcb1-3Galb1-4Glcb-Sp10	 9 2 21
17 GlcNAcb-Sp8	 9 4
GalNAcb1-4(Neu5Aca2-8Neu5Aca2-8Neu5Aca2-8Neu5Aca2­226	 9 4 393)Galb1-4Glcb-Sp0
37 (3S)Galb1-4GlcNAcb-Sp8 9 4
27
368
(3S)Galb1-4(6S)Glcb-Sp8
Neu5Aca2-6GlcNAcb1-4GlcNAcb1-4GlcNAc-Sp21
9
9
7
4
73
48
258 Neu5Aca2-3Galb1-4(Fuca1-3)GlcNAcb1-3Galb1-4GlcNAcb-Sp8 9 5 51
179 GlcNAcb1-6(GlcNAcb1-3)Galb1-4GlcNAcb-Sp8 9 3 37
GlcNAcb1-2Mana1-6(GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1­353	 9 64(Fuca1-6)GlcNAcb-Sp22
254 Neu5Aca2-3Galb1-4(Fuca1-3)GlcNAcb1-3Galb1-4(Fuca1­3)GlcNAcb1-3Galb1-4(Fuca1-3)GlcNAcb-Sp0 9 2 27
415 GalNAca1-3(Fuca1-2)Galb1-4GlcNAcb1-3GalNAca-Sp14 9 4 41
473
Fuca1-2Galb1-4(Fuca1-3)GlcNAcb1-2Mana1-6(Fuca1-2Galb1­
4(Fuca1-3)GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4(Fuca1­
6)GlcNAcb-Sp24
9 4 41
Galb1-4(Fuca1-3)GlcNAcb1-6(Galb1-3GlcNAcb1-3)Galb1-4Glc­384	 9 3Sp21
174 GlcNAca1-3Galb1-4GlcNAcb-Sp8 9 3 29
324 Neu5Gcb2-6Galb1-4GlcNAc-Sp8 9 4 40
505 (3S)GalNAcb1-4(Fuca1-3)GlcNAcb-Sp8 9 3 39
18 GlcN(Gc)b-Sp8	 9 3 37
244 Neu5Aca2-6(Neu5Aca2-3Galb1-3)GalNAca-Sp8 9 11 120
91 GalNAca1-3(Fuca1-2)Galb-Sp18	 9 4 48
405 Gala1-4Galb1-4GlcNAcb1-2Mana1-6(Gala1-4Galb1-4GlcNAcb1­2Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-Sp24 9 6 71
169 Galb1-4GlcNAcb-Sp0	 9 4 46
172 Galb1-4Glcb-Sp0 9 7 78
510 Galb1-3GlcNAca1-3Galb1-4GlcNAcb-Sp8	 9 6 67
173 Galb1-4Glcb-Sp8 9 2 26
292
490
Galb1-4(Fuca1-3)(6S)Glcb-Sp0
Gala1-3Galb1-3GlcNAcb1-6GalNAca-Sp14
9
9
5
3
54
38
457 Neu5Aca2-6Galb1-4GlcNAcb1-6(Fuca1-2Galb1-3GlcNAcb1­3)Galb1-4Glc-Sp21 9 3 37
109 Gala1-3(Fuca1-2)Galb-Sp18 9 5 63
417 Fuca1-2Galb1-4(Fuca1-3)GlcNAcb1-3GalNAca-Sp14 8 8 96
600 Galb1-4GlcNAcb1-3Galb1-3GalNAca-Sp14 8 3 41
Neu5Aca2-6Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1­
609	 6(Neu5Aca2-6Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1- 8 11 133
3)Manb1-4GlcNAcb1-4GlcNAcb-Sp12
299 (6P)Glcb-Sp10 8 5 59
237 Neu5Aca2-3GalNAca-Sp8	 8 8 97
332 4)GlcNAcb-Sp0 8 9 106
552
Galb1-3GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-6(Galb1­
3GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1­ 8 1 12
4GlcNAc-Sp25
Neu5Aca2-3Galb1-3(Fuca1-4)GlcNAcb1-3Galb1-3(Fuca1-
269 Neu5Aca2-6Galb1-4GlcNAcb-Sp0 8 5
Galb1-4GlcNAcb1-6(Fuca1-4(Fuca1-2Galb1-3)GlcNAcb1-3)Galb1­385	 8 54Glc-Sp21
112 Gala1-3GalNAca-Sp16	 8 11 130
67 Fuca1-2Galb1-3GlcNAcb1-3Galb1-4Glcb-Sp10	 8 5 55
529 GalNAcb1-4GlcNAcb1-2Mana-Sp0 8 2
293 Galb1-4(Fuca1-3)GlcNAcb1-3Galb1-3(Fuca1-4)GlcNAcb-Sp0 8 11 127
491 Galb1-3(Fuca1-4)GlcNAcb1-6GalNAca-Sp14 8 7
148 Galb1-3GlcNAcb1-3Galb1-4GlcNAcb-Sp0 8 11 134
283 Neu5Gca2-3Galb1-4(Fuca1-3)GlcNAcb-Sp0 8 5 61
166 Galb1-4GlcNAcb1-3Galb1-4Glcb-Sp8	 8 5 59
525 Galb1-3GlcNAcb1-2Mana-Sp0 8 4
145 Galb1-3GalNAcb1-4(Neu5Aca2-3)Galb1-4Glcb-Sp0	 8 2 23
113 Gala1-3GalNAcb-Sp8	 8 2
208 Mana1-2Mana1-2Mana1-3Mana-Sp9	 8 9 112
237
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Appendix
400 Neu5Aca2-3Galb1-3GlcNAcb1-3GalNAca-Sp14 8 3
94 GalNAca1-4(Fuca1-2)Galb1-4GlcNAcb-Sp8 8 6 80
Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-6(Galb1-4GlcNAcb1- 8 8 983Galb1-4GlcNAcb1-3)GalNAca-Sp14
288
Galb1-3GalNAcb1-4(Neu5Aca2-8Neu5Aca2-8Neu5Aca2-3)Galb1-
Neu5Gca-Sp8 8 4 45
611 8 5 664Glcb-Sp21
GalNAca1-3(Fuca1-2)Galb1-4Glcb-Sp0 8 3 39
374
GalNAca1-3(Fuca1-2)Galb1-3GlcNAcb1-2Mana1-6(GalNAca1­
3(Fuca1-2)Galb1-3GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1­
4GlcNAcb-Sp20
8 1 6
23 6S(3S)Galb1-4GlcNAcb-Sp0 8 2 19
279 Neu5Acb2-6GalNAca-Sp8 8 4 45
GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1­
547 6(GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1­ 8 6 75
3)Manb1-4GlcNAcb1-4GlcNAcb-Sp25
485 Mana1-6(Mana1-3)Manb1-4GlcNAcb1-4(Fuca1-6)GlcNAcb-Sp19 8 6 72
GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1­
588
4GlcNAcb1-3Galb1-4GlcNAcb1-6(GlcNAcb1-3Galb1-4GlcNAcb1­
3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAb1­ 8 4 45
2)Mana1-6(GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1­
3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-3)Manb
394 GalNAca1-3(Fuca1-2)Galb1-3GalNAca1-3(Fuca1-2)Galb1­4GlcNAcb-Sp0 8 9 118
14 Manb-Sp8 8 6 81
298 (6S)Galb1-4(6S)GlcNAcb-Sp0 8 4 49
480 Neu5Aca2-3Galb1-4GlcNAcb1-6GalNAca-Sp14 8 3 39
176 GlcNAcb1-2Galb1-3GalNAca-Sp8 8 5 64
122 Gala1-4Galb1-4GlcNAcb-Sp8 8 5 68
392 Galb1-3GlcNAcb1-3GalNAca-Sp14 8 6 73
Neu5Aca2-6Galb1-4GlcNAcb1-2Mana1-6(GlcNAcb1-2Mana1­309 8 53)Manb1-4GlcNAcb1-4GlcNAcb-Sp12
19 Galb1-4GlcNAcb1-6(Galb1-4GlcNAcb1-3)GalNAca-Sp8 8 5 70
150 Galb1-3GlcNAcb-Sp0 8 4 47
593 Neu5Aca2-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3GalNAca-Sp14 8 5 69
Gala1-3Galb1-3(Fuca1-4)GlcNAcb1-2Mana1-6(Gala1-3Galb1­396 8 43(Fuca1-4)GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4GlcNAc-Sp19
316 Mana1-2Mana1-6(Mana1-3)Mana1-6(Mana1-2Mana1-2Mana1­3)Mana-Sp9 8 5 70
479
300
Neu5Aca2-3Galb1-4GlcNAcb1-2Mana-Sp0
Neu5Aca2-3Galb1-4(Fuca1-3)GlcNAcb1-6(Galb1-3)GalNAca-Sp14
8
8
3
6
45
77
141 Galb1-3GalNAca-Sp14 8 3 33
539 Galb1-3GalNAcb1-3Gal-Sp21 8 3 36
204 GlcAb1-3Galb-Sp8 8 5 71
321 3)Manb1-4GlcNAcb1-4GlcNAcb-Sp12 8 4 54
26 (3S)Galb1-4(6S)Glcb-Sp0 8 2 27
GlcNAcb1-2Mana1-6(Neu5Aca2-6Galb1-4GlcNAcb1-2Mana1-
579
GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1­
4GlcNAcb1-2Mana1-6(GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1­
4GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1­
4(Fuca1-6)GlcNAcb-Sp24
8 2 25
278 Galb1-3(Fuca1-4)GlcNAcb1-3Galb1-3(Fuca1-4)GlcNAcb-Sp0 8 4 59
531 GlcNAcb1-2 Mana1-6(GlcNAcb1-4)(GlcNAcb1-2Mana1-3)Manb1- 8 64GlcNAcb1-4(Fuca1-6)GlcNAc-Sp21
201
95
G-ol-Sp8
GalNAcb1-3GalNAca-Sp8
8
8
3
4
36
55
137 Neu5Aca2-6(Galb1-3)GalNAca-Sp14 7 5 71
249 Fuca1-2(6S)Galb1-4Glcb-Sp0 7 12
130 Galb1-3(Fuca1-4)GlcNAc-Sp8 7 6 84
43
462
Neu5Aca2-3Galb1-4GlcNAcb1-6(Neu5Aca2-3Galb1-4GlcNAcb1­
2)Mana1-6(GlcNAcb1-4)(Neu5Aca2-3Galb1-4GlcNAcb1-2Mana1­
7
7
2
4
27
50
3)Manb1-4GlcNAcb1-4GlcNAcb-Sp21
(6S)Galb1-4Glcb-Sp8
Mana1-6(Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-Sp13 7 4 54
Galb1-3GlcNAcb1-2Mana1-6(GlcNAcb1-4)(Galb1-3GlcNAcb1­ 7 11 1512Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-Sp21
238
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Appendix
461
Neu5Aca2-3Galb1-4GlcNAcb1-4Mana1-6(GlcNAcb1-4)(Neu5Aca2­
3Galb1-4GlcNAcb1-4(Neu5Aca2-3Galb1-4GlcNAcb1-2)Mana1­
3)Manb1-4GlcNAcb1-4GlcNAcb-Sp21
7 5 71
422
530
GlcNAcb1-2(GlcNAcb1-6)Mana1-6(GlcNAcb1-2Mana1-3)Manb1­
4GlcNAcb1-4GlcNAcb-Sp19
Neu5Aca2-3Galb1-3GlcNAcb1-4Galb1-4Glcb-Sp0
7
7
3
6
39
81
399 Galb1-4GlcNAcb1-2Mana1-6(GlcNAcb1-2Mana1-3)Manb1­4GlcNAcb1-4GlcNAc-Sp12 7 4 57
GalNAca1-3(Fuca1-2)Galb1-4GlcNAcb1-6(GalNAca1-3(Fuca1-
2)Galb1-4GlcNAcb1-3)GalNAc-Sp14	 7 7 99
GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1­
4GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-6(GlcNAcb1-3Galb1­
581	 4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1- 7 1 16
4GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4(Fuca1-6)GlcNAcb­
Sp19
514 (3S)GalNAcb1-4(3S)GlcNAc-Sp8 7 10 143
443 GalNAcb1-6GalNAcb-Sp8	 7 2 23
498 Fuca1-2(6S)Galb1-3GlcNAcb-Sp0 7 10 136
363
126
Fuca1-2Galb1-4(Fuca1-3)GlcNAcb1-2Mana1-6(Fuca1-2Galb1­
4(Fuca1-3)GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4GlcNAb-Sp20
Galb1-2Galb-Sp8
7
7
4
7
60
92
170 Galb1-4GlcNAcb-Sp8 7 4 58
345 GlcNAca1-4Galb1-3GalNAc-Sp14 7 5 69
387
238
Galb1-3GlcNAcb1-3Galb1-4(Fuca1-3)GlcNAcb1-6(Galb1­
3GlcNAcb1-3)Galb1-4Glc-Sp21
Neu5Aca2-3GalNAcb1-4GlcNAcb-Sp0
7
7
4
1
50
12
105 Gala1-3(Fuca1-2)Galb1-4(Fuca1-3)GlcNAcb-Sp8 7 1 15
271 7 3 46
GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1­
550 4GlcNAcb1-2Mana1-6(GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1­4GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1­ 7 4 51
4GlcNAcb-Sp25
Neu5Aca2-6Galb1-4GlcNAcb1-3Galb1-4(Fuca1-3)GlcNAcb1-
3Galb1-4(Fuca1-3)GlcNAcb-Sp0
205 GlcAb1-6Galb-Sp8 7 6 79
195 GlcNAcb1-6Galb1-4GlcNAcb-Sp8 7 8 110
367 Neu5Aca2-6GlcNAcb1-4GlcNAc-Sp21 7 3 38
34 (3S)Galb1-4(6S)GlcNAcb-Sp0	 7 2 33
460 Neu5Aca2-3Galb1-4GlcNAcb1-2Mana1-6(GlcNAcb1-4)(Neu5Aca2­3Galb1-4GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-Sp21 7 2 29
48 Neu5,9Ac2a-Sp8 7 12 170
86 GalNAca1-3(Fuca1-2)Galb1-4GlcNAcb-Sp0 7 2 31
335 GalNAcb1-3Gala1-4Galb1-4GlcNAcb1-3Galb1-4Glcb-Sp0 7 4 61
438 Galb1-4GlcNAcb1-6(Galb1-4GlcNAcb1-2)Mana1-6(GlcNAcb1­4)(Galb1-4GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4GlcNAc-Sp21 7 3 38
117 Gala1-3Galb1-4Glcb-Sp0	 7 3 38
286 Neu5Gca2-6GalNAca-Sp0 7 3 42
Fuca1-2Galb1-4GlcNAcb1-2Mana1-6(Fuca1-2Galb1-4GlcNAcb1­362	 7 32Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-Sp20
496 Gala1-3Galb1-4GlcNAcb1-6GalNAca-Sp14 7 4
Neu5Aca2-6Galb1-4GlcNAcb1-2Mana1-6(Neu5Aca2-6Galb1­58	 7 8 1204GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-Sp24
527 Neu5Aca2-3Galb1-3GlcNAcb1-2Mana-Sp0 7 6
Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1­
4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1­
569	 6(Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1- 7 2 36
3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1­
2Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-Sp25
Neu5Aca2-6Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1­
4GlcNAcb-Sp0333 7 4 66
468 Gala1-3(Fuca1-2)Galb1-3GalNAca-Sp8	 7 6 93
71 Fuca1-2Galb1-4(Fuca1-3)GlcNAcb1-3Galb1-4(Fuca1-3)GlcNAcb1­3Galb1-4(Fuca1-3)GlcNAcb-Sp0 7 5 78
20 Galb1-4GlcNAcb1-6(Galb1-4GlcNAcb1-3)GalNAc-Sp14	 7 2 25
401 Fuca1-2Galb1-4GlcNAcb1-3GalNAca-Sp14 7 1
200 Glcb1-6Glcb-Sp8 7 5 68
64 Fuca1-2Galb1-3GalNAcb1-4(Neu5Aca2-3)Galb1-4Glcb-Sp0 7 3 41
239
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Appendix
256 Neu5Aca2-3Galb1-4(Fuca1-3)GlcNAcb-Sp8	 7 3 51
197 Glca1-4Glca-Sp8 7 5
119 Gala1-3Galb-Sp8	 7 4 63
346
90 GalNAca1-3(Fuca1-2)Galb-Sp8
7
7
4
6
62
89
Neu5Aca2-6Galb1-4GlcNAcb1-2Mana1-6(Mana1-3)Manb1-
4GlcNAcb1-4GlcNAc-Sp12
273 Neu5Aca2-6Galb1-4Glcb-Sp0 7 6
270 Neu5Aca2-6Galb1-4GlcNAcb-Sp8	 7 3 42
305 Galb1-4GlcNAca1-6Galb1-4GlcNAcb-Sp0	 7 6
284 Neu5Gca2-3Galb1-4GlcNAcb-Sp0	 7 2 27
142 Galb1-3GalNAca-Sp16 7 6 94
25 (3S)Galb1-4Glcb-Sp8	 7 3 45
72 Fuca1-2Galb1-4(Fuca1-3)GlcNAcb-Sp0 6 5 81
184 GlcNAcb1-3Galb1-4GlcNAcb-Sp8	 6 8 117
339 GlcNAca1-4Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1­4GlcNAcb-Sp0 6 3 41
520 GalNAca1-3(Fuca1-2)Galb1-4GlcNAcb1-6GalNAc-Sp14 6 6 101
365 Galb1-4GlcNAcb1-2Mana1-6(Mana1-3)Manb1-4GlcNAcb1- 6 54GlcNAcb-Sp12
GlcNAcb1-3Galb1-4GlcNAcb1-6(GlcNAcb1-3Galb1-4GlcNAcb1­596	 6 33)GalNAca-Sp14
391 Fuca1-2Galb1-3GalNAca1-3(Fuca1-2)Galb1-4GlcNAcb-Sp0 6 6 100
66 Fuca1-2Galb1-3GlcNAcb1-3Galb1-4Glcb-Sp8	 6 3 52
350 Galb1-4GlcNAcb1-2Mana1-3Manb1-4GlcNAcb1-4GlcNAc-Sp12 6 6 102
471 Glca1-4Glca1-4Glca1-4Glcb-Sp10	 6 8 126
159 Galb1-4GalNAcb1-3(Fuca1-2)Galb1-4GlcNAcb-Sp8 6 4 68
231 Neu5Aca2-3(6S)Galb1-4(Fuca1-3)GlcNAcb-Sp8	 6 3 47
246 Neu5Aca2-3Galb-Sp8 6 3 56
235 Neu5Aca2-3Galb1-3GalNAcb1-4(Neu5Aca2-3)Galb1-4Glcb-Sp0 6 7 121
302 2Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-Sp12 6 5 87
274 Neu5Aca2-6Galb1-4Glcb-Sp8 6 4 70
Neu5Aca2-6Galb1-4GlcNAcb1-2Mana1-6(Galb1-4GlcNAcb1-
451 Gala1-3(Fuca1-2)Galb1-4GlcNAcb1-6(Gala1-3(Fuca1-2)Galb1- 6 74GlcNAcb1-3)GalNAc-Sp14
442 Neu5Aca2-3Galb1-4GlcNAcb1-3Galb-Sp8	 6 5 83
456
Gala1-3(Fuca1-2)Galb1-3GlcNAcb1-2Mana1-6(Gala1-3(Fuca1-
2)Galb1-3GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4(Fuca1-
6)GlcNAcb-Sp22
6 4 61
160 Galb1-4GlcNAcb1-3GalNAca-Sp8	 6 3 50
366
Fuca1-4(Galb1-3)GlcNAcb1-2Mana1-6(Fuca1-4(Galb1­
3)GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4(Fuca1-6)GlcNAcb­
Sp22
6 5 80
Neu5Aca2-3Galb1-4GlcNAcb1-6(Neu5Aca2-3Galb1-3)GalNAca­318	 6 5Sp14
446
Fuca1-2Galb1-4 GlcNAcb1-2Mana1-6(Fuca1-2Galb1-4GlcNAcb1­
2(Fuca1-2Galb1-4GlcNAcb1-4)Mana1-3)Manb1-4GlcNAcb1­
4GlcNAcb-Sp12
6 4 73
Galb1-4(Fuca1-3)GlcNAcb1-2Mana1-6(Galb1-4(Fuca1­328	 6 33)GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-Sp20
287 Neu5Gca2-6Galb1-4GlcNAcb-Sp0 6 2 35
409 GalNAcb1-3Gala1-6Galb1-4Glcb-Sp8 6 4 73
307 GalNAcb1-3Galb-Sp8 6 1 12
Mana1-2Mana1-6(Mana1-2Mana1-3)Mana1-6(Mana1-2Mana1­317	 6 52Mana1-3)Mana-Sp9
474
Fuca1-2Galb1-3(Fuca1-4)GlcNAcb1-2Mana1-6(Fuca1-2Galb1­
3(Fuca1-4)GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4(Fuca1­
6)GlcNAcb1-4(Fuca1-6)GlcNAcb-Sp19
6 7 118
Galb1-4(Fuca1-3)GlcNAcb1-2Mana1-6(Galb1-4(Fuca1­
420	 3)GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4(Fuca1-6)GlcNAcb- 6 3 50
Sp22
73 Fuca1-2Galb1-4(Fuca1-3)GlcNAcb-Sp8 6 4 62
536 GlcNAcb1-3Galb1-4GlcNAcb1-6(GlcNAcb1-3)Galb1-4GlcNAc-Sp0 6 4 72
Neu5Aca2-6Galb1-4GlcNAcb1-2Mana1-6(Neu5Aca2-6Galb1- 6 4 624GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-Sp12
Galb1-3GlcNAcb1-6(Galb1-3GlcNAcb1-2)Mana1-6(Galb1­429	 6 2 263GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-Sp19
240
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Appendix
Gala1-3(Fuca1-2)Galb1-3GlcNAcb1-6GalNAc-Sp14 6 6 95
Neu5Aca2-6Galb1-4GlcNAcb1-6(Galb1-3GlcNAcb1-3)Galb1-4Glcb­478 6 4 62Sp21
Neu5Aca2-3Galb1-4(Fuca1-3)GlcNAcb1-6(Neu5Aca2-3Galb1-
3)GalNAc-Sp14 6 1 18
Galb1-3GlcNAcb1-2Mana1-6(Galb1-3GlcNAcb1-2Mana1-3)Manb1­325 6 3 484GlcNAcb1-4GlcNAcb-Sp19
GlcNAcb1-3GalNAca-Sp14 6 6 97
Neu5Aca2-3Galb1-3GalNAcb1-4(Neu5Aca2-8Neu5Aca2-3)Galb1­413 6 4 604Glcb-Sp0
603 Neu5Aca2-6Galb1-4GlcNAcb1-6(Galb1-3)GalNAca-Sp14 6 2 36
441 Galb1-6Galb-Sp10 6 6 105
507 GalNAca1-3(Fuca1-2)Galb1-3GlcNAcb1-6GalNAca-Sp14 6 5 78
528 Gala1-3Galb1-3GlcNAcb1-2Mana-Sp0 6 5 88
32 (3S)Galb1-4(Fuca1-3)GlcNAc-Sp0 6 3 52
423 Fuca1-2Galb1-3GlcNAcb1-3GalNAc-Sp14 6 3 52
545
Fuca1-2Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-6(Fuca1­
2Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-3)Manb1­
4GlcNAcb1-4GlcNAcb-Sp24
6 10 168
301 Galb1-3Galb1-4GlcNAcb-Sp8 6 1 15
567 GlcNAb1-3Galb1-3GalNAc-Sp14 6 7 117
Fuca1-2Galb1-3GlcNAcb1-2Mana1-6(Fuca1-2Galb1-3GlcNAcb1­361 6 42Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-Sp20
435 GlcNAcb1-6(GlcNAcb1-2)Mana1-6(GlcNAcb1-4)(GlcNAcb1-4(GlcNAcb1-2)Mana1-3)Manb1-4GlcNAcb1-4GlcNAc-Sp21 6 5
Galb1-3GlcNAcb1-3Galb1-4GlcNAcb1-6(Galb1-3GlcNAcb1­383 6 33)Galb1-4Glcb-Sp0
151 Galb1-3GlcNAcb-Sp8 6 4 75
416 GalNAca1-3GalNAcb1-3Gala1-4Galb1-4Glcb-Sp0 6 4 68
466
Neu5Aca2-6Galb1-4GlcNAcb1-6(Neu5Aca2-6Galb1-4GlcNAcb1­
2)Mana1-6(GlcNAcb1-4)(Neu5Aca2-6Galb1-4GlcNAcb1-2Mana1­
3)Manb1-4GlcNAcb1-4GlcNAcb-Sp21
6 2 44
182 GlcNAcb1-3Galb-Sp8 6 1 21
276 Neu5Aca2-8Neu5Aca-Sp8 6 4 67
49
289
Neu5,9Ac2a2-6Galb1-4GlcNAcb-Sp8
Neu5Aca2-3Galb1-4GlcNAcb1-6(Galb1-3)GalNAca-Sp14
6
6
3
3
50
60
259 Neu5Aca2-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1­4GlcNAcb-Sp0 6 3 56
30 (3S)Galb1-3GlcNAcb-Sp0 6 4 78
377 Neu5Aca2-3Galb1-4GlcNAcb1-3GalNAc-Sp14 6 4 77
553 Neu5Gca2-8Neu5Gca2-3Galb1-4GlcNAc-Sp0 6 6 104
Neu5Aca2-6Galb1-4GlcNAcb1-2Mana1-6(GlcNAcb1-4)(Neu5Aca2­464 6 36Galb1-4GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-Sp21
524 GalNAca1-3(Fuca1-2)Galb1-4 GlcNAcb1-2Mana-Sp0 6 4 69
467
Neu5Aca2-6Galb1-4GlcNAcb1-6(Neu5Aca2-6Galb1-4GlcNAcb1­
2)Mana1-6(GlcNAcb1-4)(Neu5Aca2-6Galb1-4GlcNAcb1­
4(Neu5Aca2-6Galb1-4GlcNAcb1-2)Mana1-3)Manb1-4GlcNAcb1­ 5 3 56
4GlcNAcb-Sp21
209 Mana1-2Mana1-6(Mana1-2Mana1-3)Mana-Sp9 5 3 56
232 GalNAcb1-4(Neu5Aca2-3)Galb1-4GlcNAcb-Sp0 5 6 101
522 Gala1-3Galb1-4GlcNAcb1-2Mana-Sp0 5 3 50
GlcNAcb1-3Galb1-4GlcNAcb1-6(GlcNAcb1-3Galb1-4GlcNAcb1­
559 2)Mana1-6(GlcNAcb1-3Galb1-4GlcNAcb1-2Man a1-3)Manb1- 5 3 49
4GlcNAcb1-4GlcNAc-Sp24
594 GlcNAcb1-3Galb1-4GlcNAcb1-3GalNAca-Sp14 5 4 70
161 Galb1-4GlcNAcb1-3GalNAc-Sp14 5 9 163
558 Neu5Aca2-8Neu5Aca2-3Galb1-4GlcNAc-Sp0 5 5 87
Neu5Aca2-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-6(Neu5Aca2­ 5 7 1273Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3)GalNAca-Sp14
432 4GlcNAcb1-4GlcNAc-Sp21 5 4 80
512 (6S)(4S)GalNAcb1-4GlcNAc-Sp8 5 3 47
GlcNAcb1-2Mana1-6(GlcNAcb1-4)(GlcNAcb1-2Mana1-3)Manb1-
356 (6S)GlcNAcb1-3Galb1-4GlcNAcb-Sp0 5 3
146 Galb1-3GalNAcb1-4Galb1-4Glcb-Sp8 5 3 51
Neu5Aca2-3Galb1-3GlcNAcb1-6(Neu5Aca2-3Galb1-4GlcNAcb1- 5 2 442)Mana1-6(Neu5Aca2-3Galb1-3GlcNAcb1-2Mana1-3)Manb1­
241
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Appendix
4GlcNAcb1-4GlcNAcb-Sp19
47 (6S)GlcNAcb-Sp8 5 4 78
10 Neu5Aca-Sp11 5 3
454 GalNAcb1-4Galb1-4Glcb-Sp0 5 7 127
449 Galb1-4GlcNAcb1-2Mana-Sp0 5 3
340 GlcNAca1-4Galb1-4GlcNAcb-Sp0 5 4 78
188 GlcNAcb1-6(GlcNAcb1-4)GalNAca-Sp8 5 5
403 GalNAca1-3GalNAcb1-3Gala1-4Galb1-4GlcNAcb-Sp0 5 3 68
424 Gala1-3(Fuca1-2)Galb1-3GlcNAcb1-3GalNAc-Sp14 5 4
Galb1-4GlcNAcb1-2Mana1-6(GlcNAcb1-4)(Galb1-4GlcNAcb1­436 5 2 332Mana1-3)Manb1-4GlcNAcb1-4GlcNAc-Sp21
157 Galb1-4(6S)Glcb-Sp8 5 2 46
351 Galb1-4GlcNAcb1-2Mana1-6Manb1-4GlcNAcb1-4GlcNAc-Sp12 5 3 56
486
Galb1-4GlcNAcb1-6(Galb1-4GlcNAcb1-2)Mana1-6(Galb1­
4GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4(Fuca1-6)GlcNAcb­
Sp24
5 4 88
534 Fuca1-4(Galb1-3)GlcNAcb1-2 Mana-Sp0 5 4 90
241 Neu5Aca2-3Galb1-3(Fuca1-4)GlcNAcb1-3Galb1-4(Fuca1- 5 33)GlcNAcb-Sp0
Neu5Aca2-3Galb1-3GlcNAcb1-2Mana1-6(GlcNAcb1-4)(Neu5Aca2­487 5 23Galb1-3GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4GlcNAc-Sp21
41 (6P)Mana-Sp8 5 2
532
517
Galb1-4GlcNAcb1-2 Mana1-6(GlcNAcb1-4)(Galb1-4GlcNAcb1­
2Mana1-3)Manb1-4GlcNAcb1-4(Fuca1-6)GlcNAc-Sp21
(4S)GalNAcb-Sp10
5
5
3
3
71
69
521 Neu5Aca2-6Galb1-4GlcNAcb1-2Man-Sp0 5 2 37
295 Neu5Aca2-3Galb1-3GlcNAcb1-3Galb1-3GlcNAcb-Sp0 5 4 96
Mana1-2Mana1-6(Mana1-2Mana1-3)Mana1-6(Mana1-2Mana1­213 5 6 1222Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-Sp12
261 Neu5Aca2-3Galb1-4GlcNAcb-Sp8 5 6 125
89 GlcNAcb1-3Galb1-3GalNAca-Sp8 5 4 81
372 Gala1-3(Fuca1-2)Galb1-4GlcNAcb1-2Mana1-6(Gala1-3(Fuca1­2)Galb1-4GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-Sp20 5 3 71
310 GlcNAcb1-3Man-Sp10 5 6 122
388
Galb1-4GlcNAcb1-6(Galb1-4GlcNAcb1-2)Mana1-6(Galb1­
4GlcNAcb1-4(Galb1-4GlcNAcb1-2)Mana1-3)Manb1-4GlcNAcb1­
4GlcNAcb-Sp21
5 1 26
125 Gala1-6Glcb-Sp8 5 2 43
425 GalNAca1-3(Fuca1-2)Galb1-3GlcNAcb1-3GalNAc-Sp14 5 2 36
Neu5Aca2-3Galb1-4GlcNAcb1-6(Neu5Aca2-3Galb1-4GlcNAcb1­
463 2)Mana1-6(GlcNAcb1-4)(Neu5Aca2-3Galb1-4GlcNAcb1­4(Neu5Aca2-3Galb1-4GlcNAcb1-2)Mana1-3)Manb1-4GlcNAcb1­
4GlcNAcb-Sp21
5 6 129
308 GlcAb1-3GlcNAcb-Sp8 5 6 129
313 MurNAcb1-4GlcNAcb-Sp10 5 3 72
224 Neu5Aca2-3Galb1-3GalNAca-Sp8 5 4 86
59 Fuca1-2Galb1-3GalNAcb1-3Gala-Sp9 4 4 82
535 Neu5Aca2-3Galb1-4(Fuca1-3)GlcNAcb1-2Mana-Sp0 4 5 114
518 Galb1-4(6P)GlcNAcb-Sp0 4 9 212
63 Fuca1-2Galb1-3GalNAca-Sp14 4 4 95
136 Neu5Aca2-6(Galb1-3)GalNAca-Sp8 4 6 149
537 GalNAca1-3(Fuca1-2)Galb1-3GalNAcb1-3Gala1-4Galb1-4Glc-Sp21 4 4 94
GlcNAcb1-2Mana1-6(GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1­52 4 24GlcNAcb-Sp12
156 Galb1-4(6S)Glcb-Sp0 4 4 83
Fuca1-2Galb1-4GlcNAcb1-6(Fuca1-2Galb1-4GlcNAcb1-3)GalNAc­450 4 4Sp14
294 Galb1-4GlcNAcb1-3Galb1-3GlcNAcb-Sp0 4 4
65 Fuca1-2Galb1-3GalNAcb1-4(Neu5Aca2-3)Galb1-4Glcb-Sp9 4 4 96
219 Neu5Aca2-3Galb1-4GlcNAcb1-3Galb1-4(Fuca1-3)GlcNAcb-Sp0 4 3
311 GlcNAcb1-4GlcNAcb-Sp10 4 6 142
571 (3S)GlcAb1-3Galb1-4GlcNAcb1-2Mana-Sp0 4 8
Neu5Aca2-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-6(Galb1­601 4 2 563)GalNAca-Sp14
193 GlcNAcb1-6GalNAca-Sp8 4 5 129
331 Neu5Aca2-6Galb1-4GlcNAcb1-3Galb1-3GlcNAcb-Sp0 4 3 65
242
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Appendix
348 Neu5Aca2-6Galb1-4GlcNAcb1-2Mana1-6Manb1-4GlcNAcb1­4GlcNAc-Sp12 4 3 79
191 GlcNAcb1-4GlcNAcb1-4GlcNAcb1-4GlcNAcb1-4GlcNAcb1-Sp8 4 3 81
440 Galb1-4Galb-Sp10 4 2
264
304
Neu5Aca2-3Galb1-4Glcb-Sp0
GlcNAcb1-6(Galb1-4GlcNAcb1-3)Galb1-4GlcNAc-Sp0
4
4
2
7
61
175
355 Galb1-3GlcNAcb1-2Mana1-6(Galb1-3GlcNAcb1-2Mana1-3)Manb1­4GlcNAcb1-4(Fuca1-6)GlcNAcb-Sp22 4 4 103
218 Manb1-4GlcNAcb-Sp0 4 3 66
Neu5Aca2-3Galb1-4GlcNAcb1-6(Neu5Aca2-3Galb1-4GlcNAcb1­472 4 3 883)GalNAca-Sp14
84 GalNAca1-3(Fuca1-2)Galb1-4(Fuca1-3)GlcNAcb-Sp0 4 8 201
407 Galb1-3GlcNAcb1-6Galb1-4GlcNAcb-Sp0 4 2 58
190 GlcNAcb1-4GlcNAcb1-4GlcNAcb1-4GlcNAcb1-4GlcNAcb1­4GlcNAcb1-Sp8 4 5 124
342 GlcNAca1-4Galb1-4GlcNAcb1-3Galb1-4Glcb-Sp0 4 4 102
53 GlcNAcb1-2Mana1-6(GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1­4GlcNAcb-Sp13 4 4 110
80 Fuca1-3GlcNAcb-Sp8 4 2 51
347 Mana1-6(Neu5Aca2-6Galb1-4GlcNAcb1-2Mana1-3)Manb1­4GlcNAcb1-4GlcNAc-Sp12 4 2 54
229 GalNAcb1-4(Neu5Aca2-8Neu5Aca2-3)Galb1-4Glcb-Sp0 4 2 54
375 Gala1-3(Fuca1-2)Galb1-3GlcNAcb1-2Mana1-6(Gala1-3(Fuca1­2)Galb1-3GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-Sp20 4 2 62
206 KDNa2-3Galb1-3GlcNAcb-Sp0 4 3 90
251 Neu5Aca2-3Galb1-3GlcNAcb-Sp8 4 4 101
Galb1-4GlcNAcb1-2Mana1-6(Galb1-4GlcNAcb1-4(Galb1­370 4 44GlcNAcb1-2)Mana1-3)Manb1-4GlcNAcb1-4GlcNAc-Sp21
74 Fuca1-2Galb1-4GlcNAcb1-3Galb1-4GlcNAcb-Sp0 4 6 160
497 Galb1-4(Fuca1-3)GlcNAcb1-2Mana-Sp0 4 7 180
373
Gala1-3Galb1-4(Fuca1-3)GlcNAcb1-2Mana1-6(Gala1-3Galb1­
4(Fuca1-3)GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb­
Sp20
4 3 85
124 Gala1-4GlcNAcb-Sp8 4 2 56
523 Gala1-3(Fuca1-2)Galb1-4GlcNAcb1-2Mana-Sp0 4 6 165
GlcNAcb1-2Mana1-6(Galb1-4GlcNAcb1-2Mana1-3)Manb1­398 4 24GlcNAcb1-4GlcNAc-Sp12
414 Gala1-3(Fuca1-2)Galb1-4GlcNAcb1-3GalNAca-Sp14 4 6 171
508
GlcNAcb1-6(GlcNAcb1-2)Mana1-6(GlcNAcb1-4)(GlcNAcb1­
4(GlcNAcb1-2)Mana1-3)Manb1-4GlcNAcb1-4(Fuca1-6)GlcNAc­ 4 4 101
Sp21
492 Neu5Aca2-3Galb1-3GlcNAcb1-6GalNAca-Sp14 4 3 77
202 GlcAa-Sp8 4 5 144
430 Galb1-4GlcNAcb1-6(Fuca1-2Galb1-3GlcNAcb1-3)Galb1-4Glc-Sp21 4 3 98
598 Neu5Aca2-6Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3GalNAca-Sp14 4 5 131
248 Neu5Aca2-3Galb1-3GlcNAcb1-3Galb1-4GlcNAcb-Sp0 3 2 71
177 GlcNAcb1-6(GlcNAcb1-3)GalNAca-Sp8 3 2 51
334 Gala1-4Galb1-4GlcNAcb1-3Galb1-4Glcb-Sp0 3 4 125
118 Gala1-3Galb1-4Glc-Sp10 3 3 79
433 2)Mana1-3)Manb1-4GlcNAcb1-4GlcNAc-Sp21 3 1 26
509
Galb1-4GlcNAcb1-6(Galb1-4GlcNAcb1-2)Mana1-6(GlcNAcb1­
4)Galb1-4GlcNAcb1-4(Gal b1-4GlcNAcb1-2)Mana1-3)Manb1­ 3 1 19
GlcNAcb1-2Mana1-6(GlcNAcb1-4)(GlcNAcb1-4(GlcNAcb1-
4GlcNAcb1-4(Fuca1-6)GlcNAc-Sp21
412 Galb1-3GalNAcb1-4(Neu5Aca2-8Neu5Aca2-3)Galb1-4Glcb-Sp0 3 5 147
GalNAcb1-4(Neu5Aca2-8Neu5Aca2-8Neu5Aca2-3)Galb1-4Glcb­227 3 2Sp0
28 (3S)Galb1-3(Fuca1-4)GlcNAcb-Sp8 3 2
499 Gala1-3(Fuca1-2)Galb1-4GlcNAcb1-6GalNAca-Sp14 3 3 101
192 GlcNAcb1-4GlcNAcb1-4GlcNAcb-Sp8 3 4
282 Neu5Gca2-3Galb1-3GlcNAcb-Sp0 3 3 106
494 3)GlcNAcb1-3)Galb1-4Glc-Sp21 3 2 77
210 Mana1-2Mana1-3Mana-Sp9 3 5 162
Galb1-4(Fuca1-3)GlcNAcb1-6(Neu5Aca2-6(Neu5Aca2-3Galb1-
189 GlcNAcb1-4Galb1-4GlcNAcb-Sp8 3 4
418 Gala1-3(Fuca1-2)Galb1-4(Fuca1-3)GlcNAcb1-3GalNAc-Sp14 3 6 185
243
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Appendix
57 Neu5Aca2-6Galb1-4GlcNAcb1-2Mana1-6(Neu5Aca2-6Galb1­4GlcNAcb1-2Man-a1-3)Manb1-4GlcNAcb1-4GlcNAcb-Sp21 3 3 84
556 Neu5Gca2-8Neu5Gca2-3Galb1-4GlcNAcb1-3Galb1-4GlcNAc-Sp0 3 2 76
Fuca1-2Galb1-4GlcNAcb1-2Mana1-6(Fuca1-2Galb1-4GlcNAcb1-
2Mana1-3)Manb1-4GlcNAcb1-4(Fuca1-6)GlcNAcb-Sp22	 3 5 149
Galb1-4GlcNAcb1-3Galb1-4(Fuca1-3)GlcNAcb1-3Galb1-4(Fuca1­162	 3 2 753)GlcNAcb-Sp0
371
GalNAca1-3(Fuca1-2)Galb1-4GlcNAcb1-2Mana1-6(GalNAca1­
3(Fuca1-2)Galb1-4GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1­
4GlcNAcb-Sp20
3 5 145
329 Neu5,9Ac2a2-3Galb1-4GlcNAcb-Sp0	 3 1 43
303 Galb1-4GlcNAcb1-6(Galb1-4GlcNAcb1-3)Galb1-4GlcNAc-Sp0 3 7 227
344 GlcNAca1-4Galb1-4GlcNAcb1-3Galb1-4GlcNAcb-Sp0	 3 2 82
240 Neu5Aca2-3Galb1-3(Fuca1-4)GlcNAcb-Sp8 3 4 140
Neu5Aca2-6Galb1-4GlcNAcb1-2Mana1-6(Neu5Aca2-3Galb1­319	 3 24GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-Sp12
606 Neu5Aca2-6Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-6(Neu5Aca2­6Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3)GalNAca-Sp14 3 3 116
263 Fuca1-2Galb1-4(6S)Glcb-Sp0 3 4 148
215 Mana1-2Mana1-2Mana1-6(Mana1-3)Mana-Sp9 3 1 46
Neu5Aca2-6Galb1-4GlcNAcb1-2Mana1-6(Neu5Aca2-6Galb1­
483	 4GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4(Fuca1-6)GlcNAcb- 3 5 175
Sp24
196 Glca1-4Glcb-Sp8	 3 3 101
163 Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb-Sp0 3 7 247
272 Neu5Aca2-6Galb1-4GlcNAcb1-3Galb1-4GlcNAcb-Sp0 3 1 52
568 Galb1-3GlcNAcb1-6(Galb1-3)GalNAc-Sp14	 3 2 87
245 Neu5Aca2-6(Neu5Aca2-3Galb1-3)GalNAca-Sp14 3 4 159
320
131
Galb1-4GlcNAcb1-2Mana1-6(Neu5Aca2-6Galb1-4GlcNAcb1­
2Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-Sp12
Fuca1-4(Galb1-3)GlcNAcb-Sp8
3
3
2
2
71
87
212 Mana1-2Mana1-6(Mana1-3)Mana1-6(Mana1-2Mana1-2Mana1­3)Manb1-4GlcNAcb1-4GlcNAcb-Sp12 3 2 69
243 Neu5Aca2-3Galb1-3(6S)GalNAca-Sp8 3 3
GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-6(GlcNAcb1-3Galb1­540	 3 6 2284GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-Sp12
406 Gala1-3Galb1-4GlcNAcb1-3GalNAca-Sp14 3 7 284
554 Neu5Aca2-8Neu5Gca2-3Galb1-4GlcNAc-Sp0	 3 7 281
437 Galb1-4GlcNAcb1-2Mana1-6(GlcNAcb1-4)(Galb1-4GlcNAcb1-4(Galb1-4GlcNAcb1-2)Mana1-3)Manb1-4GlcNAcb1-4GlcNAc-Sp21 3 3
GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-6(GlcNAcb1-3Galb1­541	 3 24GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-Sp25
44 (6S)Galb1-4GlcNAcb-Sp8 3 3 120
12 Galb-Sp8	 2 2 66
605 GlcNAcb1-6(Neu5Aca2-3Galb1-3)GalNAca-Sp14 2 4 176
484
Neu5Aca2-3Galb1-4GlcNAcb1-2Mana1-6(Neu5Aca2-3Galb1­
4GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4(Fuca1-6)GlcNAcb­ 2 6 266
Sp24
502 Fuca1-2(6S)Galb1-3(6S)GlcNAcb-Sp0 2 4 152
481
314
Neu5Aca2-6Galb1-4GlcNAcb1-6GalNAca-Sp14
Mana1-6Manb-Sp10
2
2
3
1
127
51
410 Gala1-3(Fuca1-2)Galb1-4(Fuca1-3)Glcb-Sp21 2 5 218
75 Fuca1-2Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb­Sp0 2 6 278
458
GalNAca1-3(Fuca1-2)Galb1-3GlcNAcb1-2Mana1-6(GalNAca1­
3(Fuca1-2)Galb1-3GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1­ 2 5 202
4(Fuca1-6)GlcNAcb-Sp22
116 Gala1-3Galb1-4GlcNAcb-Sp8 2 4 190
Neu5Gca2-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1­
544 6(Neu5Gca2-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1­
3)Manb1-4GlcNAcb1-4GlcNAcb-Sp24
2 1 55
599 GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3GalNAca-Sp14 2 6
171 Galb1-4GlcNAcb-Sp23	 2 4 189
233 GalNAcb1-4(Neu5Aca2-3)Galb1-4GlcNAcb-Sp8 2 7
186 GlcNAcb1-3Galb1-4Glcb-Sp0 2 2 119
562 GlcNAcb1-3Galb1-4GlcNAcb1-6(GlcNAcb1-3Galb1-3)GalNAca­ 2 2 124
244
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Appendix
Sp14
563 GalNAcb1-3GlcNAcb-Sp0 2 2 112
36 (3S)Galb1-4GlcNAcb-Sp0 2 2
216 Mana1-6(Mana1-3)Mana1-6(Mana1-2Mana1-3)Manb1-4GlcNAcb1­4GlcNAcb-Sp12 2 3 163
488 3)GlcNAcb1-3)Galb1-4Glc-Sp21 2 2 134
114 Gala1-3Galb1-4(Fuca1-3)GlcNAcb-Sp8 2 2 115
Neu5Aca2-6Galb1-4GlcNAcb1-6(Fuca1-2Galb1-4(Fuca1-
519 (6P)Galb1-4GlcNAcb-SP0 2 4
Mana1-6(Mana1-3)Mana1-6(Mana1-3)Manb1-4GlcNAcb1­ 2 4 2604GlcNAcb-Sp12
434 2Mana1-3)Manb1-4GlcNAcb1-4GlcNAc-Sp21 2 4 272
296 Neu5Aca2-3Galb1-4GlcNAcb1-3Galb1-3GlcNAcb-Sp0 1 2 167
GlcNAcb1-6(GlcNAcb1-2)Mana1-6(GlcNAcb1-4)(GlcNAcb1-
337 3Galb1-4GlcNAcb-Sp0 1 3 183
390 Fuca1-2Galb1-3GalNAca1-3(Fuca1-2)Galb1-4Glcb-Sp0 1 3 199
GalNAca1-3(Fuca1-2)Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-
336 GalNAca1-3(Fuca1-2)Galb1-4GlcNAcb1-3Galb1-4GlcNAcb-Sp0 1 2 161
378 Neu5Aca2-6Galb1-4GlcNAcb1-3GalNAc-Sp14 1 2 240
327 Neu5Aca2-3Galb1-4GlcNAcb1-2Mana1-6(Neu5Aca2-6Galb1­4GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-Sp12 1 3 352
323 Neu5Aca2-8Neu5Aca2-8Neu5Acb-Sp8 1 5 561
555 Neu5Gca2-8Neu5Aca2-3Galb1-4GlcNAc-Sp0 1 2 268
68
393
Fuca1-2Galb1-3GlcNAcb-Sp0
GalNAcb1-4(Neu5Aca2-3)Galb1-4GlcNAcb1-3GalNAca-Sp14
1
1
1
2
114
225
358 KDNa2-6Galb1-4GlcNAc-Sp0 1 1 134
236 Neu5Aca2-6(Neu5Aca2-3)GalNAca-Sp8 1 3 355
564 GalNAcb1-4GlcNAcb1-3GalNAcb1-4GlcNAcb-Sp0 1 1 217
92 GalNAca1-3GalNAcb-Sp8 0 1 632
83 GalNAca1-3(Fuca1-2)Galb1-3GlcNAcb-Sp0 0 2 859
180 GlcNAcb1-3GalNAca-Sp8 -1 3 -438
595 GlcNAcb1-3Galb1-4GlcNAcb1-6(Galb1-3)GalNAca-Sp14 -1 7 -963
242 Neu5Aca2-3Galb1-4(Neu5Aca2-3Galb1-3)GlcNAcb-Sp8 -1 3 -232
428
Gala1-3(Fuca1-2)Galb1-4GlcNAcb1-2Mana1-6(Gala1-3(Fuca1­
2)Galb1-4GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4(Fuca1­ -1 2 -141
6)GlcNAcb-Sp22
104 Gala1-3(Fuca1-2)Galb1-4(Fuca1-3)GlcNAcb-Sp0 -2 3
245
 
-179
  
 
 
 
 
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
 
 
   
 
 
   
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
 
 
   
     
 
 
   
     
    
Appendix
mMGL-2 FITC
Chart Glycan structure	 Average RFU StDev % CVNumber
193 GlcNAcb1-6GalNAca-Sp8 524 99 19
96 GalNAcb1-3(Fuca1-2)Galb-Sp8 495 5 1
563 GalNAcb1-3GlcNAcb-Sp0 410 36 9
4 GalNAca-Sp8 331 80 24
132 Galb1-4GlcNAcb1-6GalNAca-Sp8 318 45 14
100 GalNAcb1-4GlcNAcb-Sp8 282 9 3
99 GalNAcb1-4GlcNAcb-Sp0 234 64 28
307 GalNAcb1-3Galb-Sp8 227 41 18
564 GalNAcb1-4GlcNAcb1-3GalNAcb1-4GlcNAcb-Sp0 108 45 42
495 Fuca1-2Galb1-4GlcNAcb1-6GalNAca-Sp14 92 38 41
15
194 GlcNAcb1-6GalNAca-Sp14
87
80
4
12
5
15
489 Galb1-3GlcNAcb1-6GalNAca-Sp14 78 14 18
515 GalNAcb1-4(6S)GlcNAc-Sp8 73 23 31
453
260 Neu5Aca2-3Galb1-4GlcNAcb-Sp0
65
55
51
58
79
106
513 (6S)GalNAcb1-4GlcNAc-Sp8 53 8 15
308 GlcAb1-3GlcNAcb-Sp8 49 75 155
477 2Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-Sp21 47 31 67
93 GalNAca1-3Galb-Sp8 46 14 31
496 Gala1-3Galb1-4GlcNAcb1-6GalNAca-Sp14 44 22 49
GalNAcb-Sp8
Neu5Aca2-8Neu5Aca2-3Galb1-3GalNAcb1-4(Neu5Aca2-
8Neu5Aca2-3)Galb1-4Glcb-Sp0
Galb1-3GlcNAcb1-2Mana1-6(GlcNAcb1-4)(Galb1-3GlcNAcb1-
97	 GalNAcb1-3Gala1-4Galb1-4GlcNAcb-Sp0 44 33 76
Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1­
26 58
4GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-6(Galb1-4GlcNAcb1-
582 3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1­ 44
3Galb1-4GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4(Fuca1-
6)GlcNAcb-Sp19
 
Neu5Aca2-6Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1­
4GlcNAcb1-2Mana1-6(Neu5Aca2-6Galb1-4GlcNAcb1-3Galb1­607	 42 8 204GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1­
4GlcNAcb-Sp12
 
239 Neu5Aca2-3Galb1-3(6S)GlcNAc-Sp8 36 48 132
538 Gala1-3(Fuca1-2)Galb1-3GalNAcb1-3Gala1-4Galb1-4Glc-Sp21 36 24 67
167
87 GalNAca1-3(Fuca1-2)Galb1-4GlcNAcb-Sp8
35
34
19
15
54
45
529 GalNAcb1-4GlcNAcb1-2Mana-Sp0 33 11 32
283 Neu5Gca2-3Galb1-4(Fuca1-3)GlcNAcb-Sp0 32 15 47
98 GalNAcb1-4(Fuca1-3)GlcNAcb-Sp0 32 34 106
539 Galb1-3GalNAcb1-3Gal-Sp21 31 11 36
493
480 Neu5Aca2-3Galb1-4GlcNAcb1-6GalNAca-Sp14
31
30
4
15
12
50
353 4(Fuca1-6)GlcNAcb-Sp22 29 7 25
315 Mana1-6(Mana1-3)Mana1-6(Mana1-3)Manb-Sp10 29 29 97
145 Galb1-3GalNAcb1-4(Neu5Aca2-3)Galb1-4Glcb-Sp0 29 30 104
111 Gala1-3GalNAca-Sp8 28 5 18
286 Neu5Gca2-6GalNAca-Sp0 28 11 40
5 GalNAca-Sp15 28 16 56
Galb1-4GlcNAcb1-6(Galb1-3)GalNAca-Sp8
(3S)Galb1-3(Fuca1-4)GlcNAcb-Sp0
GlcNAcb1-2Mana1-6(GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-
579
GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1­
4GlcNAcb1-2Mana1-6(GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1­
4GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1­
4(Fuca1-6)GlcNAcb-Sp24
28 13 47
(3S)Galb1-4(6S)Glcb-Sp0	 27 14 52
544
Neu5Gca2-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1­
6(Neu5Gca2-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1­
3)Manb1-4GlcNAcb1-4GlcNAcb-Sp24
27 15 55
Mana1-6(Galb1-4GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1­352	 27 15 554GlcNAcb-Sp12
576 Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-6(Galb1­4GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1­ 27 11 43
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Appendix
4(Fuca1-6)GlcNAcb-Sp24
408 Galb1-3GlcNAca1-6Galb1-4GlcNAcb-Sp0	 26 8 33
183 GlcNAcb1-3Galb1-4GlcNAcb-Sp0 26 21
470 Glca1-6Glca1-6Glca1-6Glcb-Sp10	 26 7 28
541 GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-6(GlcNAcb1-3Galb1­4GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-Sp25 26 13 52
490 Gala1-3Galb1-3GlcNAcb1-6GalNAca-Sp14	 25 13 53
592 Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-6(Galb1-4GlcNAcb1­3Galb1-4GlcNAcb1-3)GalNAca-Sp14 25 5 21
492 Neu5Aca2-3Galb1-3GlcNAcb1-6GalNAca-Sp14	 24 5 20
181 GlcNAcb1-3GalNAca-Sp14 24 8 32
560
Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-6(Galb1-4GlcNAcb1­
3Galb1-4GlcNAcb1-2)Mana1-6(Galb1-4GlcNAcb1-3Galb1­ 24 16 68
4GlcNAcb1-2Mana1-3)Mana1-4GlcNAcb1-4GlcNAc-Sp24
500 Fuca1-2Galb1-4GlcNAcb1-2Mana-Sp0 23 17 72
GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-6(GlcNAcb1-3Galb1­
575	 4GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4(Fuca1-6)GlcNAcb- 23 15 65
Sp24
292 Galb1-4(Fuca1-3)(6S)Glcb-Sp0 23 9 38
522 Gala1-3Galb1-4GlcNAcb1-2Mana-Sp0 23 8 36
125 Gala1-6Glcb-Sp8 23 15 68
Galb1-4GlcNAcb1-6(Galb1-4GlcNAcb1-2)Mana1-6(GlcNAcb1­
439	 4)(Galb1-4GlcNAcb1-4(Galb1-4GlcNAcb1-2)Mana1-3)Manb1- 22 18 79
4GlcNAcb1-4GlcNAc-Sp21
81 Fuca1-4GlcNAcb-Sp8 22 25 114
223 Fuca1-2(6S)Galb1-4(6S)Glcb-Sp0	 22 7 33
502 Fuca1-2(6S)Galb1-3(6S)GlcNAcb-Sp0 22 19 86
143 Galb1-3GalNAcb-Sp8	 22 8 37
473
Fuca1-2Galb1-4(Fuca1-3)GlcNAcb1-2Mana1-6(Fuca1-2Galb1­
4(Fuca1-3)GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4(Fuca1­
6)GlcNAcb-Sp24
22 7 31
94 GalNAca1-4(Fuca1-2)Galb1-4GlcNAcb-Sp8	 22 16 75
65 Fuca1-2Galb1-3GalNAcb1-4(Neu5Aca2-3)Galb1-4Glcb-Sp9 22 7 33
GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1­
565 4GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-6(GlcNAcb1-3Galb1­4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1­ 22 10 47
4GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-Sp25
549
Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1­
2Mana1-6(Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1­
4GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-Sp24
21 8 37
105 Gala1-3(Fuca1-2)Galb1-4(Fuca1-3)GlcNAcb-Sp8	 21 13 60
338 3)GalNAc-Sp14 21 9 43
131 Fuca1-4(Galb1-3)GlcNAcb-Sp8 21 8 36
Neu5Aca2-3Galb1-4(Fuca1-3)GlcNAcb1-6(Neu5Aca2-3Galb1-
407 Galb1-3GlcNAcb1-6Galb1-4GlcNAcb-Sp0 21 16 78
331 Neu5Aca2-6Galb1-4GlcNAcb1-3Galb1-3GlcNAcb-Sp0	 21 14 69
578
Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1­
2Mana1-6(Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1­
4GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4(Fuca1-6)GlcNAcb­
Sp24
21 14 68
409 GalNAcb1-3Gala1-6Galb1-4Glcb-Sp8	 21 11 54
608
Neu5Aca2-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1­
4GlcNAcb1-2Mana1-6(Neu5Aca2-3Galb1-4GlcNAcb1-3Galb1­
4GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1­
4GlcNAcb-Sp12
21 10 49
9 Neu5Aca-Sp8	 21 14 67
61 Fuca1-2Galb1-3(Fuca1-4)GlcNAcb-Sp8 21 8
595 GlcNAcb1-3Galb1-4GlcNAcb1-6(Galb1-3)GalNAca-Sp14 21 13 61
609
Neu5Aca2-6Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1­
6(Neu5Aca2-6Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1­
3)Manb1-4GlcNAcb1-4GlcNAcb-Sp12
21 12 59
Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1­
548	 2Mana1-6(Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1- 21 5 25
4GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-Sp12
Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1­ 20 5 234GlcNAcb1-2Mana1-6(Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1­
247
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Appendix
3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-3)Manb1­
4GlcNAcb1-4(Fuca1-6)GlcNAcb-Sp24
GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1­
547 6(GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1­ 20 3 13
3)Manb1-4GlcNAcb1-4GlcNAcb-Sp25
293 Galb1-4(Fuca1-3)GlcNAcb1-3Galb1-3(Fuca1-4)GlcNAcb-Sp0 20 8 37
144 Galb1-3GalNAcb1-3Gala1-4Galb1-4Glcb-Sp0 20 8 39
603 Neu5Aca2-6Galb1-4GlcNAcb1-6(Galb1-3)GalNAca-Sp14 20 8 42
376 Fuca1-4(Fuca1-2Galb1-3)GlcNAcb1-2Mana1-3(Fuca1-4(Fuca1­2Galb1-3)GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-Sp19 20 6 30
108 Gala1-3(Fuca1-2)Galb-Sp8 20 7 33
166 Galb1-4GlcNAcb1-3Galb1-4Glcb-Sp8 20 25 123
568 Galb1-3GlcNAcb1-6(Galb1-3)GalNAc-Sp14 20 10 49
274 Neu5Aca2-6Galb1-4Glcb-Sp8 20 8 42
13 20 7 33
459 Galb1-4GlcNAcb1-6(Galb1-4GlcNAcb1-2)Mana1-6(Galb1­4GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-Sp19 20 15 76
520 GalNAca1-3(Fuca1-2)Galb1-4GlcNAcb1-6GalNAc-Sp14 20 16 83
481 Neu5Aca2-6Galb1-4GlcNAcb1-6GalNAca-Sp14 20 7 38
499
359 KDNa2-3Galb1-4Glc-Sp0
19
19
7
14
35
74
497 Galb1-4(Fuca1-3)GlcNAcb1-2Mana-Sp0 19 10 49
289 Neu5Aca2-3Galb1-4GlcNAcb1-6(Galb1-3)GalNAca-Sp14 19 7 38
244
526 Gala1-3(Fuca1-2)Galb1-3GlcNAcb1-6GalNAc-Sp14
19
19
13
5
65
28
228 Neu5Aca2-8Neu5Aca2-8Neu5Aca2-3Galb1-4Glcb-Sp0 19 8 45
GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1­
4GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-6(GlcNAcb1-3Galb1­
581 4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1­ 19 5 29
4GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4(Fuca1-6)GlcNAcb­
Sp19
7 Fuca-Sp9 19 14 75
Neu5Aca2-3Galb1-4GlcNAcb1-6(Neu5Aca2-3Galb1-4GlcNAcb1­
463 2)Mana1-6(GlcNAcb1-4)(Neu5Aca2-3Galb1-4GlcNAcb1­4(Neu5Aca2-3Galb1-4GlcNAcb1-2)Mana1-3)Manb1-4GlcNAcb1­ 19 16 87
4GlcNAcb-Sp21
127 Galb1-3(Fuca1-4)GlcNAcb1-3Galb1-4(Fuca1-3)GlcNAcb-Sp0 19 14 73
22 6S(3S)Galb1-4(6S)GlcNAcb-Sp0 18 15 83
591 Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-6(Galb1-3)GalNAca-Sp14 18 4 22
437 Galb1-4GlcNAcb1-2Mana1-6(GlcNAcb1-4)(Galb1-4GlcNAcb1­4(Galb1-4GlcNAcb1-2)Mana1-3)Manb1-4GlcNAcb1-4GlcNAc-Sp21 18 12 68
203 GlcAb-Sp8 18 7 40
GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1­
4GlcNAcb1-3Galb1-4GlcNAcb1-6(GlcNAcb1-3Galb1-4GlcNAcb1­
588 3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAb1­ 18 4 24
2)Mana1-6(GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1­
3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-3)Manb
Glcb-Sp8
Gala1-3(Fuca1-2)Galb1-4GlcNAcb1-6GalNAca-Sp14
Neu5Aca2-6(Neu5Aca2-3Galb1-3)GalNAca-Sp8
475
Neu5Aca2-3Galb1-3GlcNAcb1-6(Neu5Aca2-3Galb1-4GlcNAcb1­
2)Mana1-6(Neu5Aca2-3Galb1-3GlcNAcb1-2Mana1-3)Manb1­
4GlcNAcb1-4GlcNAcb-Sp19
18 6 34
64 Fuca1-2Galb1-3GalNAcb1-4(Neu5Aca2-3)Galb1-4Glcb-Sp0 18 3 18
38 (3S)Galb-Sp8 18 8 47
27 (3S)Galb1-4(6S)Glcb-Sp8 18 18 100
386 18 5 28
213 Mana1-2Mana1-6(Mana1-2Mana1-3)Mana1-6(Mana1-2Mana1­2Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-Sp12 18 10 59
Galb1-4(Fuca1-3)GlcNAcb1-6(Fuca1-4(Fuca1-2Galb1-3)GlcNAcb1-
3)Galb1-4Glc-Sp21
57 Neu5Aca2-6Galb1-4GlcNAcb1-2Mana1-6(Neu5Aca2-6Galb1­4GlcNAcb1-2Man-a1-3)Manb1-4GlcNAcb1-4GlcNAcb-Sp21 18 7 41
10 Neu5Aca-Sp11 17 7 39
334 Gala1-4Galb1-4GlcNAcb1-3Galb1-4Glcb-Sp0 17 15 85
471 Glca1-4Glca1-4Glca1-4Glcb-Sp10 17 16 94
379 Neu5Aca2-3Galb1-4(Fuca1-3)GlcNAcb1-3GalNAca-Sp14 17 13 79
433 GlcNAcb1-2Mana1-6(GlcNAcb1-4)(GlcNAcb1-4(GlcNAcb1­2)Mana1-3)Manb1-4GlcNAcb1-4GlcNAc-Sp21 17 8 46
76 Fuca1-2Galb1-4GlcNAcb-Sp0 17 10 60
248
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Appendix
Fuca1-2Galb1-4GlcNAcb1-2Mana1-6(Fuca1-2Galb1-4GlcNAcb1­362 17 6 372Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-Sp20
501 Fuca1-2Galb1-3(6S)GlcNAcb-Sp0 17 9
479 Neu5Aca2-3Galb1-4GlcNAcb1-2Mana-Sp0 17 8 46
405 Gala1-4Galb1-4GlcNAcb1-2Mana1-6(Gala1-4Galb1-4GlcNAcb1­2Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-Sp24 17 13 79
140 Galb1-3GalNAca-Sp8 17 9 56
594 GlcNAcb1-3Galb1-4GlcNAcb1-3GalNAca-Sp14 17 9 52
GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1­
546 6(GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1­
3)Manb1-4GlcNAcb1-4GlcNAcb-Sp12
17 8 48
39 (6S)(4S)Galb1-4GlcNAcb-Sp0 16 4 23
210 Mana1-2Mana1-3Mana-Sp9 16 16 97
185 GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb-Sp0 16 10 61
186 GlcNAcb1-3Galb1-4Glcb-Sp0 16 6 35
552
Galb1-3GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-6(Galb1­
3GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1­
4GlcNAc-Sp25
16 5 29
164 Galb1-4GlcNAcb1-3Galb1-4GlcNAcb-Sp0 16 6 35
291 Galb1-4(Fuca1-3)(6S)GlcNAcb-Sp0 16 8 53
507 GalNAca1-3(Fuca1-2)Galb1-3GlcNAcb1-6GalNAca-Sp14 16 4 26
503 Neu5Aca2-6GalNAcb1-4(6S)GlcNAcb-Sp8 16 13 83
162 Galb1-4GlcNAcb1-3Galb1-4(Fuca1-3)GlcNAcb1-3Galb1-4(Fuca1­3)GlcNAcb-Sp0 16 14 90
429 3GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-Sp19 16 5 31
361 Fuca1-2Galb1-3GlcNAcb1-2Mana1-6(Fuca1-2Galb1-3GlcNAcb1­2Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-Sp20 16 10 62
Galb1-3GlcNAcb1-6(Galb1-3GlcNAcb1-2)Mana1-6(Galb1-
535 Neu5Aca2-3Galb1-4(Fuca1-3)GlcNAcb1-2Mana-Sp0 16 6
Neu5Aca2-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-6(Neu5Aca2­597 16 113Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3)GalNAca-Sp14
178 GlcNAcb1-6(GlcNAcb1-3)GalNAca-Sp14 15 17
Neu5Aca2-3Galb1-4(Fuca1-3)GlcNAcb1-3Galb1-4(Fuca1­254 15 43)GlcNAcb1-3Galb1-4(Fuca1-3)GlcNAcb-Sp0
120 Gala1-4(Fuca1-2)Galb1-4GlcNAcb-Sp8 15 10 62
Neu5Aca2-6Galb1-4GlcNAcb1-2Mana1-6(Neu5Aca2-6Galb1­55 15 104GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-Sp12
30 (3S)Galb1-3GlcNAcb-Sp0 15 11 71
445 (6S)Galb1-3(6S)GlcNAc-Sp0 15 7 44
456
Gala1-3(Fuca1-2)Galb1-3GlcNAcb1-2Mana1-6(Gala1-3(Fuca1­
2)Galb1-3GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4(Fuca1­
6)GlcNAcb-Sp22
15 8 52
14 Manb-Sp8 15 12 83
104 Gala1-3(Fuca1-2)Galb1-4(Fuca1-3)GlcNAcb-Sp0 15 14 96
Neu5Aca2-6Galb1-4GlcNAcb1-6(Galb1-3GlcNAcb1-3)Galb1-4Glcb­478 15 5Sp21
559
GlcNAcb1-3Galb1-4GlcNAcb1-6(GlcNAcb1-3Galb1-4GlcNAcb1­
2)Mana1-6(GlcNAcb1-3Galb1-4GlcNAcb1-2Man a1-3)Manb1­
4GlcNAcb1-4GlcNAc-Sp24
15 7 44
121 Gala1-4Galb1-4GlcNAcb-Sp0 15 21 144
119 Gala1-3Galb-Sp8 15 9 58
GlcNAcb1-2Mana1-6(GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1­52 15 44GlcNAcb-Sp12
221 Fuca1-2(6S)Galb1-4GlcNAcb-Sp0 15 12
GlcNAca1-4Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1­339 15 74GlcNAcb-Sp0
488 3)GlcNAcb1-3)Galb1-4Glc-Sp21 15 5 32
19 Galb1-4GlcNAcb1-6(Galb1-4GlcNAcb1-3)GalNAca-Sp8 15 15 99
Neu5Aca2-6Galb1-4GlcNAcb1-6(Fuca1-2Galb1-4(Fuca1-
600 Galb1-4GlcNAcb1-3Galb1-3GalNAca-Sp14 15 13
209 Mana1-2Mana1-6(Mana1-2Mana1-3)Mana-Sp9 15 11 74
GlcNAcb1-6(GlcNAcb1-2)Mana1-6(GlcNAcb1-4)(GlcNAcb1- 15 8 574(GlcNAcb1-2)Mana1-3)Manb1-4GlcNAcb1-4GlcNAc-Sp21
Galb1-4GlcNAcb1-2Mana1-6(GlcNAcb1-2Mana1-3)Manb1­399 14 9 624GlcNAcb1-4GlcNAc-Sp12
450 Fuca1-2Galb1-4GlcNAcb1-6(Fuca1-2Galb1-4GlcNAcb1-3)GalNAc­ 14 4 28
249
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Appendix
Sp14
45 (6S)Galb1-4(6S)Glcb-Sp8 14 3 22
37 (3S)Galb1-4GlcNAcb-Sp8 14 8
18 GlcN(Gc)b-Sp8 14 6 43
372 Gala1-3(Fuca1-2)Galb1-4GlcNAcb1-2Mana1-6(Gala1-3(Fuca1­2)Galb1-4GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-Sp20 14 3 22
Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-6(Galb1-4GlcNAcb1­
3Galb1-4GlcNAb1-2)Mana1-6(Galb1-4GlcNAcb1-3Galb1­583 14 14 984GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4(Fuca1-6)GlcNAcb­
Sp24
 
70 Fuca1-2Galb1-4(Fuca1-3)GlcNAcb1-3Galb1-4(Fuca1-3)GlcNAcb­Sp0 14 7 47
444 (6S)Galb1-3GlcNAcb-Sp0 14 4 29
62 Fuca1-2Galb1-3GalNAca-Sp8 14 7 47
182 GlcNAcb1-3Galb-Sp8 14 12 81
610 GlcNAcb1-3Fuca-Sp21 14 11 77
134 GlcNAcb1-6(Galb1-3)GalNAca-Sp8 14 6 39
301 Galb1-3Galb1-4GlcNAcb-Sp8 14 8 58
60 Fuca1-2Galb1-3GalNAcb1-3Gala1-4Galb1-4Glcb-Sp9 14 6 43
114 Gala1-3Galb1-4(Fuca1-3)GlcNAcb-Sp8 14 9 62
12 Galb-Sp8 14 6 41
249 Fuca1-2(6S)Galb1-4Glcb-Sp0 14 5 37
Neu5Aca2-3Galb1-3GlcNAcb1-2Mana1-6(Neu5Aca2-3Galb1­397 14 8 573GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4GlcNAc-Sp19
11 Neu5Acb-Sp8 14 13 94
21 GlcNAcb1-6(GlcNAcb1-4)(GlcNAcb1-3)GlcNAc-Sp8 14 8 56
320 2Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-Sp12 14 11 80
454 GalNAcb1-4Galb1-4Glcb-Sp0 14 6 47
Galb1-4GlcNAcb1-2Mana1-6(Neu5Aca2-6Galb1-4GlcNAcb1-
378 Neu5Aca2-6Galb1-4GlcNAcb1-3GalNAc-Sp14 13 7 50
103 Gala1-3(Fuca1-2)Galb1-3GlcNAcb-Sp8 13 6 48
199 Glcb1-4Glcb-Sp8 13 9 68
300 Neu5Aca2-3Galb1-4(Fuca1-3)GlcNAcb1-6(Galb1-3)GalNAca-Sp14 13 7 54
518 Galb1-4(6P)GlcNAcb-Sp0 13 10 73
Neu5Aca2-3Galb1-3(Fuca1-4)GlcNAcb1-3Galb1-3(Fuca1­332 13 54)GlcNAcb-Sp0
590 Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3GalNAca-Sp14 13 5 38
135 GlcNAcb1-6(Galb1-3)GalNAca-Sp14 13 5 35
412 Galb1-3GalNAcb1-4(Neu5Aca2-8Neu5Aca2-3)Galb1-4Glcb-Sp0 13 2 18
504 GalNAcb1-4(Fuca1-3)(6S)GlcNAcb-Sp8 13 12 87
196 Glca1-4Glcb-Sp8 13 6 43
24 (3S)Galb1-4(Fuca1-3)(6S)Glc-Sp0 13 12 90
400 Neu5Aca2-3Galb1-3GlcNAcb1-3GalNAca-Sp14 13 6 46
Neu5Aca2-3Galb1-4GlcNAcb1-6(Neu5Aca2-3Galb1-4GlcNAcb1­472 13 3 273)GalNAca-Sp14
40 (4S)Galb1-4GlcNAcb-Sp8 13 12 89
555 Neu5Gca2-8Neu5Aca2-3Galb1-4GlcNAc-Sp0 13 6 47
130 Galb1-3(Fuca1-4)GlcNAc-Sp8 13 5 36
Galb1-4GlcNAcb1-2Mana1-6(Galb1-4GlcNAcb1-2Mana1-3)Manb1­354 13 12 92
Gala1-3Galb1-3GlcNAcb1-2Mana1-6(Gala1-3Galb1-3GlcNAcb1-
4GlcNAcb1-4(Fuca1-6)GlcNAcb-Sp22
395 13 9 672Mana1-3)Manb1-4GlcNAcb1-4GlcNAc-Sp19
34 (3S)Galb1-4(6S)GlcNAcb-Sp0 13 6 45
195 GlcNAcb1-6Galb1-4GlcNAcb-Sp8 13 6 44
Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1­
551 4GlcNAcb1-2Mana1-6(Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1­3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-3)Manb1­
4GlcNAcb1-4GlcNAcb-Sp25
13 6 44
28 (3S)Galb1-3(Fuca1-4)GlcNAcb-Sp8 13 5
382 Galb1-3GalNAca1-3(Fuca1-2)Galb1-4GlcNAc-Sp0 13 13 98
387 Galb1-3GlcNAcb1-3Galb1-4(Fuca1-3)GlcNAcb1-6(Galb1­3GlcNAcb1-3)Galb1-4Glc-Sp21 13 10 76
246 Neu5Aca2-3Galb-Sp8 13 4 30
3 Mana-Sp8 13 7 53
245 Neu5Aca2-6(Neu5Aca2-3Galb1-3)GalNAca-Sp14 13 9 72
423 Fuca1-2Galb1-3GlcNAcb1-3GalNAc-Sp14 13 6 46
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Appendix
426 Gala1-3Galb1-3GlcNAcb1-3GalNAc-Sp14 13 4 34
343 GlcNAca1-4Galb1-4GlcNAcb1-3Galb1-4(Fuca1-3)GlcNAcb1­3Galb1-4(Fuca1-3)GlcNAcb-Sp0 13 5 40
355 Galb1-3GlcNAcb1-2Mana1-6(Galb1-3GlcNAcb1-2Mana1-3)Manb1­4GlcNAcb1-4(Fuca1-6)GlcNAcb-Sp22 13 4 31
148 Galb1-3GlcNAcb1-3Galb1-4GlcNAcb-Sp0 13 16 126
214 Mana1-6(Mana1-3)Mana-Sp9 13 3 23
312 GlcNAcb1-4GlcNAcb-Sp12 13 12 95
106 Gala1-3(Fuca1-2)Galb1-4GlcNAc-Sp0 13 3 24
88 GalNAca1-3(Fuca1-2)Galb1-4Glcb-Sp0 13 5 39
281 Neu5Gca2-3Galb1-3(Fuca1-4)GlcNAcb-Sp0 13 13 105
566
Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1­
4GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-6(Galb1-4GlcNAcb1­
3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1­
3Galb1-4GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-Sp25
12 7 53
285 Neu5Gca2-3Galb1-4Glcb-Sp0 12 16 126
275 Neu5Aca2-6Galb-Sp8 12 8 68
531 GlcNAcb1-2 Mana1-6(GlcNAcb1-4)(GlcNAcb1-2Mana1-3)Manb1­4GlcNAcb1-4(Fuca1-6)GlcNAc-Sp21 12 5 38
20 Galb1-4GlcNAcb1-6(Galb1-4GlcNAcb1-3)GalNAc-Sp14 12 5 39
GlcNAcb1-6(GlcNAcb1-2)Mana1-6(GlcNAcb1-2Mana1-3)Manb1­476	 12 5 424GlcNAcb1-4(Fuca1-6)GlcNAcb-Sp24
 
Galb1-3GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1­
572 12
6(Galb1-3GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAb1-
2)Mana1-6(Galb1-3GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-
4GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4(Fuca1-6)GlcNAcb-
5 44
Sp24
126 Galb1-2Galb-Sp8 12 6 50
415 GalNAca1-3(Fuca1-2)Galb1-4GlcNAcb1-3GalNAca-Sp14 12 4 36
GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1­
577	 6(GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1- 12 13 109
3)Manb1-4GlcNAcb1-4(Fuca1-6)GlcNAcb-Sp24
122 Gala1-4Galb1-4GlcNAcb-Sp8 12 16 130
537 GalNAca1-3(Fuca1-2)Galb1-3GalNAcb1-3Gala1-4Galb1-4Glc-Sp21 12 6 54
75 Fuca1-2Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb­Sp0 12 8 66
50 Mana1-6(Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-Sp12	 12 4 32
324 Neu5Gcb2-6Galb1-4GlcNAc-Sp8 12 8 67
556 Neu5Gca2-8Neu5Gca2-3Galb1-4GlcNAcb1-3Galb1-4GlcNAc-Sp0 12 4 38
216 Mana1-6(Mana1-3)Mana1-6(Mana1-2Mana1-3)Manb1-4GlcNAcb1­4GlcNAcb-Sp12 12 2 16
302 Neu5Aca2-6Galb1-4GlcNAcb1-2Mana1-6(Galb1-4GlcNAcb1­2Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-Sp12 12 6 49
109 Gala1-3(Fuca1-2)Galb-Sp18 12 4 31
172 Galb1-4Glcb-Sp0 12 5 42
542
Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-6(Galb1­
4GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1­
4GlcNAcb-Sp12
12 3 23
514 (3S)GalNAcb1-4(3S)GlcNAc-Sp8 12 7 60
234
240 Neu5Aca2-3Galb1-3(Fuca1-4)GlcNAcb-Sp8
12
11
5
4
41
35
180 GlcNAcb1-3GalNAca-Sp8 11 8 69
384 Galb1-4(Fuca1-3)GlcNAcb1-6(Galb1-3GlcNAcb1-3)Galb1-4Glc­Sp21 11 3 24
GalNAcb1-4(Neu5Aca2-3)Galb1-4Glcb-Sp0
290 Galb1-3GlcNAcb1-3Galb1-3GlcNAcb-Sp0 11 8 68
346 Neu5Aca2-6Galb1-4GlcNAcb1-2Mana1-6(Mana1-3)Manb1­4GlcNAcb1-4GlcNAc-Sp12 11 8 67
530 Neu5Aca2-3Galb1-3GlcNAcb1-4Galb1-4Glcb-Sp0 11 7 66
328 Galb1-4(Fuca1-3)GlcNAcb1-2Mana1-6(Galb1-4(Fuca1­3)GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-Sp20 11 7 64
557 Neu5Gca2-8Neu5Gca2-6Galb1-4GlcNAc-Sp0 11 2 18
351 Galb1-4GlcNAcb1-2Mana1-6Manb1-4GlcNAcb1-4GlcNAc-Sp12 11 2 15
506 3)GalNAca-Sp14 11 7 66
419 GalNAca1-3(Fuca1-2)Galb1-4(Fuca1-3)GlcNAcb1-3GalNAc-Sp14 11 5 48
242 Neu5Aca2-3Galb1-4(Neu5Aca2-3Galb1-3)GlcNAcb-Sp8 11 3 24
Fuca1-2Galb1-3GlcNAcb1-6(Fuca1-2Galb1-3GlcNAcb1-
251
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Appendix
Neu5Aca2-6Galb1-4GlcNAcb1-2Mana1-6(Neu5Aca2-6Galb1­
483	 4GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4(Fuca1-6)GlcNAcb- 11 5 49
Sp24
Galb1-4GlcNAca1-6Galb1-4GlcNAcb-Sp0 11 6 58
GalNAcb1-4(Neu5Aca2-8Neu5Aca2-8Neu5Aca2-3)Galb1-4Glcb­227	 11 4 40Sp0
276 Neu5Aca2-8Neu5Aca-Sp8 11 3
6 Fuca-Sp8	 11 7 61
208 Mana1-2Mana1-2Mana1-3Mana-Sp9	 11 5
158 Galb1-4GalNAca1-3(Fuca1-2)Galb1-4GlcNAcb-Sp8	 11 8 69
313 MurNAcb1-4GlcNAcb-Sp10 11 9 85
294 Galb1-4GlcNAcb1-3Galb1-3GlcNAcb-Sp0	 11 7 66
428
Gala1-3(Fuca1-2)Galb1-4GlcNAcb1-2Mana1-6(Gala1-3(Fuca1­
2)Galb1-4GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4(Fuca1­
6)GlcNAcb-Sp22
11 3 27
198 Glca1-6Glca1-6Glcb-Sp8	 11 5 45
377 Neu5Aca2-3Galb1-4GlcNAcb1-3GalNAc-Sp14 11 8 75
Neu5Aca2-3Galb1-4GlcNAcb1-2Mana1-6(Neu5Aca2-3Galb1­
484	 4GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4(Fuca1-6)GlcNAcb- 11 3 29
Sp24
218 Manb1-4GlcNAcb-Sp0 11 9 85
311 GlcNAcb1-4GlcNAcb-Sp10	 11 9 79
446
Fuca1-2Galb1-4 GlcNAcb1-2Mana1-6(Fuca1-2Galb1-4GlcNAcb1­
2(Fuca1-2Galb1-4GlcNAcb1-4)Mana1-3)Manb1-4GlcNAcb1­
4GlcNAcb-Sp12
11 3 25
129 Galb1-3(Fuca1-4)GlcNAc-Sp0	 11 7 64
288 Neu5Gca-Sp8 11 2 23
16 GlcNAcb-Sp0	 11 4 41
424 Gala1-3(Fuca1-2)Galb1-3GlcNAcb1-3GalNAc-Sp14 11 4 41
235 Neu5Aca2-3Galb1-3GalNAcb1-4(Neu5Aca2-3)Galb1-4Glcb-Sp0 11 2 21
268 Neu5Aca2-6Galb1-4(6S)GlcNAcb-Sp8 11 10 92
505 (3S)GalNAcb1-4(Fuca1-3)GlcNAcb-Sp8	 11 8 74
192 GlcNAcb1-4GlcNAcb1-4GlcNAcb-Sp8 11 9 84
59 Fuca1-2Galb1-3GalNAcb1-3Gala-Sp9	 11 10 99
447
Fuca1-2Galb1-4(Fuca1-3)GlcNAcb1-2Mana1-6(Fuca1-2Galb1­
4(Fuca1-3)GlcNAcb1-4(Fuca1-2Galb1-4(Fuca1-3)GlcNAcb1­
2)Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-Sp12
11 6 58
160 Galb1-4GlcNAcb1-3GalNAca-Sp8	 11 6 61
Neu5Aca2-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1­259 4GlcNAcb-Sp0	 10 5
Neu5Aca2-3Galb1-4GlcNAcb1-2Mana1-6(Neu5Aca2-3Galb1­326	 10 54GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-Sp12
562 GlcNAcb1-3Galb1-4GlcNAcb1-6(GlcNAcb1-3Galb1-3)GalNAca­Sp14 10 11 104
Neu5Aca2-6Galb1-4GlcNAcb1-2Mana1-6(GlcNAcb1-2Mana1­309	 10 73)Manb1-4GlcNAcb1-4GlcNAcb-Sp12
23 6S(3S)Galb1-4GlcNAcb-Sp0 10 5
Neu5Aca2-8Neu5Aca2-3Galb1-3GalNAcb1-4(Neu5Aca2-3)Galb1­574	 10 44Glc-Sp21
335 GalNAcb1-3Gala1-4Galb1-4GlcNAcb1-3Galb1-4Glcb-Sp0 10 5 51
Neu5Aca2-3Galb1-3GalNAcb1-4(Neu5Aca2-8Neu5Aca2-3)Galb1­413	 10 74Glcb-Sp0
29 (3S)Galb1-3GalNAca-Sp8 10 7 72
102 Gala1-3(Fuca1-2)Galb1-3GlcNAcb-Sp0	 10 4 36
35 (3S)Galb1-4(6S)GlcNAcb-Sp8	 10 4 44
410 Gala1-3(Fuca1-2)Galb1-4(Fuca1-3)Glcb-Sp21	 10 7 66
110 Gala1-4(Gala1-3)Galb1-4GlcNAcb-Sp8 10 11
Fuca1-2Galb1-4GlcNAcb1-2Mana1-6(Fuca1-2Galb1-4GlcNAcb1­421	 10 5 522Mana1-3)Manb1-4GlcNAcb1-4(Fuca1-6)GlcNAcb-Sp22
330 Neu5,9Ac2a2-3Galb1-3GlcNAcb-Sp0 10 1 9
Mana1-2Mana1-6(Mana1-3)Mana1-6(Mana1-2Mana1-2Mana1­316	 10 18 1773)Mana-Sp9
220 (3S)Galb1-4(Fuca1-3)(6S)GlcNAcb-Sp8 10 3 31
344 GlcNAca1-4Galb1-4GlcNAcb1-3Galb1-4GlcNAcb-Sp0 10 10 96
314 Mana1-6Manb-Sp10 10 7 72
606 Neu5Aca2-6Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-6(Neu5Aca2- 10 9 88
252
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Appendix
6Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3)GalNAca-Sp14
171 Galb1-4GlcNAcb-Sp23 10 5
261 Neu5Aca2-3Galb1-4GlcNAcb-Sp8	 10 2 22
Gala1-3Galb1-4GlcNAcb1-2Mana1-6(Gala1-3Galb1-4GlcNAcb1-
2Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-Sp20	 10 7 69
206	 KDNa2-3Galb1-3GlcNAcb-Sp0 10 5 54
Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1­
587 10
3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1­
4 41
4GlcNAcb1-6(Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-
4GlcNAcb1-3Galb1-4GlcNAb1-2)Mana1-6(Galb1-4GlcNAcb1-
2Mana1-3)Manb1-4GlcNAcb1-4(Fuca1-6)GlcNAcb­
Galb1-3GlcNAcb1-3Galb1-4GlcNAcb1-6(Galb1-3GlcNAcb1­383	 10 11 1143)Galb1-4Glcb-Sp0
190 GlcNAcb1-4GlcNAcb1-4GlcNAcb1-4GlcNAcb1-4GlcNAcb1­4GlcNAcb1-Sp8 10 4 45
460 Neu5Aca2-3Galb1-4GlcNAcb1-2Mana1-6(GlcNAcb1-4)(Neu5Aca2­3Galb1-4GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-Sp21 10 6 64
78 Fuca1-2Galb1-4Glcb-Sp0 10 9 88
118 Gala1-3Galb1-4Glc-Sp10 10 8 82
430
89 GlcNAcb1-3Galb1-3GalNAca-Sp8
10
10
7
9
70
89
406 Gala1-3Galb1-4GlcNAcb1-3GalNAca-Sp14 10 2 22
219 Neu5Aca2-3Galb1-4GlcNAcb1-3Galb1-4(Fuca1-3)GlcNAcb-Sp0 10 9 93
394
270 Neu5Aca2-6Galb1-4GlcNAcb-Sp8
10
10
9
4
90
40
184 GlcNAcb1-3Galb1-4GlcNAcb-Sp8 10 5 52
347 Mana1-6(Neu5Aca2-6Galb1-4GlcNAcb1-2Mana1-3)Manb1­4GlcNAcb1-4GlcNAc-Sp12 10 7 77
Galb1-4GlcNAcb1-6(Fuca1-2Galb1-3GlcNAcb1-3)Galb1-4Glc-Sp21
GalNAca1-3(Fuca1-2)Galb1-3GalNAca1-3(Fuca1-2)Galb1-
4GlcNAcb-Sp0
465
Neu5Aca2-6Galb1-4GlcNAcb1-4Mana1-6(GlcNAcb1-4)(Neu5Aca2­
6Galb1-4GlcNAcb1-4(Neu5Aca2-6Galb1-4GlcNAcb1-2)Mana1­
3)Manb1-4GlcNAcb1-4GlcNAcb-Sp21
10 6 65
GlcNAcb1-2Mana1-6(GlcNAcb1-4(GlcNAcb1-2)Mana1-3)Manb1­389	 10 64GlcNAcb1-4GlcNAc-Sp21
77 Fuca1-2Galb1-4GlcNAcb-Sp8 10 9 97
521 Neu5Aca2-6Galb1-4GlcNAcb1-2Man-Sp0 10 10 109
86 GalNAca1-3(Fuca1-2)Galb1-4GlcNAcb-Sp0 10 5 48
487 Neu5Aca2-3Galb1-3GlcNAcb1-2Mana1-6(GlcNAcb1-4)(Neu5Aca2­3Galb1-3GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4GlcNAc-Sp21 10 4 37
256
123 Gala1-4Galb1-4Glcb-Sp0
10
10
8
10
79
109
411 Sp21 10 10 101
299 (6P)Glcb-Sp10 10 10 104
404 2Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-Sp19 10 5 51
319 Neu5Aca2-6Galb1-4GlcNAcb1-2Mana1-6(Neu5Aca2-3Galb1­4GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-Sp12 9 7 75
Neu5Aca2-3Galb1-4(Fuca1-3)GlcNAcb-Sp8
Galb1-4GlcNAcb1-6(Neu5Aca2-6Galb1-3GlcNAcb1-3)Galb1-4Glc-
Gala1-4Galb1-3GlcNAcb1-2Mana1-6(Gala1-4Galb1-3GlcNAcb1-
457 Neu5Aca2-6Galb1-4GlcNAcb1-6(Fuca1-2Galb1-3GlcNAcb1­3)Galb1-4Glc-Sp21 9 2 17
170 Galb1-4GlcNAcb-Sp8 9 8 82
258 Neu5Aca2-3Galb1-4(Fuca1-3)GlcNAcb1-3Galb1-4GlcNAcb-Sp8 9 6 63
337 GalNAca1-3(Fuca1-2)Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1­3Galb1-4GlcNAcb-Sp0 9 6 68
48
277 Neu5Aca2-8Neu5Aca2-3Galb1-4Glcb-Sp0
9
9
4
7
45
71
534 Fuca1-4(Galb1-3)GlcNAcb1-2 Mana-Sp0 9 5 59
358 KDNa2-6Galb1-4GlcNAc-Sp0 9 5 51
350 Galb1-4GlcNAcb1-2Mana1-3Manb1-4GlcNAcb1-4GlcNAc-Sp12 9 10 103
233 GalNAcb1-4(Neu5Aca2-3)Galb1-4GlcNAcb-Sp8 9 8 86
525 Galb1-3GlcNAcb1-2Mana-Sp0 9 8 85
95 GalNAcb1-3GalNAca-Sp8 9 4 39
482 3)GalNAca-Sp14 9 10 107
141 Galb1-3GalNAca-Sp14 9 2 24
71 Fuca1-2Galb1-4(Fuca1-3)GlcNAcb1-3Galb1-4(Fuca1-3)GlcNAcb1­ 9 7 80
Neu5,9Ac2a-Sp8
Neu5Aca2-6Galb1-4 GlcNAcb1-6(Neu5Aca2-6Galb1-4GlcNAcb1-
253
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Appendix
3Galb1-4(Fuca1-3)GlcNAcb-Sp0
149 Galb1-3GlcNAcb1-3Galb1-4Glcb-Sp10 9 5 58
593 Neu5Aca2-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3GalNAca-Sp14 9 5
360 KDNa2-3Galb1-3GalNAca-Sp14 9 4 41
398 GlcNAcb1-2Mana1-6(Galb1-4GlcNAcb1-2Mana1-3)Manb1­4GlcNAcb1-4GlcNAc-Sp12 9 12 135
528 Gala1-3Galb1-3GlcNAcb1-2Mana-Sp0 9 2 22
602 Neu5Aca2-6Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-6(Galb1­3)GalNAca-Sp14 9 6 72
229 GalNAcb1-4(Neu5Aca2-8Neu5Aca2-3)Galb1-4Glcb-Sp0 9 3 32
177 GlcNAcb1-6(GlcNAcb1-3)GalNAca-Sp8 9 5 57
GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1­
586
4GlcNAcb1-6(GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1­
3Galb1-4GlcNAb1-2)Mana1-6(GlcNAcb1-3Galb1-4GlcNAcb1­
3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-3)Manb1­
4GlcNAcb1-4(Fuca1-6)GlcNAcb-Sp24
9 5 53
571 (3S)GlcAb1-3Galb1-4GlcNAcb1-2Mana-Sp0 9 3 35
298 (6S)Galb1-4(6S)GlcNAcb-Sp0 9 5 55
325
231 Neu5Aca2-3(6S)Galb1-4(Fuca1-3)GlcNAcb-Sp8
9
9
6
4
63
41
Galb1-3GlcNAcb1-2Mana1-6(Galb1-3GlcNAcb1-2Mana1-3)Manb1-
4GlcNAcb1-4GlcNAcb-Sp19
237 Neu5Aca2-3GalNAca-Sp8 9 4 47
205 GlcAb1-6Galb-Sp8 9 1 13
36 (3S)Galb1-4GlcNAcb-Sp0 9 6 69
287 Neu5Gca2-6Galb1-4GlcNAcb-Sp0 9 12 135
434 GlcNAcb1-6(GlcNAcb1-2)Mana1-6(GlcNAcb1-4)(GlcNAcb1­2Mana1-3)Manb1-4GlcNAcb1-4GlcNAc-Sp21 9 1 15
498 Fuca1-2(6S)Galb1-3GlcNAcb-Sp0 9 5 63
265 Neu5Aca2-3Galb1-4Glcb-Sp8 9 4 50
263 Fuca1-2Galb1-4(6S)Glcb-Sp0 9 11 127
128 Galb1-3GlcNAcb1-3Galb1-4(Fuca1-3)GlcNAcb-Sp0 9 6 72
Galb1-3GalNAcb1-4(Neu5Aca2-8Neu5Aca2-8Neu5Aca2-3)Galb1­611 9 74Glcb-Sp21
448 Galb1-4(Fuca1-3)GlcNAcb1-6GalNAc-Sp14 8 3
GalNAca1-3(Fuca1-2)Galb1-4GlcNAcb1-6(GalNAca1-3(Fuca1­452 8 42)Galb1-4GlcNAcb1-3)GalNAc-Sp14
79 Fuca1-2Galb-Sp8 8 8 90
83 GalNAca1-3(Fuca1-2)Galb1-3GlcNAcb-Sp0 8 6 72
191 GlcNAcb1-4GlcNAcb1-4GlcNAcb1-4GlcNAcb1-4GlcNAcb1-Sp8 8 5 61
279
511
Neu5Acb2-6GalNAca-Sp8
Galb1-3(6S)GlcNAcb-Sp8
8
8
6
4
77
49
247 Neu5Aca2-3Galb1-3GalNAcb1-3Gala1-4Galb1-4Glcb-Sp0 8 6 67
32 (3S)Galb1-4(Fuca1-3)GlcNAc-Sp0 8 6 75
116 Gala1-3Galb1-4GlcNAcb-Sp8 8 1 18
63 Fuca1-2Galb1-3GalNAca-Sp14 8 5 63
72 Fuca1-2Galb1-4(Fuca1-3)GlcNAcb-Sp0 8 4 50
8 Rhaa-Sp8 8 3 38
381 Galb1-3GalNAca1-3(Fuca1-2)Galb1-4Glc-Sp0 8 5 65
189 GlcNAcb1-4Galb1-4GlcNAcb-Sp8 8 9 105
138 Neu5Acb2-6(Galb1-3)GalNAca-Sp8 8 2 27
212 3)Manb1-4GlcNAcb1-4GlcNAcb-Sp12 8 2 28
204 GlcAb1-3Galb-Sp8 8 2 26
Mana1-2Mana1-6(Mana1-3)Mana1-6(Mana1-2Mana1-2Mana1-
207 KDNa2-3Galb1-4GlcNAcb-Sp0 8 4 48
49 Neu5,9Ac2a2-6Galb1-4GlcNAcb-Sp8 8 7 83
523 Gala1-3(Fuca1-2)Galb1-4GlcNAcb1-2Mana-Sp0 8 5 67
GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1­
4GlcNAcb1-2Mana1-6(GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1­550 8 2 214GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1­
4GlcNAcb-Sp25
 
329 Neu5,9Ac2a2-3Galb1-4GlcNAcb-Sp0 8 6 81
215 Mana1-2Mana1-2Mana1-6(Mana1-3)Mana-Sp9 8 3 36
154 Galb1-4(Fuca1-3)GlcNAcb1-3Galb1-4(Fuca1-3)GlcNAcb-Sp0 8 3
Gala1-3(Fuca1-2)Galb1-4GlcNAcb1-6(Gala1-3(Fuca1-2)Galb1­451 8 4 464GlcNAcb1-3)GalNAc-Sp14
250 Neu5Aca2-3Galb1-3GlcNAcb-Sp0 8 10 133
254
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Appendix
303 Galb1-4GlcNAcb1-6(Galb1-4GlcNAcb1-3)Galb1-4GlcNAc-Sp0 8 4 53
2 Glca-Sp8 8 4 57
151 Galb1-3GlcNAcb-Sp8	 8 4 56
605 GlcNAcb1-6(Neu5Aca2-3Galb1-3)GalNAca-Sp14 8 4
150
264
Galb1-3GlcNAcb-Sp0
Neu5Aca2-3Galb1-4Glcb-Sp0
8
8
4
4
52
45
230 Neu5Aca2-8Neu5Aca2-8Neu5Aca-Sp8 8 3 40
267 Neu5Aca2-6GalNAcb1-4GlcNAcb-Sp0 8 6
173 Galb1-4Glcb-Sp8 8 7 85
363 4(Fuca1-3)GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4GlcNAb-Sp20 8 3 36
295 Neu5Aca2-3Galb1-3GlcNAcb1-3Galb1-3GlcNAcb-Sp0 8 3 34
Fuca1-2Galb1-4(Fuca1-3)GlcNAcb1-2Mana1-6(Fuca1-2Galb1-
396 Gala1-3Galb1-3(Fuca1-4)GlcNAcb1-2Mana1-6(Gala1-3Galb1- 8 53(Fuca1-4)GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4GlcNAc-Sp19
153
85
Galb1-4(Fuca1-3)GlcNAcb-Sp8
(3S)Galb1-4(Fuca1-3)Glcb-Sp0
8
8
5
3
62
41
161 Galb1-4GlcNAcb1-3GalNAc-Sp14 8 6 77
175 GlcNAca1-6Galb1-4GlcNAcb-Sp8 8 3 37
Galb1-4(Fuca1-3)GlcNAcb1-3Galb1-4(Fuca1-3)GlcNAcb1-3Galb1­155	 8 4 554(Fuca1-3)GlcNAcb-Sp0
273 Neu5Aca2-6Galb1-4Glcb-Sp0 8 1 12
Neu5Aca2-6Galb1-4GlcNAcb1-6(Neu5Aca2-6Galb1-4GlcNAcb1­
2)Mana1-6(GlcNAcb1-4)(Neu5Aca2-6Galb1-4GlcNAcb1­467	 8 2 234(Neu5Aca2-6Galb1-4GlcNAcb1-2)Mana1-3)Manb1-4GlcNAcb1­
4GlcNAcb-Sp21
 
73 Fuca1-2Galb1-4(Fuca1-3)GlcNAcb-Sp8 8 5 71
Neu5Aca2-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1­
604	 6(Neu5Aca2-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1- 7 8 103
3)Manb1-4GlcNAcb1-4GlcNAcb-Sp12
336 GalNAca1-3(Fuca1-2)Galb1-4GlcNAcb1-3Galb1-4GlcNAcb-Sp0 7 1 8
297 4S(3S)Galb1-4GlcNAcb-Sp0	 7 4 59
512 (6S)(4S)GalNAcb1-4GlcNAc-Sp8 7 3 46
136 Neu5Aca2-6(Galb1-3)GalNAca-Sp8	 7 9 121
46 Neu5Aca2-3(6S)Galb1-4GlcNAcb-Sp8 7 6 78
455
GalNAca1-3(Fuca1-2)Galb1-4GlcNAcb1-2Mana1-6(GalNAca1­
3(Fuca1-2)Galb1-4GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1­ 7 4 55
4(Fuca1-6)GlcNAcb-Sp22
458
GalNAca1-3(Fuca1-2)Galb1-3GlcNAcb1-2Mana1-6(GalNAca1­
3(Fuca1-2)Galb1-3GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1­
4(Fuca1-6)GlcNAcb-Sp22
7 3 37
356 (6S)GlcNAcb1-3Galb1-4GlcNAcb-Sp0 7 5 63
432 GlcNAcb1-2Mana1-6(GlcNAcb1-4)(GlcNAcb1-2Mana1-3)Manb1­4GlcNAcb1-4GlcNAc-Sp21 7 4 51
Mana1-2Mana1-6(Mana1-2Mana1-3)Mana1-6(Mana1-2Mana1­317	 7 5 702Mana1-3)Mana-Sp9
82 Fucb1-3GlcNAcb-Sp8 7 3 48
Galb1-3GlcNAcb1-3Galb1-4GlcNAcb1-6(Galb1-3GlcNAcb1­
3Galb1-4GlcNAb1-2)Mana1-6(Galb1-3GlcNAcb1-3Galb1­573	 7 2 334GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4(Fuca1-6)GlcNAcb­
Sp24
 
558 Neu5Aca2-8Neu5Aca2-3Galb1-4GlcNAc-Sp0 7 3 46
367 Neu5Aca2-6GlcNAcb1-4GlcNAc-Sp21	 7 3 39
25 (3S)Galb1-4Glcb-Sp8 7 10 138
567 GlcNAb1-3Galb1-3GalNAc-Sp14	 7 7 97
33 (3S)Galb1-4(Fuca1-3)GlcNAc-Sp8	 7 1 19
Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1­
4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1­
569	 6(Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1- 7 2 30
3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1­
2Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-Sp25
225 Neu5Aca2-3Galb1-3GalNAca-Sp14 7 3 48
124 Gala1-4GlcNAcb-Sp8	 7 2 21
345 GlcNAca1-4Galb1-3GalNAc-Sp14 7 5
282 Neu5Gca2-3Galb1-3GlcNAcb-Sp0	 7 5 67
84 GalNAca1-3(Fuca1-2)Galb1-4(Fuca1-3)GlcNAcb-Sp0	 7 8
438 Galb1-4GlcNAcb1-6(Galb1-4GlcNAcb1-2)Mana1-6(GlcNAcb1- 7 3 45
255
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24
Appendix
4)(Galb1-4GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4GlcNAc-Sp21
Galb1-3GalNAcb1-4Galb1-4Glcb-Sp8 7 1 12
Neu5Aca2-6Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1­333 7 2 234GlcNAcb-Sp0
533 Galb1-4GlcNAcb1-2 Mana1-6(Galb1-4GlcNAcb1-4)(Galb1­4GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4(Fuca1-6)GlcNAc-Sp21 7 7 106
236 Neu5Aca2-6(Neu5Aca2-3)GalNAca-Sp8 7 2 29
553 Neu5Gca2-8Neu5Gca2-3Galb1-4GlcNAc-Sp0 7 2
156 Galb1-4(6S)Glcb-Sp0 7 0 7
341 GlcNAca1-4Galb1-3GlcNAcb-Sp0 7 7 103
536 GlcNAcb1-3Galb1-4GlcNAcb1-6(GlcNAcb1-3)Galb1-4GlcNAc-Sp0 7 5 75
570 (3S)GlcAb1-3Galb1-4GlcNAcb1-3Galb1-4Glc-Sp0 7 5 77
187 GlcNAcb1-4-MDPLys 7 3 46
393 GalNAcb1-4(Neu5Aca2-3)Galb1-4GlcNAcb1-3GalNAca-Sp14 7 3 50
469 Gala1-3(Fuca1-2)Galb1-3GalNAcb-Sp8 7 8 121
232 GalNAcb1-4(Neu5Aca2-3)Galb1-4GlcNAcb-Sp0 7 2 25
91 GalNAca1-3(Fuca1-2)Galb-Sp18 7 5 78
601 Neu5Aca2-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-6(Galb1- 7 23)GalNAca-Sp14
168 Galb1-4GlcNAcb1-6(Galb1-3)GalNAc-Sp14 7 6 87
461
Neu5Aca2-3Galb1-4GlcNAcb1-4Mana1-6(GlcNAcb1-4)(Neu5Aca2­
3Galb1-4GlcNAcb1-4(Neu5Aca2-3Galb1-4GlcNAcb1-2)Mana1­
3)Manb1-4GlcNAcb1-4GlcNAcb-Sp21
7 5 72
GlcNAcb1-2(GlcNAcb1-6)Mana1-6(GlcNAcb1-2Mana1-3)Manb1­422 7 34GlcNAcb1-4GlcNAcb-Sp19
543
Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-6(Galb1­
4GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1­
4GlcNAcb-Sp24
7 7 107
80 Fuca1-3GlcNAcb-Sp8 7 9 142
402 Galb1-4(Fuca1-3)GlcNAcb1-3GalNAca-Sp14 7 3 49
Neu5Aca2-3Galb1-4GlcNAcb1-2Mana1-6(Neu5Aca2-6Galb1­327 6 44GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-Sp12
474
Fuca1-2Galb1-3(Fuca1-4)GlcNAcb1-2Mana1-6(Fuca1-2Galb1­
3(Fuca1-4)GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4(Fuca1­
6)GlcNAcb1-4(Fuca1-6)GlcNAcb-Sp19
6 3 53
68 Fuca1-2Galb1-3GlcNAcb-Sp0 6 5 83
527 Neu5Aca2-3Galb1-3GlcNAcb1-2Mana-Sp0 6 5 87
Fuca1-2Galb1-3GlcNAcb1-2Mana1-6(Fuca1-2Galb1-3GlcNAcb1­427 6 3 422Mana1-3)Manb1-4GlcNAcb1-4(Fuca1-6)GlcNAcb-Sp22
462
Neu5Aca2-3Galb1-4GlcNAcb1-6(Neu5Aca2-3Galb1-4GlcNAcb1­
2)Mana1-6(GlcNAcb1-4)(Neu5Aca2-3Galb1-4GlcNAcb1-2Mana1­
3)Manb1-4GlcNAcb1-4GlcNAcb-Sp21
6 2 37
163 Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb-Sp0 6 4 69
241
243 Neu5Aca2-3Galb1-3(6S)GalNAca-Sp8
6
6
7
5
115
75
Neu5Aca2-3Galb1-3(Fuca1-4)GlcNAcb1-3Galb1-4(Fuca1-
3)GlcNAcb-Sp0
494 3)GlcNAcb1-3)Galb1-4Glc-Sp21 6 2 39
188 GlcNAcb1-6(GlcNAcb1-4)GalNAca-Sp8 6 4 65
Galb1-4(Fuca1-3)GlcNAcb1-6(Neu5Aca2-6(Neu5Aca2-3Galb1-
112 Gala1-3GalNAca-Sp16 6 4 68
401 Fuca1-2Galb1-4GlcNAcb1-3GalNAca-Sp14 6 8 131
468 Gala1-3(Fuca1-2)Galb1-3GalNAca-Sp8 6 6 105
157 Galb1-4(6S)Glcb-Sp8 6 6 101
375 Gala1-3(Fuca1-2)Galb1-3GlcNAcb1-2Mana1-6(Gala1-3(Fuca1-2)Galb1-3GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-Sp20 6 5
Galb1-4GlcNAcb1-2Mana1-6(Galb1-4GlcNAcb1-4(Galb1­370 6 34GlcNAcb1-2)Mana1-3)Manb1-4GlcNAcb1-4GlcNAc-Sp21
115 Gala1-3Galb1-3GlcNAcb-Sp0 6 1
391 Fuca1-2Galb1-3GalNAca1-3(Fuca1-2)Galb1-4GlcNAcb-Sp0 6 1 25
284 Neu5Gca2-3Galb1-4GlcNAcb-Sp0 6 3
224 Neu5Aca2-3Galb1-3GalNAca-Sp8 6 5 81
117 Gala1-3Galb1-4Glcb-Sp0 6 5
1 Gala-Sp8 6 5 91
257 Neu5Aca2-3Galb1-4(Fuca1-3)GlcNAcb1-3Galb-Sp8 6 5
441 Galb1-6Galb-Sp10 6 7 132
349 Neu5Aca2-6Galb1-4GlcNAcb1-2Mana1-3Manb1-4GlcNAcb1­ 6 6 103
256
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4GlcNAc-Sp12
222 Fuca1-2Galb1-4(6S)GlcNAcb-Sp8 6 1 23
74 Fuca1-2Galb1-4GlcNAcb1-3Galb1-4GlcNAcb-Sp0 6 2 35
51 Mana1-6(Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-Sp13 6 7 122
365 Galb1-4GlcNAcb1-2Mana1-6(Mana1-3)Manb1-4GlcNAcb1­4GlcNAcb-Sp12 6 4 64
322 Neu5Aca2-8Neu5Acb-Sp17	 6 7 121
466
Neu5Aca2-6Galb1-4GlcNAcb1-6(Neu5Aca2-6Galb1-4GlcNAcb1­
2)Mana1-6(GlcNAcb1-4)(Neu5Aca2-6Galb1-4GlcNAcb1-2Mana1­
3)Manb1-4GlcNAcb1-4GlcNAcb-Sp21
6 5 90
269	 Neu5Aca2-6Galb1-4GlcNAcb-Sp0 5 6 114
Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1­
585 5
6(Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAb1-
2)Mana1-6(Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-
4GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4(Fuca1-6)GlcNAcb-
3 60
Sp24
431 Fuca1-3GlcNAcb1-6(Galb1-4GlcNAcb1-3)Galb1-4Glc-Sp21 5 5 84
508
GlcNAcb1-6(GlcNAcb1-2)Mana1-6(GlcNAcb1-4)(GlcNAcb1­
4(GlcNAcb1-2)Mana1-3)Manb1-4GlcNAcb1-4(Fuca1-6)GlcNAc­
Sp21
5 6 116
Galb1-4GlcNAcb1-6(Galb1-4GlcNAcb1-2)Mana1-6(Galb1­
486 4GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4(Fuca1-6)GlcNAcb­ 5 3 52
Sp24
56
211 Mana1-6(Mana1-2Mana1-3)Mana1-6(Mana1-2Mana1-3)Manb1­4GlcNAcb1-4GlcNAcb-Sp12
5
5
6
6
119
121
416 GalNAca1-3GalNAcb1-3Gala1-4Galb1-4Glcb-Sp0 5 2 41
53 GlcNAcb1-2Mana1-6(GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1­4GlcNAcb-Sp13 5 2 36
31 (3S)Galb1-3GlcNAcb-Sp8 5 3 49
262 Neu5Aca2-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb-Sp0 5 3 49
253 Neu5Aca2-3Galb1-4(Fuca1-3)(6S)GlcNAcb-Sp8 5 5 89
43 (6S)Galb1-4Glcb-Sp8 5 2 42
169
90 GalNAca1-3(Fuca1-2)Galb-Sp8
5
5
8
4
149
77
418 Gala1-3(Fuca1-2)Galb1-4(Fuca1-3)GlcNAcb1-3GalNAc-Sp14 5 4 72
Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1­
4GlcNAcb1-3Galb1-4GlcNAcb1-6(Galb1-4GlcNAcb1-3Galb1­
589 4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1­ 5 2 43
4GlcNAb1-2)Mana1-6(Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1­
3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4G
67 Fuca1-2Galb1-3GlcNAcb1-3Galb1-4Glcb-Sp10 5 7 150
368 Neu5Aca2-6GlcNAcb1-4GlcNAcb1-4GlcNAc-Sp21 5 2 41
385 4Glc-Sp21 5 9 175
390 Fuca1-2Galb1-3GalNAca1-3(Fuca1-2)Galb1-4Glcb-Sp0 5 6 130
107 Gala1-3(Fuca1-2)Galb1-4Glcb-Sp0 5 7 138
554 Neu5Aca2-8Neu5Gca2-3Galb1-4GlcNAc-Sp0 5 4 90
66
142 Galb1-3GalNAca-Sp16
5
5
8
2
155
40
Neu5Aca2-6Galb1-4GlcNAcb1-2Mana1-6(Neu5Aca2-6Galb1-
4GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-Sp13
Galb1-4GlcNAcb-Sp0
Galb1-4GlcNAcb1-6(Fuca1-4(Fuca1-2Galb1-3)GlcNAcb1-3)Galb1-
Fuca1-2Galb1-3GlcNAcb1-3Galb1-4Glcb-Sp8
540 GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-6(GlcNAcb1-3Galb1­4GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-Sp12 5 3 59
323 Neu5Aca2-8Neu5Aca2-8Neu5Acb-Sp8 5 5 95
357
517 (4S)GalNAcb-Sp10
5
5
2
3
37
61
348 Neu5Aca2-6Galb1-4GlcNAcb1-2Mana1-6Manb1-4GlcNAcb1­4GlcNAc-Sp12 4 2 35
532 Galb1-4GlcNAcb1-2 Mana1-6(GlcNAcb1-4)(Galb1-4GlcNAcb1­2Mana1-3)Manb1-4GlcNAcb1-4(Fuca1-6)GlcNAc-Sp21 4 3 60
47 (6S)GlcNAcb-Sp8 4 4 89
Gala1-3Galb1-4(Fuca1-3)GlcNAcb1-2Mana1-6(Gala1-3Galb1­
373 4(Fuca1-3)GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb­ 4 2 49
Sp20
KDNa2-3Galb1-4(Fuca1-3)GlcNAc-Sp0
278 Galb1-3(Fuca1-4)GlcNAcb1-3Galb1-3(Fuca1-4)GlcNAcb-Sp0 4 3 58
42 (6S)Galb1-4Glcb-Sp0	 4 7 155
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Appendix
596 GlcNAcb1-3Galb1-4GlcNAcb1-6(GlcNAcb1-3Galb1-4GlcNAcb1­3)GalNAca-Sp14 4 3 62
304 GlcNAcb1-6(Galb1-4GlcNAcb1-3)Galb1-4GlcNAc-Sp0 4 5 110
440 Galb1-4Galb-Sp10 4 1
133
GalNAcb1-4GlcNAcb1-2Mana1-6(GalNAcb1-4GlcNAcb1-2Mana1-
Galb1-4GlcNAcb1-6GalNAc-Sp14 4 3 79
380 4 2 413)Manb1-4GlcNAcb1-4GlcNAc-Sp12
41 (6P)Mana-Sp8 4 8 190
271
388
Galb1-4GlcNAcb1-6(Galb1-4GlcNAcb1-2)Mana1-6(Galb1­
4GlcNAcb1-4(Galb1-4GlcNAcb1-2)Mana1-3)Manb1-4GlcNAcb1­
4
4
3
2
79
56
4GlcNAcb-Sp21
Neu5Aca2-6Galb1-4GlcNAcb1-3Galb1-4(Fuca1-3)GlcNAcb1-
3Galb1-4(Fuca1-3)GlcNAcb-Sp0
92 GalNAca1-3GalNAcb-Sp8 4 4 105
238
202
Neu5Aca2-3GalNAcb1-4GlcNAcb-Sp0
GlcAa-Sp8
4
4
7
5
169
118
226 GalNAcb1-4(Neu5Aca2-8Neu5Aca2-8Neu5Aca2-8Neu5Aca2­3)Galb1-4Glcb-Sp0 4 8 200
248 Neu5Aca2-3Galb1-3GlcNAcb1-3Galb1-4GlcNAcb-Sp0 4 3 74
374
GalNAca1-3(Fuca1-2)Galb1-3GlcNAcb1-2Mana1-6(GalNAca1­
3(Fuca1-2)Galb1-3GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1­ 4 5 133
4GlcNAcb-Sp20
491 Galb1-3(Fuca1-4)GlcNAcb1-6GalNAca-Sp14 4 1 27
425 GalNAca1-3(Fuca1-2)Galb1-3GlcNAcb1-3GalNAc-Sp14 4 2 67
280 Neu5Acb2-6Galb1-4GlcNAcb-Sp8 4 2 49
44 (6S)Galb1-4GlcNAcb-Sp8 4 3 74
599 GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3GalNAca-Sp14 4 4 113
69 Fuca1-2Galb1-3GlcNAcb-Sp8 4 3 94
318 Neu5Aca2-3Galb1-4GlcNAcb1-6(Neu5Aca2-3Galb1-3)GalNAca­Sp14 4 5 147
GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-6(GlcNAcb1­
3Galb1-4GlcNAcb1-3Galb1-4GlcNAb1-2)Mana1-6(GlcNAcb1­584 4 1 413Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-3)Manb1­
4GlcNAcb1-4(Fuca1-6)GlcNAcb-Sp24
306 Galb1-4GlcNAcb1-6Galb1-4GlcNAcb-Sp0 3 2 51
GlcNAcb1-2Mana1-6(Neu5Aca2-6Galb1-4GlcNAcb1-2Mana1­321 3 43)Manb1-4GlcNAcb1-4GlcNAcb-Sp12
509
Galb1-4GlcNAcb1-6(Galb1-4GlcNAcb1-2)Mana1-6(GlcNAcb1­
4)Galb1-4GlcNAcb1-4(Gal b1-4GlcNAcb1-2)Mana1-3)Manb1­
4GlcNAcb1-4(Fuca1-6)GlcNAc-Sp21
3 3 98
296 Neu5Aca2-3Galb1-4GlcNAcb1-3Galb1-3GlcNAcb-Sp0 3 5 144
464 6Galb1-4GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-Sp21 3 4 121
201 G-ol-Sp8 3 2 47
Neu5Aca2-6Galb1-4GlcNAcb1-2Mana1-6(GlcNAcb1-4)(Neu5Aca2-
417 Fuca1-2Galb1-4(Fuca1-3)GlcNAcb1-3GalNAca-Sp14 3 2 77
200 Glcb1-6Glcb-Sp8 3 1 42
392 Galb1-3GlcNAcb1-3GalNAca-Sp14 3 1 20
Galb1-4GlcNAcb1-2Mana1-6(GlcNAcb1-4)(Galb1-4GlcNAcb1­436 3 32Mana1-3)Manb1-4GlcNAcb1-4GlcNAc-Sp21
58 4GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-Sp24 3 3 93
420
Galb1-4(Fuca1-3)GlcNAcb1-2Mana1-6(Galb1-4(Fuca1­
3)GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4(Fuca1-6)GlcNAcb­ 3 3 106
Sp22
Neu5Aca2-6Galb1-4GlcNAcb1-2Mana1-6(Neu5Aca2-6Galb1-
598 Neu5Aca2-6Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3GalNAca-Sp14 3 1 42
414 Gala1-3(Fuca1-2)Galb1-4GlcNAcb1-3GalNAca-Sp14 3 2 68
197 Glca1-4Glca-Sp8 3 3
179 GlcNAcb1-6(GlcNAcb1-3)Galb1-4GlcNAcb-Sp8 3 1 38
342 GlcNAca1-4Galb1-4GlcNAcb1-3Galb1-4Glcb-Sp0 3 4
255
251
Neu5Aca2-3Galb1-4(Fuca1-3)GlcNAcb-Sp0
Neu5Aca2-3Galb1-3GlcNAcb-Sp8
3
3
4
5
137
207
174 GlcNAca1-3Galb1-4GlcNAcb-Sp8 2 6 230
545
Fuca1-2Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-6(Fuca1­
2Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-3)Manb1­
4GlcNAcb1-4GlcNAcb-Sp24
2 6 240
443 GalNAcb1-6GalNAcb-Sp8 2 2 95
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266 Neu5Aca2-6GalNAca-Sp8 2 4
159 Galb1-4GalNAcb1-3(Fuca1-2)Galb1-4GlcNAcb-Sp8 2 3 119
442 Neu5Aca2-3Galb1-4GlcNAcb1-3Galb-Sp8 2 4
101 Gala1-2Galb-Sp8 2 5 230
152 Galb1-4(Fuca1-3)GlcNAcb-Sp0 2 2
Galb1-4GlcNAcb1-2Mana1-6(Galb1-4GlcNAcb1-2Mana1-3)Manb1­54 2 4 1724GlcNAcb1-4GlcNAcb-Sp12
17 GlcNAcb-Sp8 2 7
403 GalNAca1-3GalNAcb1-3Gala1-4Galb1-4GlcNAcb-Sp0 2 5 231
139 Neu5Aca2-6(Galb1-3)GlcNAcb1-4Galb1-4Glcb-Sp10 2 5 242
137 Neu5Aca2-6(Galb1-3)GalNAca-Sp14 2 1 35
113 Gala1-3GalNAcb-Sp8 2 3 141
Mana1-6(Mana1-3)Mana1-6(Mana1-3)Manb1-4GlcNAcb1­217 2 44GlcNAcb-Sp12
485 Mana1-6(Mana1-3)Manb1-4GlcNAcb1-4(Fuca1-6)GlcNAcb-Sp19 2 4 228
519 (6P)Galb1-4GlcNAcb-SP0 2 5 283
272 Neu5Aca2-6Galb1-4GlcNAcb1-3Galb1-4GlcNAcb-Sp0 2 6 367
252 Neu5Aca2-3Galb1-4(6S)GlcNAcb-Sp8 2 3 176
516 (3S)GalNAcb1-4GlcNAc-Sp8 2 3 227
366
Fuca1-4(Galb1-3)GlcNAcb1-2Mana1-6(Fuca1-4(Galb1­
3)GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4(Fuca1-6)GlcNAcb­ 1 1 70
Sp22
165 Galb1-4GlcNAcb1-3Galb1-4Glcb-Sp0 1 6 427
340
Galb1-4(Fuca1-3)GlcNAcb1-6(Fuca1-2Galb1-4GlcNAcb1-3)Galb1-
GlcNAca1-4Galb1-4GlcNAcb-Sp0 1 2 161
369 1 2 1184Glc-Sp21
510 Galb1-3GlcNAca1-3Galb1-4GlcNAcb-Sp8 1 1 99
561
310 GlcNAcb1-3Man-Sp10
1
1
3
3
279
334
Gala1-3Galb1-4GlcNAcb1-2Mana1-6(Gala1-3Galb1-4GlcNAcb1-
2Mana1-3)Manb1-4GlcNAcb1-4GlcNAc-Sp24
176 GlcNAcb1-2Galb1-3GalNAca-Sp8 1 6 710
147 Galb1-3Galb-Sp8 1 1 119
449 Galb1-4GlcNAcb1-2Mana-Sp0 1 3 510
524 GalNAca1-3(Fuca1-2)Galb1-4 GlcNAcb1-2Mana-Sp0 -1 1 -111
371
GalNAca1-3(Fuca1-2)Galb1-4GlcNAcb1-2Mana1-6(GalNAca1­
3(Fuca1-2)Galb1-4GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1­
4GlcNAcb-Sp20
-1 2 -191
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0022-2836/$ - see front matter © 2009 EEngineered receptor fragments and glycoprotein ligands employed in
different assay formats have been used to dissect the basis for the dramatic
enhancement of binding of two model membrane receptors, dendritic cell-
specific intercellular adhesion molecule 3-grabbing nonintegrin (DC-SIGN)
and the macrophage galactose lectin, to glycoprotein ligands compared to
simple sugars. These approaches make it possible to quantify the importance
of two major factors that combine to enhance the affinity of single
carbohydrate-recognition domains (CRDs) for glycoprotein ligands by 100-
to 300-fold. First, the presence of extended binding sites within a single CRD
can enhance interaction with branched glycans, resulting in increases of
fivefold to 20-fold in affinity. Second, presentation of glycans on aglycoprotein
surface increases affinity by 15-to 20-fold, possibly due to low-specificity
interactionswith the surface of the protein or restriction in the conformation of
the glycans. In contrast, when solution-phase networking is avoided,
enhancement due to binding of multiple branches of a glycan to multiple
CRDs in the oligomeric forms of these receptors is minimal and binding of a
receptor oligomer to multiple glycans on a single glycoprotein makes only a
twofold contribution to overall affinity. Thus, in these cases, multivalent
interactions of individual glycoproteins with individual receptor oligomers
have a limited role in achieving high affinity. These findings, combined with
considerations of membrane receptor geometry, are consistent with the idea
that further enhancement of the binding to multivalent glycoprotein ligands
requires interaction of multiple receptor oligomers with the ligands.© 2009 Elsevier Ltd. All rights reserved.Edited by I. Wilson Keywords: glycan-binding receptors; lectins; glycoproteins; affinityess:
RCNational Institute
, Mill Hill, London
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lsevier Ltd. All rights reserveIntroduction
Receptor-mediated binding of sugars underpins
recognition events important for cell–cell adhesion,
serum glycoprotein clearance, innate immune rec-
ognition of pathogens and other biological pro-
cesses.1-4 Such glycan-mediated binding events in
solution and at cell surfaces typically involve multi-
meric glycan-binding receptors, also known as
lectins, interacting with glycoproteins bearing mul-
tiple oligosaccharides. The importance of multi-
valency in the interaction of glycans with receptors
is widely documented for glycan-binding molecules
of diverse bacterial, plant and animal origin.5-8
Levels of enhancement of ligand binding resulting
from multivalency have reached 106-fold in somed.
686 High Affinity Glycoprotein–Receptor Bindingassay conditions.5,9,10 For the C-type animal lectins, a
diverse group of glycan-binding receptors contain-
ing carbohydrate-recognition domains (CRDs) that
share a Ca2+-dependent mechanism of interaction
with monosaccharide residues, the fundamental
binding interaction is typically very weak, with
dissociation constants of the order of 1 mM.11-13 A
number of different factors have been invoked to
explain how affinity and specificity of glycan-
binding receptors containing C-type CRDs can be
increased to achieve biologically relevant interac-
tions (Fig. 1). In spite of the high levels of affinity
enhancement reported for earlier studies, the con-
tributions of these individual factors have often been
difficult to dissect and some affinity enhancements
have been measured under conditions that would
not be relevant to the natural biological situation. For
example, the three-dimensional network arrange-
ment seen for soluble lectins14 (Fig. 1i) would not
generally be possible for membrane-resident glycan-
binding receptors.
New experimental approaches to measuring bind-
ing interactions have facilitated exploration of some
of the sources of affinity in greater detail. ForFig. 1. Potential sources of enhanced affinities in glyco
attachment of multiple glycans to a glycoprotein increases the
binding site interactions can accommodate secondary contact w
elaborations on individual branches. (d) Direct protein–protein
the protein portion of the glycoprotein. (e) The presence of
secondary interactions. (f) and (g), Multiple terminal residu
glycoprotein can interact with multiple CRDs in a receptor olig
interact with glycans on multiple glycoprotein ligands. (i) In s
ligands with oligomeric lectins. CRDs are shown diagrammat
cylinders. A galactose-binding receptor is shown for illustratiexample, the importance of ligand mobility for
interaction with multiple CRDs has been studied
recently using surface-force measurements of the
receptor dendritic cell cell-specific intercellular ad-
hesion molecule 3-grabbing nonintegrin (DC-SIGN),
which is a tetramer that binds to high-mannose
oligosaccharides such as those found on viral
pathogens, including human immunodeficiency
virus.13,15,16 The results demonstrate that conforma-
tional flexibility in the dispositions of CRDs in this
tetrameric receptor observed in structural ana-
lysis17,18 makes interactions of a single oligomer
with multiple glycans possible. Such interactions,
combinedwith ligandmobility, would facilitate two-
dimensional lattice formation (Fig. 1h). A further
recent development is the ability to engineer both
receptors and their glycoprotein ligands. In the case
of DC-SIGN, the ability to express isolated mono-
meric CRDs and tetrameric extracellular domains of
the receptor allows comparison of the effects of CRD
clusters.13 Using this approach, it has been possible
to demonstrate that the CRD of DC-SIGN shows
tenfold higher affinity for a branched glycan than for
mannose, demonstrating the importance of interac-protein-receptor interactions. (a) Glycan branching and
number of terminal sugar residues. (b) and (c) Extended
ith branches on multi-antennary glycans or with terminal
interactions can occur between a CRD and the surface of
multiple glycans on a glycoprotein ligand can lead to
es on one glycan or on different glycans attached to a
omer. (h) On cell surfaces, CRDs in receptor oligomers can
olution, lattices can form from interactions of multivalent
ically as spheres and glycoprotein ligands are indicated as
on purposes.
687High Affinity Glycoprotein–Receptor Bindingtions of a single CRD with multiple branches of a
single glycan (Fig 1b). Structural analysis has shown
that this enhanced affinity results from an extended
binding site on the surface of the CRD, allowing
interaction with the branched oligosaccharide
structure.19 The possibility of producing engineered
glycoproteins as ligands for receptors has been less
exploited to date. Also, very few measurements of
single glycan–CRD interactions have been reported,
in part because these do not fall into an affinity range
that is easily assayed, but label-free methods such as
surface plasmon resonance have the potential to
address this gap.
In the current studies, the behavior of isolated
CRDs and CRDs clustered in naturally occurring
oligomers have been compared in parallel condi-
tions, using engineered glycoprotein ligands pre-
senting different numbers of glycans on a common
backbone in multiple assay formats. The results
using DC-SIGN and the structurally and function-
ally divergent macrophage galactose lectin as model
receptors reveal that affinity enhancements for
binding of glycoprotein ligands of greater than
1000-fold can result from the combined effects of
presentation on a protein surface and the presence of
extended binding sites in the receptor CRDs.Fig. 2. Determination of the affinity of DC-SIGN for glyco
monomeric CRD to immobilized SBA and glycopeptide deriv
curves with a linear increase in nonspecific background bin
glycopeptide from SBA to immobilized CRD from DC-SIGN. K
(d) Binding competition assays in which immobilized CRD fro
the presence of competing ligands. Data were fit to simple firResults
Using DC-SIGN to assess affinity enhancement
resulting from glycan presentation on proteins
In initial studies, DC-SIGN was used to demon-
strate the importance of some potential factors in
enhancing glycoprotein binding to a CRD and to
validate appropriate assay formats. The availability
of a highly soluble, monomeric CRD from DC-SIGN
and the fact that high-mannose oligosaccharides
bind to this receptor with affinities that fall within
the range that can be determined using surface
plasmon resonance provided an opportunity to
measure the interaction directly. Making use of the
fact that each subunit of soybean agglutinin (SBA)
bears a single, uniform Man9GlcNAc2 oligosac-
charide,20 N-hydroxysuccinimide chemistry was
used to prepare surfaces coated with the intact
glycoprotein and with the glycopeptide isolated
from it, in order to assess the effect of glycan
presentation on a protein backbone (Fig. 1d). Effects
of valency were eliminated by analyzing the
interaction with monomeric CRDs. Because of the
rapid rates of association and dissociation, interac-peptide and glycoprotein ligands. (a) and (b) Binding of
ed from SBA. Data were fit to simple first-order binding
ding to derive dissociation constants. (c) Binding of the
D was derived from fitting as in the previous experiments.
m DC-SIGNwas probed with 125I-labeled mannose-BSA in
st-order competition curves to derive KI values.
Fig. 3. Binding competition assays comparing binding of
a tri-antennary glycopeptide to MGL. Binding curves for
monomeric CRD are shown in blue and curves for trimeric
extracellular domain are shown in red. The KI values
obtained from these experiments are summarized in Table 2.
688 High Affinity Glycoprotein–Receptor Bindingtions were measured under steady-state conditions
and analyzed by fitting the data to a simple
saturation binding model (Fig. 2a and b). The results
suggest that presentation of the oligosaccharide on a
glycoprotein results in a roughly 15-fold enhance-
ment of the binding affinity. However, the data for
the glycopeptide binding experiment fall mostly
below the apparent KD obtained from fitting the
curve, because of limits on the protein concentration
that could be achieved. A more definitive result was
obtained by immobilizing the CRD, because higher
concentrations of glycopeptide could be achieved in
the fluid phase (Fig. 2c). The measured KD of 76 μM
suggests that the enhancement resulting from
presentation of the Man9GlcNAc2 oligosaccharide
on a protein scaffold is closer to 20-fold.
The same interactions were compared in a binding
competition assay, in which the CRD was immobi-
lized on a polystyrene surface and competition for
binding to an iodinated mannose–BSA reporter
ligand was measured (Fig. 2d). These experiments
were done with concentrations of reporter ligand at
least tenfold below the KD value for the reporter
ligand, in a region where bound ligand is linearly
proportional to input ligand concentration. Under
such conditions, the KI values for the competing
ligands closely approximate their KD values.21 The
ratio of KI,mannose to KI,glycopeptide is 51 (3.5 mM/
68 μM), which indicates that DC-SIGN binds to a
Man9GlcNAc2 glycopeptide with more than 50-fold
higher affinity than it binds tomannose. On the basis
of the presence of three terminal mannose residues,
the affinity for the glycopeptide would be expected
to be only threefold higher than the affinity for
mannose, so the actual affinity ratio is roughly 51/3,
which is 17-fold higher thanwould be expected. This
value is consistent with previous studies and can be
explained on the basis of the enhanced affinity for the
branched mannose structure that has been observed
to interact with an extended binding site in the
CRD.22,23 The ratio of the affinities for the glycopep-
tide and the intact soybean agglutinin (KI,glycopeptide/
KI,SBA= 68 μM/2.4 μM) suggests a further enhance-
ment of 28-fold for binding to the glycoprotein
compared to the glycopeptide.
The absolute values of the affinities measured in
the competition assay and the enhancement result-
ing from presentation of the oligosaccharide on a
protein scaffold are remarkably consistent with the
values from the direct binding analysis, considering
the widely different assay formats involved. This
result suggests that the competition assay also
measures largely a single glycan–CRD interaction.
For the free glycopeptide, this is expected, but it
might seem more surprising for the intact glycopro-
tein, which is tetrameric. However, the multiple
glycans on the tetramer are apparently not well
disposed for binding to the CRDs exposed on a
surface. Only two glycans are presented on each face
of the soybean agglutinin tetramer,24 and the close
spacing of these glycans relative to the size of a CRD,
as well as the precise orientation required to
accommodate the oligosaccharide in the extendedbinding site on the CRD, apparently make it difficult
to align more than one glycan for high-affinity
binding to CRDs immobilized on a plastic surface
and there is minimal enhancement in affinity. The
consistency of the results in these different assay
formats validates the competition assay as a way to
compare affinities, which allows analysis of other
receptor systems where the surface plasmon reso-
nance approach is not applicable.
Comparing the affinity of the CRD from DC-SIGN
for mannose as measured in the competition assay
(KI= 3.5 mM; Fig. 2d) with the most conservative
value for the CRD–glycoprotein interaction that
comes from the surface plasmon resonance experi-
ment (KD= 4.0 μM; Fig. 2a), the ratio of affinities is
875. This affinity is nearly 300-fold higher than the
threefold enhancement that would be expected based
on the presence of three terminal mannose residues
per soybean agglutinin polypeptide. This nearly 300-
fold increase in affinity results from combined
enhancements of 15-to 20-fold each from the presence
of an extended binding site for the oligosaccharide
ligand and presentation of glycans on a protein,
without any need to invoke multivalent binding.
Effect of glycan branching on binding to a
galactose-specific receptor
In order to demonstrate that the enhancement
effects for individual C-type CRDs interacting with
branched glycans presented on proteins represent a
general phenomenon, it was of interest to examine
another oligomeric receptor with substantially
different organization and ligand-binding specifici-
ty. Oligomeric membrane-bound, glycan-binding
receptors with C-type CRDs fall into two divergent
groups on the basis of their primary binding
specificity for mannose and related monosacchar-
ides or galactose and related monosaccharides.25
While DC-SIGN falls in the mannose-binding group,
the macrophage galactose lectin (MGL) is a repre-
sentative galactose-binding receptor that in rat and
Table 1. Inhibition constants for asialofetuin glycopeptide binding to MGL
CRD ECD
KI (μM) 260±20 160±45
KGal/KI 21.5 35
Enhancement due to CRD affinity for branched glycans (fold) 7.2×
Enhancement due to ECD affinity for branched glycans (fold) 11.7×
Enhancement due to multiple CRDs binding branches (fold) 1.6×
Binding inhibition experiments were done on plates coated with the CRD or ECD portions of MGL using 125I-labeled Gal-BSA as the
reporter ligand.
689High Affinity Glycoprotein–Receptor Bindinghumans consists of a single type of subunit,26,27 and
is able to bind to viral glycoproteins, such as those
on Ebola and other filoviruses.28 MGL is homolo-
gous to the hepatic asialoglycoprotein receptor and
the sequence of the neck that links the CRDs to the
membrane anchor is consistent with the presence of
a potential coiled-coil domain that would stabilize
an oligomeric structure like the trimer formed by the
major subunit of the hepatic receptor.29 Chemical
crosslinking and gel-filtration analysis confirmed
that the extracellular domain of MGL expressed in
bacteria forms trimers (Supplementary Data Fig. 1).
The effect of glycan branching on interaction with
MGL was investigated by probing both monomeric
CRDs and trimeric extracellular domains of MGL
with a desialylated tri-antennary glycopeptide,
isolated from fetuin, in the competition bindingFig. 4. Creation and characterization of glycosylation varia
with 1 to 4 glycosylation sites. (e) SDS-PAGE of a selection of
chromatography on immobilized nickel columns were visualiz
model was created with InsightII and Molscript56 based on thassay (Fig. 3). The relative affinity of the CRD for the
glycopeptide compared to galactose is 21.5 (Table 1),
which is 7.2-fold higher than the expected threefold
enhancement that would be expected based solely
on the presence of three terminal galactose residues.
This roughly sevenfold enhanced affinity for
branched glycans is somewhat like that observed
for DC-SIGN (illustrated in Fig. 1b). Binding to the
trimeric extracellular domain was enhanced a
further 1.6-fold (Table 1), suggesting that binding
of multiple terminal sugars by multiple CRDs in the
extracellular domain (illustrated in Fig. 1f) makes
only a small contribution to the overall affinity of the
intact receptor for a branched glycan. The effect of
branching on binding to MGL is consistent with
previous results from testing this protein against a
glycan array, because several of the ligands givingnts of orosomucoid. (a)–(d) Modeled structures of mutants
glycosylation variants. Glycoproteins purified by affinity
ed on the gel by staining with Coomassie brilliant blue. The
e structure of bovine lactoglobulin (PDB ID 1B8E).57
Table 2. Distribution of N-linked glycans on variant asialo-orosomucoid molecules
Variant Bi-antennary (%) Tri-antennary (%) Tetra-antennary (%) Terminal galactose residues
1a 45 51 3 2.6
1b 67 30 2 2.3
1c 89 11 1 2.2
Average for single-site variants 2.4
2a 25 59 16 5.8
2b 47 47 5 5.1
2c 45 36 19 5.5
2d 32 53 16 5.8
2e 37 43 21 5.8
2f 40 40 20 5.6
Average for two-site variants 5.6
3 36 43 21 8.6
4 35 39 26 11.6
5 33 42 26 14.8
Serum-deriveda 14 38 48 16.7
a Values from Ref. [33].
690 High Affinity Glycoprotein–Receptor Bindingthe highest signals for MGL are branched structures
terminating in galactose,30 as well as quantitative
binding assays with linear and branched sugar
structures.31,32 However, the present results dem-
onstrate that, as in the case of DC-SIGN, this
enhancement results primarily from multiple inter-
actions within a CRD and that only a limited further
enhancement results from simultaneous interactions
with multiple CRDs in a receptor oligomer.
Effect of protein presentation on binding to MGL
To facilitate analysis of the additional factors that
contribute to the affinity of MGL for glycoprotein
ligands, variant forms of orosomucoid, a monomeric
serum glycoprotein also known as α1-acid glycopro-
tein, that bear differing numbers of glycans were
developed. Human orosomucoid contains five sites
forN-linked glycosylation, each ofwhich is occupied
by a complex oligosaccharide (Fig. 4).33 Site-directed
mutagenesis was used to generate vectors for the
expression of modified forms of histidine-tagged
orosomucoidwith one to five glycosylation sites. The
proteins were produced in Chinese hamster ovary
cells, purified by affinity chromatography on chelat-
ed nickel columns, and treated with neuraminidase
to remove terminal sialic acid residues. A selection ofFig. 5. Competition experiments to quantify binding of or
ligands with a range of affinities are shown, with measured dthe desialylated glycoproteins separated by SDS-
PAGE is shown in Fig. 4e. The differences in the
mobilities of the proteins in the gel confirmed that
selected glycosylation sites were missing, but that
the remaining glycosylation sites are fully occupied.
The multiple bands for each protein reflect the
presence of different glycoforms of each variant.
The glycans attached to the engineered forms of
orosomucoid were characterized by single and tan-
demmass spectrometry (SupplementaryData Figs. 2
and 3) and compared in a semi-quantitative manner
(Table 2).34 The results confirm that the sialic acid
residues have been removed efficiently and indicate
that each of the glycoproteins bears a mixture of bi-,
tri-, and tetra-antennary complex glycans. Compar-
ing the single-site variants reveals that the position of
glycosylation does affect the degree of branching
and this effect is carried over into the proteins with
multiple glycosylation sites. However, there is no
simple correlation between position or number of
glycosylation sites and the extent of branching.
The glycoprotein presentation effect was investi-
gated using the engineered glycoprotein ligands
containing only a single glycosylation site as well as
a glycopeptide pool from one of the variants. The
results, illustrated in Fig. 5 and summarized in Table
3, reveal that the affinity of MGL for the three singlyosomucoid variants to the CRD from MGL. Examples of
ata shown as circles and fitted curves indicated as lines.
Table 3. Inhibition constants for binding to MGL
Ligand
CRD ECD
KI,ligand
(μM) KI,Gal/KI,ligand
KI,Gal/KI,ligand
per terminal Gal
KI,ligand
(μM) KI,Gal/KI,ligand
KI,Gal/KI,ligand
per terminal Gal
Galactose 5600±150
OR-1b glycopeptide 450±10 12.4 5.1
OR-1a 31±2 34±1
OR-1b 20±6 20±2
OR-1c 17±3 20±1
Average 23±6 243 101 25±7 224 93
OR-2a 4.7 3.1
OR-2b 13 7.5
OR-2c 11 2.1
OR-2d 10 5.0
OR-2e 2.3 8.5
OR-2f 6.4 2.5
Average 8±4 700 125 4.8±2.5 1170 209
OR-3 6.5 930 110 1.5 3700 434
OR-4 3.6 1550 134 0.9 6200 540
OR-5 1.4±0.1 4000 270 0.65±0.12 8615 582
Serum-derived OR 0.12±0.01 31,000 1850 0.18±0.02 47,000 2800
Binding inhibition experiments were done on plates coated with the CRD or ECD portions of MGL, using 125I-labeled Gal-BSA as the
reporter ligand.
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factor of less than 2, in spite of a range of nearly
fivefold in the relative proportions of bi-and tri-
antennary glycans attached to these variants. These
results suggest that there is relatively little difference
in the affinity of the receptor for the bi-and tri-
antennary oligosaccharides. However, the relative
affinity of the CRD of MGL for the glycopeptide
from variant OR-1b (KI,Gal/KI,glycopeptide= 12.4;
Table 3) is roughly fivefold higher than the 2.3-fold
enhancement that would be expected based on the
presence of an average of 2.3 terminal galactose
residues per glycopeptide. This number is almost as
high as the sevenfold enhancement observed for the
tri-antennary glycopeptide from asialofetuin (TableFig. 6. Summary of the sources of enhanced affinity for gly
linked by the fold enhancement resulting from various factor1), confirming that the degree of branching makes
only a modest contribution to enhanced affinity. The
most striking comparison is the difference in
affinities for the intact glycoproteins bearing a single
glycan (KI= 23 μM; Table 3) and the isolated
glycopeptide derived from one of these glycoprotein
(OR-1b, KI= 450 μM; Table 3), which reveals a 20-
fold enhancement in affinity resulting from presen-
tation of the glycoprotein rather than the glycopep-
tide. Thus, for a glycoprotein bearing a single glycan
interacting with a single CRD, there is a 100-fold
enhancement in affinity even when normalized to
the number of terminal galactose residues present,
resulting from the fivefold effect of the affinity of the
CRD for branched glycans and the 20-fold effect ofcoproteins binding to MGL. The KI values from Table 3 are
s. Letters in parentheses refer to the illustrations in Fig. 1.
692 High Affinity Glycoprotein–Receptor Bindingpresentation of the glycan on a protein. These
contributions are summarized in Fig. 6.
The binding of the CRD of MGL to orosomucoid
variants with increasing numbers of glycans reveals
that themonomeric CRDhas up to 2.7-fold increased
affinity for orosomucoid variants with increasing
numbers of glycans, as the KI,Gal/KI,ligand value
normalized to the number of terminal galactose
residues increases from 101 to 270 on going from one
to five glycans on the orosomucoid (Table 3). This
increase could mean that, in addition to secondary
interactions with branches within a glycan and with
the protein to which the glycan is bound, the CRD
can interact with other oligosaccharides attached to
the glycoprotein ligand. However, it may also reflect
the potential of some variants occasionally to bridge
between two monomers immobilized on the poly-
styrene surface. Variation in the affinities of MGL for
different variants of orosomucoid with two attached
glycans probably reflects differences in the spacing
of the glycans, but in the absence of more structural
information about how the glycans project from the
surface of the protein, it is difficult to discern a
specific pattern correlating spacing with enhanced
affinity.
Effect of MGL oligomerization on binding to
glycoprotein ligands
With knowledge of the effect of glycan branching
and presentation on the affinity of individual CRDs
for their ligands, it is possible to use the engineered
glycoproteins to investigate the effect of receptor
oligomerization on affinity for multivalent ligands.
Binding of the singly glycosylated variants of
orosomucoid to the trimeric extracellular domain
of MGL does not differ significantly from binding to
the monomeric CRD, indicating that binding of
multiple CRDs in the trimer to branches of a single
glycan on the glycoprotein is not a factor in
enhanced glycoprotein ligand binding (Table 3
and Fig. 6). The 1.6-fold tighter binding of the free
tri-antennary glycopeptide from asialofetuin to the
trimer compared to the monomer (Table 1) might
reflect accessibility not present in the protein-bound
oligosaccharide.
Binding of multiple glycans on a target ligand to
multiple CRDs in a receptor oligomer represents one
form of affinity enhancement through multivalency
that has been observed for soluble lectins (Fig. 1g).
As expected for this effect, the affinity of the trimeric
extracellular domain of MGL shows a further
enhancement compared to the monomeric CRD
when binding to orosomucoid variants with two or
more glycans (Fig. 6). However, the magnitude of
this enhancement is only about twofold, compared
to much higher levels of enhancement observed for
other glycan-binding proteins, such as pentameric
bacterial toxins.5 The key difference in this case is
that the natural targets for such toxins are mem-
branes with multiple, widely spaced glycolipid
ligands rather than simple soluble glycoproteins
with relatively closely spaced glycans. Solublemultivalent ligands designed to interact with the
toxins consist of multiple target glycans arrays on a
scaffold that positions them at sufficient distances to
interact with the multiple binding sites in the toxin
oligomer.
Further affinity enhancements in native
asialo-orosomucoid
Comparison of the binding of MGL to asialo-
orosomucoid derived from human blood with the
protein bearing five glycans expressed in Chinese
hamster ovary cells reveals that even with five
glycans, the expressed protein has a lower affinity
for both receptors than the natural protein (Table
3). As shown in Table 2, the orosomucoid from
Chinese hamster ovary cells has a smaller fraction
of tetra-antennary and a larger fraction of bi-
antennary glycans compared to serum-derived
asialo-orosomucoid,33 but the comparisons de-
scribed earlier suggest that the increased degree
of branching has only a modest effect on the affinity
of binding to a CRD. Thus, it is likely that this
difference reflects the presence of additional termi-
nal glycan elaborations found on the natural
protein but not synthesized in the cultured cells.
For example, addition of outer arm fucose residues
is known to be a common modification of serum
orosomucoid,35 generating the Lewisx epitope,
which gives strong signals in glycan array analysis
of MGL.30 Such structures are not found on the
expressed proteins. A difference in binding of the
natural and expressed proteins is observed for both
the monomeric CRD and the trimeric extracellular
domain, which is consistent with the suggestion
that the difference lies in the interaction of
individual CRDs with individual branching and
terminal structures.Discussion
The observation that comparable affinity enhance-
ments for binding of single protein-bound glycans to
monomeric CRDs are observed for receptors as
distantly related as DC-SIGN and MGL, and the
fact that the enhancement is not unique to a glycan at
a single site on a glycoprotein suggests a relatively
nonspecific effect. At least two mechanisms can be
suggested: low-specificity interactions between the
surfaces of the CRD and the protein portion of the
glycoprotein ligand, or restriction in the conforma-
tion of the glycans when they are attached to
glycoprotein. As an illustration of the first mecha-
nism, binding of the C-type CRD of E-selectin to P-
selectin glycoprotein ligand 1 is enhanced by inter-
action with sulfated tyrosine residues in a region of
the protein adjacent to the glycan that binds in the
primary binding site of the CRD.36 Mutagenesis
studies suggest that in this case, the negative charges
on the sulfated tyrosine residues provide a relatively
nonspecific interaction that adds to the overall
affinity for the glycoprotein ligand. There is also
693High Affinity Glycoprotein–Receptor Bindingsubstantial evidence that the flexibility of glycans is
restricted when they are attached to proteins, which
would lead to a decreased entropy penalty and
hence increased affinity of a CRD for glycans
presented in preferred conformations on glycopro-
tein backbones. Examples of glycoproteins in which
the interaction of glycans with the protein surface
have been examined in molecular detail include
CD2,37 the α subunit of human chorionic gona-
dotropin,38 ribonuclease B,39 and viral envelope
glycoproteins including the Epstein-Barr virus
major envelope glycoprotein.40 Interactions between
the glycan and protein portion of the glycoprotein
typically occur between the first and second GlcNAc
residues in the core and can result in the glycan lying
parallel with the protein surface. Although the
terminal residues of the glycan would remain
accessible for lectin binding, the overall conforma-
tional space accessible to these glycans is substan-
tially reduced.
The affinity measurements reported here were
made in assay formats that allow us to dissect out
effects associated with interactions of individual
oligosaccharides and glycoproteins with individual
CRDs and receptor oligomers. Combining the
enhancements for binding of glycoproteins to
MGL, as summarized in Table 3 and Fig. 6, results
in an overall enhancement of nearly 3000-fold for
binding of the natural, multiply glycosylated asialo-
orosomucoid to the receptor trimer, corresponding
to a sub-micromolar affinity. Multivalent interaction
between glycoproteins and oligomeric receptors
makes only a very modest contribution to this total
enhancement.
When comparing the increase in affinity observed
in these studies with enhancements of up to 106-
fold that have been reported for oligosaccharide
binding to solubilized receptors or receptors on cell
surfaces,7,41 and for soluble multivalent lectins such
as the galectins,42 it is important to note that in the
work presented here the interactions have been
assessed in assays that segregate out the effects of
two-and three-dimensional lattice formation (Fig. 1h
and i). Three-dimensional lattice formation is well
documented for the interactions of galectins with
multivalent ligands,7,8,43,44 but such three-dimen-
sional lattice formation, which probably contributes
to high-affinity interaction in assays using solubi-
lized membrane receptors, would not reflect a
geometrically plausible arrangement for these recep-
tors in their natural membrane environment. Two-
dimensional lattice formation in membranes is a
much more plausible explanation for the further
enhancements observed in experiments on hepato-
cytes with natural or synthetic oligosaccharides or
glycopeptides.7,41,45 Such enhancements have been
observed with free oligosaccharides, corresponding
to bridging of the type illustrated in the left-hand
portion of Fig. 1h. However, the geometrical
arrangement of binding sites in receptor oligomers
and the extended interactions of the CRDs with
oligosaccharide ligands might interfere with such
interactions. In addition, free oligosaccharide orglycopeptide ligands have been observed in extend-
ed conformations when complexed with multivalent
lectins in three-dimensional lattices.43,46 These struc-
tures suggest that the affinity for single glycans could
be overestimated in such studies compared to what
would be achieved for glycans that are attached to
glycoproteins and are thus constrained in conforma-
tion. In the natural situation, two-dimensional lattice
formation might be more likely to result from
binding of multiple receptor oligomers to multiple
glycans on a glycoprotein, as shown at the right in
Fig. 1h. The possibility of pattern matching between
fixed arrays of CRDs and the terminal sugars on
oligosaccharides, either in receptor oligomers or in
cell surface lattices has been suggested.47 However,
experiments with DC-SIGN binding to oligosacchar-
ides on a membrane surface indicate that, in some
cases, receptor mobility and flexibility in the posi-
tioning of CRDs might be necessary for the receptors
to adapt to the disposition of glycans on surfaces.15Material and Methods
Expression of fragments from glycan-binding receptor
Expression of the extracellular domain and CRD from
DC-SIGN13 and CRDs from rat MGL and RHL-112
followed published procedures. The extracellular do-
main of DC-SIGN was further purified on a Mono-Q
anion-exchange column.13 The extracellular domains of
MGL (NCBI accession number P49301) from residue 59 to
the C-terminus were expressed in an analogous T7
promoter system with an extra alanine residue appended
at the N-terminus.
Glycoproteins and glycopeptide preparation
Bovine fetuin (Sigma) and soybean agglutinin, prepared
by affinity chromatography,48 were dissolved to 100 mg in
5 ml of 1% (w/v) ammonium bicarbonate and digested for
20 h at 37 °C with 5 mg of subtilisin (Sigma), resulting in
short peptide fragments. Digested material was treated
with 2 mM phenylmethylsulphonyl fluoride (Sigma;
prepared at 30 mg/ml in ethanol) and lyophilized before
being dissolved in 0.5ml of 5% (v/v) acetic acid and loaded
onto a Sephadex G-50 column (7 mm×500 mm) run in 1%
acetic acid.49 Sugar-containing fractions (0.5 ml) were
pooled. Glycopeptides were treated with neuraminidase
and repurified by passage through the Sephadex G-50
column.
Production of orosomucoid variants
A cDNA for orosomucoid was cloned from a human
liver cDNA library (ClonTech) using forward primer:
AACCTCCTGGTCTCAGTATGGCGCTGTCCTGGG and
reverse primer: TTCTAGTGATGGTGATGGTGATGT-
CCGGATTCCCCCTCCTCCTGTTTCCTCTC (Invitrogen)
which created a His6 tag at the C-terminal end of the
encoded protein. Glycosylation site mutations were
created by inserting double-stranded synthetic oligonu-
cleotides that included the desired mutations between
appropriate restriction sites in the cDNA. In each case, the
AAC or AAT codon for the asparagine residue of the N-
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the glutamine codon CAG. Mutations were verified by
DNA sequencing, and the wild type and modified cDNAs
were transferred into the eukaryotic expression vector
pED.50 The dihydrofolate reductase-deficient Chinese
hamster ovary (CHO) cell line DXB11 was transfected
with mutant constructs using the calcium phosphate
method.51 Following selection for two weeks in MEM
alpha medium without nucleosides supplemented with
10% (v/v) dialyzed fetal calf serum, colonies were
combined. Protein expression was amplified by passaging
cells into medium containing methotrexate at 0.02 μM,
0.1 μM and 0.5 μM over a period of several weeks.
For production of protein, cells were grown to
confluence in selection medium and transferred to
serum-free medium: CHO-S-SFM II (Invitrogen) supple-
mented with 50 mM Hepes, pH 7.55, 4 μM CaCl2 and
0.5 μM methotrexate. Medium was harvested every two
days for eight days, pooled, made to 0.5 M NaCl, 25 mM
Tris–HCl, pH 7.8, 20 mM imidazole, centrifuged at
10,000 g for 15 min and loaded onto a 2 ml nickel-NTA-
Sepharose column (Amersham Biosciences) equilibrated
with N1 buffer (0.5 MNaCl, 25 mMTris–HCl, pH 7.8). The
column was washed with 8 ml of N1 buffer containing
20 mM imidazole and eluted with 8×1 ml of N1 buffer
containing 100 mM imidazole. Fractions were analyzed by
SDS-PAGE and those containing protein were pooled,
diluted fivefold in N1 buffer and re-loaded onto a 2 ml Ni-
NTA-Sepharose column. The column was eluted with
8×1 ml of N1 buffer containing 200 mM imidazole to
concentrate the protein. The final protein-containing
fractions were dialyzed against 50 mM sodium citrate,
pH 6.0 and incubated with Clostridium perfringens neur-
aminidase (New England Biolabs) at 37 °C overnight. In
order to remove the neuraminidase, fractions were made
up to 0.5 M NaCl, 25 mM Tris–HCl, pH 7.8, 20 mM
imidazole and loaded again onto a 2-ml Ni-NTA-
Sepharose column and eluted with 8×1 ml of N1 buffer
containing 200 mM imidazole. Protein yields were 1 ∼
2 mg of desialylated variant orosomucoid per 100 ml of
collected cell culture medium.
Surface plasmon resonance studies
Analysis was done with a BiaCore 3000 instrument.
CM5 sensor chips (Pharmacia Biosensor) were activated
with N-hydroxysuccinimide and 1-ethyl-3-(3-dimethyla-
minopropyl) carbodiimide following the supplier's proto-
cols. Coupling was performed for 10 min at a flow rate of
10 μl/min with 50 μg/ml ligand in 10 M sodium acetate,
pH 5.0 for proteins and pH 4.0 for glycopeptide, followed
by blocking with 1 M ethanolamine–HCl. All analysis was
done in running buffer (10 mM Hepes, 150 mM NaCl,
5 mMCaCl2 with 0.005% (v/v) P20 (surfactant), pH 7.4), at
25 °C and a flow rate of 10 μl/min. Sensor chip surfaces
were regenerated with EDTA-containing regeneration
buffer. SigmaPlot was used to fit data to an equation for
simple, saturable binding with a dissociation constant KD
superimposed on a linearly increasing background of non-
specific binding.12
Competition binding assays
Competition assays, in which receptor fragments were
immobilized on polystyrene wells (Immulon 4 HBX
from Thermo Labsystems), were done as described,
using 125I-labeled Gal-BSA and 125I-labeled Man-BSA as
a reporter ligands.12,13 In each experiment, duplicatetitrations were performed and the average values for
each concentration were used in a nonlinear, least-squares
fitting program (SigmaPlot) to determine the concentra-
tions of competing ligand required for 50% inhibition of
reporter ligand binding (KI).12 The data are presented as
average±standard deviation for at least three independent
experiments.Glycan analysis
Reduction and carboxymethylation were done as
described.52 Samples were reduced at 37 °C for 1.5 h in
50 mM Tris–HCl buffer, pH 8.5, containing 2 mg/ml
dithiothreitol, and carboxymethylated by reaction with
12 mg/ml iodoacetic acid at room temperature for 1 h.
Carboxymethylation was terminated by dialysis against
50 mM ammonium bicarbonate, pH 8.5, at 4 °C for 36 h,
followed by lyophilization. Samples were incubated with
trypsin (Sigma) at a 50:1 (w/w) ratio in 50 mM ammo-
nium bicarbonate, pH 8.5, for 16 h at 37 °C. The digestion
was terminated by incubation at 100 °C for 3 min,
followed by C18 Sep-Pak chromatography (Waters).
Bound peptides were eluted with either 20% (v/v) or
40% (v/v) propanol in 5% (v/v) aqueous acetic acid,
pooled and lyophilized. Digestion with peptide N-
glycosidase F (Roche Molecular Biochemicals) was done
in ammonium bicarbonate (50 mM, pH 8.5) for 16 h at
37 °C using 3 U of enzyme. The reaction was terminated
by lyophilization and the released N-glycans were
separated from peptides and O-glycopeptides by passage
through a Sep-Pak C18 (Waters) column and permethy-
lated using the NaOH procedure.52 Matrix-assisted laser
desorption/ionization time-of-flight (MALDI-TOF) data
were acquired on a Voyager-DE sSTR mass spectrometer
(PerSeptive Biosystems) in the reflectron mode with
delayed extraction. Permethylated samples were dis-
solved in 10 μl of 80% (v/v) methanol in water, and 1 μl
of dissolved sample was premixed with 1 μl of matrix
(10 mg/ml 2,5-dihydroxybenzoic acid in 80% (v/v)
aqueous methanol) before loading onto a metal plate.
The matrix-assisted laser desorption-ionization time-of-
flight tandem mass spectrometry experiments were done
with a 4800 Proteomics Analyzer (Applied Biosystems)
operated in reflectron positive ion mode.Other analytical procedures
SDS-PAGE was done by the method of Laemmli.53
Sugar-containing fractions were assayed by the anthrone
assay,54 and protein was assayed by the method of
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Abstract
Modular calcium-dependent carbohydrate-recognition domains (CRDs) of mam-
malian glycan-binding receptors (C-type lectins), engineered to have novel
glycan-binding selectivity, have been developed as tools for the study of glycans
on cell surfaces. Structure-based specificity swapping between domains can be
complemented by empirical characterization of ligand-binding specificity using
glycan arrays. Both natural and modified CRDs can be used as probes for
detecting and isolating glycoproteins that bear specific glycan epitopes and
that act as target ligands for glycan-binding receptors. CRD-based affinity chro-
matography facilitates proteomic and glycomic analysis of such ligands.
1. Overview
Calcium-dependent carbohydrate-recognition domains (C-type
CRDs) form the sugar-binding portions of a large and diverse family of
mammalian glycan-binding receptors (C-type lectins) (Drickamer, 1999).
Although these protein modules share conserved framework amino acids,
the sugar-binding sites are diverse. These sites fall broadly into two classes,
with primary specificity either for mannose and GlcNAc or for galactose
and GalNAc, based on interaction of the 3- and 4-hydroxyl groups with a
conserved calcium ion (Drickamer, 1999; Weis and Drickamer, 1996).
Additional interactions in some of the binding sites lead to more selective
binding to specific types of oligosaccharides. Binding of C-type CRDs to
sugars on glycoproteins and cell surfaces forms a basis for cell adhesion,
serum glycoprotein turnover, and recognition of pathogens in the innate
immune system, which reflect the roles of additional domains in the
receptors (Garcı´a-Vallejo and van Kooyk, 2009; Taylor and Drickamer,
2007; van Kooyk and Rabinovich, 2008). For example, when CRDs in
serum mannose-binding protein interact with sugars on the surfaces of
bacterial and fungal pathogens, proteases bound to collagen-like stalks
adjacent to the CRDs are able to activate complement (Wallis, 2007).
Several features of the C-type CRDs make them attractive as potential
tools for characterizing glycosylation of cells and proteins. The CRDs are
modular and many can be readily expressed in bacterial expression systems.
The presence of several disulfide bonds makes the protein stable to immo-
bilization and labeling chemistries. In addition, the calcium dependence of
the ligand-binding activity means that bound ligands can be efficiently
released with chelating agent, such as EDTA, following which binding
activity is readily restored by readdition of calcium ions. In addition to
these features of naturally occurring C-type CRDs, protein engineering
experiments have demonstrated the feasibility of modifying the sugar-binding
characteristics of the CRDs with relatively minor changes in their amino acid
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sequences. For example, changes in just 10 residues are sufficient to convert
the CRD of mannose-binding protein from mannose/GlcNAc specificity to
galactose/GalNAc specificity (Iobst and Drickamer, 1994).
2. Engineering Glycan-Binding Specificity
Attempts to modify sugar-binding specificity of C-type CRDs have
been informed by knowledge of the structures of multiple CRD–ligand
complexes. Combination of sequence comparisons with structural and muta-
genesis studies has led to an appreciation for the role of acidic and amide side
chains that ligate a calcium ion and also form part of the sugar-binding site
(Weis and Drickamer, 1996). In addition, in galactose-binding sites, an
aromatic residue, often a tryptophan, usually plays a key role in packing
against the apolar B face of the sugar (Iobst and Drickamer, 1994; Kolatkar
and Weis, 1996). These features are encoded in a contiguous stretch of 9–14
amino acid residues that forms one side of the sugar-binding region (Fig. 9.1).
Changes of the sequences in this region reliably lead to predictable swaps in
specificity between mannose-type and galactose-type binding sites.
Additional specificity is conferred by interactions with protuberances in
the surface of the CRD on the other side of the binding site, but in a manner
that is less readily predictable from sequence comparisons (Feinberg et al.,
2000, 2007; Somers et al., 2000). Thus, defining the specificity of engi-
neered carbohydrate-binding domains depends on the ability to screen for
interesting sugar-binding selectivity. Glycan arrays have recently emerged as
excellent tools for the broad characterization of binding specificity,
providing a powerful empirical complement to the structure-based design
approach (Blixt et al., 2004; Feizi et al., 2003; Taylor and Drickamer, 2009).
The importance of glycan array screening is illustrated in Fig. 9.2, in which
galactose-binding activity has been introduced into three different CRDs
that naturally bind to mannose-type sugars. Although all three modified
proteins contain the same galactose-specificity sequence and bind to galac-
tose-Sepharose affinity columns, they show very different interactions with
oligosaccharide ligands. All three proteins are oligomeric, so they have the
potential to make multivalent interactions that provide the avidity necessary
to withstand the washing steps used in processing of the arrays.
The galactose-binding version of mannose-binding protein (Gal-MBP)
bindsmultiple classes of galactose-terminated glycans (Powlesland et al., 2009).
Amongst the better ligands are oligosaccharides that bear terminal fucosylated
epitopes, although some nonfucosylated ligands also rank high amongst the
ligands. By comparison, the galactose-binding version of langerin (Gal-lan-
gerin) binds exclusively to terminal Lewisa and Lewisx groups, and the galac-
tose-binding version of DC-SIGN (Gal-DC-SIGN) (Guo et al., 2006) does
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not show strong binding to any ligands on the array. Interestingly, none of
these patterns matches the specificities seen for natural galactose-binding
proteins from which the inserted sequence was derived. These results reflect
the effects of the surface residues on the unmodified sideof the binding site, and
they emphasize the importance of experimental characterization of the glycan-
binding activity of engineered binding proteins.
2.1. Protocol 1: Characterization of engineered CRDs using
glycan arrays
For oligomeric proteins, direct labeling with fluorescein isothiocyanate gives
good signals on the array (Guo et al., 2004). Proteins need to be transferred
out of Tris-containing buffers, either by dialysis or by repurification on a
Figure 9.1 Strategy for introduction of galactose-binding activity into CRDs. (A)
Alignment shows sequences of the galactose-binding major subunit of the human
asialoglycoprotein receptor (human hepatic lectin 1, HHL1), rat serum mannose-
binding protein, human langerin, and human DC-SIGN. Conserved framework resi-
dues are highlighted in green and residues that ligate Ca2þ and sugar are highlighted in
yellow. The blue region has been transferred from the galactose-binding CRD to the
three mannose-binding CRDs. (B) The corresponding region of the crystal structure of
Gal-MBP is shown in cyan. Figure was created with PyMol using coordinates from
Protein DataBank entry 1afb.
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sugar-Sepharose column. Buffers containing 150–500 mM NaCl and either
25 mMNa-HEPES, pH 7.8, or 25 mM bicine-Cl, pH 9.0, can be used. For a
1-ml column, after application of the protein, the column is rinsed with 5 ml
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Figure 9.2 Glycan array analysis of CRDs modified to bind galactose. The arrays were
screened with approximately 200 mg/ml of each of the fluorescein-labeled proteins.
Gal-MBP and Gal-langerin are trimers, while Gal-DC-SIGN is a tetramer. Consortium
for Functional Glycomics array version 2.1 was screened with Gal-MBP (A) while
the other proteins were screened on array version 4.1 (B,C). Glycans terminating in
Lewisa and Lewisx epitopes are highlighted in red, while other glycans containing
galactose residues with free 3- and 4-hydroxyl groups are shaded green, and those
with GalNAc residues with free 3- and 4-hydroxyl groups are shaded cyan.
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of buffer containing 25 mM CaCl2 and eluted with 5 aliquots of 0.5 ml of
buffer containing 2.5 mM EDTA. Aliquots of approximately 2 ml containing
200–400 mg of protein are mixed with 5 aliquots of 10 ml of fluorescein
isothiocyanate dissolved at 1 mg/ml in dimethyl sulfoxide and left to react
overnight at 4 C. The reaction is quenched by addition of buffer containing
25 mM Tris–Cl and 25 mM CaCl2 and the protein is separated from
unreacted reagent by column repurification as described above, but with
buffers containing 25 mM Tris–Cl, pH 7.8.
For expression of biotin-tagged protein, synthetic oligonucleotides are
used to append the biotinylation sequence GlyLeuAsnAspIlePheGluAlaGln-
LysIleGluTrpHisGlu at the C-termini of the extracellular domain fragments
(Schatz, 1993). Proteins are expressed in Escherichia coli strains containing
plasmid pACYC-184 with the birA gene (Avidity, Denver CO) and grown
in the presence of 20 mg/ml chloramphenicol and 12.5 mg/ml biotin. The
system works both for proteins expressed in a T5T system in strains, such as
BL21(DE3), in which proteins are expressed as inclusion bodies followed by
refolding (Graham et al., 2009), or in an ompA system in strains, such as
JA221, in which the protein is directed to the periplasm and folds directly
(Powlesland et al., 2008). Following purification, the tagged protein is
adjusted to 25 mM CaCl2 and Alexa 488-labeled streptavidin (Invitrogen) is
added so that the ratio of CRD to streptavidin monomers is roughly 2:1.
After incubation overnight at 4 C, complexes are isolated by affinity chro-
matography on 1-ml monosaccharide affinity columns as described above.
Fractions containing labeled protein are used to probe the glycan
array developed by the Consortium for Functional Glycomics (www.func-
tionalglycomics.org) following their standard protocol. The presence of
2 mMCaCl2, in the binding and wash buffers, is sufficient to support binding.
Glycan arrays provide a broad overview of the types of ligands bound by
receptors with engineered CRDs, but there is need for caution in making
quantitative interpretations of the results. For this purpose, solid-phase
binding assays can often be employed. Because of the weak intrinsic affinity
of C-type CRDs for individual oligosaccharides, these assays are usually best
carried out in a competition format using a highly valent neoglycoprotein
reporter ligand (Coombs et al., 2010). Provided that the ligand is used at
levels well below saturation, the observed inhibition constants provide a
close approximation to the binding affinity constants (Levitzki, 1997). An
example is shown in Fig. 9.3, in which a segment of LSECtin, a receptor
with a mannose-type binding site, has been transferred into the CRD of the
major subunit of the human asialoglycoprotein receptor, which would
naturally bind galactose-type sugars (Spiess, 1990). In this case, the compe-
tition illustrates that modified receptor binds mannose, but the very high
affinity of LSECtin for the disaccharide GlcNAcb1-2Man compared to
mannose (Powlesland et al., 2008) is not conferred by the region that has
been transferred.
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2.2. Characterization of engineered CRDs using solid-phase
binding assays
Details of solid-phase binding assays have been described in this series
(Taylor and Drickamer, 2003).
3. CRDs as Probes for Detection of Glycans
on Blots
Radiolabeling of natural and engineered CRDs that have a range of
specificities toward different carbohydrate structures creates a panel of
molecular probes that can be used to detect the presence of distinct glycan
structures on glycoproteins. These labeled probes are particularly useful for
detecting glycoprotein ligands on blots of SDS–polyacrylamide gels of cell
extracts (Coombs et al., 2005; Powlesland et al., 2008).
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Figure 9.3 Binding competition assays to characterize CRDs modified to bind man-
nose. (A) Alignment shows sequences of the galactose-binding major subunit of the
human asialoglycoprotein receptor (human hepatic lectin 1, HHL1) and the receptor
LSECtin, which binds selectively to the disaccharide GlcNAcb1-2Man. Conserved
framework residues are highlighted in green and residues that ligate Ca2þ and sugar
are highlighted in yellow. The blue region has been transferred from the LSECtin CRD
to the HHL1 CRD. (B,C) Wild-type LSECtin and Man-HHL1 were immobilized on
wells and probed with 125I-Man33-BSA in the presence of varying concentrations of
inhibitors as described in (Powlesland et al., 2008).
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3.1. Protocol 2: Labeling and detection of ligands
Protein for radiolabeling should ideally be at concentrations of at least 0.5–1mg/
ml and needs to be transferred into buffer containing 100 mM bicine-Cl, pH
8.5, by dialysis or affinity chromatography as described inProtocol 1. Labelingof
1-ml aliquots of protein is performed with 250 mCi of 125I Bolton–Hunter
reagent (Bolton and Hunter, 1973) dried from 20 ml of benzene under a stream
of nitrogen immediately prior to use. After incubation at room temperature for
30 min, the labeled protein is separated from unreacted reagent as described in
Protocol 1. Labeling efficiency can be checked by counting 1 ml of each fraction
in a gamma counter. Fractions containing the highest levels of radioactivity are
diluted into 25 ml of binding buffer (150–500 mMNaCl, 25 mM Tris–Cl, pH
7.8, 25 mM CaCl2) containing 2% hemoglobin.
For detection of receptor-binding, glycoproteins resolved on SDS–
polyacrylamide gels are electroblotted onto nitrocellulose membranes
(Burnette, 1981). After blocking in 2% hemoglobin in loading buffer
overnight at 4 C, the membrane is incubated with radiolabeled receptor
for 120 min at room temperature with gentle shaking and washed four times
with 100 ml of binding buffer, with 5 min shaking for each wash. Radioac-
tivity is detected using a phosphorimager.
4. CRDs as Affinity Tools for Probing of
Cell Surface Glycosylation
Immobilized CRDs provide a convenient tool for enrichment of glyco-
proteins that are target ligands for glycan-binding receptors (Fig. 9.4). Proteo-
mic and glycomic approaches can be used to confirm the presence of distinct
glycan structures and to identify the major protein carriers of these structures
within the enriched pool. While natural CRDs from receptors can sometimes
be used in such studies, it is often difficult to produce sufficient quantities of
oligomeric forms of these proteins for construction of affinity columns. In such
cases, it is often more practical to use CRDs that can be readily produced in
bacterial expression systems but which have been engineered to share ligand-
binding properties with the receptor of interest. Figure 9.5 illustrates how this
strategy has been used to identifying a highly restricted population of glyco-
proteins responsible for presenting Lewisx and other fucosylated glycan struc-
tures in the breast cancer cell line MCF7 (Powlesland et al., 2009).
4.1. Protocol 3: Generation of affinity columns
Protein for preparing affinity columns should be at high concentration,
typically at least 1–2 mg/ml, as the efficiency of the coupling reaction is
considerably lower for more dilute samples. The protein is dialyzed
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overnight against coupling buffer (150 mM NaCl, 100 mM HEPES,
pH 8.0, 50 mM CaCl2). Most CRDs couple efficiently to Affigel 10
agarose-N-hydroxysuccinimide conjugate (BioRad Laboratories), which
is rinsed with 10 ml of cold H2O in a 10-ml Polyprep chromatography
column (BioRad Laboratories) before 2 ml of the dialyzed protein is added.
Both ends of the column are sealed and the suspension is mixed vigorously
followed by end-over-end mixing at 4 C for 4 h. The column is drained
and rinsed with 10 ml of blocking buffer (150 mM NaCl, 25 mM Tris–Cl,
pH 7.8, 25 mM CaCl2). Capping of remaining N-hydroxysuccinimide
groups is ensured by storage in blocking buffer overnight before use.
4.2. Protocol 4: Cell fractionation on affinity columns
Membrane glycoproteins are typically purified from 0.5–1  108 cells.
Adherent cells are washed twice with 10 ml of phosphate-buffered saline
(PBS) and harvested by scraping into 10 ml of PBS followed by centrifuga-
tion at 450g for 2 min. Suspension cells are harvested by centrifugation at
Cells
Lysate
Purified
glycoproteins
Blotting with
lectins and antibodies
Direct trypsin
digestion
Gel
electrophoresis
In-gel trypsin
digestion
Mass spectrometry
and database searching
HPLC
Glycomic analysis
Protocol 3
Protocol 4
Glycoprotein enrichment
by affinity chromatography
Solubilization
Protocol 2
Protocol 7
Protocol 8
Protocol 5 Protocol 6
Figure 9.4 Flow diagram for use of CRD affinity columns in proteomic and glycomic
analysis. Relationships between the steps described in individual protocols are shown.
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450g for 2 min and washed twice by resuspension in 10 ml PBS. Pellets
resuspended in 10 ml of cell lysis buffer (150 mM NaCl, 25 mM Tris–Cl,
pH 7.8, 2 mMCaCl2, 0.1% Triton X-100) supplemented with Triton to 1%
and containing protease inhibitors (cocktail set I from CalBiochem), are
sonicated for 10 s using a small probe at low power, as only gentle sonication
is required. After incubation on ice for 30 min, the lysate is precleared by
centrifugation at 100,000g for 15 min at 4 C and passed over the affinity
column. The column is washed with 5 ml of cell lysis buffer and glycopro-
teins are eluted in five 1-ml fractions of elution buffer (150 mM NaCl,
25 mM Tris–Cl, pH 7.8, 2.5 mM EDTA, 0.1% Triton X-100).
The column can be regenerated by washing with loading buffer so that
the purity of glycoproteins that bind to the affinity resin can be increased by
a second round of purification. Pooled elution fractions are adjusted to
25 mM CaCl2 and passed back over the affinity column. The column is
washed with 5 ml of high salt loading buffer (1.25MNaCl, 25 mM Tris–Cl,
pH 7.8, 25 mM CaCl2, 0.1% Triton X-100) and 5 ml of low salt loading
buffer (150 mMNaCl, 25 mM Tris–Cl, pH 7.8, 25 mMCaCl2, 0.1% Triton
X-100) and eluted with five 1-ml fractions of elution buffer. Purified
Column 1
Coomassie blue Coomassie blue
Wash Elution Wash
125I-Gal-MBP blot
Elution Elution
Column 2
CD98hc
LAT1
Gal-MBP
kDa
175
83
62
48
33
25
17
Figure 9.5 Example of purification of glycoproteins ligands from MCF7 cells. Glyco-
proteins on metastatic breast cancer cells that are capped with Lewisx and related sugar
structures may bind to the scavenger receptor C-type lectin on endothelial cells, leading
to extravasation at sites of secondary tumor formation (Elola et al., 2007). As the
trimeric extracellular domain of this protein is not readily produced in large amounts,
the engineered galactose-binding CRD from mannose-binding protein (Gal-MBP) was
used for affinity purification of the potential ligands from the surface of MCF-7 cells.
After two rounds of affinity chromatography, a single major glycoprotein ligand, CD98,
and its associated light chain, LAT1, were identified by proteomic analysis (Powlesland
et al., 2009).
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glycoproteins can be monitored on SDS–polyacrylamide gels followed by
staining with Coomassie blue.
Two alternative methods of protein identification, both based on the
analysis of tryptic peptides by mass spectrometry (MS), can be employed in
the proteomic strategy. For purified glycoproteins that are present in high
concentration and are well resolved on SDS–polyacrylamide gels, excision
of the protein from the gel and subsequent identification provides a useful
means of identifying the major species present. However, glycoproteins are
often present at concentrations not suitable for such in-gel analysis. Also,
highly glycosylated proteins often do not form well-resolved bands for
excision. In these cases, it is possible to analyze the total population of
glycoproteins purified by in-solution digestion and purification of the
resulting peptides by liquid chromatography followed by sequencing using
tandem mass spectrometry (LC-MS/MS).
4.3. Protocol 5: Gel analysis of isolated glycoproteins and
identification using in-gel trypsin digestion followed by
mass spectrometry
Proteins in the elution fractions are precipitated by addition of trichloroa-
cetic acid to a final concentration of 10% and incubation on ice for 10 min.
Typically, 20% of the elution fraction is precipitated, but this fraction can be
adjusted to ensure that any major populations of glycoproteins are visible by
Coomassie blue staining. Samples are centrifuged at 16,000g for 5 min,
and the pellets are washed twice with 1 ml of ethanol:ether (1:1), and dried
for 2 min under vacuum. Precipitated fractions are analyzed on SDS–
polyacrylamide gels followed by staining with Coomassie blue. After the
gel is destained and soaked in water, major protein bands are excised in
sections of approximately 1 mm and cut into 1 mm  1 mm pieces.
Coomassie blue stain is removed from the gel pieces by incubation in a
mixture of 200 ml of 50 mM ammonium bicarbonate, pH 8.4, and 200 ml of
acetonitrile for 5 min at room temperature, and the gel pieces are dried in a
vacuum centrifuge. Incubation at 56 C for 30 min in 200 ml of 10 mM
dithiothreitol dissolved in 50 mM ammonium bicarbonate, pH 8.4, is
followed by washing in 200 ml of acetonitrile and drying in a vacuum
centrifuge. Alkylation is performed on the dried gel pieces in the dark at
room temperature for 30 min with 200 ml of 55 mM iodoacetic acid
dissolved in 50 mM ammonium bicarbonate, pH 8.4. The iodoacetic acid
solution is removed and the gel pieces are washed in 500 ml of 50 mM
ammonium bicarbonate, pH 8.4, for 15 min at room temperature.
The volume of the gel pieces is reduced by adding 200 ml of acetonitrile
for 5 min and drying in a vacuum centrifuge. The dried gel pieces are
rehydrated in 20 ml of 25 ng/ml sequencing grade modified trypsin
(E.C.3.4.21.4, Promega) dissolved in 50 mM ammonium bicarbonate,
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pH 8.4, and incubated for 15 min at room temperature. After addition of a
further 20 ml of 50 mM ammonium bicarbonate, pH 8.4, to the gel pieces,
the digestion is allowed to proceed overnight at 37 C.
The supernatant from the gel pieces is transferred to a new tube. Peptides
are extracted from the gel pieces by incubation in 50 ml of 0.1% trifluor-
oacetic acid in H2O for 10 min at 37
C followed by the addition of 100 ml
of acetonitrile and incubation for a further 15 min at 37 C. The supernatant
is combined with the previous supernatant and the elution process is
repeated. The volume of the final pooled supernatants is reduced to
approximately 30 ml using a vacuum centrifuge.
4.4. Protocol 6: Analysis of purified ligands by in-solution
trypsin digestion followed by LC-MS/MS
Peak elution fractions are precipitated by the addition of trichloroacetic acid
to a final concentration of 10% and incubation on ice for 10 min. Samples
are centrifuged at 16,000g for 5 min, washed twice with 1 ml of ethanol:
ether (1:1), and dried for 2 min under vacuum. Precipitated fractions are
dissolved in 25 ml 8M urea containing 10 mMHEPES, pH 8.0, diluted with
25 ml 50 mM ammonium bicarbonate, pH 8.4, and reduced with 2 ml
0.5 mg/ml dithiothreitol at room temperature for 30 min. Alkylation is
performed with 10 ml of 0.5 mg/ml iodoacetic acid at room temperature for
20 min. After dilution with 325 ml of 50 mM ammonium bicarbonate and
digestion overnight at 37 Cwith 2 mg of sequencing grade modified trypsin
(E.C.3.4.21.4, Promega), samples are dried on a vacuum centrifuge and
resuspended in 80 ml of 0.1% trifluoroacetic acid. Peptides are desalted and
purified by nanoliquid chromatography on a 75 mm  15 cm C18 nano-
capillary column (Pepmap analytical column from LC Packings). Peptides
are loaded in buffer A (2% acetonitrile containing 0.1% trifluoroacetic acid)
and eluted with a gradient of 8–45% buffer B (90% acetonitrile containing
0.1% trifluoroacetic acid) over 60 min at a flow rate of 0.3 ml/min. Peptides
with retention times of between 12 and 60min are collected in 30-s intervals
by spotting directly onto a stainless steel target plate using a Probot
(LC Packings) with a-cyano-4 hydroxycinnamic acid used as matrix.
4.5. Protocol 7: Mass spectrometry of tryptic peptides
For in-gel trypsin digestion, 0.5 ml of sample is spotted onto a stainless steel
target plate and 0.5 ml of 10 mg/ml a-cyano-4 hydroxycinnamic acid
dissolved in acetonitrile:0.1% trifluoroacetic acid (1:1) is spotted on top of
the sample, and allowed to air dry before analysis. Matrix-assisted laser-
desorption mass spectrometry (MALDI-MS) profiling is complemented
with tandem mass spectrometry (MS/MS) of the 10 most abundant ions
in each sample. A typical instrument for this analysis is an Applied
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Biosystems 4800 MALDI time-of-flight tandem mass spectrometer, and the
Applied Biosystems GPS Explorer software can be used for analysis of
peptide mass fingerprint data and peak picking. A signal-to-noise threshold
of 10 is employed and sequazyme peptide mass standards can be used as
external standards for calibration.
For peptides purified by liquid chromatography, prespotted samples are
analyzed by MALDI-MS profiling, and major peaks are selected for colli-
sion-induced dissociation and sequencing by MS/MS. The Applied Bio-
systems GPS Explorer software can be used to select a maximum of 10 peaks
from each sample for sequencing. Peaks with identical masses present in
multiple spots should only be sequenced once.
4.6. Protocol 8: Informatics
The MS and MS/MS data for the tryptic peptides eluted from gels is used to
search the SWISSPROT protein database with the Mascot database search
algorithm (http://www.matrixscience.com) using the following parameters:
peptide masses are stated as monoisotopic, methionine residues are assumed
to be partially oxidized, carboxymethylation of cysteine residues is consid-
ered; the mass tolerance is kept at 75 ppm, fragment ion tolerance is kept at
0.1 Da, and tryptic digests are assumed to have no missed cleavages. To
increase the speed of searching, the taxonomy group searched should be
fixed based on the origin of the sample. Peptides positively identified from
MS and MS/MS data can be combined to give a probability-based Mowse
protein score (Perkins et al., 1999), equal to 10 log(P), where P is the
probability that the observed match is a random event. Protein identifica-
tions with a probability score of greater than 95% are considered significant.
Additional searches can subsequently be conducted with varied parameters.
Due to the complexity of the sample, only MS/MS data from LC-
purified tryptic peptides is used to search the SwissProt database with the
Mascot database search algorithm for peptide sequences consistent with the
ion fragments observed. Probability-based Mowse scores are generated for
each peptide sequence identified and only values of greater than 95%
significance should be considered (Perkins et al., 1999). The Mowse scores
of peptides from an individual protein can be combined to give a total ion
score for that protein.
4.7. Glycomics
N-linked and O-linked glycans on glycoproteins that have been purified by
affinity chromatography can be either enzymatically or chemically cleaved
from protein carriers using well-established procedures (Sutton-Smith and
Dell, 2005). Information about the structural composition of these glycans
can be obtained by a variety of mass spectrometric approaches. In particular,
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MALDI-MS profiling coupled with fragmentation data from MS/MS anal-
ysis of selected ions can be combined with knowledge of biosynthetic
pathways to predict the major glycan structures present (North et al., 2009).
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